{"d57237b2df83c773a63a0cbfa654b93c4541b677": [["IntroductionA novel coronavirus, SARS-CoV-2, first identified as the causative agent of a late 2019 outbreak of atypical pneumonia in Wuhan, China, was declared a pandemic by the World Health Organization in March 2020.", [["pneumonia", "DISEASE", 121, 130], ["coronavirus", "ORGANISM", 20, 31], ["SARS-CoV-2", "ORGANISM", 33, 43], ["coronavirus", "SPECIES", 20, 31], ["SARS-CoV-2", "SPECIES", 33, 43], ["IntroductionA novel coronavirus", "PROBLEM", 0, 31], ["CoV", "TEST", 38, 41], ["atypical pneumonia", "PROBLEM", 112, 130], ["atypical", "OBSERVATION_MODIFIER", 112, 120], ["pneumonia", "OBSERVATION", 121, 130]]], ["It is not only the high transmissibility of SARS-CoV-2 that made it a significant public health concern, but also the heterogeneity and seriousness of clinical manifestations in the form of COVID-19 disease.", [["SARS", "DISEASE", 44, 48], ["SARS-CoV-2", "ORGANISM", 44, 54], ["SARS-CoV", "SPECIES", 44, 52], ["clinical manifestations", "PROBLEM", 151, 174], ["COVID-19 disease", "PROBLEM", 190, 206], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["disease", "OBSERVATION", 199, 206]]], ["The death toll worldwide had reached in excess of 814,000, with the United States accounting for over 20% of those deaths (~177,773).", [["death", "DISEASE", 4, 9], ["deaths", "DISEASE", 115, 121]]], ["1 Over the past 6 months the medical and scientific community has worked to characterize the pathologic course and determine the best treatment options for COVID- 19 .", [["COVID", "TEST", 156, 161]]], ["[3] [4] [5] An early report for the Mayo Clinic EAP showed reduced mortality in patients who received CCP early (within 3 days of diagnosis) and a mortality benefit with higher IgG antibody levels in the transfused plasma.", [["plasma", "ANATOMY", 215, 221], ["patients", "ORGANISM", 80, 88], ["plasma", "ORGANISM_SUBSTANCE", 215, 221], ["IgG antibody", "PROTEIN", 177, 189], ["patients", "SPECIES", 80, 88], ["reduced mortality", "PROBLEM", 59, 76], ["a mortality benefit", "PROBLEM", 145, 164], ["higher IgG antibody levels", "TEST", 170, 196], ["the transfused plasma", "TREATMENT", 200, 221]]], ["6 The safety of CCP transfusions was similar to standard plasma transfusions.", [["plasma", "ANATOMY", 57, 63], ["CCP", "SIMPLE_CHEMICAL", 16, 19], ["plasma", "ORGANISM_SUBSTANCE", 57, 63], ["CCP transfusions", "TREATMENT", 16, 32], ["standard plasma transfusions", "TREATMENT", 48, 76]]], ["7 A randomized controlled trial conducted in Wuhan, however, did not report improved outcomes with CCP treatment for patients with severe COVID-19, although the study was terminated early due to a decrease in the COVID-19 case load.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["A randomized controlled trial", "TREATMENT", 2, 31], ["CCP treatment", "TREATMENT", 99, 112], ["severe COVID", "PROBLEM", 131, 143], ["the study", "TEST", 157, 166], ["a decrease", "PROBLEM", 195, 205], ["the COVID", "TEST", 209, 218], ["decrease", "OBSERVATION_MODIFIER", 197, 205]]], ["8 The transfusion community mobilized efforts to recruit and collect CCP from recovered patients in the context of rapidly evolving FDA guidance and testing technologies.", [["patients", "ORGANISM", 88, 96], ["CCP", "PROTEIN", 69, 72], ["patients", "SPECIES", 88, 96], ["The transfusion community", "TREATMENT", 2, 27], ["CCP", "TEST", 69, 72], ["testing technologies", "TEST", 149, 169]]], ["In previous outbreaks, the clinical benefit of CP was related to the dose of neutralizing antibodies in the plasma.", [["plasma", "ANATOMY", 108, 114], ["CP", "CHEMICAL", 47, 49], ["plasma", "ORGANISM_SUBSTANCE", 108, 114], ["neutralizing antibodies", "PROTEIN", 77, 100], ["CP", "PROBLEM", 47, 49], ["neutralizing antibodies", "TREATMENT", 77, 100], ["the plasma", "TEST", 104, 114]]], ["9, 10 Neutralizing antibodies directly block viral attachment to the host cell and subsequent fusion.", [["cell", "ANATOMY", 74, 78], ["host cell", "CELL", 69, 78], ["Neutralizing antibodies", "PROTEIN", 6, 29], ["Neutralizing antibodies", "TREATMENT", 6, 29], ["subsequent fusion", "TREATMENT", 83, 100], ["host cell", "OBSERVATION", 69, 78], ["fusion", "OBSERVATION", 94, 100]]], ["11 Despite some encouraging data, the clinical utility of CCP in COVID-19 has not been established, and the optimal dose and types of anti-SARS-CoV-2 antibodies in CCP remain uncertain.IntroductionCurrent FDA guidance through the CCP Emergency Use Agreement (EUA) guidelines recommends high titer CCP with an S/CO of >12 with the Ortho VITROS Anti-SARS-CoV-2 Ig only assay (Ortho Clinical Diagnostics, Raritan, New Jersey) which correlates to a neutralizing nAb titer of >1:250.", [["COVID-19", "CHEMICAL", 65, 73], ["anti-SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 134, 160], ["nAb", "GENE_OR_GENE_PRODUCT", 458, 461], ["anti-SARS-CoV-2 antibodies", "PROTEIN", 134, 160], ["nAb", "PROTEIN", 458, 461], ["CCP in COVID", "TEST", 58, 70], ["anti-SARS", "TEST", 134, 143], ["CoV", "TEST", 144, 147], ["an S/CO", "TEST", 306, 313], ["CoV", "TEST", 353, 356], ["a neutralizing nAb titer", "TEST", 443, 467]]], ["13 FDA has recognized that qualification of CCP products on the basis of nAb titer is challenging, given that conventional neutralizing antibody titer assays are cell-based, not amendable to high throughput testing, and not standardized.", [["cell", "ANATOMY", 162, 166], ["nAb", "GENE_OR_GENE_PRODUCT", 73, 76], ["cell", "CELL", 162, 166], ["CCP products", "PROTEIN", 44, 56], ["nAb", "PROTEIN", 73, 76], ["CCP products", "TREATMENT", 44, 56], ["nAb titer", "TREATMENT", 73, 82], ["conventional neutralizing antibody titer assays", "TEST", 110, 157]]], ["To that end on April 20, 2020, Creative Testing Solutions (CTS) implemented the VITROS Anti-SARS-CoV-2 Total Ig assay (CoV2T, Ortho Clinical Diagnostics, Raritan, New Jersey), which had received FDA emergency use authorization (EUA) on April 3, 2020.", [["CTS", "TEST", 59, 62], ["the VITROS Anti-SARS", "TEST", 76, 96], ["CoV", "TEST", 97, 100]]], ["The assay detects binding antibodies (bAb) to the S1 subunit of the SARS-CoV-2 spike glycoprotein.IntroductionThree large blood collection organizations began using the CoV2T semiquantitative test to ascertain donor seroreactivity to qualify CCP products, although the correlation of CoV2T signal-to-cutoff ratio (S/CO) with SARS-CoV-2 nAb titers was unknown.", [["blood", "ANATOMY", 122, 127], ["bAb", "GENE_OR_GENE_PRODUCT", 38, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["CoV2T", "GENE_OR_GENE_PRODUCT", 284, 289], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 325, 335], ["binding antibodies", "PROTEIN", 18, 36], ["bAb", "PROTEIN", 38, 41], ["S1 subunit", "PROTEIN", 50, 60], ["SARS-CoV-2 spike glycoprotein", "PROTEIN", 68, 97], ["CCP products", "PROTEIN", 242, 254], ["CoV2T", "PROTEIN", 284, 289], ["The assay", "TEST", 0, 9], ["binding antibodies", "TEST", 18, 36], ["the SARS", "TEST", 64, 72], ["CoV", "TEST", 73, 76], ["Three large blood collection organizations", "TREATMENT", 110, 152], ["the CoV2T semiquantitative test", "TEST", 165, 196], ["donor seroreactivity", "PROBLEM", 210, 230], ["CCP products", "TREATMENT", 242, 254], ["CoV2T signal", "TEST", 284, 296], ["cutoff ratio", "TEST", 300, 312], ["S/CO", "TEST", 314, 318], ["SARS", "TEST", 325, 329], ["CoV", "TEST", 330, 333], ["nAb titers", "TEST", 336, 346], ["large", "OBSERVATION_MODIFIER", 116, 121], ["blood collection", "OBSERVATION", 122, 138]]], ["In this study we endeavored to determine the effectiveness of CoV2T S/CO in predicting titers of nAbs to the immunodominant S protein, measured using SARS-CoV-2 Reporter Viral Particle Neutralization (RVPN) assay (Vitalant Research Institute (VRI), San Francisco, CA).", [["CO", "CHEMICAL", 70, 72], ["nAbs", "GENE_OR_GENE_PRODUCT", 97, 101], ["Viral", "ORGANISM", 170, 175], ["CoV2T S", "PROTEIN", 62, 69], ["nAbs", "PROTEIN", 97, 101], ["immunodominant S protein", "PROTEIN", 109, 133], ["SARS-CoV", "SPECIES", 150, 158], ["this study", "TEST", 3, 13], ["nAbs", "PROBLEM", 97, 101], ["the immunodominant S protein", "TEST", 105, 133], ["SARS", "TEST", 150, 154], ["CoV", "TEST", 155, 158], ["Reporter Viral Particle Neutralization", "TREATMENT", 161, 199]]], ["We evaluated the reliability of a range of CoV2T S/CO thresholds for predicting nAb titer, in an effort to derive optimal testing algorithms for CCP qualification.Materials and MethodsWe tested serum samples from 753 CCP donations collected by the American Red Cross (ARC), OneBlood and Vitalant during April and May 2020 with both the Ortho VITROS\u00ae CoV2T serologic assay and the VRI RVPN assay.CCP Donor QualificationCCP donor collection began in early April 2020.", [["serum samples", "ANATOMY", 194, 207], ["nAb", "GENE_OR_GENE_PRODUCT", 80, 83], ["serum samples", "ORGANISM_SUBSTANCE", 194, 207], ["CO thresholds", "TEST", 51, 64], ["predicting nAb titer", "PROBLEM", 69, 89], ["optimal testing algorithms", "TEST", 114, 140], ["CCP qualification", "TEST", 145, 162], ["MethodsWe tested serum samples", "TEST", 177, 207], ["CCP donations", "TEST", 217, 230], ["CoV2T serologic assay", "TEST", 350, 371], ["the VRI RVPN assay", "TEST", 376, 394], ["CCP Donor QualificationCCP donor collection", "PROBLEM", 395, 438], ["QualificationCCP", "OBSERVATION_MODIFIER", 405, 421], ["donor collection", "OBSERVATION", 422, 438]]], ["ARC study donors were collected from 4/8/20-5/19/20, OneBlood from 3/30/2020 -5/12/2020, and Vitalant from 4/12/2020-5/13/220.", [["donors", "ORGANISM", 10, 16], ["ARC study donors", "TEST", 0, 16]]], ["FDA mandated CCP donor qualification evolved throughout the study period due to testing availability and evolution of the pandemic in the United States.", [["the study", "TEST", 56, 65], ["testing availability", "TEST", 80, 100]]], ["Evidence of COVID-19 was required in the form of a documented positive SARS-CoV-2 molecular or serologic test, and either complete resolution of symptoms at least 28 days prior to donation or complete resolution 14 days prior to donation with negative molecular test result.", [["COVID-19", "DNA", 12, 20], ["COVID", "TEST", 12, 17], ["a documented positive SARS", "PROBLEM", 49, 75], ["CoV", "TEST", 76, 79], ["serologic test", "TEST", 95, 109], ["symptoms", "PROBLEM", 145, 153]]], ["All CCP donors were also required to meet traditional allogeneic blood donor criteria per the Code of Federal Regulations (21 CFR 630.10 and 630.15).", [["blood", "ANATOMY", 65, 70], ["donors", "ORGANISM", 8, 14], ["blood", "MULTI-TISSUE_STRUCTURE", 65, 70], ["CFR", "TEST", 126, 129], ["CCP donors", "OBSERVATION", 4, 14]]], ["14 At time of plasma collection, donors consented to use of de-identified donor information and test results for research purposes.", [["plasma", "ANATOMY", 14, 20], ["plasma", "ORGANISM_SUBSTANCE", 14, 20], ["donors", "ORGANISM", 33, 39], ["plasma collection", "TEST", 14, 31], ["de-identified donor information", "TEST", 60, 91], ["research purposes", "TEST", 113, 130]]], ["ARC collected apheresis plasma units All rights reserved.", [["apheresis plasma", "ANATOMY", 14, 30], ["plasma", "ORGANISM_SUBSTANCE", 24, 30], ["ARC collected apheresis plasma units", "TREATMENT", 0, 36], ["apheresis", "OBSERVATION", 14, 23]]], ["No reuse allowed without permission.CCP Donor Qualification(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.CCP Donor QualificationThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint on Alyx and Amicus devices (Fresenius Kabi USA LLC, Lake Zurich, IL).", [["Alyx", "SIMPLE_CHEMICAL", 366, 370], ["The copyright holder", "TREATMENT", 217, 237], ["medRxiv", "TREATMENT", 346, 353], ["Alyx", "TREATMENT", 366, 370], ["Amicus devices", "TREATMENT", 375, 389], ["med", "ANATOMY", 138, 141], ["LLC", "ANATOMY", 410, 413]]], ["At OneBlood, whole blood plasma collection was performed using the Haemonetics Leukotrap blood collection system (Haemonetics, Braintree, Mass.).", [["whole blood plasma", "ANATOMY", 13, 31], ["blood", "ANATOMY", 89, 94], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["whole blood plasma collection", "TEST", 13, 42], ["the Haemonetics Leukotrap blood collection system", "TREATMENT", 63, 112], ["Mass", "OBSERVATION", 138, 142]]], ["Apheresis plasma collection was performed at both OneBlood and Vitalant using Alyx devices and Trima (Terumo BCT, Lakewood, CO) apheresis systems following manufacturers' recommendations.CCP Donor QualificationOn April 27, 2020, ARC began CCP donor qualification with the CoV2T assay.", [["plasma", "ANATOMY", 10, 16], ["plasma", "ORGANISM_SUBSTANCE", 10, 16], ["CoV2T", "PROTEIN", 272, 277], ["Apheresis plasma collection", "PROBLEM", 0, 27], ["Alyx devices", "TREATMENT", 78, 90], ["Trima (Terumo BCT, Lakewood, CO) apheresis systems", "TREATMENT", 95, 145], ["the CoV2T assay", "TEST", 268, 283]]], ["Units from donors with a signal to cutoff (S/CO) ratio >1.0 (reactive per package insert) were labeled as CCP units.", [["donors", "ORGANISM", 11, 17], ["a signal to cutoff", "TEST", 23, 41], ["S/CO) ratio", "TEST", 43, 54]]], ["Retrospective testing was accomplished for the donors collected from 4/8/2020 -4/26/2020 from frozen serum drawn at time of collection.", [["serum", "ANATOMY", 101, 106], ["donors", "ORGANISM", 47, 53], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["Retrospective testing", "TEST", 0, 21], ["the donors", "TEST", 43, 53], ["frozen serum", "TEST", 94, 106], ["collection", "PROBLEM", 124, 134], ["collection", "OBSERVATION", 124, 134]]], ["Vitalant began CoV2T testing on 5/6/2020 but start-up reporting delays precluded its use as a release criterion until after 5/13/2020 with retrospective testing on previously frozen samples completed thereafter.", [["samples", "ANATOMY", 182, 189], ["Vitalant", "CHEMICAL", 0, 8], ["CoV2T testing", "TEST", 15, 28], ["retrospective testing", "TEST", 139, 160], ["previously frozen samples", "TEST", 164, 189]]], ["Vitalant also used an S/CO >1.0 as a CCP unit release criterion.", [["Vitalant", "CHEMICAL", 0, 8], ["CO", "CHEMICAL", 24, 26], ["Vitalant", "SIMPLE_CHEMICAL", 0, 8], ["an S/CO", "TEST", 19, 26], ["a CCP unit release criterion", "TREATMENT", 35, 63]]], ["Vitalant has allowed repeat CCP donations every 7 days.Preparation of SamplesEither refrigerated serum from the routine donation testing tubes, or frozen serums from randomly selected CCP donations were sent to the CTS in St. Petersburg, Florida.", [["serum", "ANATOMY", 97, 102], ["serums", "ANATOMY", 154, 160], ["Vitalant", "CHEMICAL", 0, 8], ["CTS", "DISEASE", 215, 218], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["serums", "ORGANISM_SUBSTANCE", 154, 160], ["repeat CCP donations", "TREATMENT", 21, 41], ["the routine donation testing tubes", "TEST", 108, 142], ["frozen serums", "TEST", 147, 160], ["CCP donations", "TEST", 184, 197], ["the CTS", "TEST", 211, 218]]], ["Serum aliquots were prepared at CTS for CoV2T testing by individual donation.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum aliquots", "TEST", 0, 14], ["CoV2T testing", "TEST", 40, 53]]], ["Regardless of VITROS Anti-SARS-CoV-2 Total Ab reactivity status, the serums aliquots were refrozen after testing and then shipped on dry ice to Vitalant Research Institute (VRI; San Francisco, CA) for assessment of the sample's SARS-CoV-2 neutralization activity.Preparation of SamplesAll rights reserved.", [["SARS", "DISEASE", 228, 232], ["serums", "ORGANISM", 69, 75], ["VITROS", "TEST", 14, 20], ["Anti-SARS", "TEST", 21, 30], ["CoV", "TEST", 31, 34], ["the serums aliquots", "TEST", 65, 84], ["testing", "TEST", 105, 112], ["assessment", "TEST", 201, 211], ["the sample's SARS", "TEST", 215, 232], ["CoV", "TEST", 233, 236]]], ["No reuse allowed without permission.Preparation of Samples(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Preparation of SamplesThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprintSerologic TestingVITROS Anti-SARS-CoV-2 Total testing was performed following the manufacturer's package insert instructions.", [["medRxiv", "TREATMENT", 344, 351], ["Serologic", "TEST", 360, 369], ["Anti-SARS-CoV", "TEST", 384, 397], ["Total testing", "TEST", 400, 413], ["the manufacturer's package insert instructions", "TREATMENT", 438, 484], ["med", "ANATOMY", 137, 140]]], ["15 The VITROS CoV2T test is an antigen sandwich immunoassay designed to qualitatively detect antibody to the S1 subunit of the SARS-CoV-2 spike or Nonreactive (S/CO < 1.0), although the S/CO can also be obtained from the system.Neutralization TestingStudy samples were tested with the SARS-CoV-2 Reporter Viral Particle Neutralization (RVPN) assay at VRI.", [["samples", "ANATOMY", 256, 263], ["CO", "CHEMICAL", 188, 190], ["CO", "SIMPLE_CHEMICAL", 188, 190], ["Viral", "ORGANISM", 305, 310], ["CoV2T", "PROTEIN", 14, 19], ["S1 subunit", "PROTEIN", 109, 119], ["SARS-CoV", "SPECIES", 285, 293], ["The VITROS CoV2T test", "TEST", 3, 24], ["an antigen sandwich immunoassay", "TEST", 28, 59], ["the SARS", "TEST", 123, 131], ["CoV", "TEST", 132, 135], ["Nonreactive (S/CO", "TEST", 147, 164], ["the S/CO", "TEST", 182, 190], ["Neutralization TestingStudy samples", "TEST", 228, 263], ["the SARS", "TEST", 281, 289], ["CoV", "TEST", 290, 293], ["Reporter Viral Particle Neutralization (RVPN", "TREATMENT", 296, 340]]], ["16 Upon receipt serum samples were plated in a 96-well plate and heatinactivated (HI) for 30 min at 56\u00b0C. Reporter viral particles (RVPs) represent a safe and rapid way of quantitatively measuring neutralization, by using SARS-CoV-2 Spike glycoprotein All rights reserved.", [["serum samples", "ANATOMY", 16, 29], ["serum samples", "ORGANISM_SUBSTANCE", 16, 29], ["serum samples", "TEST", 16, 29], ["Reporter viral particles (RVPs)", "PROBLEM", 106, 137], ["SARS", "TEST", 222, 226], ["CoV", "TEST", 227, 230], ["viral particles", "OBSERVATION", 115, 130]]], ["No reuse allowed without permission.Neutralization Testing(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Neutralization TestingThe copyright holder for this preprint this version posted September 2, 2020. . pseudotyped onto a rhabdovirus reporter virus.", [["pseudotyped", "ORGANISM", 295, 306], ["rhabdovirus", "GENE_OR_GENE_PRODUCT", 314, 325], ["Neutralization Testing", "TEST", 36, 58], ["pseudotyped", "PROBLEM", 295, 306], ["a rhabdovirus reporter virus", "PROBLEM", 312, 340], ["med", "ANATOMY", 137, 140], ["rhabdovirus reporter virus", "OBSERVATION", 314, 340]]], ["Neutralization was performed using vesicular stomatitis virus (VSV)-based pseudovirions (PV) as previously described.", [["vesicular stomatitis", "DISEASE", 35, 55], ["vesicular stomatitis virus", "ORGANISM", 35, 61], ["VSV", "ORGANISM", 63, 66], ["PV", "MULTI-TISSUE_STRUCTURE", 89, 91], ["stomatitis virus", "SPECIES", 45, 61], ["stomatitis virus", "SPECIES", 45, 61], ["VSV", "SPECIES", 63, 66], ["PV", "SPECIES", 89, 91], ["Neutralization", "TREATMENT", 0, 14], ["vesicular stomatitis virus (VSV)", "TREATMENT", 35, 67], ["vesicular stomatitis", "ANATOMY", 35, 55]]], ["16Statistical AnalysisCoV2T sensitivity and specificity for selection of CCP at four RVPN NT50 threshold nAb titers Based on the prevalence of CCP above the RVPN threshold titers, positive and negative predictive values (PPV and NPV, respectively) were calculated.", [["CCP", "PROTEIN", 73, 76], ["CCP", "PROTEIN", 143, 146], ["RVPN", "PROTEIN", 157, 161], ["CCP", "TEST", 73, 76], ["CCP", "TEST", 143, 146], ["the RVPN threshold titers", "TEST", 153, 178], ["PPV", "TEST", 221, 224], ["NPV", "TEST", 229, 232]]], ["Two-stage CCP release strategies were examined at several CoV2T acceptance values by determining the proportion of CCP within a S/CO range for reflex RVPN that exceed the selected nAb threshold (SAS 9.4, All rights reserved.", [["CO", "CHEMICAL", 130, 132], ["CoV2T", "PROTEIN", 58, 63], ["CCP", "PROTEIN", 115, 118], ["Two-stage CCP release strategies", "TREATMENT", 0, 32], ["a S/CO range", "TREATMENT", 126, 138], ["reflex RVPN", "TREATMENT", 143, 154], ["SAS", "TEST", 195, 198]]], ["No reuse allowed without permission.Statistical Analysis(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Statistical AnalysisThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint SAS Institute, Cary, NC).", [["Statistical Analysis", "TEST", 36, 56], ["med", "ANATOMY", 135, 138]]], ["A non-parametric Spearman rank correlation coefficient was performed between CoV2T and RVPN (SAS 9.4, SAS Institute, Cary, NC).Donor Demographics753 CCP donors were tested from three blood centers across the United States (Table 1) The ARC samples had a slightly lower percent reactive on the VITROS CoV2T, and a lower median nAb titer in the RVPN.", [["blood", "ANATOMY", 183, 188], ["ARC samples", "ANATOMY", 236, 247], ["donors", "ORGANISM", 153, 159], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["ARC samples", "CANCER", 236, 247], ["nAb", "GENE_OR_GENE_PRODUCT", 326, 329], ["RVPN", "CANCER", 343, 347], ["VITROS CoV2T", "PROTEIN", 293, 305], ["nAb", "PROTEIN", 326, 329], ["CoV2T", "TEST", 77, 82], ["SAS", "TEST", 93, 96], ["CCP donors", "TEST", 149, 159], ["The ARC samples", "TEST", 232, 247], ["a slightly lower percent reactive", "PROBLEM", 252, 285], ["the VITROS CoV2T", "TEST", 289, 305], ["a lower median nAb titer", "TREATMENT", 311, 335], ["ARC", "OBSERVATION_MODIFIER", 236, 239], ["slightly", "OBSERVATION_MODIFIER", 254, 262], ["lower", "OBSERVATION_MODIFIER", 263, 268], ["percent", "OBSERVATION_MODIFIER", 269, 276], ["reactive", "OBSERVATION_MODIFIER", 277, 285], ["lower", "ANATOMY_MODIFIER", 313, 318], ["nAb titer", "OBSERVATION", 326, 335]]], ["This may have been a consequence of the difference in collection catchments; and would be expected to change as the pandemic peak progresses around the country.", [["the difference in collection catchments", "PROBLEM", 36, 75], ["difference", "OBSERVATION_MODIFIER", 40, 50]]], ["This is not relevant for evaluation of the CoV2T predictive performance.Population CoV2T and RVPN TestingThe 753 CCP donors had a median CoV2T S/CO of 71.2 (IQR 19.9-156) and a median NT50 of 528 (IQR 182-1627) ( Table 1) .", [["CoV2T", "CANCER", 43, 48], ["donors", "ORGANISM", 117, 123], ["CoV2T", "PROTEIN", 43, 48], ["evaluation", "TEST", 25, 35], ["the CoV2T predictive performance", "TEST", 39, 71], ["a median CoV2T S/CO", "TEST", 128, 147], ["IQR", "TEST", 157, 160], ["a median NT50", "TEST", 175, 188]]], ["94% were reactive for CoV2T and had a neutralizing All rights reserved.", [["CoV2T", "TEST", 22, 27], ["a neutralizing All rights", "TREATMENT", 36, 61]]], ["No reuse allowed without permission.Population CoV2T and RVPN Testing(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Population CoV2T and RVPN TestingThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint titer >40 with 6% \"sero-silent\" with nonreactive S/CO and absence of a neutralizing titer.", [["CO", "CHEMICAL", 434, 436], ["RVPN Testing", "TEST", 57, 69], ["nonreactive S/CO", "PROBLEM", 420, 436], ["a neutralizing titer", "PROBLEM", 452, 472], ["med", "ANATOMY", 148, 151]]], ["Figure 2 shows the distribution of study population based on CoV2T S/CO results against RVPN titers.Population CoV2T and RVPN TestingThe distribution is not normal and suggests a direct linear relationship between CoV2T and RVPN consistent with other studies.", [["RVPN", "GENE_OR_GENE_PRODUCT", 88, 92], ["CoV2T", "GENE_OR_GENE_PRODUCT", 214, 219], ["RVPN", "GENE_OR_GENE_PRODUCT", 224, 228], ["CoV2T", "PROTEIN", 214, 219], ["study population", "TEST", 35, 51], ["CoV2T S/CO", "TEST", 61, 71], ["RVPN titers", "PROBLEM", 88, 99], ["Population CoV2T and RVPN Testing", "TEST", 100, 133], ["a direct linear relationship between CoV2T and RVPN", "PROBLEM", 177, 228], ["other studies", "TEST", 245, 258], ["not", "UNCERTAINTY", 153, 156], ["normal", "OBSERVATION", 157, 163], ["consistent with", "UNCERTAINTY", 229, 244]]], ["18 A Spearman rank correlation coefficient showed low correlation between CoV2T and RVPN (r = 0.34217).", [["CoV2T", "PROTEIN", 74, 79], ["A Spearman rank correlation", "TEST", 3, 30], ["CoV2T", "TEST", 74, 79], ["RVPN", "TEST", 84, 88]]], ["Table 2 summarizes proportions of reactive CCP donations at S/CO thresholds of 1, 10, 20, 30, and 60 that yields RVPN NT50 titers meeting proposed CCP minimum potency levels.Population CoV2T and RVPN TestingAs the S/CO threshold approaches 60 the proportion of selected donors meeting candidate NT50 titers increaseswith 98% of donors with S/CO \u226560 had NT50 \u22651:80 and 79% \u22651:320.Population CoV2T and RVPN TestingHowever, at an S/CO threshold of 60, 45% of donors do not meet the 60 S/CO criterion ( Table 2 ), many of whom have high neutralization titers.Population CoV2T and RVPN TestingThe CoV2T ROCs are shown in Figure 3 for NT50 thresholds of 1:80, 1:160, 1:320 and 1:640.", [["donors", "ORGANISM", 270, 276], ["NT50", "GENE_OR_GENE_PRODUCT", 295, 299], ["donors", "ORGANISM", 328, 334], ["donors", "ORGANISM", 456, 462], ["CoV2T ROCs", "DNA", 592, 602], ["S/CO thresholds", "TEST", 60, 75], ["the S/CO threshold approaches", "TREATMENT", 210, 239], ["titers", "TEST", 300, 306], ["S/CO", "TEST", 340, 344], ["RVPN Testing", "TEST", 400, 412], ["an S/CO threshold", "TEST", 424, 441], ["high neutralization titers", "PROBLEM", 528, 554], ["Population CoV2T", "TEST", 555, 571], ["The CoV2T ROCs", "TEST", 588, 602], ["reactive", "OBSERVATION_MODIFIER", 34, 42], ["CCP donations", "OBSERVATION", 43, 56], ["high", "OBSERVATION_MODIFIER", 528, 532], ["neutralization titers", "OBSERVATION", 533, 554]]], ["As the threshold nAb titer criterion increases, the performance of the CoV2T assay for selecting CCP above the threshold deteriorates (AUC 0.88, 0.82, 0.76, 0.71).", [["nAb", "GENE_OR_GENE_PRODUCT", 17, 20], ["CoV2T", "PROTEIN", 71, 76], ["CCP", "PROTEIN", 97, 100], ["the threshold nAb titer criterion", "TEST", 3, 36], ["the CoV2T assay", "TEST", 67, 82], ["selecting CCP", "TEST", 87, 100], ["AUC", "TEST", 135, 138]]], ["Potential CoV2T S/CO cutoffs are superimposed on the ROC illustrating how increasing the S/CO criterion results in a tradeoff effect of decreasing sensitivity (probability of a true positive selection) while decreasing the risk of a false positive selection.", [["CoV2T S", "GENE_OR_GENE_PRODUCT", 10, 17], ["Potential CoV2T S/CO cutoffs", "PROBLEM", 0, 28], ["the ROC", "TEST", 49, 56], ["the S/CO criterion", "TEST", 85, 103], ["decreasing sensitivity", "PROBLEM", 136, 158], ["a true positive selection", "PROBLEM", 175, 200], ["a false positive selection", "PROBLEM", 231, 257], ["false positive selection", "OBSERVATION", 233, 257]]], ["This is also shown in Table 3 with various combinations of CoV2T cutoff S/CO and desired CCP NT50.", [["CO", "CHEMICAL", 74, 76], ["CCP NT50", "PROTEIN", 89, 97], ["desired CCP NT50", "TREATMENT", 81, 97]]], ["Based on the prevalence of NT50 greater than threshold values, the PPV and NPV for the CoV2T assay illustrate the tradeoff associated with increasing the NT50 requirement.Population CoV2T and RVPN TestingWe examined the effect of a two-stage selection process for CCP donations (Figure 4) : Stage 1 is a CCP rejection with S/CO<1.0 and immediate acceptance for S/CO>acceptance criterion; Stage 2 is reflexed secondary screening for 1.030 are anticipated to be at or above 1:160 and 60.2% of the reflexed tested units would be releasable with RVPN NT50>1:160.", [["CoV2T", "PROTEIN", 87, 92], ["the PPV", "TREATMENT", 63, 70], ["NPV", "TREATMENT", 75, 78], ["the CoV2T assay", "TEST", 83, 98], ["increasing the NT50 requirement", "PROBLEM", 139, 170], ["a two-stage selection process", "TREATMENT", 230, 259], ["CCP donations", "TEST", 264, 277], ["Stage 1", "PROBLEM", 291, 298], ["a CCP rejection", "PROBLEM", 302, 317], ["S/CO", "TEST", 323, 327], ["increasing", "OBSERVATION_MODIFIER", 139, 149], ["rejection", "OBSERVATION", 308, 317]]], ["This results in 91.7% of the final released inventory expected to have NT50>1:160.", [["NT50", "TEST", 71, 75]]], ["Approximately 11% of the all tested CCP would be rejected and not released as CCP.DiscussionCOVID-19 has presented new and daunting challenges for our society worldwide.", [["CCP", "PROTEIN", 36, 39], ["CCP", "PROTEIN", 78, 81], ["the all tested CCP", "TEST", 21, 39]]], ["The last six months have seen incredible strides in public health and prevention as well as understanding of disease pathogenesis and formulation of effective treatment protocols.", [["disease pathogenesis", "PROBLEM", 109, 129], ["effective treatment protocols", "TREATMENT", 149, 178]]], ["Viral specific therapy is still in development setting the stage for temporary use of an historical treatment: convalescent plasma.", [["plasma", "ANATOMY", 124, 130], ["plasma", "ORGANISM_SUBSTANCE", 124, 130], ["Viral specific therapy", "TREATMENT", 0, 22], ["an historical treatment", "TREATMENT", 86, 109], ["convalescent plasma", "TREATMENT", 111, 130], ["specific therapy", "OBSERVATION", 6, 22]]], ["Initial studies using CCP have suggested efficacy particularly when used earlier in the disease course though the most efficacious nAb titer and dose has not yet been determined.", [["CCP", "GENE_OR_GENE_PRODUCT", 22, 25], ["nAb", "SIMPLE_CHEMICAL", 131, 134], ["CCP", "PROTEIN", 22, 25], ["nAb", "PROTEIN", 131, 134], ["Initial studies", "TEST", 0, 15], ["CCP", "TEST", 22, 25]]], ["6, 19 Although bAbs may protect through multiple effector pathways, the effectiveness of passive immunotherapy is believed to be broadly proportional to the potency of the intervention as determined with nAb titers.", [["bAbs", "GENE_OR_GENE_PRODUCT", 15, 19], ["nAb", "GENE_OR_GENE_PRODUCT", 204, 207], ["nAb", "PROTEIN", 204, 207], ["passive immunotherapy", "TREATMENT", 89, 110], ["the intervention", "TREATMENT", 168, 184]]], ["As applied to CCP on the large-scale experience in the US, it is not possible to provide timely screening of CCP products due to technological limitations.", [["the US", "TEST", 51, 57], ["CCP products", "TREATMENT", 109, 121]]], ["Therefore, it is imperative to apply high throughput bAb assays as indicators of nAb levels.", [["nAb", "GENE_OR_GENE_PRODUCT", 81, 84], ["bAb", "PROTEIN", 53, 56], ["nAb", "PROTEIN", 81, 84], ["nAb levels", "TEST", 81, 91]]], ["We have demonstrated that the CoV2T test system, while not a perfect predictor of nAb titers, is All rights reserved.", [["CoV2T", "GENE_OR_GENE_PRODUCT", 30, 35], ["CoV2T", "PROTEIN", 30, 35], ["the CoV2T test system", "TEST", 26, 47]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint capable of identifying donors with no Ab response.", [["donors", "ORGANISM", 360, 366], ["Ab", "GENE_OR_GENE_PRODUCT", 375, 377], ["medRxiv", "TREATMENT", 320, 327], ["Ab response", "PROBLEM", 375, 386], ["med", "ANATOMY", 125, 128]]], ["The test system also presents a S/CO readout with a large dynamic range.", [["CO", "CHEMICAL", 34, 36], ["The test system", "TEST", 0, 15], ["large", "OBSERVATION_MODIFIER", 52, 57], ["dynamic range", "OBSERVATION", 58, 71]]], ["This output range can be exploited to provide reasonable PPV as a screening tool.", [["a screening tool", "TEST", 64, 80]]], ["For example, a S/CO criterion of 30 applied to a previously qualified CCP donor population is expected to result in 90% of CCP with NT50 \u22651:160.", [["a S/CO criterion", "TEST", 13, 29], ["CCP", "TEST", 123, 126]]], ["We further illustrated that reflex testing of CCPP in the intermediate zone of S/CO 1-30 could provide additional units at or above the desired NT50.", [["CO 1-30", "CHEMICAL", 81, 88], ["CCPP", "SIMPLE_CHEMICAL", 46, 50], ["NT50", "PROTEIN", 144, 148], ["reflex testing", "TEST", 28, 42], ["CCPP", "TEST", 46, 50], ["S/CO", "TEST", 79, 83]]], ["Such an approach will permit high throughput screening for timely provision of CCP.DiscussionThe selection of targeted nAb titers for clinical use will significantly affect the yield and availability of CCP transfusion.", [["nAb", "ORGANISM", 119, 122], ["CCP", "GENE_OR_GENE_PRODUCT", 203, 206], ["CCP", "PROTEIN", 79, 82], ["targeted nAb titers", "TREATMENT", 110, 129], ["CCP transfusion", "TREATMENT", 203, 218]]], ["Due to inherent limitations of large volume testing for neutralization titers, we present a potential reflex testing algorithm using initial high-throughput CoV2T testing.", [["CoV2T", "PROTEIN", 157, 162], ["large volume testing", "TEST", 31, 51], ["neutralization titers", "TREATMENT", 56, 77], ["a potential reflex testing algorithm", "TEST", 90, 126], ["CoV2T testing", "TEST", 157, 170], ["large", "OBSERVATION_MODIFIER", 31, 36]]], ["The S/CO thresholds selected for routine product release will need to balance the risk of releasing products without the minimum target nAb titer.", [["CO", "CHEMICAL", 6, 8], ["nAb", "GENE_OR_GENE_PRODUCT", 136, 139], ["nAb", "PROTEIN", 136, 139], ["The S/CO thresholds", "TREATMENT", 0, 19], ["routine product release", "TREATMENT", 33, 56], ["releasing products", "TREATMENT", 90, 108]]], ["Organizations may consider this testing scheme or develop others to effectively select for CCP.", [["CCP", "PROTEIN", 91, 94], ["this testing scheme", "TEST", 27, 46]]], ["Another approach that could be considered is pooling of CCP units from different donors.", [["donors", "ORGANISM", 81, 87], ["CCP units", "TREATMENT", 56, 65], ["could be considered", "UNCERTAINTY", 22, 41]]], ["This would narrow the distribution of nAb titers in the CPP and take advantage of regression to the mean.", [["nAb", "GENE_OR_GENE_PRODUCT", 38, 41], ["nAb", "PROTEIN", 38, 41], ["the CPP", "TEST", 52, 59], ["narrow", "OBSERVATION_MODIFIER", 11, 17], ["distribution", "OBSERVATION_MODIFIER", 22, 34], ["nAb titers", "OBSERVATION", 38, 48]]], ["In other words, the lower titer units would be balanced by the higher titer units and result in higher proportions of pooled CCP above any desired nAb titer.", [["CCP", "GENE_OR_GENE_PRODUCT", 125, 128], ["nAb", "GENE_OR_GENE_PRODUCT", 147, 150], ["CCP", "PROTEIN", 125, 128], ["nAb", "PROTEIN", 147, 150], ["the lower titer units", "TREATMENT", 16, 37], ["pooled CCP", "PROBLEM", 118, 128]]], ["Regardless, any algorithm would need to effectively evaluate testing performance characteristics including sensitivity and specificity as well as PPV and NPV while correlating with clinical outcomes.DiscussionOur study did have several limitations.", [["sensitivity", "TEST", 107, 118], ["specificity", "TEST", 123, 134], ["PPV", "TEST", 146, 149], ["NPV", "TEST", 154, 157], ["DiscussionOur study", "TEST", 199, 218]]], ["The SARS-CoV-2 RVPN detects the presence of neutralizing antibody directed against the virus, but there is still a potential that cross-reactivity with other coronavirus species may occur.", [["SARS-CoV-2", "ORGANISM", 4, 14], ["coronavirus", "ORGANISM", 158, 169], ["SARS-CoV-2 RVPN", "DNA", 4, 19], ["neutralizing antibody", "PROTEIN", 44, 65], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV-2 RVPN", "TEST", 9, 19], ["neutralizing antibody", "TREATMENT", 44, 65], ["the virus", "PROBLEM", 83, 92], ["other coronavirus species", "PROBLEM", 152, 177], ["neutralizing antibody", "OBSERVATION", 44, 65], ["virus", "OBSERVATION", 87, 92], ["coronavirus species", "OBSERVATION", 158, 177]]], ["In addition, though represented in 39 different states, the study population was not entirely representative of the potential CCP donor pool within the All rights reserved.", [["the study population", "TEST", 56, 76]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint United States which as of August 25, 2020 exceeds 124, 036.", [["med", "ANATOMY", 125, 128]]], ["1, 17 Despite being the largest published report of CCP donors to date, our population was still relatively small and collected in the early days of the pandemic.", [["donors", "ORGANISM", 56, 62], ["CCP donors", "TREATMENT", 52, 62], ["the pandemic", "PROBLEM", 149, 161], ["small", "OBSERVATION_MODIFIER", 108, 113]]], ["Our cross-sectional analysis showed 94% seropositivity to both the CoV2T and the RVPN with 6% sero-silent consistent with a recent serosurvey of recovered COVID-19 patients.", [["CoV2T", "CANCER", 67, 72], ["RVPN", "CANCER", 81, 85], ["patients", "ORGANISM", 164, 172], ["CoV2T", "DNA", 67, 72], ["patients", "SPECIES", 164, 172], ["Our cross-sectional analysis", "TEST", 0, 28], ["consistent with", "UNCERTAINTY", 106, 121]]], ["20 However, our testing only examined humoral response to the immune dominate S-protein.", [["S-protein", "GENE_OR_GENE_PRODUCT", 78, 87], ["immune dominate S-protein", "PROTEIN", 62, 87], ["our testing", "TEST", 12, 23]]], ["Additional studies are necessary to examine humoral response to additional viral antigens and correlate with days from COVID-19 symptom onset and severity of illness.DiscussionAb reactivity on the CoV2T testing system appears to be quite stable over at least 90 days (unpublished), however, other assay platforms targeting Ig-only suggest waning for the IgG response, and possibly, nAb as well.", [["illness", "DISEASE", 158, 165], ["Ig", "GENE_OR_GENE_PRODUCT", 323, 325], ["IgG", "GENE_OR_GENE_PRODUCT", 354, 357], ["nAb", "GENE_OR_GENE_PRODUCT", 382, 385], ["viral antigens", "PROTEIN", 75, 89], ["Ig", "PROTEIN", 323, 325], ["IgG", "PROTEIN", 354, 357], ["nAb", "PROTEIN", 382, 385], ["Additional studies", "TEST", 0, 18], ["additional viral antigens", "PROBLEM", 64, 89], ["COVID", "TEST", 119, 124], ["illness", "PROBLEM", 158, 165], ["the CoV2T testing system", "TEST", 193, 217], ["Ig", "TEST", 323, 325], ["the IgG response", "TEST", 350, 366], ["stable", "OBSERVATION_MODIFIER", 238, 244]]], ["21, 22 Waning of nAb over time when the CoV2T test presents a stable signal strength would reduce the utility of this system as a predictor of nAb and selection of CCP for transfusion.", [["nAb", "SIMPLE_CHEMICAL", 143, 146], ["CCP", "GENE_OR_GENE_PRODUCT", 164, 167], ["CoV2T", "PROTEIN", 40, 45], ["CCP", "PROTEIN", 164, 167], ["the CoV2T test", "TEST", 36, 50], ["transfusion", "TREATMENT", 172, 183]]], ["Though not directly applicable to recent FDA EUA guidance regarding CCP unit test, the information obtained from correlating these two testing platforms is helpful in directing specific reflex testing for donors not meeting initial testing criteria.DiscussionAll rights reserved.", [["donors", "ORGANISM", 205, 211], ["CCP unit", "DNA", 68, 76], ["CCP unit test", "TEST", 68, 81], ["these two testing platforms", "TEST", 125, 152], ["specific reflex testing", "TEST", 177, 200]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020.", [["med", "ANATOMY", 125, 128], ["med", "ANATOMY", 416, 419], ["med", "ANATOMY", 641, 644]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint Figure 2 .", [["med", "ANATOMY", 125, 128]]], ["Distribution of CoV2T S/Co versus RVPN NT50.", [["Co", "CHEMICAL", 24, 26], ["CoV2T S/Co", "GENE_OR_GENE_PRODUCT", 16, 26], ["RVPN NT50", "GENE_OR_GENE_PRODUCT", 34, 43], ["CoV2T S", "PROTEIN", 16, 23], ["RVPN NT50", "PROTEIN", 34, 43], ["RVPN NT50", "TREATMENT", 34, 43]]], ["The distribution is not normal but suggests a direct linear correlation between the two tests.", [["the two tests", "TEST", 80, 93], ["not", "UNCERTAINTY", 20, 23], ["normal", "OBSERVATION", 24, 30]]], ["Truncated RVPN results beyond the assay response range are evident at 1:40 and 1:100,000.", [["RVPN", "GENE_OR_GENE_PRODUCT", 10, 14], ["RVPN", "PROTEIN", 10, 14], ["Truncated RVPN", "TEST", 0, 14], ["the assay response range", "TEST", 30, 54]]], ["Slope and R 2 of the regression line excluding the truncated results is y = 2.10 + 0.39x with an R 2 = 0.14. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20184895 doi: medRxiv preprint", [["Slope", "TEST", 0, 5], ["the regression line", "TREATMENT", 17, 36], ["medRxiv", "TREATMENT", 965, 972], ["med", "ANATOMY", 188, 191], ["med", "ANATOMY", 479, 482], ["med", "ANATOMY", 770, 773]]]], "d192c576f0b41a5ad6d6bccf30675fcbdd3519af": [["In the COVID-19 pandemic in Brazil, do brown lives matter?In The Lancet Global Health, a pioneering study by Pedro Baqui and colleagues 1 confirms in Brazil findings observed in other countries hit hard by COVID-19: that mortality rates from the pandemic differ by geographical region and ethnicity, with disproportionate impact for Black populations and other ethnic minorities.", [["a pioneering study", "TEST", 87, 105], ["Black populations", "PROBLEM", 333, 350]]], ["However, in this Comment, we go beyond ethnicity, focusing on social and environmental determinants of health for about 50% of Brazilians.In the COVID-19 pandemic in Brazil, do brown lives matter?Using COVID-19 hospital mortality data from SIVEP-Gripe (Sistema de Informa\u00e7\u00e3o de Vigil\u00e2ncia Epidemiol\u00f3gica da Gripe) dataset, Baqui and colleagues did a cross-sectional observational study to assess regional variations in patients with COVID-19 admitted to hospital by state and by two socioeconomically grouped regions (north and central-south).", [["Brazilians", "ORGANISM", 127, 137], ["patients", "ORGANISM", 419, 427], ["patients", "SPECIES", 419, 427], ["a cross-sectional observational study", "TEST", 348, 385]]], ["The ethnicity of patients was categorised according to the five categories used by the Brazilian Institute of Geography and Statistics: Branco (White), Preto (Black), Amarelo (East Asian), Ind\u00edgeno (Indigenous), or Pardo (mixed ethnicity).", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["Amarelo", "TREATMENT", 167, 174]]], ["The authors used mixed-effects Cox regression survival analysis to estimate the effects of ethnicity and comorbidity at an individual level in the context of regional variation.In the COVID-19 pandemic in Brazil, do brown lives matter?Baqui and colleagues found that, compared with White Brazilians, Pardo and Black Brazilians who were hospitalised had significantly higher mortality risk (hazard ratio 1\u00b745, 95% CI 1\u00b733-1\u00b758 for Pardo Brazilians; 1\u00b732, 1\u00b715-1\u00b752 for Black Brazilians).", [["Brazilians", "ORGANISM", 316, 326], ["Cox regression survival analysis", "TEST", 31, 63], ["comorbidity", "PROBLEM", 105, 116], ["hazard ratio", "TEST", 390, 402], ["CI", "TEST", 413, 415], ["regional variation", "OBSERVATION", 158, 176]]], ["Pardo ethnicity was the second most important risk factor after age for death.", [["death", "DISEASE", 72, 77], ["death", "PROBLEM", 72, 77]]], ["The authors also showed that, in the north region, hospitalised patients had higher risk of death from COVID-19 than those in the central-south region.", [["death", "DISEASE", 92, 97], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["death", "PROBLEM", 92, 97], ["COVID", "TEST", 103, 108], ["central", "ANATOMY_MODIFIER", 130, 137], ["south", "ANATOMY_MODIFIER", 138, 143], ["region", "ANATOMY_MODIFIER", 144, 150]]], ["Rio de Janeiro was an outlier, with mortality rates similar to those of northern states.In the COVID-19 pandemic in Brazil, do brown lives matter?We add to their findings that incidence rates were also higher in northern regions.", [["higher", "OBSERVATION_MODIFIER", 202, 208]]], ["4 Speculation that severe acute respiratory syndrome coronavirus 2 would have milder transmission in low latitudes has delayed actions in northern regions.", [["acute respiratory syndrome coronavirus", "DISEASE", 26, 64], ["severe acute respiratory syndrome coronavirus", "SPECIES", 19, 64], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 19, 64], ["milder transmission in low latitudes", "PROBLEM", 78, 114], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["respiratory syndrome coronavirus", "OBSERVATION", 32, 64], ["milder", "OBSERVATION_MODIFIER", 78, 84], ["low latitudes", "OBSERVATION_MODIFIER", 101, 114]]], ["Therefore, discussions regarding ethnicity and regional variations must be integrated, not only because northern states and Rio de Janeiro have higher proportions of Pardo and Black populations, but also because the root causes of higher mortality are overlapping.", [["root", "ANATOMY", 216, 220], ["root", "ORGAN", 216, 220], ["Pardo", "TREATMENT", 166, 171], ["Black populations", "PROBLEM", 176, 193], ["root", "ANATOMY", 216, 220], ["higher", "OBSERVATION_MODIFIER", 231, 237], ["mortality", "OBSERVATION", 238, 247]]], ["The percentage of low-income families living in subnormal housing, with higher average numbers of individuals per room, is more elevated in northern areas than in the centralsouth region and higher among Pardo and Black families than in White families.", [["percentage", "OBSERVATION_MODIFIER", 4, 14], ["low", "OBSERVATION_MODIFIER", 18, 21], ["elevated", "OBSERVATION_MODIFIER", 128, 136]]], ["These conditions favour intense circulation of respiratory pathogens.", [["respiratory", "ANATOMY", 47, 58], ["respiratory pathogens", "PROBLEM", 47, 68], ["intense", "OBSERVATION_MODIFIER", 24, 31], ["respiratory pathogens", "OBSERVATION", 47, 68]]], ["Low-income neighbourhoods also have higher population density and low adherence to social distance measures.", [["higher population density", "PROBLEM", 36, 61], ["social distance measures", "TREATMENT", 83, 107], ["higher", "OBSERVATION_MODIFIER", 36, 42], ["population", "OBSERVATION_MODIFIER", 43, 53], ["density", "OBSERVATION", 54, 61], ["low adherence", "OBSERVATION_MODIFIER", 66, 79]]], ["Additionally, lower schooling in northern regions and among Pardo and Black populations might jeopardise the comprehension of risks and measures proposed by sanitary authorities, as well as judgment of the right time to seek medical assistance.", [["lower schooling in northern regions", "PROBLEM", 14, 49], ["lower", "OBSERVATION_MODIFIER", 14, 19], ["schooling", "OBSERVATION", 20, 29]]], ["Additionally, in the north region, lower percentages of the urban population are served by piped water compared with those of other regions (69\u00b75% in the north, 88\u00b77% in the northeast, and 96% in southern regions).", [["north", "ANATOMY_MODIFIER", 21, 26], ["region", "ANATOMY_MODIFIER", 27, 33], ["lower", "OBSERVATION_MODIFIER", 35, 40], ["percentages", "OBSERVATION_MODIFIER", 41, 52], ["urban population", "OBSERVATION", 60, 76]]], ["5 This situation means that a substantial proportion of the northern urban population has difficulty in adhering to the simplest prevention recommendation of hygiene, such as washing hands.In the COVID-19 pandemic in Brazil, do brown lives matter?The prevalence of comorbidities among Pardo and Black populations in Brazil is higher than among other ethnicities, including overweight and obesity, 6 risk factors for severity of symptoms of COVID-19.", [["overweight", "DISEASE", 373, 383], ["obesity", "DISEASE", 388, 395], ["COVID", "DISEASE", 440, 445], ["comorbidities", "PROBLEM", 265, 278], ["Black populations", "PROBLEM", 295, 312], ["overweight and obesity", "PROBLEM", 373, 395], ["symptoms", "PROBLEM", 428, 436], ["COVID", "TEST", 440, 445], ["substantial", "OBSERVATION_MODIFIER", 30, 41], ["proportion", "OBSERVATION_MODIFIER", 42, 52], ["Black", "OBSERVATION_MODIFIER", 295, 300], ["populations", "OBSERVATION_MODIFIER", 301, 312], ["higher", "OBSERVATION_MODIFIER", 326, 332], ["obesity", "OBSERVATION", 388, 395]]], ["[2] [3] [4] Hypovitaminosis D is also more prevalent among Pardo and Black people in Brazil than among other ethnicities.", [["[2] [3] [4] Hypovitaminosis D", "CHEMICAL", 0, 29], ["[2] [3] [4] Hypovitaminosis D", "SIMPLE_CHEMICAL", 0, 29], ["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["Hypovitaminosis D", "PROBLEM", 12, 29]]], ["7 The lower the level of schooling, the higher the chances of obesity in Brazilian women.", [["obesity", "DISEASE", 62, 69], ["women", "ORGANISM", 83, 88], ["women", "SPECIES", 83, 88], ["obesity", "PROBLEM", 62, 69], ["lower", "OBSERVATION_MODIFIER", 6, 11], ["higher", "OBSERVATION_MODIFIER", 40, 46], ["obesity", "OBSERVATION", 62, 69]]], ["6 With soaring numbers of cases, cities in the northern region faced collapse of their health system, with worst cases occurring in Manaus, Fortaleza, and Natal.", [["collapse", "OBSERVATION", 69, 77]]], ["However, we note that phases of the epidemic vary within the country, and the northern region has probably reached the peak of the first wave of transmissions, whereas this might not be the case for other regions.", [["peak", "OBSERVATION_MODIFIER", 119, 123]]], ["Additionally, substantial under-reporting of deaths and cases of COVID-19 is occurring, related to low testing.", [["deaths", "DISEASE", 45, 51], ["COVID", "DISEASE", 65, 70], ["COVID", "TEST", 65, 70], ["substantial", "OBSERVATION_MODIFIER", 14, 25]]], ["This under-reporting is more intense in the northern region, which might reinforce health inequities.In the COVID-19 pandemic in Brazil, do brown lives matter?We draw attention to issues of mobility and historical shortages of doctors in villages and poverty areas, which are not discussed in Baqui and colleagues' study.", [["more intense", "OBSERVATION_MODIFIER", 24, 36]]], ["In the Amazon, most people move around by boat through igarap\u00e9s and rivers, and trips to cities with health equipment and medical doctors might take hours or even days.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26]]], ["The poor, mostly Pardo and Black, live in shantytowns on steep slopes with no streets or health services, where ambulance access is difficult; or in suburbs with precarious and very crowded public transportation, facilitating transmission.", [["poor", "OBSERVATION_MODIFIER", 4, 8]]], ["In those cases, the delay to hospital admission might be fatal.", [["fatal", "OBSERVATION", 57, 62]]], ["Additionally, this population works mainly in unstable jobs with no payment for sick days, and thus are likely to postpone going to health services until disease symptoms are acute.", [["disease symptoms", "PROBLEM", 154, 170], ["acute", "PROBLEM", 175, 180], ["acute", "OBSERVATION_MODIFIER", 175, 180]]], ["Most doctors are White and might show less empathy for Pardo and Black patients.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["By contrast, the majority of non-medical health staff is composed of Pardo and Black people, who are more exposed to COVID-19 risks, as pointed out by Baqui and colleagues, sometimes without adequate protection equipment and tests to identify early contagion.In the COVID-19 pandemic in Brazil, do brown lives matter?In Rio de Janeiro, but not exclusively, hospital equipment, beds, and ICUs were poorly managed, which left many people to die in inadequate places or at home.", [["people", "ORGANISM", 85, 91], ["people", "ORGANISM", 429, 435], ["people", "SPECIES", 85, 91], ["people", "SPECIES", 429, 435], ["tests", "TEST", 225, 230]]], ["Therefore, there are people for whom and places where vulnerability and susceptibility 8 act together to exacerbate the risks of COVID-19, and this is compounded by a resistance of the Ministry of Health to account for ethnicity in its approach to the pandemic.", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27], ["COVID", "TEST", 129, 134]]], ["Shedding light on these issues is a merit of Baqui and colleagues' study.In the COVID-19 pandemic in Brazil, do brown lives matter?We declare no competing interests.", [["colleagues' study", "TEST", 55, 72]]], ["We thank the Brazilian National Council for Scientific and Technological Development for a productivity grant for HR and postdoc scholarship for VML.", [["VML", "DISEASE", 145, 148], ["VML", "CANCER", 145, 148], ["VML", "PROBLEM", 145, 148]]]], "a42eb4bfb6bba9c965a342a74e8d75a7f3a0b534": [["IntroductionIt is an established truth that science serves humanity by developing new and useful technologies, discovering new phenomena, forwarding knowledge and understanding.", [["new phenomena", "PROBLEM", 123, 136]]], ["As a natural phenomenon, scientists tend to concentrate on the beneficial uses of scientific research, but each of them should also concentrate on the potential destructive misuses, in as far as is known, assumed or reasonably predicted.", [["a natural phenomenon", "PROBLEM", 3, 23], ["destructive", "OBSERVATION_MODIFIER", 161, 172]]], ["Considering the fast accumulation of sophisticated scientific and biotechnological information, it is upon the scientist and his community to inform and warn the public about the potential destructive misuses of biotechnological research and findings.", [["destructive", "OBSERVATION_MODIFIER", 189, 200]]], ["It is instrumental for the public to be aware of the risks posed by certain dangerous biological agents that are used, manipulated or developed in the course of biotechnological research.", [["certain dangerous biological agents", "TREATMENT", 68, 103]]], ["The public must be aware of and be reminded that certain biological agents can be used as biological lethal weapons for mass-destruction, or misused for deliberately inflicting infectious diseases.", [["infectious diseases", "DISEASE", 177, 196], ["certain biological agents", "TREATMENT", 49, 74], ["mass", "PROBLEM", 120, 124], ["destruction", "PROBLEM", 125, 136], ["deliberately inflicting infectious diseases", "PROBLEM", 153, 196], ["destruction", "OBSERVATION", 125, 136]]], ["It is upon the public at large, in applying its collective moral conscience, guided by relevant knowledge and information, to choose what scientific research and advanced technologies should be furthered, banned, or temporarily withheld.IntroductionIt is to be emphasized that the international community has already long ago expressed its determination 'to exclude completely the possibility of bacteriological In signing the Biological and Toxin Weapons Convention of 1972 (BWC), 3 in adherence with the Geneva Protocol 4 and principles of the UN Charter, each State Party undertook:Introduction[N]ever, in any circumstances to develop, produce, stockpile or otherwise acquire or retain: (1) Microbial or other biological agents, or toxins whatever their origin or method of production, of types and in quantities that have no justification for prophylactic, protective or other peaceful purposes; [and or] (2) Weapons, equipment or means of delivery designed to use such agents or toxins for hostile purposes or in armed conflict.", [["advanced technologies", "TREATMENT", 162, 183], ["bacteriological", "TEST", 396, 411], ["the Geneva Protocol", "TREATMENT", 502, 521], ["toxins", "PROBLEM", 735, 741], ["prophylactic", "TREATMENT", 847, 859], ["delivery", "TREATMENT", 944, 952], ["such agents", "TREATMENT", 969, 980], ["toxins", "TREATMENT", 984, 990]]], ["It was observed that because of the dual-use possibilities and blurred borders between peaceful and offensive uses of biotechnology, it is difficult to implement the BWC.", [["blurred borders", "PROBLEM", 63, 78]]], ["It is instrumental to implement the strict prohibitions vital for the survival of humanity, but it is also instrumental to ensure the furtherance of peaceful biotechnological research.IntroductionFreedom of scientific research, publication and dissemination of its findings is recognized in the civilized world as part of the human basic right for 'freedom of expression'.", [["human", "ORGANISM", 326, 331], ["human", "SPECIES", 326, 331], ["human", "SPECIES", 326, 331], ["right", "ANATOMY_MODIFIER", 338, 343]]], ["However, in confronting today's threats and potential dangers, it is imperative to frame their protection within a legal framework, adequately balancing between 'fair and legitimate uses' and the potential 'destructive misuses'.", [["the potential 'destructive misuses'", "PROBLEM", 192, 227], ["destructive", "OBSERVATION_MODIFIER", 207, 218]]], ["Commercialization of biotechnological findings became an important vehicle in the knowledge-based global economy, but it is the law that makes them merchantable by securing their intellectual property rights.", [["global", "OBSERVATION_MODIFIER", 98, 104], ["economy", "OBSERVATION", 105, 112]]], ["There is a need for an interactive collaboration between the scientific community, the public at large, through its legislative bodies, the legal practitioners, the media and the judiciary in providing a balanced adequate normative infrastructure, designed for ensuring furtherance of scientific research and free dissemination of its results, subject to protection of public health, security and safety.Biotechnology in the Dual-Use DilemmaAlthough biotechnology is not a new technology, in the last 30-40 years it demonstrates itself in a diversity of new 'get-ups' and a wide range of new procedures, such as genetic engineering; bioengineering; artificial selection, modification and manipulation of biological agents.", [["new procedures", "TREATMENT", 588, 602], ["genetic engineering", "TREATMENT", 612, 631], ["artificial selection", "TREATMENT", 649, 669], ["modification", "TREATMENT", 671, 683], ["manipulation of biological agents", "TREATMENT", 688, 721], ["large", "OBSERVATION_MODIFIER", 97, 102]]], ["All the laboratory-based techniques such as rDNA; tissue culture processes, gene-transfer techniques and other various methods for manipulating organic material, are applied with a purpose to serve humanity, medicine, agriculture, animal life, food-supply and the environment.", [["tissue culture", "ANATOMY", 50, 64], ["rDNA", "CELLULAR_COMPONENT", 44, 48], ["rDNA", "DNA", 44, 48], ["tissue culture processes", "TEST", 50, 74], ["gene-transfer techniques", "TREATMENT", 76, 100], ["other various methods", "TREATMENT", 105, 126], ["manipulating organic material", "PROBLEM", 131, 160]]], ["Dispersion of knowledge, rapidity of innovation and invention are encouraged by the social and economic regimes of many nations.", [["rapidity", "OBSERVATION_MODIFIER", 25, 33]]], ["This is also the case for biotechnological research and its flourishing development for procurement of new products and processes.Biotechnology in the Dual-Use DilemmaThe major components of biotechnology are 'biological agents' which are dealt with, kept, developed, used for research, handled, possessed, stockpiled or transferred, almost daily, in the realm of institutional or private biomedical and microbiological laboratories, or on the premises of biotechnological industries.", [["biotechnological research", "TREATMENT", 26, 51], ["'biological agents", "TREATMENT", 209, 227], ["microbiological laboratories", "TEST", 404, 432], ["new", "OBSERVATION_MODIFIER", 103, 106], ["products", "OBSERVATION", 107, 115], ["major", "OBSERVATION_MODIFIER", 171, 176], ["components", "OBSERVATION_MODIFIER", 177, 187]]], ["Many new techniques and procedures are invented for manipulating and treating biological agents and a wide range of innovative equipment is available.", [["procedures", "TREATMENT", 24, 34], ["biological agents", "TREATMENT", 78, 95], ["a wide range of innovative equipment", "TREATMENT", 100, 136], ["new", "OBSERVATION_MODIFIER", 5, 8]]], ["Until not long ago the main concern, surrounding practice and research in biology, was focused on safety measures in the 'work place', mainly for the protection of researchers and 'workers', dealing in dangerous biological agents, especially in micro-biological laboratories.", [["safety measures", "TREATMENT", 98, 113]]], ["Microbiological laboratories have been considered as work places that pose infectious disease risks to persons that work in the laboratory or are in its vicinity.", [["persons", "ORGANISM", 103, 110], ["persons", "SPECIES", 103, 110], ["Microbiological laboratories", "TEST", 0, 28]]], ["The history of microbiology describes laboratory-associated infections and cases of typhoid, cholera, brucellosis, and tetanus.", [["infections", "DISEASE", 60, 70], ["typhoid", "DISEASE", 84, 91], ["cholera", "DISEASE", 93, 100], ["brucellosis", "DISEASE", 102, 113], ["tetanus", "DISEASE", 119, 126], ["associated infections", "PROBLEM", 49, 70], ["typhoid", "PROBLEM", 84, 91], ["cholera", "PROBLEM", 93, 100], ["brucellosis", "PROBLEM", 102, 113], ["tetanus", "TREATMENT", 119, 126], ["infections", "OBSERVATION", 60, 70], ["typhoid", "OBSERVATION", 84, 91], ["brucellosis", "OBSERVATION", 102, 113]]], ["A number of cases were attributed to carelessness or poor technique in the handling of infectious materials.", [["carelessness", "PROBLEM", 37, 49], ["poor technique", "PROBLEM", 53, 67], ["infectious", "OBSERVATION", 87, 97]]], ["'Handling of cultures or specimens or the inhalation of dust containing dangerous organisms [was found] eminently dangerous to laboratory workers\u2026'; 7 'Exposure to infectious aerosols was considered as the most common source of infection.' 8 In the 1990s, a growing concern was expressed about the re-emergence of M tuberculosis.", [["cultures", "ANATOMY", 13, 21], ["specimens", "ANATOMY", 25, 34], ["infection", "DISEASE", 228, 237], ["tuberculosis", "DISEASE", 316, 328], ["M tuberculosis", "SPECIES", 314, 328], ["M tuberculosis", "SPECIES", 314, 328], ["cultures", "TEST", 13, 21], ["dust containing dangerous organisms", "PROBLEM", 56, 91], ["infectious aerosols", "PROBLEM", 164, 183], ["infection", "PROBLEM", 228, 237], ["M tuberculosis", "PROBLEM", 314, 328], ["infection", "OBSERVATION", 228, 237], ["tuberculosis", "OBSERVATION", 316, 328]]], ["The 'routine application of recombinant DNA technologies has required a thorough risk assessment of their inherent unknowns.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["recombinant DNA technologies", "TREATMENT", 28, 56], ["a thorough risk assessment", "TEST", 70, 96]]], ["Nevertheless, it seemed that the scientific community assumed that in the course of scientific research, all manipulations with biological agents are legitimate for beneficial R&D. For years, a strong tendency has existed by the scientific community, to oppose intrusive regulation of their work.", [["biological agents", "TREATMENT", 128, 145], ["beneficial R&D", "PROBLEM", 165, 179]]], ["It was widely propagated and accepted that all scientific research has to rely on self-governance by the scientists depending on their integrity, morals and stringent ethical rules, rather than being incarcerated into legal normative frameworks, prescribed by the legislators.Biotechnology in the Dual-Use DilemmaUnfortunately, in result of the tragic events of September 11, 2001, followed by a wave of Anthrax envelopes dispatched in the USA, the attention of the world community has been focused on the hazardous aspects of biotechnology, which although known from before, were somehow, generally disregarded.", [["Anthrax", "DISEASE", 404, 411], ["Anthrax envelopes", "PROBLEM", 404, 421]]], ["The recent events have tilted the balance, justifying rethinking of existing policies and change of approach.", [["change of approach", "TREATMENT", 90, 108]]], ["It became clear that biotechnology in its manifold 'get-ups' and 'dualuse' processes and products, alongside its legitimate uses, poses a 'clear and present danger' if used for destructive purposes.", [["'dualuse' processes", "TREATMENT", 65, 84], ["clear", "OBSERVATION", 10, 15]]], ["The world community has been reminded that certain biological agents, e.g., toxins, viruses and bacteria, innocently dealt with or invented and developed for scientific research or medicine have been and can be used as biological weapons for mass-destruction.", [["toxins", "PROBLEM", 76, 82], ["viruses", "PROBLEM", 84, 91], ["bacteria", "PROBLEM", 96, 104], ["medicine", "TREATMENT", 181, 189], ["mass-destruction", "PROBLEM", 242, 258], ["mass", "OBSERVATION", 242, 246], ["destruction", "OBSERVATION", 247, 258]]], ["This depends on the nature of the biological agent. its preparation; its ability for 'survival' in the environment; its dispersion ability; scope of contamination, etc. Scientific writings underlined the difficulty in detectability and the delayed ouevert effect of a released biological agent.", [["the biological agent", "TREATMENT", 30, 50], ["its preparation", "TREATMENT", 52, 67], ["contamination", "PROBLEM", 149, 162], ["the difficulty in detectability", "PROBLEM", 200, 231], ["a released biological agent", "TREATMENT", 266, 293]]], ["Voices stressed the simplicity of access to dangerous biological agents, easy development and simple employment for bioterrorism in whatever destructive manner, 'not entailing excessive costs'!", [["dangerous biological agents", "TREATMENT", 44, 71]]], ["Pathogens can be obtained from\u2026[their] natural environment, \u2026 [from] a microbiology laboratory or bank \u2026 An alternative to acquiring agents is creating them \u2026 Advances in biotechnology have made it possible to synthesize certain viruses based on their genome, or on genetic instructions \u2026 or to modify agents and alter their function.", [["Pathogens", "PROBLEM", 0, 9], ["certain viruses", "PROBLEM", 221, 236]]], ["10 It was stressed that agents modified for increased pathogenecity and a shorter incubation period could cause severe, fast-acting diseases.", [["increased pathogenecity", "PROBLEM", 44, 67], ["a shorter incubation period", "TREATMENT", 72, 99], ["severe, fast-acting diseases", "PROBLEM", 112, 140], ["severe", "OBSERVATION_MODIFIER", 112, 118]]], ["Other modifications could make treatments, vaccines, or the body's immune system, useless.", [["body", "ANATOMY", 60, 64], ["body", "ORGANISM_SUBDIVISION", 60, 64], ["Other modifications", "TREATMENT", 0, 19], ["treatments", "TREATMENT", 31, 41], ["vaccines", "TREATMENT", 43, 51], ["the body's immune system", "TREATMENT", 56, 80]]], ["11 Attention was drawn to possible dangers if deadly microorganisms may unintentionally, through negligence or carelessness, 'escape' from a laboratory or while in transit.", [["carelessness", "DISEASE", 111, 123], ["deadly microorganisms", "PROBLEM", 46, 67]]], ["It was also stressed that in course of dealing with such agents, a scientist may not knowingly become infected by a life-threatening disease and become a carrier of it into his community or even further.", [["a life-threatening disease", "PROBLEM", 114, 140]]], ["In cases of recklessness or negligence, he may enable access to such agents for hostile purposes.Biotechnology in the Dual-Use DilemmaIt is claimed that biotechnology has reached its peak and enables unlimited intervention in any life form on earth, providing tools to shape future generations and even substitute life forms by synthetic living organisms built 'from scratch'.", [["recklessness", "DISEASE", 12, 24], ["recklessness", "PROBLEM", 12, 24], ["negligence", "PROBLEM", 28, 38], ["hostile purposes", "TREATMENT", 80, 96]]], ["12 It has been observed that many of the new techniques, tools and technological equipment used in beneficial procedures are misused for destructive manipulations using the same knowledge, sometimes obtained from easy accessible scientific literature.", [["technological equipment", "TREATMENT", 67, 90], ["beneficial procedures", "TREATMENT", 99, 120], ["destructive manipulations", "PROBLEM", 137, 162], ["new", "OBSERVATION_MODIFIER", 41, 44]]], ["Questions are raised as to its openness.Biotechnology in the Dual-Use DilemmaConsidering the duality of biotechnological R&D, it is essential that each practicing scientist, in working with dangerous agents liable to be used as biological weapons, should remember at each stage of his scientific work that he is in the forefront for preventing or minimizing any possible misuse.", [["dangerous agents", "TREATMENT", 190, 206]]], ["He is the master of knowledge, thus it is his responsibility to take precautionary measures, in as much as possible and reasonable, in order to prevent such occurrences.", [["precautionary measures", "TREATMENT", 69, 91]]], ["Adherence to ethical guidelines and moral principles by each individual scientist and his peers is very important, but apparently not sufficient, anymore.Biotechnology in the Dual-Use DilemmaIt is important not to withhold incentives for innovation, encouraging development of countermeasures and promoting investments secured by the patent systems.", [["ethical guidelines", "TREATMENT", 13, 31], ["moral principles", "TREATMENT", 36, 52], ["countermeasures", "TREATMENT", 277, 292], ["promoting investments", "TREATMENT", 297, 318], ["patent", "OBSERVATION", 334, 340]]], ["The general clause denying patentability to inventions challenging 'public order or morality' may prove its impotency in such cases.Biotechnology in the Dual-Use DilemmaBiological weapons such as disease-causing bacterial agents have a long history of being used in battle along chemical and nuclear weapons, for military purposes and not just as strategic deterrents.", [["disease", "PROBLEM", 196, 203], ["bacterial agents", "TREATMENT", 212, 228]]], ["It is reported that 'natural pathogenic microorganisms, such as anthrax, plague, yellow fever, smallpox and their toxic products were used in weaponization processes by culturing these agents, converting and using them in powder or liquid form, for arming rockets, warheads short or long range missiles, etc'.", [["anthrax", "DISEASE", 64, 71], ["yellow fever", "DISEASE", 81, 93], ["smallpox", "DISEASE", 95, 103], ["yellow fever", "ORGANISM", 81, 93], ["yellow fever", "SPECIES", 81, 93], ["'natural pathogenic microorganisms", "PROBLEM", 20, 54], ["anthrax", "PROBLEM", 64, 71], ["plague", "PROBLEM", 73, 79], ["yellow fever", "PROBLEM", 81, 93], ["smallpox", "TREATMENT", 95, 103], ["their toxic products", "TREATMENT", 108, 128], ["arming rockets", "TREATMENT", 249, 263]]], ["It is recognized that the dual-use characteristics of biotechnology and its products pose a difficult dilemma for the scientific and legal communities and for the public at large.", [["a difficult dilemma", "PROBLEM", 90, 109]]], ["However, while science races ahead in an unprecedented pace, law limps heavily in its far back and the public remains dormant until some disaster scares it.", [["dormant", "OBSERVATION", 118, 125]]], ["Considering the new developments and the presently known dual-uses of biotechnology, it may be said that there is already a public consensus that biotechnological research in dealing with dangerous biological agents requires a strict and comprehensive normative framework.", [["dangerous biological agents", "TREATMENT", 188, 215], ["new", "OBSERVATION_MODIFIER", 16, 19]]], ["Many of the signatory nations, in adhering to the convention, have prohibited further development of biological weapons and destroyed their existing arsenals, but it is known, that some of the adhering parties have secretly continued and some non-parties are even hurriedly competing in developing new sophisticated biological weapons.Biotechnology in the Dual-Use DilemmaIt should be mentioned that most nations in the civilized world have provided bio-safety regulations aiming to ensure safe practice and control in 'dealing' with dangerous biological agents in microbiological and biomedical laboratories.", [["DilemmaIt", "TREATMENT", 365, 374], ["bio-safety regulations", "TREATMENT", 450, 472], ["safe practice", "TREATMENT", 490, 503], ["dangerous biological agents", "TREATMENT", 534, 561]]], ["It is claimed that considering the affluent sources of biological information, regulating scientific publications on a national level, is useless.Biotechnology in the Dual-Use DilemmaBut as said, in light of the disastrous events and future threats and dangers in the year of 2001, long existing concepts begin to change.", [["the disastrous events", "PROBLEM", 208, 229], ["disastrous", "OBSERVATION", 212, 222]]], ["It became clear that a thorough examination of the existing bio-safety regulations in the field of biotechnological research is to be performed with a view on bio-security, subject to national security concerns of each nation.", [["a thorough examination", "TEST", 21, 43]]], ["Increased awareness, preparedness and an immediate vigorous response to the serious threats on public health, safety and security, became an immediate must.", [["Increased awareness", "PROBLEM", 0, 19]]], ["14 Policymakers, the legal and the scientific community at large, were urged to give an adequate response to this challenge.Biotechnology in the Dual-Use DilemmaSome nations responded immediately in a comprehensive well-balanced manner, some in a hasty non-balanced manner, and some have not responded, yet.A Random-Look on Bio-Safety & Bio-Security ProvisionsShocked by the disastrous attack of September 11, 2001, on the World Trade Center, followed a week later, by letters containing anthrax spores, which killed five people, infected 22 others and caused an international trauma, 15 many nations, e.g., the United States, the United Kingdom and the European Union, responded to the emergency situation, quickly and vigorously.", [["anthrax", "DISEASE", 488, 495], ["trauma", "DISEASE", 577, 583], ["anthrax", "ORGANISM", 488, 495], ["people", "ORGANISM", 522, 528], ["people", "SPECIES", 522, 528], ["this challenge", "TREATMENT", 109, 123], ["an international trauma", "PROBLEM", 560, 583]]], ["Existing legal frameworks regulating biotechnological research were strengthened, criminal punishment toughened and new stringent legislation was enacted to prevent use of biological agents as weapons of mass destruction, prohibiting malicious transfer or intentional destructive release.", [["new stringent legislation", "TREATMENT", 116, 141], ["biological agents", "TREATMENT", 172, 189], ["mass destruction", "PROBLEM", 204, 220], ["intentional destructive release", "PROBLEM", 256, 287], ["mass", "OBSERVATION", 204, 208], ["destructive", "OBSERVATION_MODIFIER", 268, 279]]], ["Stricter oversight and inspection procedures and enhanced safety and biosecurity measures were prescribed for applying in biomedical laboratories, dealing with 'dual-use' dangerous biological agents, in order to prevent unwanted access to or unintentional escape or seepage of these agents.United StatesCongress responded promptly by enacting the USA Patriot Act of 2001, with the aim, (as is also apparent from its full official title) 'to deter and punish terrorist acts in the United States and around the world\u2026.' 16 The Act strengthened the criminal law in combat against terrorism, enhanced law enforcement in regards to the use of weapons of mass-destruction and introduced drastic investigatory tools and interrogative mechanisms.", [["inspection procedures", "TEST", 23, 44], ["biosecurity measures", "TREATMENT", 69, 89], ["' dangerous biological agents", "TREATMENT", 169, 198], ["these agents", "TREATMENT", 277, 289], ["mass-destruction", "PROBLEM", 649, 665], ["introduced drastic investigatory tools", "PROBLEM", 670, 708], ["mass", "OBSERVATION", 649, 653], ["destruction", "OBSERVATION", 654, 665], ["drastic", "OBSERVATION_MODIFIER", 681, 688]]], ["Severe penalties were prescribed for knowingly possessing (in certain circumstances), 'biological agents, toxins, or delivery systems', especially by certain restricted persons; enhanced domestic security was provided and assistance in enforcement of Criminal provisions was extended.", [["persons", "ORGANISM", 169, 176], ["persons", "SPECIES", 169, 176], ["Severe penalties", "PROBLEM", 0, 16], ["toxins", "PROBLEM", 106, 112], ["penalties", "OBSERVATION", 7, 16]]], ["Criminal Code), in a very wide-embracing non-definitive manner that:United States'international terrorism' includes activities 'that appear to be intended to affect the conduct of government by mass destruction' and 'domestic terrorism' includes criminal acts 'dangerous to human life, that appear to be intended to intimidate or coerce a civilian population, to influence government policy\u2026., or to affect government conduct by mass destruction, assassination, or kidnapping'.United StatesThe Act provides jurisdiction over crimes committed at U.S. facilities abroad; neutralizes the statute of limitations for certain terrorism offenses; prescribes penalties for attempts and conspiracies, 'the same as those for terrorism offenses'.", [["human", "ORGANISM", 274, 279], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 274, 279], ["mass destruction'", "PROBLEM", 194, 211], ["mass destruction", "PROBLEM", 429, 445], ["conspiracies", "TREATMENT", 678, 690], ["mass", "OBSERVATION", 429, 433]]], ["18 It contains stringent measures for confiscation and seizure of property, enhanced surveillance procedures, money laundering counter measures, disclosure of suspicious bank-activities, etc. 19 The USA Patriot Act 2001, in being enacted as a vigorous tool to combat world terrorism has extended and enhanced an already existing-substantial body of provisions relating specifically to biological weapons, namely The Biological Weapons Anti-Terrorism Act of 1989 20 (BWAT 1989) Whoever knowingly develops, produces, stockpiles, transfers, acquires, retains, or possesses any biological agent, toxin, or delivery system for use as a weapon, or knowingly assists a foreign state or any organization to do so, -shall be fined \u2026 or imprisoned for life or any term of years, or both.", [["seizure", "DISEASE", 55, 62], ["body", "ORGANISM_SUBDIVISION", 341, 345], ["stringent measures", "TREATMENT", 15, 33], ["confiscation", "PROBLEM", 38, 50], ["seizure of property", "PROBLEM", 55, 74], ["enhanced surveillance procedures", "TEST", 76, 108], ["a foreign state", "PROBLEM", 660, 675], ["stringent", "OBSERVATION_MODIFIER", 15, 24]]], ["22United StatesWith the aim not to restrict scientific research, the BWAT specifically proclaimed that: 'Nothing in this Act is intended to restrain or restrict peaceful scientific research or development.' 23 The Act clearly stated that the prohibition on using biological agents does not apply to uses 'for prophylactic, protective, or other peaceful purposes'.", [["biological agents", "TREATMENT", 263, 280], ["prophylactic", "TREATMENT", 309, 321], ["protective", "TREATMENT", 323, 333]]], ["24 In broadly defining the meaning of a 'biological agent', 'Toxin', 'Delivery system', and 'Vector', 25 the Act provided that any biological agent or toxin 'of a type or in a quantity that under the circumstances has no apparent justification for prophylactic, protective, or other peaceful purposes', may be seized and destroyed.United StatesThe Antiterrorism and Effective Death Penalty Act 1996 prescribed strict control of biological agents and authorized the Secretary of Health and Human Services (HHS) to regulate the possession and transfer of potentially hazardous biological agents, in order to prevent exposure to such agents and protect public health and safety.", [["Death", "DISEASE", 376, 381], ["Toxin", "GENE_OR_GENE_PRODUCT", 61, 66], ["Human", "ORGANISM", 489, 494], ["Human", "SPECIES", 489, 494], ["a 'biological agent'", "TREATMENT", 38, 58], ["'Delivery system'", "TREATMENT", 69, 86], ["prophylactic, protective", "TREATMENT", 248, 272], ["biological agents", "TREATMENT", 428, 445], ["hazardous biological agents", "TREATMENT", 565, 592], ["such agents", "TREATMENT", 626, 637], ["no apparent", "UNCERTAINTY", 218, 229]]], ["It strengthened penalties for threatening, attempting, or conspiring to use a biological agent as a weapon for mass-destruction.", [["a biological agent", "TREATMENT", 76, 94], ["mass", "PROBLEM", 111, 115], ["destruction", "PROBLEM", 116, 127], ["mass", "OBSERVATION", 111, 115], ["destruction", "OBSERVATION", 116, 127]]], ["It extended the definition of 'biological weapons' by including engineered biological products, infectious substances and bioengineered components of a microorganism, virus or biological product.", [["engineered biological products", "TREATMENT", 64, 94], ["infectious substances", "TREATMENT", 96, 117], ["a microorganism", "PROBLEM", 150, 165], ["virus", "PROBLEM", 167, 172], ["infectious", "OBSERVATION_MODIFIER", 96, 106]]], ["Also 'toxic material of plants, animals, viruses, fungi or infectious substances or a recombinant molecule that may be engineered as a result of biotechnology' were included under 'Biological Weapons Restrictions'.", [["recombinant molecule", "PROTEIN", 86, 106], ["'toxic material of plants", "PROBLEM", 5, 30], ["viruses", "PROBLEM", 41, 48], ["fungi", "PROBLEM", 50, 55], ["infectious substances", "PROBLEM", 59, 80], ["a recombinant molecule", "PROBLEM", 84, 106], ["biotechnology'", "TREATMENT", 145, 159], ["toxic", "OBSERVATION_MODIFIER", 6, 11], ["plants", "OBSERVATION", 24, 30], ["infectious", "OBSERVATION_MODIFIER", 59, 69]]], ["26 Aware of the potential hazards from biological agents, in stressing the importance of the precautionary principle, the AEDPA 1996 imposes on the Secretary the duty to establish and maintain, through regulations, 'a list of each biological agent that has the potential to pose a severe threat to public health and safety'.", [["biological agents", "TREATMENT", 39, 56]]], ["In determining whether to include an agent on the list, the Secretary shall consider:United States[T]he effect on human health from exposure to the agent; the degree of contagiousness of the agent and the methods by which the agent is transferred to humans; the availability and effectiveness of immunization to prevent and treatments for any illness resulting from infection by the agent; and any other criteria that the Secretary considers appropriate.United StatesIn deciding on all these the Secretary shall consult with scientific experts representing appropriate professional groups.", [["illness", "DISEASE", 343, 350], ["infection", "DISEASE", 366, 375], ["human", "ORGANISM", 114, 119], ["humans", "ORGANISM", 250, 256], ["human", "SPECIES", 114, 119], ["humans", "SPECIES", 250, 256], ["human", "SPECIES", 114, 119], ["humans", "SPECIES", 250, 256], ["the agent", "TREATMENT", 144, 153], ["the agent", "TREATMENT", 187, 196], ["immunization", "TREATMENT", 296, 308], ["treatments", "TREATMENT", 324, 334], ["any illness", "PROBLEM", 339, 350], ["infection", "PROBLEM", 366, 375]]], ["27 safety requirements and procedures for the transfer of biological listed agents and for the 'proper training and appropriate skills to handle such agents' and also for 'proper laboratory facilities to contain and dispose of such agents'.", [["procedures", "TREATMENT", 27, 37], ["biological listed agents", "TREATMENT", 58, 82], ["the 'proper training", "TREATMENT", 91, 111], ["such agents", "TREATMENT", 227, 238]]], ["The Secretary shall ensure safeguards to prevent access to such agents for use in domestic and international terrorism or for any other criminal purpose and shall establish procedures 'to protect the public safety in the event of a transfer or potential transfer of a biological agent in violation of the safety procedures\u2026.' 28 In securing furtherance of scientific research and development, the act stipulates that measures shall be provided to ensure '[a]ppropriate availability of biological agents for research, education and other legitimate purposes'.", [["such agents", "TREATMENT", 59, 70], ["a biological agent", "TREATMENT", 266, 284], ["the safety procedures", "TREATMENT", 301, 322], ["biological agents", "TREATMENT", 485, 502]]], ["29 Subsequently, with the aim to further '[i]mprove the Ability of the US to Prevent, Prepare for and Respond to Bioterrorism and other Health Emergencies' the U.S. congress enacted The Public Health Security and Bioterrorism Preparedness & Response Act of 2002.", [["Bioterrorism", "DISEASE", 113, 125]]], ["30 In its operative wide-embracing manner the Act requires development and implementation of a coordinated strategy to be periodically reviewed and revised,, if needed.", [["a coordinated strategy", "TREATMENT", 93, 115], ["operative", "OBSERVATION_MODIFIER", 10, 19], ["wide", "OBSERVATION_MODIFIER", 20, 24]]], ["Invention, development and maintaining of medical countermeasures, is to be strongly encouraged.", [["medical countermeasures", "TREATMENT", 42, 65]]], ["31 'Security should be provided for R&D of countermeasures, and for evaluation and production of new and emerging technologies against Bioterrorist attacks and other public health emergencies\u2026.' 32 'Stockpiles of drugs, vaccines and other biological products, medical devices, and other supplies\u2026 appropriate and practicable [for health security]\u2026 in the event of a bioterrorist attack' should be maintained.", [["Bioterrorist attacks", "DISEASE", 135, 155], ["countermeasures", "TREATMENT", 43, 58], ["evaluation", "TEST", 68, 78], ["drugs", "TREATMENT", 213, 218], ["vaccines", "TREATMENT", 220, 228], ["other biological products", "TREATMENT", 233, 258], ["medical devices", "TREATMENT", 260, 275]]], ["33 In its wide spectrum of prescribed 'Enhanced Regulatory Control of Certain Biological Agents and Toxins', the Act stresses the necessity and importance of maintaining, by regulations, the 'list of each biological agent and each toxin that has the potential to pose a severe threat to public health and safety'.", [["Certain Biological Agents", "TREATMENT", 70, 95], ["Toxins'", "TREATMENT", 100, 107], ["each biological agent", "TREATMENT", 200, 221], ["wide", "OBSERVATION_MODIFIER", 10, 14]]], ["36 Registration procedures shall ensure that persons seeking registration 'have a lawful purpose to possess, use, or transfer such agents and toxins'.", [["persons", "ORGANISM", 45, 52], ["persons", "SPECIES", 45, 52], ["Registration procedures", "TREATMENT", 3, 26]]], ["37 Information in regards to details and characterization of listed agents and toxins shall be required to facilitate their identification, including their source.", [["toxins", "TREATMENT", 79, 85]]], ["A national database shall be maintained by the Secretary and is to include the names and locations of registered persons; the listed agents and toxins that such persons possess, use or transfer and information regarding their characterization.", [["persons", "ORGANISM", 113, 120], ["persons", "ORGANISM", 161, 168], ["persons", "SPECIES", 113, 120], ["persons", "SPECIES", 161, 168]]], ["38 A prompt notification is to be given to the relevant enforcement agencies in case of theft or loss of listed agents.", [["listed agents", "TREATMENT", 105, 118]]], ["39 A registered person shall give prompt notification whenever a release of a listed agent or toxin has occurred outside of the bio-containment area of his facility.", [["person", "SPECIES", 16, 22], ["a listed agent", "TREATMENT", 76, 90], ["toxin", "PROBLEM", 94, 99]]], ["Compliance with these requirements shall be ensured by the Secretary, in consultation with the Attorney General, as part of the registration system.' 40 Requirements and limitations for access to listed agents should be imposed by regulations in accordance with stringent stipulations by law.", [["access to listed agents", "TREATMENT", 186, 209]]], ["42 Exemptions are prescribed for clinical or diagnostic laboratories by providing that:United StatesRegulations under subsec (a) and (b) shall exempt clinical or diagnostic laboratories and other persons who possess, use, or transfer listed agents or toxins that are contained in specimens presented for diagnosis, verification, or proficiency testing, provided that (A) the identification of such agents or toxins is reported\u2026; and (B) such agents or toxins are transferred or destroyed in a manner set forth by the Secretary by regulation.", [["specimens", "ANATOMY", 280, 289], ["persons", "ORGANISM", 196, 203], ["persons", "SPECIES", 196, 203], ["diagnostic laboratories", "TEST", 45, 68], ["toxins", "PROBLEM", 251, 257], ["proficiency testing", "TEST", 332, 351], ["toxins", "PROBLEM", 408, 414], ["toxins", "TREATMENT", 452, 458]]], ["43 Products shall also be exempted if the 'products are, bear, or contain listed agents or toxins and are cleared, approved, licensed, or registered under any of the Acts.' 44 The Secretary shall have the authority to inspect persons subject to the regula-tions\u2026to ensure compliance with these regulations.' 45 An additional Act, the Project Bioshield Act (2003) , was enacted with the aim to protect public health from biological terror.", [["persons", "ORGANISM", 226, 233], ["persons", "SPECIES", 226, 233], ["toxins", "PROBLEM", 91, 97]]], ["The Act provides authority for use of certain procedures regarding biomedical countermeasure research and development activities in stating that the Secretary may conduct and support such activities if these concern 'qualified countermeasures' (a priority countermeasure that affects national security).", [["certain procedures", "TREATMENT", 38, 56], ["biomedical countermeasure research", "TREATMENT", 67, 101]]], ["The Secretary may require, in any grant or agreement 'with respect to a bio-containment laboratory or other related or ancillary specialized research facility\u2026necessary for \u2026performing, administering or supporting qualified countermeasure R&D', that the facility of the recipient of such a grant 'shall be available as needed to the Secretary, to respond to public health emergencies affecting national security needs.' 46 It is to mention that on January 31, 2007, the U.S. President issued a Directive 47 drawing upon the 'potential of the scientific community in the public and private sectors to address [the] medical countermeasure requirements relating to CBRN [chemical, biological radioactive and nuclear] threats'.", [["CBRN", "CHEMICAL", 662, 666], ["CBRN", "SIMPLE_CHEMICAL", 662, 666], ["medical countermeasure requirements", "TREATMENT", 614, 649]]], ["These have to 'balance the immediate need to provide a capability to mitigate the most catastrophic, current CBRN threats, with long-term requirements to develop more flexible broader spectrum countermeasures, to address future threats'.United KingdomA special Anti-terrorism, Crime and Security Act 2001 (ATCSA) 48 was enacted amending the existing Biological Weapons Act 1974 (BWA 1974) 49 which prescribed 'restrictions on development of certain 'biological agents, 'toxins' and 'biological weapons' in providing that:United KingdomNo person shall develop, produce, stockpile, acquire or retain -(a) any biological agent or toxin of a type and in a quantity that has no justification for prophylactic, protective or other peaceful purposes; or (b) any weapon, equipment or means of delivery designed to use biological agents or toxins for hostile purposes or in armed conflict.", [["person", "SPECIES", 538, 544], ["long-term requirements", "TREATMENT", 128, 150], ["flexible broader spectrum countermeasures", "TREATMENT", 167, 208], ["prophylactic", "TREATMENT", 691, 703], ["delivery", "TREATMENT", 785, 793], ["biological agents", "TREATMENT", 810, 827], ["toxins", "TREATMENT", 831, 837]]], ["50United KingdomIn consequence of the amendment, a new inserted Section 1(1A) extends the spectrum of deterrence by prohibiting transfer or entering into an agreement for transfer, or making arrangements for transfer of any biological agent or toxin, (by any person to another person or by others), 'if the biological agent or toxin is likely to be kept or used otherwise than for prophylactic, protective or other peaceful purposes and he knows or has reason to believe that that is the case'.", [["person", "SPECIES", 259, 265], ["person", "SPECIES", 277, 283], ["a new inserted Section", "TREATMENT", 49, 71], ["any biological agent", "TREATMENT", 220, 240], ["toxin", "TREATMENT", 327, 332], ["prophylactic", "TREATMENT", 381, 393]]], ["51 The BWA 1974 provides that: 'Any person contravening this section shall be guilty of an offence and shall, on con- 46 viction upon indictment, be liable to imprisonment for life.' 52 'Biological agent' and 'Toxin', are defined as 'any microbial or other biological agent or toxin -whatever its origin or method of production'.", [["Toxin", "GENE_OR_GENE_PRODUCT", 210, 215], ["toxin", "SIMPLE_CHEMICAL", 277, 282], ["person", "SPECIES", 36, 42], ["'Toxin'", "TREATMENT", 209, 216], ["toxin", "PROBLEM", 277, 282]]], ["53 The range of prohibited punishable acts was extended by including 'attempt, preparation, conspiracy, assistance, promotion, persuasion, and other acts and extraterritorial jurisdiction applies 'to acts done outside the UK, but only if they are done by a UK person'.", [["person", "SPECIES", 260, 266], ["range", "OBSERVATION_MODIFIER", 7, 12]]], ["54 The Anti-Terrorism, Crime and Security Act (ATCSA) in dealing with 'weapons of mass-destruction' prohibits any conduct of 'aiding, abetting counseling procuring or inciting a person who is not a UK person 'to do a relevant act' outside the UK is an offence punishable by life imprisonment.", [["person", "SPECIES", 178, 184], ["person", "SPECIES", 201, 207], ["mass", "PROBLEM", 82, 86], ["destruction'", "PROBLEM", 87, 99], ["mass", "OBSERVATION", 82, 86], ["destruction", "OBSERVATION", 87, 98]]], ["55 It is not necessary to have any particular person in mind as the person in whom he intends to induce the belief in question'.", [["person", "SPECIES", 46, 52], ["person", "SPECIES", 68, 74], ["not necessary", "UNCERTAINTY", 9, 22]]], ["56 The Health and Safety at Work etc. Act 1974 57 aims to protect health, safety and welfare in connection with work, and 'Control of Dangerous Substances and Certain Emissions into the Atmosphere'.", [["Dangerous Substances", "TREATMENT", 134, 154]]], ["It prescribes general duties for employers and self-employed persons, of such undertakings, towards persons other than their employees, thus extending protection to the wider public.United KingdomIt shall be the duty of every employer to conduct his undertaking in such way as to ensure, so far as is reasonably practicable\u2026 that he and other persons (not his employees) who may be affected [by his conduct with dangerous substances\u2026] are not thereby exposed to risks to their health or safety\u2026.", [["persons", "ORGANISM", 61, 68], ["persons", "ORGANISM", 100, 107], ["persons", "ORGANISM", 343, 350], ["persons", "SPECIES", 61, 68], ["persons", "SPECIES", 100, 107], ["persons", "SPECIES", 343, 350]]], ["58United KingdomIn such cases it shall be his duty to give, to persons who may be affected, 'the prescribed information about such aspects of the way in which he conducts his undertaking as might affect their health or safety.' 59European UnionA communication from the EC to the Council and EP, was issued on November 29, 2001, in regards to 'Civil Protection', stating that in consequence of the unprecedented outraging terrorist attacks of September 11, 2001 in the USA, the European community and its individual members are 'prompted to enhance their preparedness and readiness to prevent or mitigate the impact of such reoccurring terrorist attacks'.", [["persons", "ORGANISM", 63, 70], ["EC", "CELL", 269, 271], ["EC", "CELL_TYPE", 269, 271], ["persons", "SPECIES", 63, 70]]], ["53 improving cooperation between the Member States 'on the evaluation of risks, alerts, intervention,\u2026 storage\u2026 detection and identification of infectious and toxic agents as well as the prevention and treatment of chemical and biological attacks'.", [["the evaluation", "TEST", 55, 69], ["intervention", "TREATMENT", 88, 100], ["infectious", "PROBLEM", 144, 154], ["toxic agents", "TREATMENT", 159, 171], ["treatment", "TREATMENT", 202, 211], ["chemical and biological attacks", "PROBLEM", 215, 246], ["infectious", "OBSERVATION", 144, 154]]], ["Appointment of a European coordinator for civil protection measures was considered as part of the program.", [["civil protection measures", "TREATMENT", 42, 67]]], ["A joint evaluation of the current knowledge and research capacities should be undertaken.", [["A joint evaluation", "TEST", 0, 18], ["research capacities", "TEST", 48, 67], ["joint", "ANATOMY", 2, 7]]], ["However, it also emphasized that there is an obligation to prevent exploitation of the positive results of this research for malicious purposes.European UnionWithin the new Sixth Framework Program for R&D (2002 -2006) , the Joint Center for Research (JRC) was to initiate: a bio-response working group\u2026.comprising state-of-the-art laboratories\u2026and world experts\u2026to detect and identify relevant transgenic strains\u2026[for] addressing biological attacks to the food chain\u2026 to determine the new scientific issues and questions related to bioterrorism and\u2026 to assess the technological, social, economic and psychological vulnerabilities of [the] modern societies with regard to possible terrorist attacks.", [["malicious purposes", "TEST", 125, 143], ["Research (JRC)", "TREATMENT", 241, 255], ["terrorist attacks", "PROBLEM", 680, 697], ["Joint", "ANATOMY", 224, 229]]], ["62European UnionThe Council Regulation setting up a Community Regime for the control of exports of dual-use items and technology 63 , aimed to provide effective control on export of dual use items, has established (in its Annex 1), the common list of dual use items implementing the internationally agreed dual use controls including (among others) the Wassenaar Arrangement and the Australia Group to be updated in conformity with the relevant obligations and commitments.", [["a Community Regime", "TREATMENT", 50, 68]]], ["64Conflicts and Controversies in a climate of Uncertainties.Taking as an example the profusion of existing and amended legal provisions, in the randomly surveyed communities, it should be known that in recent years serious efforts have been made by legislators to control the use and prevent misuse of biological agents.", [["biological agents", "TREATMENT", 302, 319]]], ["It is to stress that the most severe punishment has been prescribed for malicious uses of biological agents.", [["biological agents", "TREATMENT", 90, 107]]], ["It definitely demonstrates public aversion to such deeds, as also to lesser vio- 61 lent crimes, but it would be na\u00efve to believe that a severe penal sanction is 'the tool' for preventing, diverting or deterring monstrosities.Conflicts and Controversies in a climate of Uncertainties.In a post-factum case of employing biological weapons for mass-destruction, enforcement of the penal sanction is entirely abortive, especially in the present trend of suicidal attacks.", [["monstrosities", "DISEASE", 212, 225], ["suicidal attacks", "DISEASE", 451, 467], ["a severe penal sanction", "PROBLEM", 135, 158], ["diverting", "TREATMENT", 189, 198], ["mass", "PROBLEM", 342, 346], ["destruction", "PROBLEM", 347, 358], ["suicidal attacks", "PROBLEM", 451, 467], ["public aversion", "OBSERVATION", 27, 42], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["penal", "OBSERVATION", 144, 149], ["mass", "OBSERVATION", 342, 346], ["destruction", "OBSERVATION", 347, 358], ["penal sanction", "OBSERVATION", 379, 393]]], ["It may also be said that in many communities there already exists a regulatory framework, providing adequate precautionary bio-safety and bio-security measures for preventing or minimizing recklessness and possible destructive uses of dangerous biological agents.", [["recklessness", "DISEASE", 189, 201], ["bio-security measures", "TREATMENT", 138, 159], ["minimizing recklessness", "PROBLEM", 178, 201], ["dangerous biological agents", "TREATMENT", 235, 262], ["possible", "UNCERTAINTY", 206, 214], ["destructive", "OBSERVATION_MODIFIER", 215, 226]]], ["However, as already said, the unprecedented race and advances in biological, biomedical research and technological development, in comparison with the conventional slow pace of the legislative process, make it impossible for the authorized bodies to embrace all the advances, even if speeded up in consequence of recent events.", [["recent events", "PROBLEM", 313, 326]]], ["Thus, it is important to emphasize that awareness and alertness of each individual scientist in dealing with dangerous biological agents and the willingness of the entire scientific community for recognizing the seriousness and feasibility of the possible misuse of biological agents and toxins -is very instrumental.", [["dangerous biological agents", "TREATMENT", 109, 136], ["biological agents", "TREATMENT", 266, 283]]], ["Knowledge, understanding and awareness of the general public is also an important factor in the general effort to prevent, minimize or combat bio-terrorism.Conflicts and Controversies in a climate of Uncertainties.However, 'negative feedback' is a known phenomenon.", [["a known phenomenon", "PROBLEM", 246, 264]]], ["Human nature does not respond to warnings, be it even against the most horrifying atrocities, as were witnessed during WWII.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5]]], ["There is apparently an innate human tendency to ignore dangers and to see those as remote and theoretical.", [["human", "ORGANISM", 30, 35], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["innate human", "OBSERVATION_MODIFIER", 23, 35], ["tendency", "OBSERVATION", 36, 44]]], ["The public was informed that they succeeded 'to build from scratch an entire microbial chromosome, a loop of synthetic DNA, carrying all the instructions that a simple cell needs to live and reproduce'.", [["chromosome", "ANATOMY", 87, 97], ["cell", "ANATOMY", 168, 172], ["microbial chromosome", "CELLULAR_COMPONENT", 77, 97], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["cell", "CELL", 168, 172], ["microbial chromosome", "DNA", 77, 97], ["synthetic DNA", "DNA", 109, 122], ["a loop of synthetic DNA", "TREATMENT", 99, 122]]], ["66 Craig Venter was quoted saying that 'the goal is to design novel microbes whose handcrafted genomes endow them with the ability to produce useful chemicals, including renewable synthetic fuels that could substitute for oil'!", [["renewable synthetic fuels", "TREATMENT", 170, 195]]], ["This definitely stresses the beneficial application of the revolutionary invention, but some of his peers oppose the use of synthetic DNA pronouncing a warning that 'without better oversight of the fledgling field, synthetic biology is more likely to lead to the creation of potent biological weapons and runaway microbes that could wreak environmental 65 'A man is doomed to destroy himself and at the same time to refuse to believe he is doing so', havoc'.", [["DNA", "CELLULAR_COMPONENT", 134, 137], ["man", "ORGANISM", 359, 362], ["man", "SPECIES", 359, 362], ["synthetic DNA", "PROBLEM", 124, 137]]], ["67 A Montreal-based group even called for a moratorium on the release and commercialization of synthetic organisms, pending further public debate'.", [["the release", "TREATMENT", 58, 69], ["synthetic organisms", "PROBLEM", 95, 114]]], ["68 Attention is drawn also to the reported efforts to re-create by reverse engineering, old dangerous viruses including the most deadly 1918 flu-virus, or to produce a new type of virus or vaccine, by another new technology.", [["deadly 1918 flu-virus", "SPECIES", 129, 150], ["old dangerous viruses", "PROBLEM", 88, 109], ["a new type of virus", "PROBLEM", 166, 185], ["vaccine", "TREATMENT", 189, 196]]], ["In giving justification to such dealings, the public is informed that these advances in science may give a rapid response to some of the newly emerging dangerous infectious diseases and protect the public from the potentially devastating consequences of a pandemic disease outbreak (e.g., EBOLA and SARS).", [["infectious diseases", "DISEASE", 162, 181], ["SARS", "DISEASE", 299, 303], ["dangerous infectious diseases", "PROBLEM", 152, 181], ["a pandemic disease outbreak", "PROBLEM", 254, 281]]], ["Should the racing scientist, on his track to future inventions, be the one and only decision-maker in the name of 'public good'?Conflicts and Controversies in a climate of Uncertainties.Attention is drawn to another controversial case relating to a public warning, which was recently discussed in Steven J. Hatfill v. The New York Times Co., 70 Hatfill, who was considered an experts in the area of biological weapons and agents by government officials and the scientific community alike, propagated increased government vigilance to combat bioterrorism and in 1999 co-authored an article which 'urged the public health community to step up efforts to be prepared for a chemical or biological attack.' 73 In determining the plaintiff's status, based on the mentioned facts, whether he was a private or a public figure or a public official, the court concluded that he qualifies as a 'public official', notwithstanding the plaintiff's claim that he was a private person, 'involuntary dragged into the controversial situation'.", [["person", "SPECIES", 962, 968]]], ["In describing him as 'a vocal critic of the government's level of preparedness for a bioterrorist attack' and in reference to his lectures, writings, participation on panels, and interviews, as well as his own resume as an expert in the field of biological weaponry, the court concluded: 'The Plaintiff voluntarily assumed a role of special prominence in the public debate over the nation's preparedness for a biological attack, and indeed sought to influence government policy.", [["prominence", "OBSERVATION", 341, 351]]], ["Assuming that it was a warning by a recognized expert expressed in classified circles but also on public media, did the decision makers act upon it, and did it raise public concern?Conflicts and Controversies in a climate of Uncertainties.Another offshoot of the anthrax letters was the controversial case of 'ciprofloxacin'('Cipro).", [["anthrax", "DISEASE", 263, 270], ["ciprofloxacin", "CHEMICAL", 310, 323], ["Cipro", "CHEMICAL", 326, 331], ["ciprofloxacin", "CHEMICAL", 310, 323], ["ciprofloxacin", "SIMPLE_CHEMICAL", 310, 323], ["'ciprofloxacin'", "TREATMENT", 309, 324], ["Cipro", "TREATMENT", 326, 331]]], ["On one hand there was the right of a patentee to retain his monopoly on a patented drug, on the other hand was the dilemma whether to enforce or not to enforce government's statutory right to override patent rights in cases of emergency, and its duty to protect public health and safety, which usually is to prevail, provided it is executed stringently.", [["right", "ANATOMY_MODIFIER", 26, 31], ["patent", "OBSERVATION", 201, 207]]], ["74 77 Plaintiffs, Vietnamese nationals, filed suit against defendants, manufacturers of herbicides, for allegedly causing wrongful death, severe bodily injuries (such as: birth defects, breast and lung cancer, ovarian tumors) and other health problems in result of their exposure to dioxin during the United State's use of herbicides in the Vietnam War.", [["breast", "ANATOMY", 186, 192], ["lung cancer", "ANATOMY", 197, 208], ["ovarian tumors", "ANATOMY", 210, 224], ["death", "DISEASE", 131, 136], ["bodily injuries", "DISEASE", 145, 160], ["birth defects", "DISEASE", 171, 184], ["breast and lung cancer", "DISEASE", 186, 208], ["ovarian tumors", "DISEASE", 210, 224], ["dioxin", "CHEMICAL", 283, 289], ["dioxin", "CHEMICAL", 283, 289], ["breast", "CANCER", 186, 192], ["lung cancer", "CANCER", 197, 208], ["ovarian tumors", "CANCER", 210, 224], ["dioxin", "SIMPLE_CHEMICAL", 283, 289], ["wrongful death", "PROBLEM", 122, 136], ["severe bodily injuries", "PROBLEM", 138, 160], ["birth defects", "PROBLEM", 171, 184], ["breast and lung cancer", "PROBLEM", 186, 208], ["ovarian tumors", "PROBLEM", 210, 224], ["other health problems", "PROBLEM", 230, 251], ["dioxin", "TREATMENT", 283, 289], ["herbicides", "TREATMENT", 323, 333], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["injuries", "OBSERVATION", 152, 160], ["breast", "ANATOMY", 186, 192], ["lung", "ANATOMY", 197, 201], ["cancer", "OBSERVATION", 202, 208], ["ovarian", "ANATOMY", 210, 217], ["tumors", "OBSERVATION", 218, 224]]], ["The plaintiffs alleged violation of international and domestic law in fulfilling the military's demand for herbicides.", [["herbicides", "PROBLEM", 107, 117]]], ["They did not allege that the government intended to harm human beings through its use of Agent Orange.Conflicts and Controversies in a climate of Uncertainties.In reviewing the history of the herbicide operation that was employed by the US military forces in Vietnam, court relied on the argument by the Defense ministry that 'one of the most difficult problems of military operations in South Vietnam' was 'the inability to observe the enemy in the dense forest and jungle'.", [["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["Agent Orange", "TREATMENT", 89, 101], ["the herbicide operation", "TREATMENT", 188, 211], ["military operations", "TREATMENT", 365, 384], ["dense", "OBSERVATION_MODIFIER", 450, 455], ["forest", "OBSERVATION", 456, 462]]], ["It was stressed that the army was instructed to 'carefully select crop destruction tar-gets\u2026 in areas remote from population\u2026 [and] only of military significance'.", [["tar", "CHEMICAL", 83, 86]]], ["In reviewing the justicibility of the herbicide program the judges emphasized that the operations became a matter of scientific controversy almost from their inception, but the herbicide program was continued because of 'substantial military benefit'.", [["the operations", "TREATMENT", 83, 97], ["the herbicide program", "TREATMENT", 173, 194]]], ["Court stressed that in April 1970 some components of the herbicide were banned from most U.S domestic uses on the basis of evidence of its 'possible teratogenicity'.", [["the herbicide", "TREATMENT", 53, 66], ["teratogenicity", "PROBLEM", 149, 163]]], ["On April 15, 1970, DOD suspended military use of Agent Orange upon evidence of toxicity of the dioxin component.", [["toxicity", "DISEASE", 79, 87], ["dioxin", "CHEMICAL", 95, 101], ["dioxin", "CHEMICAL", 95, 101], ["dioxin", "SIMPLE_CHEMICAL", 95, 101], ["Agent Orange", "TREATMENT", 49, 61], ["toxicity of the dioxin component", "PROBLEM", 79, 111]]], ["In January 1971, the last spray mission took place.Conflicts and Controversies in a climate of Uncertainties.After a lengthy discussion on a diversity of complicated legal issues, the Court concluded that the herbicide spraying complained of did not constitute a war crime in pre-1975.", [["herbicide", "CHEMICAL", 209, 218]]], ["Since 'Agent Orange was intended for defoliation and destruction of crops and not as a poison targeting human populations, its use did not violate the international norms\u2026.'", [["human", "ORGANISM", 104, 109], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["defoliation", "PROBLEM", 37, 48], ["destruction of crops", "PROBLEM", 53, 73]]], ["There is nothing in the UN Charter outlawing the use of herbicides in Viet-nam\u2026.' 78 The court observed: 'Norms that depend on modifiers such as disproportionate or unnecessary, invite case-by-case balancing of competing interests and black-letter rules become vague and easily manipulated.' 79 One wonders whether 'Agent Orange' operation would go on if the US government would have timely applied the 'precautionary principle' while the climate was of uncertainty which unfortunately became later, a certainty!.", [["vague", "PROBLEM", 261, 266]]], ["One wonders what lesson will be learned from this recent court case?! 80ConclusionAll these are very complicated issues, and no clear-cut answer can easily be provided.", [["very complicated issues", "PROBLEM", 96, 119], ["very", "OBSERVATION_MODIFIER", 96, 100], ["complicated", "OBSERVATION", 101, 112]]], ["Especially difficult is to find an adequate balance in conflicts between human rights and national or international security.", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78]]], ["Experienced in adjudication one may dare to say that there is a general universal 'feel and touch ' in justice, but moral and ethical attitudes that are part of 'justice', differ from nation to nation and from person to person, embracing a diversity of considerations, justified by one party and sometimes condemned by another.", [["person", "SPECIES", 210, 216], ["person", "SPECIES", 220, 226]]], ["As already mentioned, science and new technologies enrich humanity, but along with its enrichment, some of the innovative scientific findings or sophisticated technologies often seriously threaten humanity.", [["new", "OBSERVATION_MODIFIER", 34, 37]]], ["Science in its dual capabilities, on the one hand as the benefactor of humanity, and on its other hand as the cause for threats on its survival, is under a heavy responsibility to balance between those capabilities, first within its own boundaries and later in cooperation with other relevant disciplines.ConclusionIt shall be remembered that in the dynamics of daily life many people are reckless, careless or negligent in performing their chores and legal responsibilities.", [["hand", "ORGANISM_SUBDIVISION", 98, 102], ["people", "ORGANISM", 378, 384], ["people", "SPECIES", 378, 384], ["dual capabilities", "OBSERVATION_MODIFIER", 15, 32]]], ["Without undermining the severity of such cases, it is to stress that the injury in most of these cases is limited to a certain individual or a group of individuals.", [["the injury", "PROBLEM", 69, 79], ["injury", "OBSERVATION", 73, 79]]], ["But in cases of careless, negligent or wrongful dealing with lethal biological agents, letting those 'escape' or be reached by terrorist hands, there is a danger of mass-destruction.", [["hands", "ORGANISM_SUBDIVISION", 137, 142], ["lethal biological agents", "TREATMENT", 61, 85], ["mass-destruction", "PROBLEM", 165, 181], ["mass", "OBSERVATION", 165, 169], ["destruction", "OBSERVATION", 170, 181]]], ["The 'precautionary principle' is to be applied, however any normative framework for preventing, decreasing or minimizing any hostile use or misuse must provide for the undisturbed continuation of scientific research and possibilities of scientific publications, provided these do not diminish the efforts for protecting national security and public health and safety.ConclusionIt is to think and provide answers and recommendations as to:Conclusion1.", [["The 'precautionary principle'", "TREATMENT", 0, 29]]], ["What criteria shall be applied for resolving conflict of interests and controversies between the utilitarian-economic approach to scientific research, especially now in the field of new biotechnology and other approaches such as political; ethical, moral; social or religious?ConclusionMost of the above compiled laws state clearly that 'nothing\u2026 is intended to restrain or restrict peaceful scientific R&D' and prohibitions on using biological agents do not apply to uses 'for prophylactic, protective, or other peaceful purposes'.", [["biological agents", "TREATMENT", 434, 451], ["prophylactic", "TREATMENT", 478, 490], ["protective", "TREATMENT", 492, 502]]], ["Although trained in deciding on whatever issue that seeks adjudication, in the rapidly changing global world and highly sophisticated developments in the life sciences, there is a growing gap between scientific expertise and judicial knowledge.", [["a growing gap", "PROBLEM", 178, 191]]], ["There is a need for cross-ventilation between all the relevant disciplines which Professor Straus is practicing in his daily chores.ConclusionNo man is an island.", [["man", "ORGANISM", 145, 148], ["man", "SPECIES", 145, 148], ["cross-ventilation", "TREATMENT", 20, 37], ["island", "OBSERVATION", 155, 161]]]], "PMC7498233": [["We read with enthusiasm about retinal changes in patients with COVID-19 symptoms, reported by Paula M Marinho and colleagues.1 The COVID-19 pandemic is a global health emergency challenging citizens, health authorities, and scientists.2 The academic response to the pandemic has been amazing.", [["retinal", "ANATOMY", 30, 37], ["retinal", "MULTI-TISSUE_STRUCTURE", 30, 37], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["retinal changes", "PROBLEM", 30, 45], ["COVID-19 symptoms", "PROBLEM", 63, 80]]]], "6faad85f40398b07d566694f1b1b83a522982691": [["INTRODUCTIONCOVID-19 is a disease entity caused by a new coronavirus, named by the WHO as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["coronavirus", "DISEASE", 57, 68], ["acute respiratory syndrome coronavirus", "DISEASE", 97, 135], ["coronavirus", "ORGANISM", 57, 68], ["SARS-CoV-2", "ORGANISM", 139, 149], ["severe acute respiratory syndrome coronavirus", "SPECIES", 90, 135], ["SARS-CoV-2", "SPECIES", 139, 149], ["a disease entity", "PROBLEM", 24, 40], ["a new coronavirus", "PROBLEM", 51, 68], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 90, 135], ["CoV", "TEST", 144, 147], ["disease", "OBSERVATION", 26, 33], ["new", "OBSERVATION_MODIFIER", 53, 56], ["coronavirus", "OBSERVATION", 57, 68], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory syndrome", "OBSERVATION", 103, 123]]], ["It is a positive-sense singlestranded RNA virus which can be spread by droplets from person to person.", [["person", "SPECIES", 85, 91], ["person", "SPECIES", 95, 101], ["a positive-sense singlestranded RNA virus", "PROBLEM", 6, 47], ["RNA virus", "OBSERVATION", 38, 47]]], ["1 Since the first case was identified in Wuhan, Hubei, China, SARS-CoV-2 rapidly spread from a single city to the entire country in just 30 days.", [["SARS", "DISEASE", 62, 66], ["SARS-CoV-2", "ORGANISM", 62, 72], ["SARS-CoV", "SPECIES", 62, 70]]], ["2 On March 11, 2020, the WHO has declared the novel coronavirus outbreak a global pandemic.", [["coronavirus", "DISEASE", 52, 63], ["coronavirus", "ORGANISM", 52, 63], ["the novel coronavirus", "PROBLEM", 42, 63], ["coronavirus", "OBSERVATION", 52, 63], ["global", "OBSERVATION_MODIFIER", 75, 81], ["pandemic", "OBSERVATION_MODIFIER", 82, 90]]], ["3 As of May 20, 2020, there have been 4,789,205 confirmed cases of COVID-19, causing 318,789 deaths in 216 countries worldwide with more than 1.5 million confirmed cases in the USA.", [["COVID-19", "CHEMICAL", 67, 75], ["deaths", "DISEASE", 93, 99], ["COVID", "TEST", 67, 72]]], ["4 Acute kidney injury (AKI) is a common complication in both medical and surgical patients.", [["kidney", "ANATOMY", 8, 14], ["Acute kidney injury", "DISEASE", 2, 21], ["AKI", "DISEASE", 23, 26], ["kidney", "ORGAN", 8, 14], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Acute kidney injury", "PROBLEM", 2, 21], ["AKI", "PROBLEM", 23, 26], ["a common complication", "PROBLEM", 31, 52], ["Acute", "OBSERVATION_MODIFIER", 2, 7], ["kidney", "ANATOMY", 8, 14], ["injury", "OBSERVATION", 15, 21], ["AKI", "OBSERVATION", 23, 26]]], ["The incidence of AKI was reported between 8% and 18% of hospitalized patients based on the Grampian Laboratory Outcomes Morbidity and Mortality Study II.", [["AKI", "DISEASE", 17, 20], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["AKI", "PROBLEM", 17, 20], ["AKI", "OBSERVATION", 17, 20]]], ["5 In thisSignificance of this studyWhat is already known about this subject? \u25ba COVID-19 is a newly assigned disease entity caused by severe acute respiratory syndrome coronavirus 2. \u25ba The incidence of acute kidney injury (AKI) in COVID-19 is unknown.Significance of this studyWhat are the new findings? \u25ba The pooled incidence of AKI among patients with COVID-19 was 8.4% with a pooled incidence of renal replacement therapy of 3.6%. \u25ba Critically ill patients with COVID-19 had higher incidence of AKI compared with hospitalized patients. \u25ba AKI was associated with increased mortality by 13-fold (OR 13.33, 95% CI 4.05 to 43.91). \u25ba Increasing age, history of diabetes, history of hypertension and higher baseline serum creatinine levels were associated with AKI based on adjusted meta-regression analysis.Significance of this studyHow might these results change the focus of research or clinical practice? \u25ba AKI may be uncommon in patients with COVID-19.", [["kidney", "ANATOMY", 207, 213], ["renal", "ANATOMY", 398, 403], ["serum", "ANATOMY", 712, 717], ["COVID-19", "CHEMICAL", 79, 87], ["acute respiratory syndrome coronavirus", "DISEASE", 140, 178], ["acute kidney injury", "DISEASE", 201, 220], ["AKI", "DISEASE", 222, 225], ["AKI", "DISEASE", 329, 332], ["AKI", "DISEASE", 497, 500], ["AKI", "DISEASE", 540, 543], ["diabetes", "DISEASE", 658, 666], ["hypertension", "DISEASE", 679, 691], ["creatinine", "CHEMICAL", 718, 728], ["AKI", "DISEASE", 757, 760], ["AKI", "DISEASE", 907, 910], ["creatinine", "CHEMICAL", 718, 728], ["COVID-19", "CHEMICAL", 944, 952], ["kidney", "ORGAN", 207, 213], ["patients", "ORGANISM", 339, 347], ["renal", "ORGAN", 398, 403], ["patients", "ORGANISM", 450, 458], ["patients", "ORGANISM", 528, 536], ["serum", "ORGANISM_SUBSTANCE", 712, 717], ["creatinine", "SIMPLE_CHEMICAL", 718, 728], ["patients", "ORGANISM", 930, 938], ["patients", "SPECIES", 339, 347], ["patients", "SPECIES", 450, 458], ["patients", "SPECIES", 528, 536], ["patients", "SPECIES", 930, 938], ["severe acute respiratory syndrome coronavirus", "SPECIES", 133, 178], ["this study", "TEST", 25, 35], ["a newly assigned disease entity", "PROBLEM", 91, 122], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 133, 178], ["acute kidney injury", "PROBLEM", 201, 220], ["AKI", "PROBLEM", 222, 225], ["COVID", "TEST", 230, 235], ["this study", "TEST", 266, 276], ["AKI", "PROBLEM", 329, 332], ["COVID", "TEST", 353, 358], ["renal replacement therapy", "TREATMENT", 398, 423], ["COVID", "TEST", 464, 469], ["AKI", "PROBLEM", 497, 500], ["AKI", "PROBLEM", 540, 543], ["increased mortality", "PROBLEM", 564, 583], ["CI", "TEST", 610, 612], ["diabetes", "PROBLEM", 658, 666], ["hypertension", "PROBLEM", 679, 691], ["higher baseline serum creatinine levels", "PROBLEM", 696, 735], ["AKI", "PROBLEM", 757, 760], ["adjusted meta-regression analysis", "TEST", 770, 803], ["this study", "TEST", 820, 830], ["AKI", "PROBLEM", 907, 910], ["COVID", "TEST", 944, 949], ["disease", "OBSERVATION", 108, 115], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory syndrome coronavirus", "OBSERVATION", 146, 178], ["acute", "OBSERVATION_MODIFIER", 201, 206], ["kidney", "ANATOMY", 207, 213], ["injury", "OBSERVATION", 214, 220], ["AKI", "OBSERVATION", 222, 225], ["new", "OBSERVATION_MODIFIER", 289, 292], ["AKI", "OBSERVATION", 329, 332], ["renal", "ANATOMY", 398, 403], ["replacement", "OBSERVATION", 404, 415], ["AKI", "OBSERVATION", 497, 500], ["AKI", "OBSERVATION", 540, 543], ["diabetes", "OBSERVATION", 658, 666], ["hypertension", "OBSERVATION", 679, 691], ["AKI", "OBSERVATION", 907, 910], ["may be", "UNCERTAINTY", 911, 917]]], ["However, if present, AKI was associated with increased mortality.", [["AKI", "DISEASE", 21, 24], ["AKI", "PROBLEM", 21, 24], ["increased mortality", "PROBLEM", 45, 64], ["AKI", "OBSERVATION", 21, 24], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["mortality", "OBSERVATION", 55, 64]]], ["Avoiding AKI especially in patients who have predisposing risk factors may improve the outcome of COVID-19.Original researchstudy, Sawhney et al have shown that AKI is associated with increased mortality within 1 year and after 10 years of follow-up.", [["AKI", "DISEASE", 9, 12], ["AKI", "DISEASE", 161, 164], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["AKI", "PROBLEM", 9, 12], ["predisposing risk factors", "PROBLEM", 45, 70], ["COVID", "TEST", 98, 103], ["AKI", "PROBLEM", 161, 164], ["AKI", "OBSERVATION", 161, 164]]], ["5 From a multinational database, the incidence of AKI in mechanically ventilated patients was reported at 22%, slightly higher than general inpatients.", [["AKI", "DISEASE", 50, 53], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["a multinational database", "TEST", 7, 31], ["AKI", "PROBLEM", 50, 53], ["mechanically ventilated", "TREATMENT", 57, 80], ["AKI", "OBSERVATION", 50, 53], ["mechanically ventilated", "OBSERVATION", 57, 80]]], ["6 Most of these patients developed AKI within 48 hours after intensive care unit (ICU) admission.", [["AKI", "DISEASE", 35, 38], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["AKI", "PROBLEM", 35, 38], ["AKI", "OBSERVATION", 35, 38]]], ["6 Several factors, such as use of vasopressors, intra-aortic balloon pump, chronic kidney disease (CKD), and high Acute Physiologic Assessment and Chronic Health Evaluation II score, are the risk factors for severe AKI requiring renal replacement therapy (RRT) in the ICU.", [["intra-aortic", "ANATOMY", 48, 60], ["kidney", "ANATOMY", 83, 89], ["renal", "ANATOMY", 229, 234], ["chronic kidney disease", "DISEASE", 75, 97], ["CKD", "DISEASE", 99, 102], ["AKI", "DISEASE", 215, 218], ["kidney", "ORGAN", 83, 89], ["renal", "ORGAN", 229, 234], ["vasopressors", "TREATMENT", 34, 46], ["intra-aortic balloon pump", "TREATMENT", 48, 73], ["chronic kidney disease", "PROBLEM", 75, 97], ["CKD)", "PROBLEM", 99, 103], ["high Acute Physiologic Assessment", "PROBLEM", 109, 142], ["the risk factors", "PROBLEM", 187, 203], ["severe AKI", "PROBLEM", 208, 218], ["renal replacement therapy", "TREATMENT", 229, 254], ["RRT", "TREATMENT", 256, 259], ["intra-aortic", "ANATOMY", 48, 60], ["balloon pump", "OBSERVATION", 61, 73], ["chronic", "OBSERVATION_MODIFIER", 75, 82], ["kidney", "ANATOMY", 83, 89], ["disease", "OBSERVATION", 90, 97], ["CKD", "OBSERVATION", 99, 102], ["high", "OBSERVATION_MODIFIER", 109, 113], ["Acute", "OBSERVATION_MODIFIER", 114, 119], ["Physiologic", "OBSERVATION", 120, 131], ["Chronic", "OBSERVATION_MODIFIER", 147, 154], ["severe", "OBSERVATION_MODIFIER", 208, 214], ["AKI", "OBSERVATION", 215, 218], ["renal", "ANATOMY", 229, 234], ["replacement", "OBSERVATION", 235, 246]]], ["7 Although it has been well established that AKI is linked to elevated mortality in hospitalized patients, 8 whether this knowledge would extend to patients with COVID-19 remained unanswered.", [["AKI", "DISEASE", 45, 48], ["COVID-19", "CHEMICAL", 162, 170], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 148, 156], ["AKI", "PROBLEM", 45, 48], ["COVID", "TEST", 162, 167], ["AKI", "OBSERVATION", 45, 48]]], ["Several studies have provided front-line data about the mortality risks in patients with confirmed COVID-19.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Several studies", "TEST", 0, 15], ["COVID", "TEST", 99, 104]]], ["Zhou et al 9 conducted a multicenter, retrospective cohort study of 191 patients with confirmed COVID-19 in Wuhan and identified several risk factors for mortality.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["retrospective cohort study", "TEST", 38, 64], ["mortality", "PROBLEM", 154, 163]]], ["However, evidence is lacking on studies reporting the association between mortality risk and AKI in patients with COVID-19.", [["AKI", "DISEASE", 93, 96], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["studies", "TEST", 32, 39], ["mortality risk", "PROBLEM", 74, 88], ["AKI", "PROBLEM", 93, 96], ["COVID", "TEST", 114, 119], ["AKI", "OBSERVATION", 93, 96]]], ["Herein, we performed a systematic review with meta-analysis aiming to provide more information about the incidence of AKI and the association between AKI and mortality in patients with COVID-19.MATERIALS AND METHODS Information sources and search strategyThis systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology statements.", [["AKI", "DISEASE", 118, 121], ["AKI", "DISEASE", 150, 153], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["meta-analysis", "TREATMENT", 46, 59], ["AKI", "PROBLEM", 118, 121], ["AKI", "PROBLEM", 150, 153], ["COVID", "TEST", 185, 190], ["Systematic Reviews", "TEST", 321, 339], ["Meta-Analyses", "TEST", 344, 357], ["Observational Studies", "TEST", 388, 409], ["AKI", "OBSERVATION", 118, 121], ["AKI", "OBSERVATION", 150, 153]]], ["10 11 We conducted a systematic literature search of Ovid MEDLINE, EMBASE, and the Cochrane Library from database inception through April 24, 2020 without language restriction.", [["language restriction", "TREATMENT", 155, 175]]], ["The search strategy for each database is elaborated in online supplementary document 1.", [["each database", "TEST", 24, 37]]], ["To avoid potential publication bias and replication of study samples, we did not search through medrxiv. org due to lack of peer review process.", [["study samples", "TEST", 55, 68], ["medrxiv", "TREATMENT", 96, 103], ["org", "TREATMENT", 105, 108]]], ["Studies published in Chinese language were translated by CQ and a medical translator.Study selectionBecause COVID-19 is an emerging pandemic, a large number of studies were published within a short period of time.", [["CQ", "CHEMICAL", 57, 59], ["COVID-19", "CHEMICAL", 108, 116], ["Study selection", "TEST", 85, 100], ["COVID", "TEST", 108, 113], ["studies", "TEST", 160, 167], ["pandemic", "OBSERVATION", 132, 140], ["large", "OBSERVATION_MODIFIER", 144, 149]]], ["Thus, we cautiously screened all citations to avoid duplication of the patient populations among studies.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78]]], ["Inclusion criteria included observational studies of patients infected with SARS-CoV-2 and reported the mortality as one of the outcomes of interest.", [["SARS", "DISEASE", 76, 80], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["SARS-CoV", "SPECIES", 76, 84], ["observational studies", "TEST", 28, 49]]], ["SARS-CoV-2 infection was confirmed by positive real-time reverse transcription PCR test.", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV-2", "SPECIES", 0, 10], ["SARS", "PROBLEM", 0, 4], ["CoV-2 infection", "PROBLEM", 5, 20], ["transcription PCR test", "TEST", 65, 87], ["infection", "OBSERVATION", 11, 20]]], ["Eligible studies needed to provide the following information: age, sex, diagnosis, patients' comorbidities, incidence of AKI, need of RRT and mortality.", [["AKI", "DISEASE", 121, 124], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Eligible studies", "TEST", 0, 16], ["patients' comorbidities", "PROBLEM", 83, 106], ["AKI", "PROBLEM", 121, 124], ["RRT", "TREATMENT", 134, 137], ["AKI", "OBSERVATION", 121, 124]]], ["Retrieved articles were independently examined for eligibility by 2 authors (PH and CQ).", [["PH", "TEST", 77, 79]]], ["All references were managed through EndNote X9.2 software (Clarivate Analytics, Philadelphia, PA, USA).Data collection processA structured data collection form was developed to gather the following data from each included study: title, author name, publication year, country where the study was conducted, location where data were collected, type of study, patients' diagnoses, sample size, age, sex, comorbidities, incidence of AKI, incidence of RRT, mortality and definition of AKI.", [["AKI", "DISEASE", 429, 432], ["AKI", "DISEASE", 480, 483], ["patients", "ORGANISM", 357, 365], ["patients", "SPECIES", 357, 365], ["Data collection processA structured data collection", "TEST", 103, 154], ["the study", "TEST", 281, 290], ["comorbidities", "PROBLEM", 401, 414], ["AKI", "PROBLEM", 429, 432], ["RRT", "TREATMENT", 447, 450], ["AKI", "PROBLEM", 480, 483], ["size", "OBSERVATION_MODIFIER", 385, 389], ["AKI", "OBSERVATION", 429, 432], ["AKI", "OBSERVATION", 480, 483]]], ["The risk of bias was assessed using ROBINS-I (risk of bias in non-randomized study -of interventions) tool for non-randomized studies of interventions.", [["non-randomized study", "TEST", 62, 82], ["interventions", "TREATMENT", 87, 100], ["non-randomized studies", "TEST", 111, 133], ["interventions", "TREATMENT", 137, 150]]], ["12 The quality of studies that fulfilled the inclusion criteria was rated as low, moderate or high risk of bias.MeasurementsThe incidence of AKI, RRT and mortality were reported in percentage with 95% CI.", [["AKI", "DISEASE", 141, 144], ["studies", "TEST", 18, 25], ["AKI", "PROBLEM", 141, 144], ["RRT", "TREATMENT", 146, 149], ["moderate", "OBSERVATION_MODIFIER", 82, 90], ["AKI", "OBSERVATION", 141, 144]]], ["The OR for mortality from AKI was also reported with 95% CI.Statistical analysisWe used the Comprehensive Meta-Analysis software V.3.3.070 (Biostat, Englewood, NJ, USA) to conduct meta-analyses and SPSS V.23.0 (IBM) for descriptive analyses.", [["AKI", "DISEASE", 26, 29], ["AKI", "PROBLEM", 26, 29], ["meta-analyses", "TEST", 180, 193], ["SPSS", "TEST", 198, 202], ["descriptive analyses", "TEST", 220, 240], ["AKI", "OBSERVATION", 26, 29]]], ["Statistical heterogeneity of studies was assessed using Cochran's Q test and I 2 index.", [["studies", "TEST", 29, 36], ["Cochran's Q test", "TEST", 56, 72]]], ["We analyzed the results by using the random effects model to minimize the heterogeneity or between-study variance.Sensitivity analysis, subgroup analysis, meta-regression and publication biasSensitivity analyses were performed in order to minimize the heterogeneity among studies by subtracting 1 study at a time.", [["the heterogeneity", "PROBLEM", 70, 87], ["Sensitivity analysis", "TEST", 114, 134], ["subgroup analysis", "TEST", 136, 153], ["meta-regression", "TEST", 155, 170], ["publication biasSensitivity analyses", "TEST", 175, 211]]], ["Subgroup analysis was performed based on the disease severity (critically ill patients vs hospitalized patients).", [["critically ill", "DISEASE", 63, 77], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 103, 111], ["Subgroup analysis", "TEST", 0, 17], ["the disease severity", "PROBLEM", 41, 61]]], ["Meta-regression analysis was performed to elaborate theOriginal researchassociation between (1) incidence of AKI and mortality, and (2) clinical characteristics and incidence of AKI using the random effects model.", [["AKI", "DISEASE", 109, 112], ["AKI", "DISEASE", 178, 181], ["Meta-regression analysis", "TEST", 0, 24], ["AKI", "PROBLEM", 109, 112], ["AKI", "PROBLEM", 178, 181], ["the random effects model", "TREATMENT", 188, 212], ["AKI", "OBSERVATION", 109, 112], ["AKI", "OBSERVATION", 178, 181]]], ["Publication bias was analyzed using Egger's regression intercept and funnel plot if the number of included studies was greater than 10.", [["Publication bias", "TEST", 0, 16], ["funnel plot", "TEST", 69, 80], ["studies", "TEST", 107, 114]]], ["Of 740 citations, we found 26 studies that reported the incidence of AKI as well as mortality in 5497 confirmed cases of SARS-CoV-2 infection (Incidence of AKIA total of 5497 patients from 26 studies were included in the meta-analysis of AKI incidence following COVID-19.", [["AKI", "DISEASE", 69, 72], ["SARS-CoV-2 infection", "DISEASE", 121, 141], ["AKI", "DISEASE", 238, 241], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["SARS-CoV-2", "SPECIES", 121, 131], ["AKI", "PROBLEM", 69, 72], ["SARS", "PROBLEM", 121, 125], ["CoV", "PROBLEM", 126, 129], ["2 infection", "PROBLEM", 130, 141], ["AKIA", "TEST", 156, 160], ["AKI incidence", "PROBLEM", 238, 251], ["COVID", "TEST", 262, 267], ["AKI", "OBSERVATION", 69, 72]]], ["By using random effects model, we found that the pooled incidence of AKI in patients with confirmed SARS-CoV-2 infection was 8.4% (95% CI 6.0% to 11.7%; I 2 by fixed effects=88.9%; figure 2A ).MortalityA total of 5497 patients from 26 studies were included in the meta-analysis of mortality from COVID-19.", [["AKI", "DISEASE", 69, 72], ["SARS-CoV-2 infection", "DISEASE", 100, 120], ["patients", "ORGANISM", 76, 84], ["SARS-CoV-2", "ORGANISM", 100, 110], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 76, 84], ["CoV-", "SPECIES", 105, 109], ["patients", "SPECIES", 218, 226], ["SARS-CoV-2", "SPECIES", 100, 110], ["AKI", "PROBLEM", 69, 72], ["SARS", "PROBLEM", 100, 104], ["CoV", "TEST", 105, 108], ["2 infection", "PROBLEM", 109, 120], ["CI", "TEST", 135, 137], ["fixed effects", "TEST", 160, 173], ["COVID", "TEST", 296, 301], ["AKI", "OBSERVATION", 69, 72]]], ["We found that the pooled estimated mortality was 18.7% (95% CI 13.2% to 25.8%; I 2 by fixed effects model=95.0%; figure 2B ).Incidence of RRTOf 14 studies included with a total of 3364 patients, the pooled incidence of RRT use was 3.6% (95% CI 1.8% to 7.1%; I 2 by fixed effects model=82.2%; figure 2C ).OR for mortality from AKIThe OR of mortality from AKI was analyzed based on the data available from 8 studies.", [["AKI", "DISEASE", 354, 357], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["the pooled estimated mortality", "TEST", 14, 44], ["CI", "TEST", 60, 62], ["model", "TEST", 100, 105], ["RRTOf 14 studies", "TEST", 138, 154], ["CI", "TEST", 241, 243], ["fixed effects model", "TEST", 265, 284], ["mortality", "PROBLEM", 311, 320], ["AKI", "PROBLEM", 354, 357], ["the data", "TEST", 380, 388]]], ["The pooled estimated OR for mortality in patients with AKI was 13.33 (95% CI 4.05 to 43.91; I 2 by fixed effects=85.0%; figure 2D ).", [["AKI", "DISEASE", 55, 58], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["AKI", "TEST", 55, 58], ["CI", "TEST", 74, 76]]], ["This finding remained significant through sensitivity analyses.", [["sensitivity analyses", "TEST", 42, 62], ["significant", "OBSERVATION_MODIFIER", 22, 33]]], ["The incidence of AKI and mortality were also evaluated separately.", [["AKI", "DISEASE", 17, 20], ["AKI", "PROBLEM", 17, 20], ["AKI", "OBSERVATION", 17, 20]]], ["Of the 8 studies (n=1971) that reported the OR for mortality from AKI, the pooled incidence of AKI and mortality was 10.1% (95% CI 6.0% to 16.4%; I 2 by fixed effects model=90.8%) and 26.8% (95% CI 16.9% to 39.7%; I 2 by fixed effects model=96.1%), respectively (online supplementary document 3).", [["AKI", "DISEASE", 66, 69], ["AKI", "DISEASE", 95, 98], ["AKI", "PROBLEM", 66, 69], ["AKI", "PROBLEM", 95, 98], ["mortality", "TEST", 103, 112], ["CI", "TEST", 128, 130], ["model", "TEST", 167, 172], ["CI", "TEST", 195, 197], ["I", "TEST", 214, 215], ["model", "TEST", 235, 240], ["AKI", "OBSERVATION", 66, 69], ["AKI", "OBSERVATION", 95, 98]]], ["Egger's regression intercept for AKI incidence and mortality was 0.752 and 0.549, respectively, suggesting no publication bias. \u2020Including cardiovascular disease, heart failure, valvular heart disease or atrial fibrillation. \u2021Including chronic obstructive lung disease, asthma or interstitial lung disease.OR for mortality from AKIAKI, acute kidney injury; CKD, chronic kidney disease; CRRT, continuous renal replacement therapy; DM, diabetes mellitus; HTN, hypertension; RRT, renal replacement therapy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.Meta-regression analysis: AKI and mortalityWe performed a meta-regression analysis to evaluate the association between AKI and mortality by using random effects model.", [["cardiovascular", "ANATOMY", 139, 153], ["heart", "ANATOMY", 163, 168], ["valvular", "ANATOMY", 178, 186], ["heart", "ANATOMY", 187, 192], ["atrial", "ANATOMY", 204, 210], ["lung", "ANATOMY", 256, 260], ["interstitial lung", "ANATOMY", 280, 297], ["kidney", "ANATOMY", 342, 348], ["kidney", "ANATOMY", 370, 376], ["renal", "ANATOMY", 403, 408], ["renal", "ANATOMY", 477, 482], ["AKI", "DISEASE", 33, 36], ["cardiovascular disease", "DISEASE", 139, 161], ["heart failure", "DISEASE", 163, 176], ["valvular heart disease", "DISEASE", 178, 200], ["atrial fibrillation", "DISEASE", 204, 223], ["chronic obstructive lung disease", "DISEASE", 236, 268], ["asthma", "DISEASE", 270, 276], ["interstitial lung disease", "DISEASE", 280, 305], ["AKIAKI", "DISEASE", 328, 334], ["acute kidney injury", "DISEASE", 336, 355], ["CKD", "DISEASE", 357, 360], ["chronic kidney disease", "DISEASE", 362, 384], ["DM", "DISEASE", 430, 432], ["diabetes mellitus", "DISEASE", 434, 451], ["HTN", "DISEASE", 453, 456], ["hypertension", "DISEASE", 458, 470], ["SARS", "DISEASE", 504, 508], ["acute respiratory syndrome coronavirus", "DISEASE", 523, 561], ["AKI", "DISEASE", 590, 593], ["AKI", "DISEASE", 683, 686], ["cardiovascular", "ANATOMICAL_SYSTEM", 139, 153], ["heart", "ORGAN", 163, 168], ["heart", "ORGAN", 187, 192], ["atrial", "MULTI-TISSUE_STRUCTURE", 204, 210], ["lung", "ORGAN", 256, 260], ["lung", "ORGAN", 293, 297], ["kidney", "ORGAN", 342, 348], ["kidney", "ORGAN", 370, 376], ["renal", "ORGAN", 403, 408], ["renal", "ORGAN", 477, 482], ["SARS-CoV", "SPECIES", 504, 512], ["severe acute respiratory syndrome coronavirus", "SPECIES", 516, 561], ["AKI incidence", "PROBLEM", 33, 46], ["mortality", "TEST", 51, 60], ["publication bias", "PROBLEM", 110, 126], ["cardiovascular disease", "PROBLEM", 139, 161], ["heart failure", "PROBLEM", 163, 176], ["valvular heart disease", "PROBLEM", 178, 200], ["atrial fibrillation", "PROBLEM", 204, 223], ["chronic obstructive lung disease", "PROBLEM", 236, 268], ["asthma", "PROBLEM", 270, 276], ["interstitial lung disease", "PROBLEM", 280, 305], ["acute kidney injury", "PROBLEM", 336, 355], ["CKD", "PROBLEM", 357, 360], ["chronic kidney disease", "PROBLEM", 362, 384], ["CRRT", "TREATMENT", 386, 390], ["continuous renal replacement therapy", "TREATMENT", 392, 428], ["DM", "PROBLEM", 430, 432], ["diabetes mellitus", "PROBLEM", 434, 451], ["HTN", "PROBLEM", 453, 456], ["hypertension", "PROBLEM", 458, 470], ["RRT", "TREATMENT", 472, 475], ["renal replacement therapy", "TREATMENT", 477, 502], ["SARS", "PROBLEM", 504, 508], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 516, 561], ["Meta-regression analysis", "TEST", 564, 588], ["AKI", "PROBLEM", 590, 593], ["a meta-regression analysis", "TEST", 620, 646], ["AKI", "PROBLEM", 683, 686], ["random effects model", "TREATMENT", 710, 730], ["no", "UNCERTAINTY", 107, 109], ["publication bias", "OBSERVATION", 110, 126], ["cardiovascular", "ANATOMY", 139, 153], ["disease", "OBSERVATION", 154, 161], ["heart", "ANATOMY", 163, 168], ["failure", "OBSERVATION", 169, 176], ["valvular", "OBSERVATION", 178, 186], ["heart", "ANATOMY", 187, 192], ["disease", "OBSERVATION", 193, 200], ["atrial", "ANATOMY", 204, 210], ["fibrillation", "OBSERVATION", 211, 223], ["chronic", "OBSERVATION_MODIFIER", 236, 243], ["obstructive", "OBSERVATION_MODIFIER", 244, 255], ["lung", "ANATOMY", 256, 260], ["disease", "OBSERVATION", 261, 268], ["asthma", "OBSERVATION", 270, 276], ["interstitial", "ANATOMY_MODIFIER", 280, 292], ["lung", "ANATOMY", 293, 297], ["disease", "OBSERVATION", 298, 305], ["acute", "OBSERVATION_MODIFIER", 336, 341], ["kidney", "ANATOMY", 342, 348], ["injury", "OBSERVATION", 349, 355], ["CKD", "OBSERVATION", 357, 360], ["chronic", "OBSERVATION_MODIFIER", 362, 369], ["kidney", "ANATOMY", 370, 376], ["disease", "OBSERVATION", 377, 384], ["renal", "ANATOMY", 403, 408], ["replacement", "OBSERVATION", 409, 420], ["HTN", "OBSERVATION", 453, 456], ["hypertension", "OBSERVATION", 458, 470], ["renal", "ANATOMY", 477, 482], ["replacement", "OBSERVATION", 483, 494], ["severe", "OBSERVATION_MODIFIER", 516, 522], ["acute", "OBSERVATION_MODIFIER", 523, 528], ["respiratory syndrome coronavirus", "OBSERVATION", 529, 561], ["AKI", "OBSERVATION", 590, 593], ["AKI", "OBSERVATION", 683, 686]]], ["Interestingly, we found that the incidence of AKI was positively associated with increased mortality in patients with COVID-19 from both unadjusted and adjusted models.", [["AKI", "DISEASE", 46, 49], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["AKI", "PROBLEM", 46, 49], ["increased mortality", "PROBLEM", 81, 100], ["COVID", "TEST", 118, 123], ["AKI", "OBSERVATION", 46, 49], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["mortality", "OBSERVATION", 91, 100]]], ["The coefficients were 9.6311 (Q=17.47; p<0.001; unadjusted; figure 3) and 6.1815 (Q=26.18; p=0.02; adjusted for age and sex), respectively.", [["The coefficients", "TEST", 0, 16], ["p", "TEST", 39, 40], ["figure", "TEST", 60, 66], ["p", "TEST", 91, 92]]], ["However, AKI was not an independent risk factor for mortality after the following variables were held constant: age, sex, diabetes, hypertension and baseline serum creatinine level (Q=15.88, p=0.37).", [["serum", "ANATOMY", 158, 163], ["AKI", "DISEASE", 9, 12], ["diabetes", "DISEASE", 122, 130], ["hypertension", "DISEASE", 132, 144], ["creatinine", "CHEMICAL", 164, 174], ["creatinine", "CHEMICAL", 164, 174], ["serum", "ORGANISM_SUBSTANCE", 158, 163], ["creatinine", "SIMPLE_CHEMICAL", 164, 174], ["AKI", "PROBLEM", 9, 12], ["diabetes", "PROBLEM", 122, 130], ["hypertension", "PROBLEM", 132, 144], ["baseline serum creatinine level", "PROBLEM", 149, 180], ["p", "TEST", 191, 192], ["AKI", "OBSERVATION", 9, 12], ["hypertension", "OBSERVATION", 132, 144]]], ["The results of meta-regression analyses are detailed in online supplementary document 2.", [["meta-regression analyses", "TEST", 15, 39]]], ["Table 2 elaborates the results of meta-regression analysis for each covariate.", [["meta-regression analysis", "TEST", 34, 58]]], ["In brief, age, history of diabetes, history of hypertension and baseline serum creatinine levels were predictive of increased AKI in both unadjusted model and model 1.", [["serum", "ANATOMY", 73, 78], ["diabetes", "DISEASE", 26, 34], ["hypertension", "DISEASE", 47, 59], ["creatinine", "CHEMICAL", 79, 89], ["AKI", "DISEASE", 126, 129], ["creatinine", "CHEMICAL", 79, 89], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["creatinine", "SIMPLE_CHEMICAL", 79, 89], ["diabetes", "PROBLEM", 26, 34], ["hypertension", "PROBLEM", 47, 59], ["baseline serum creatinine levels", "PROBLEM", 64, 96], ["increased AKI", "PROBLEM", 116, 129], ["diabetes", "OBSERVATION", 26, 34], ["hypertension", "OBSERVATION", 47, 59], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["AKI", "OBSERVATION", 126, 129]]], ["Scatterplots of each significant covariate are illustrated in figure 4 .", [["significant", "OBSERVATION_MODIFIER", 21, 32], ["covariate", "OBSERVATION", 33, 42]]], ["However, only baseline serum creatinine levels were associated with increased incidence of AKI in model 2.Publication biasThe funnel plots for the analysis of AKI incidence and mortality are illustrated in online supplementary figure S1.", [["serum", "ANATOMY", 23, 28], ["creatinine", "CHEMICAL", 29, 39], ["AKI", "DISEASE", 91, 94], ["AKI", "DISEASE", 159, 162], ["creatinine", "CHEMICAL", 29, 39], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["creatinine", "SIMPLE_CHEMICAL", 29, 39], ["baseline serum creatinine levels", "TEST", 14, 46], ["AKI in model 2", "PROBLEM", 91, 105], ["the analysis", "TEST", 143, 155], ["AKI incidence", "PROBLEM", 159, 172], ["mortality", "PROBLEM", 177, 186], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["AKI", "OBSERVATION", 91, 94], ["funnel plots", "OBSERVATION", 126, 138], ["AKI", "OBSERVATION", 159, 162]]], ["Egger's regression intercept for the incidence of AKI, mortality, and incidence of RRT was 0.392, 0.628 and 0.273, respectively, indicating no potential publication bias.DISCUSSIONWe identified the incidence of AKI in patients with COVID-19 to be approximately 8.4% with the incidence of RRT of 3.6%.", [["AKI", "DISEASE", 50, 53], ["AKI", "DISEASE", 211, 214], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["AKI", "PROBLEM", 50, 53], ["RRT", "TEST", 83, 86], ["AKI", "PROBLEM", 211, 214], ["COVID", "TEST", 232, 237], ["RRT", "TEST", 288, 291], ["AKI", "OBSERVATION", 50, 53], ["no potential", "UNCERTAINTY", 140, 152], ["publication bias", "OBSERVATION", 153, 169], ["AKI", "OBSERVATION", 211, 214]]], ["This is surprisingly less than general hospitalized patients in which the incidence of AKI was reported at 22%.", [["AKI", "DISEASE", 87, 90], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["AKI", "PROBLEM", 87, 90], ["less", "OBSERVATION_MODIFIER", 21, 25], ["AKI", "OBSERVATION", 87, 90]]], ["8 Compared with Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks, patients infected with SARS-CoV-2 had a lower incidence of kidney involvement.", [["kidney", "ANATOMY", 142, 148], ["Middle East respiratory syndrome coronavirus", "DISEASE", 16, 60], ["SARS", "DISEASE", 106, 110], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 16, 60], ["MERS-CoV", "ORGANISM", 62, 70], ["patients", "ORGANISM", 83, 91], ["SARS-CoV-2", "ORGANISM", 106, 116], ["kidney", "ORGAN", 142, 148], ["patients", "SPECIES", 83, 91], ["Middle East respiratory syndrome coronavirus", "SPECIES", 16, 60], ["MERS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 106, 114], ["Middle East respiratory syndrome", "PROBLEM", 16, 48], ["coronavirus", "PROBLEM", 49, 60], ["outbreaks", "PROBLEM", 72, 81], ["SARS", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114], ["kidney involvement", "PROBLEM", 142, 160], ["Middle", "ANATOMY_MODIFIER", 16, 22], ["respiratory syndrome", "OBSERVATION", 28, 48], ["kidney", "ANATOMY", 142, 148], ["involvement", "OBSERVATION", 149, 160]]], ["Available evidence reported that the incidence of AKI ranged from 17.2% to 26.7% in MERS-CoVinfected patients.", [["AKI", "DISEASE", 50, 53], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["AKI", "TEST", 50, 53], ["AKI", "OBSERVATION", 50, 53]]], ["15Original researchnations including the USA, the UK, Italy, France, Germany and Iran are being collected and would impact the overall incidence of AKI in patients with COVID-19.", [["AKI", "DISEASE", 148, 151], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["AKI", "PROBLEM", 148, 151], ["COVID", "TEST", 169, 174], ["AKI", "OBSERVATION", 148, 151]]], ["We identified that increasing age, diabetes, hypertension and elevated baseline serum creatinine levels are possible predisposing factors for AKI in patients infected with SARS-CoV-2.", [["serum", "ANATOMY", 80, 85], ["diabetes", "DISEASE", 35, 43], ["hypertension", "DISEASE", 45, 57], ["creatinine", "CHEMICAL", 86, 96], ["AKI", "DISEASE", 142, 145], ["SARS", "DISEASE", 172, 176], ["creatinine", "CHEMICAL", 86, 96], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["creatinine", "SIMPLE_CHEMICAL", 86, 96], ["patients", "ORGANISM", 149, 157], ["SARS-CoV-2", "ORGANISM", 172, 182], ["patients", "SPECIES", 149, 157], ["SARS-CoV", "SPECIES", 172, 180], ["diabetes", "PROBLEM", 35, 43], ["hypertension", "PROBLEM", 45, 57], ["elevated baseline serum creatinine levels", "PROBLEM", 62, 103], ["predisposing factors", "PROBLEM", 117, 137], ["AKI", "PROBLEM", 142, 145], ["SARS", "PROBLEM", 172, 176], ["increasing", "OBSERVATION_MODIFIER", 19, 29], ["diabetes", "OBSERVATION", 35, 43], ["hypertension", "OBSERVATION", 45, 57], ["elevated", "OBSERVATION_MODIFIER", 62, 70]]], ["Consistent with our backbone knowledge, advanced age and diabetes are well-known risk factors for AKI.", [["diabetes", "DISEASE", 57, 65], ["AKI", "DISEASE", 98, 101], ["diabetes", "PROBLEM", 57, 65], ["AKI", "PROBLEM", 98, 101], ["AKI", "OBSERVATION", 98, 101]]], ["19 Similar to SARS-CoV, Chu et al demonstrated that age, history hypertension and hypoalbuminemia are potential risk factors for AKI in these patients.", [["SARS", "DISEASE", 14, 18], ["hypertension", "DISEASE", 65, 77], ["hypoalbuminemia", "DISEASE", 82, 97], ["AKI", "DISEASE", 129, 132], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["SARS-CoV", "SPECIES", 14, 22], ["hypertension", "PROBLEM", 65, 77], ["hypoalbuminemia", "PROBLEM", 82, 97], ["potential risk factors", "PROBLEM", 102, 124], ["AKI", "PROBLEM", 129, 132], ["hypertension", "OBSERVATION", 65, 77], ["hypoalbuminemia", "OBSERVATION", 82, 97]]], ["18 However, we added that patients with elevated baseline serum creatinine levels were associated with higher incidence of AKI even after adjusted for other covariates.", [["serum", "ANATOMY", 58, 63], ["creatinine", "CHEMICAL", 64, 74], ["AKI", "DISEASE", 123, 126], ["creatinine", "CHEMICAL", 64, 74], ["patients", "ORGANISM", 26, 34], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["creatinine", "GENE_OR_GENE_PRODUCT", 64, 74], ["patients", "SPECIES", 26, 34], ["elevated baseline serum creatinine levels", "PROBLEM", 40, 81], ["AKI", "PROBLEM", 123, 126], ["AKI", "OBSERVATION", 123, 126]]], ["These patients might include, but not limited to, patients with CKD or patients with some degrees of renal impairment that did not fulfill the criteria for AKI.", [["renal", "ANATOMY", 101, 106], ["CKD", "DISEASE", 64, 67], ["renal impairment", "DISEASE", 101, 117], ["AKI", "DISEASE", 156, 159], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 71, 79], ["renal", "ORGAN", 101, 106], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 71, 79], ["CKD", "PROBLEM", 64, 67], ["renal impairment", "PROBLEM", 101, 117], ["AKI", "PROBLEM", 156, 159], ["renal", "ANATOMY", 101, 106], ["impairment", "OBSERVATION", 107, 117], ["AKI", "OBSERVATION", 156, 159]]], ["Physicians should pay close attention to these patients as they are at significant risk of developing AKI.Original researchWe have demonstrated that AKI is significantly more common in critically ill patients compared with hospitalized patients (19.9% vs 7.3%).", [["AKI", "DISEASE", 102, 105], ["AKI", "DISEASE", 149, 152], ["critically ill", "DISEASE", 185, 199], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 200, 208], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 200, 208], ["patients", "SPECIES", 236, 244], ["developing AKI", "PROBLEM", 91, 105], ["AKI", "PROBLEM", 149, 152], ["AKI", "OBSERVATION", 102, 105], ["AKI", "OBSERVATION", 149, 152]]], ["The overall incidence of AKI in ICU patients ranged from 20% to 50%, higher than those of non-ICU patients.", [["AKI", "DISEASE", 25, 28], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 98, 106], ["AKI", "PROBLEM", 25, 28], ["AKI", "OBSERVATION", 25, 28]]], ["20 Depending on the diagnoses and comorbidities, lower incidence of AKI was seen in elective surgical patients while patients with sepsis had the highest incidence of AKI.", [["AKI", "DISEASE", 68, 71], ["sepsis", "DISEASE", 131, 137], ["AKI", "DISEASE", 167, 170], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 117, 125], ["comorbidities", "PROBLEM", 34, 47], ["AKI", "PROBLEM", 68, 71], ["elective surgical patients", "TREATMENT", 84, 110], ["sepsis", "PROBLEM", 131, 137], ["AKI", "PROBLEM", 167, 170], ["lower", "OBSERVATION_MODIFIER", 49, 54], ["AKI", "OBSERVATION", 68, 71], ["sepsis", "OBSERVATION", 131, 137], ["AKI", "OBSERVATION", 167, 170]]], ["20 In our study, although critically ill patients had higher mortality than hospitalized patients, the difference, however, was not statistically significant.", [["critically ill", "DISEASE", 26, 40], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 89, 97], ["our study", "TEST", 6, 15]]], ["Studies that included hospitalized patients with COVID-19 did not report the mortality in general inpatients and critically ill patients separately.", [["critically ill", "DISEASE", 113, 127], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 128, 136], ["COVID", "TEST", 49, 54]]], ["Thus, one could argue that the true mortality in non-critically ill patients should be lower than what we reported here.", [["non-critically ill", "DISEASE", 49, 67], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["The underlying etiology of AKI is likely multifactorial.", [["AKI", "DISEASE", 27, 30], ["AKI", "PROBLEM", 27, 30], ["AKI", "OBSERVATION", 27, 30], ["likely", "UNCERTAINTY", 34, 40], ["multifactorial", "OBSERVATION_MODIFIER", 41, 55]]], ["Systemic inflammation, sepsis, hemodynamic instability or concurrent use of diuretics may lead to pre-renal azotemia or acute tubular necrosis (ATN).", [["pre-renal", "ANATOMY", 98, 107], ["tubular", "ANATOMY", 126, 133], ["inflammation", "DISEASE", 9, 21], ["sepsis", "DISEASE", 23, 29], ["hemodynamic instability", "DISEASE", 31, 54], ["azotemia", "DISEASE", 108, 116], ["acute tubular necrosis", "DISEASE", 120, 142], ["ATN", "DISEASE", 144, 147], ["tubular", "ORGAN", 126, 133], ["Systemic inflammation", "PROBLEM", 0, 21], ["sepsis", "PROBLEM", 23, 29], ["hemodynamic instability", "PROBLEM", 31, 54], ["diuretics", "TREATMENT", 76, 85], ["pre-renal azotemia", "PROBLEM", 98, 116], ["acute tubular necrosis", "PROBLEM", 120, 142], ["ATN", "PROBLEM", 144, 147], ["inflammation", "OBSERVATION", 9, 21], ["sepsis", "OBSERVATION", 23, 29], ["hemodynamic instability", "OBSERVATION", 31, 54], ["pre-renal", "OBSERVATION_MODIFIER", 98, 107], ["azotemia", "OBSERVATION", 108, 116], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["tubular", "ANATOMY_MODIFIER", 126, 133], ["necrosis", "OBSERVATION", 134, 142], ["ATN", "OBSERVATION", 144, 147]]], ["In critically ill patients, it may be necessary to do radiographic studies with iodinated contrast which could lead to contrast-induced AKI.", [["critically ill", "DISEASE", 3, 17], ["AKI", "DISEASE", 136, 139], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["radiographic studies", "TEST", 54, 74], ["iodinated contrast", "TEST", 80, 98], ["contrast-induced AKI", "PROBLEM", 119, 139], ["AKI", "OBSERVATION", 136, 139]]], ["Additionally, thrombotic microangiopathy leading to ATN is also possible, particularly given that recent evidence suggests that patients with COVID-19 are at greater risk of experiencing thromboembolic events.", [["thrombotic microangiopathy", "DISEASE", 14, 40], ["ATN", "DISEASE", 52, 55], ["thromboembolic", "DISEASE", 187, 201], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["thrombotic microangiopathy", "PROBLEM", 14, 40], ["ATN", "PROBLEM", 52, 55], ["COVID", "TEST", 142, 147], ["thromboembolic events", "PROBLEM", 187, 208], ["thrombotic", "OBSERVATION_MODIFIER", 14, 24], ["microangiopathy", "OBSERVATION", 25, 40], ["ATN", "OBSERVATION", 52, 55], ["thromboembolic", "OBSERVATION", 187, 201]]], ["21 The use of broadspectrum empirical antibiotics especially in high doses may also lead to ATN and interstitial nephritis.", [["interstitial", "ANATOMY", 100, 112], ["ATN", "DISEASE", 92, 95], ["interstitial nephritis", "DISEASE", 100, 122], ["ATN", "SIMPLE_CHEMICAL", 92, 95], ["broadspectrum empirical antibiotics", "TREATMENT", 14, 49], ["ATN", "PROBLEM", 92, 95], ["interstitial nephritis", "PROBLEM", 100, 122], ["ATN", "OBSERVATION", 92, 95], ["interstitial", "ANATOMY_MODIFIER", 100, 112], ["nephritis", "OBSERVATION", 113, 122]]], ["Initial treatment regimens, such as lopinavir-ritonavir, high-dose oseltamivir or high-dose hydroxychloroquine may contribute to the development of AKI as well.", [["lopinavir-ritonavir", "CHEMICAL", 36, 55], ["oseltamivir", "CHEMICAL", 67, 78], ["hydroxychloroquine", "CHEMICAL", 92, 110], ["AKI", "DISEASE", 148, 151], ["lopinavir", "CHEMICAL", 36, 45], ["ritonavir", "CHEMICAL", 46, 55], ["oseltamivir", "CHEMICAL", 67, 78], ["hydroxychloroquine", "CHEMICAL", 92, 110], ["lopinavir", "SIMPLE_CHEMICAL", 36, 45], ["ritonavir", "SIMPLE_CHEMICAL", 46, 55], ["oseltamivir", "SIMPLE_CHEMICAL", 67, 78], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 92, 110], ["Initial treatment regimens", "TREATMENT", 0, 26], ["lopinavir", "TREATMENT", 36, 45], ["ritonavir", "TREATMENT", 46, 55], ["high-dose oseltamivir", "TREATMENT", 57, 78], ["high-dose hydroxychloroquine", "TREATMENT", 82, 110], ["AKI", "PROBLEM", 148, 151], ["AKI", "OBSERVATION", 148, 151]]], ["22 23 However, newer therapeutic breakthroughs, such as remdesivir (NCT04292730, NCT04323761), tocilizumab (NCT04317092), favipiravir (NCT04310228), sarilumab (NCT04327388), sirolimus (NCT04341675) and combined hydroxychloroquine and azithromycin (NCT04329832) are being investigated and we are optimistic to see how these treatments improve the clinical outcomes of patients with COVID-19 and the incidence of AKI.", [["remdesivir", "CHEMICAL", 56, 66], ["tocilizumab", "CHEMICAL", 95, 106], ["favipiravir", "CHEMICAL", 122, 133], ["NCT04310228", "CHEMICAL", 135, 146], ["sarilumab", "CHEMICAL", 149, 158], ["NCT04327388", "CHEMICAL", 160, 171], ["sirolimus", "CHEMICAL", 174, 183], ["NCT04341675", "CHEMICAL", 185, 196], ["hydroxychloroquine", "CHEMICAL", 211, 229], ["azithromycin", "CHEMICAL", 234, 246], ["AKI", "DISEASE", 411, 414], ["remdesivir", "CHEMICAL", 56, 66], ["NCT04292730", "CHEMICAL", 68, 79], ["NCT04323761", "CHEMICAL", 81, 92], ["NCT04317092", "CHEMICAL", 108, 119], ["favipiravir", "CHEMICAL", 122, 133], ["NCT04310228", "CHEMICAL", 135, 146], ["sarilumab", "CHEMICAL", 149, 158], ["NCT04327388", "CHEMICAL", 160, 171], ["sirolimus", "CHEMICAL", 174, 183], ["NCT04341675", "CHEMICAL", 185, 196], ["hydroxychloroquine", "CHEMICAL", 211, 229], ["azithromycin", "CHEMICAL", 234, 246], ["NCT04329832", "CHEMICAL", 248, 259], ["remdesivir", "SIMPLE_CHEMICAL", 56, 66], ["tocilizumab", "SIMPLE_CHEMICAL", 95, 106], ["favipiravir", "SIMPLE_CHEMICAL", 122, 133], ["NCT04310228", "SIMPLE_CHEMICAL", 135, 146], ["sarilumab", "SIMPLE_CHEMICAL", 149, 158], ["NCT04327388", "SIMPLE_CHEMICAL", 160, 171], ["sirolimus", "SIMPLE_CHEMICAL", 174, 183], ["NCT04341675", "SIMPLE_CHEMICAL", 185, 196], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 211, 229], ["azithromycin", "SIMPLE_CHEMICAL", 234, 246], ["patients", "ORGANISM", 367, 375], ["patients", "SPECIES", 367, 375], ["tocilizumab", "TREATMENT", 95, 106], ["favipiravir", "TREATMENT", 122, 133], ["sarilumab", "TREATMENT", 149, 158], ["sirolimus", "TREATMENT", 174, 183], ["hydroxychloroquine", "TREATMENT", 211, 229], ["azithromycin", "TREATMENT", 234, 246], ["these treatments", "TREATMENT", 317, 333], ["COVID", "TEST", 381, 386], ["AKI", "PROBLEM", 411, 414], ["AKI", "OBSERVATION", 411, 414]]], ["Furthermore, it is possible that the virus itself can infect podocytes and renal tubular cells leading to nephrotoxicity and AKI based on a human cell study model.", [["podocytes", "ANATOMY", 61, 70], ["renal tubular cells", "ANATOMY", 75, 94], ["cell", "ANATOMY", 146, 150], ["nephrotoxicity", "DISEASE", 106, 120], ["AKI", "DISEASE", 125, 128], ["podocytes", "CELL", 61, 70], ["renal tubular cells", "CELL", 75, 94], ["human", "ORGANISM", 140, 145], ["cell", "CELL", 146, 150], ["podocytes", "CELL_TYPE", 61, 70], ["renal tubular cells", "CELL_TYPE", 75, 94], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["the virus", "PROBLEM", 33, 42], ["podocytes", "PROBLEM", 61, 70], ["renal tubular cells", "PROBLEM", 75, 94], ["nephrotoxicity", "PROBLEM", 106, 120], ["AKI", "PROBLEM", 125, 128], ["a human cell study model", "TEST", 138, 162], ["virus", "OBSERVATION", 37, 42], ["renal", "ANATOMY", 75, 80], ["tubular cells", "OBSERVATION", 81, 94], ["nephrotoxicity", "OBSERVATION", 106, 120], ["AKI", "OBSERVATION", 125, 128]]], ["24 Some studies also reported that viral RNA was detectable in urine of the infected patients.", [["urine", "ANATOMY", 63, 68], ["urine", "ORGANISM_SUBSTANCE", 63, 68], ["patients", "ORGANISM", 85, 93], ["viral RNA", "RNA", 35, 44], ["patients", "SPECIES", 85, 93], ["Some studies", "TEST", 3, 15], ["viral RNA", "PROBLEM", 35, 44], ["viral RNA", "OBSERVATION", 35, 44], ["infected", "OBSERVATION", 76, 84]]], ["25 26 However, whether these findings correlate with the pathogenesis remains unproven.Original researchOur meta-regression analyses demonstrated that the incidence of AKI was associated with increased mortality in patients with COVID-19 after adjustment for age and sex but not with adjustment for additional variables, such as hypertension, diabetes and baseline serum creatinine level.", [["serum", "ANATOMY", 365, 370], ["AKI", "DISEASE", 168, 171], ["hypertension", "DISEASE", 329, 341], ["diabetes", "DISEASE", 343, 351], ["creatinine", "CHEMICAL", 371, 381], ["creatinine", "CHEMICAL", 371, 381], ["patients", "ORGANISM", 215, 223], ["serum", "ORGANISM_SUBSTANCE", 365, 370], ["creatinine", "SIMPLE_CHEMICAL", 371, 381], ["patients", "SPECIES", 215, 223], ["Original researchOur meta-regression analyses", "TEST", 87, 132], ["AKI", "PROBLEM", 168, 171], ["increased mortality", "PROBLEM", 192, 211], ["COVID", "TEST", 229, 234], ["additional variables", "PROBLEM", 299, 319], ["hypertension", "PROBLEM", 329, 341], ["diabetes", "PROBLEM", 343, 351], ["baseline serum creatinine level", "PROBLEM", 356, 387], ["AKI", "OBSERVATION", 168, 171], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["mortality", "OBSERVATION", 202, 211], ["hypertension", "OBSERVATION", 329, 341]]], ["This implies that the overall mortality from COVID-19 could be confounded by other factors other than AKI.", [["AKI", "DISEASE", 102, 105], ["COVID-19", "CHEMICAL", 45, 53], ["COVID", "TEST", 45, 50], ["AKI", "PROBLEM", 102, 105], ["AKI", "OBSERVATION", 102, 105]]], ["However, our findings are comparable to what was previously described during SARS-CoV outbreak.", [["SARS-CoV outbreak", "DISEASE", 77, 94], ["SARS-CoV", "ORGANISM", 77, 85], ["SARS-CoV", "SPECIES", 77, 85]]], ["Up to 91.7% of SARS-CoV-infected patients with acute renal impairment died and the relative risk for mortality from acute renal impairment was 16.91 (95% CI 8.37 to 34.16; p<0.001).", [["renal", "ANATOMY", 53, 58], ["renal", "ANATOMY", 122, 127], ["SARS-CoV-infected", "DISEASE", 15, 32], ["acute renal impairment", "DISEASE", 47, 69], ["acute renal impairment", "DISEASE", 116, 138], ["SARS-CoV", "ORGANISM", 15, 23], ["patients", "ORGANISM", 33, 41], ["renal", "ORGAN", 53, 58], ["renal", "ORGAN", 122, 127], ["patients", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["acute renal impairment", "PROBLEM", 47, 69], ["acute renal impairment", "PROBLEM", 116, 138], ["CI", "TEST", 154, 156], ["p", "TEST", 172, 173], ["infected", "OBSERVATION", 24, 32], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["renal", "ANATOMY", 53, 58], ["impairment", "OBSERVATION", 59, 69], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["renal", "ANATOMY", 122, 127], ["impairment", "OBSERVATION", 128, 138]]], ["18 However, although we reported an OR of 13.3-fold for mortality from AKI, this crude OR was unadjusted for other variables due to statistical limitation.", [["AKI", "DISEASE", 71, 74], ["mortality", "PROBLEM", 56, 65], ["AKI", "PROBLEM", 71, 74], ["statistical limitation", "PROBLEM", 132, 154], ["AKI", "OBSERVATION", 71, 74]]], ["Large multinational studies comparing the clinical characteristics of survivors and non-survivors using multivariate analysis are ideal to describe the odds for mortality from AKI.Original researchHerein, we are the first to report the pooled incidence of AKI and its association with mortality in patients with COVID-19.", [["AKI", "DISEASE", 176, 179], ["AKI", "DISEASE", 256, 259], ["patients", "ORGANISM", 298, 306], ["patients", "SPECIES", 298, 306], ["Large multinational studies", "TEST", 0, 27], ["multivariate analysis", "TEST", 104, 125], ["AKI", "PROBLEM", 176, 179], ["AKI", "PROBLEM", 256, 259], ["COVID", "TEST", 312, 317], ["AKI", "OBSERVATION", 176, 179], ["AKI", "OBSERVATION", 256, 259]]], ["However, our study is subjected to certain limitations.", [["our study", "TEST", 9, 18]]], ["First, all studies were retrospective, making them susceptible to selection bias.", [["all studies", "TEST", 7, 18]]], ["However, given the current situation of SARS-CoV-2 outbreak, available data from clinical trials are limited.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV", "SPECIES", 40, 48], ["SARS", "PROBLEM", 40, 44]]], ["Second, the pooled mortality in our study was higher than what previously reported by the WHO.", [["the pooled mortality", "PROBLEM", 8, 28], ["our study", "TEST", 32, 41], ["mortality", "OBSERVATION", 19, 28]]], ["This could be secondary to selection bias as AKI was mainly described in critically ill patients.", [["AKI", "DISEASE", 45, 48], ["critically ill", "DISEASE", 73, 87], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["AKI", "PROBLEM", 45, 48]]], ["Third, stages and etiologies of AKI were not identified in all studies.", [["AKI", "DISEASE", 32, 35], ["AKI", "PROBLEM", 32, 35], ["all studies", "TEST", 59, 70], ["AKI", "OBSERVATION", 32, 35]]], ["One could argue that worsening stages of AKI are likely to be associated with higher mortality.", [["AKI", "DISEASE", 41, 44], ["AKI", "PROBLEM", 41, 44], ["worsening", "OBSERVATION_MODIFIER", 21, 30], ["AKI", "OBSERVATION", 41, 44]]], ["Additionally, the included studies provided limited data on the characteristics of patients with AKI, such as urine output status, and the need for dialysis.", [["urine", "ANATOMY", 110, 115], ["AKI", "DISEASE", 97, 100], ["patients", "ORGANISM", 83, 91], ["urine", "ORGANISM_SUBSTANCE", 110, 115], ["patients", "SPECIES", 83, 91], ["the included studies", "TEST", 14, 34], ["AKI", "PROBLEM", 97, 100], ["urine output", "TEST", 110, 122], ["dialysis", "TREATMENT", 148, 156], ["AKI", "OBSERVATION", 97, 100]]], ["This information is crucial to determine the severity and recoverability of AKI.", [["AKI", "DISEASE", 76, 79], ["AKI", "PROBLEM", 76, 79], ["AKI", "OBSERVATION", 76, 79]]], ["Fourth, the majority of included patients were Asian race as these studies were originated from China.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["these studies", "TEST", 61, 74]]], ["Certainly, there are some concerns that the data obtained from these studies may be incomplete due to ethical issues or lack of adequate follow-up duration especially in the early phase of the pandemic.", [["the data", "TEST", 40, 48], ["these studies", "TEST", 63, 76], ["ethical issues", "PROBLEM", 102, 116]]], ["Fifth, the definition for AKI was not uniformly described in every study.", [["AKI", "DISEASE", 26, 29], ["AKI", "PROBLEM", 26, 29], ["AKI", "OBSERVATION", 26, 29]]], ["Sixth, there were insufficient data to conduct the survival analysis since most studies did not provide the data on the time to death.", [["death", "DISEASE", 128, 133], ["the survival analysis", "TEST", 47, 68], ["most studies", "TEST", 75, 87]]], ["Moreover, the incidence of RRT may be under-represented at some facilities due to medical staff and/or equipment shortage.", [["RRT", "TREATMENT", 27, 30]]], ["Finally, the clinical information about COVID-19 is dynamic as the current practice varies based on evolving clinical evidence or similarly, the behavior of virus may revolve throughout the different phases in the pandemic.Original researchIn conclusion, at least to this point, AKI is an uncommon complication of COVID-19.", [["AKI", "DISEASE", 279, 282], ["COVID-19", "CHEMICAL", 314, 322], ["COVID", "TEST", 40, 45], ["the behavior of virus", "PROBLEM", 141, 162], ["AKI", "PROBLEM", 279, 282], ["COVID", "TEST", 314, 319], ["virus", "OBSERVATION", 157, 162], ["AKI", "OBSERVATION", 279, 282], ["uncommon", "OBSERVATION_MODIFIER", 289, 297], ["complication", "OBSERVATION", 298, 310]]], ["The incidence of AKI is high in critically ill patients with COVID-19.", [["AKI", "DISEASE", 17, 20], ["critically ill", "DISEASE", 32, 46], ["COVID-19", "CHEMICAL", 61, 69], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["AKI", "PROBLEM", 17, 20], ["COVID", "TEST", 61, 66], ["AKI", "OBSERVATION", 17, 20], ["high", "OBSERVATION_MODIFIER", 24, 28]]], ["Our study suggests an association between AKI and increased mortality.", [["AKI", "DISEASE", 42, 45], ["Our study", "TEST", 0, 9], ["AKI", "PROBLEM", 42, 45], ["increased mortality", "PROBLEM", 50, 69], ["AKI", "OBSERVATION", 42, 45], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["mortality", "OBSERVATION", 60, 69]]], ["Age, diabetes, hypertension, and elevated baseline serum creatinine levels were associated with increased AKI.", [["serum", "ANATOMY", 51, 56], ["diabetes", "DISEASE", 5, 13], ["hypertension", "DISEASE", 15, 27], ["creatinine", "CHEMICAL", 57, 67], ["AKI", "DISEASE", 106, 109], ["creatinine", "CHEMICAL", 57, 67], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["creatinine", "SIMPLE_CHEMICAL", 57, 67], ["diabetes", "PROBLEM", 5, 13], ["hypertension", "PROBLEM", 15, 27], ["elevated baseline serum creatinine levels", "PROBLEM", 33, 74], ["increased AKI", "PROBLEM", 96, 109], ["diabetes", "OBSERVATION", 5, 13], ["hypertension", "OBSERVATION", 15, 27], ["elevated", "OBSERVATION_MODIFIER", 33, 41], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["AKI", "OBSERVATION", 106, 109]]], ["More studies, including the ones from multinational databases, are encouraged to confirm our findings.Original researchContributors PH and WC performed literature search.", [["More studies", "TEST", 0, 12], ["multinational databases", "TEST", 38, 61], ["Original researchContributors PH", "TEST", 102, 134]]], ["PH, CQ, BB, and CT performed citation screening and data collection.", [["CQ", "CHEMICAL", 4, 6], ["CQ", "SIMPLE_CHEMICAL", 4, 6], ["PH", "TEST", 0, 2], ["CQ", "TEST", 4, 6], ["BB", "TEST", 8, 10], ["CT", "TEST", 16, 18], ["citation screening", "TEST", 29, 47], ["data collection", "TEST", 52, 67]]], ["PH analyzed the data.", [["PH", "TEST", 0, 2], ["the data", "TEST", 12, 20]]], ["PH, CQ and BB drafted the manuscript.", [["CQ", "CHEMICAL", 4, 6], ["CQ", "SIMPLE_CHEMICAL", 4, 6], ["PH", "TEST", 0, 2], ["CQ", "TEST", 4, 6], ["BB", "TEST", 11, 13]]], ["PH, SV, WC and NG revised the full text for submission.FundingThe authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.FundingCompeting interests None declared.Patient consent for publication Not required.Provenance and peer review Not commissioned; externally peer reviewed.Data availability statementAll data relevant to the study are included in the article or uploaded as supplementary information.Data availability statementThis article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ.", [["NG", "CHEMICAL", 15, 17], ["Patient", "SPECIES", 244, 251], ["PH", "TEST", 0, 2], ["NG", "TREATMENT", 15, 17], ["the study", "TEST", 407, 416], ["SV", "ANATOMY", 4, 6]]], ["You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.ORCID iDsPanupong Hansrivijit http:// orcid. org/ 0000-0002-5041-4290 Charat Thongprayoon http:// orcid. org/ 0000-0002-8313-3604", [["org/ 0000-0002-5041-4290", "SPECIES", 226, 250], ["org/ 0000-0002-8313-3604", "SPECIES", 286, 310]]]], "3b45489e57a93648e455f0ef47892355cc930a5b": [["IntroductionThe mammalian target of rapamycin complex 1 (mTORC1) is a heteromeric protein kinase which phosphorylates a diverse array of substrates.", [["rapamycin", "CHEMICAL", 36, 45], ["rapamycin", "CHEMICAL", 36, 45], ["mammalian target of rapamycin complex 1", "GENE_OR_GENE_PRODUCT", 16, 55], ["mTORC1", "GENE_OR_GENE_PRODUCT", 57, 63], ["mammalian target of rapamycin complex 1", "PROTEIN", 16, 55], ["mTORC1", "PROTEIN", 57, 63], ["heteromeric protein kinase", "PROTEIN", 70, 96], ["rapamycin complex", "TREATMENT", 36, 53], ["a heteromeric protein kinase", "TEST", 68, 96]]], ["It thereby activates multiple anabolic cellular processes, including protein synthesis, lipogenesis, and ribosome biogenesis, while also inhibiting catabolic processes, in particular, autophagy [1] . mTORC1 phosphorylates the protein kinase Unc-51 like autophagy activating kinase 1 (ULK1), thereby inhibiting its ability to stimulate autophagy [2] .", [["cellular", "ANATOMY", 39, 47], ["ribosome", "ANATOMY", 105, 113], ["cellular", "CELL", 39, 47], ["ribosome", "CELLULAR_COMPONENT", 105, 113], ["mTORC1", "GENE_OR_GENE_PRODUCT", 200, 206], ["Unc-51 like autophagy activating kinase 1", "GENE_OR_GENE_PRODUCT", 241, 282], ["ULK1", "GENE_OR_GENE_PRODUCT", 284, 288], ["mTORC1", "PROTEIN", 200, 206], ["protein kinase Unc-51", "PROTEIN", 226, 247], ["autophagy activating kinase 1", "PROTEIN", 253, 282], ["ULK1", "PROTEIN", 284, 288], ["multiple anabolic cellular processes", "PROBLEM", 21, 57], ["protein synthesis", "PROBLEM", 69, 86], ["lipogenesis", "PROBLEM", 88, 99], ["ribosome biogenesis", "PROBLEM", 105, 124], ["mTORC1 phosphorylates", "TEST", 200, 221], ["the protein kinase Unc", "TEST", 222, 244], ["autophagy activating kinase", "TEST", 253, 280], ["multiple", "OBSERVATION_MODIFIER", 21, 29], ["anabolic cellular processes", "OBSERVATION", 30, 57], ["ribosome biogenesis", "OBSERVATION", 105, 124]]], ["In addition, the transcription factor EB (TFEB), which promotes transcription of numerous genes encoding proteins involved in autophagy, is inhibited as a result of its phosphorylation by mTORC1 [3] and thus promotes lysosomal biogenesis [4, 5] .", [["lysosomal", "ANATOMY", 217, 226], ["EB", "GENE_OR_GENE_PRODUCT", 38, 40], ["TFEB", "GENE_OR_GENE_PRODUCT", 42, 46], ["mTORC1 [3", "GENE_OR_GENE_PRODUCT", 188, 197], ["lysosomal", "CELLULAR_COMPONENT", 217, 226], ["transcription factor EB", "PROTEIN", 17, 40], ["TFEB", "PROTEIN", 42, 46], ["mTORC1", "PROTEIN", 188, 194], ["the transcription factor EB", "TEST", 13, 40], ["numerous genes encoding proteins", "PROBLEM", 81, 113], ["lysosomal biogenesis", "OBSERVATION", 217, 237]]], ["Thus, mTORC1 suppresses autophagy in two distinct and complementary ways: one acting acutely (via ULK1) and the other over a longer term (TFEB).IntroductionAutophagy requires the function of lysosomes whose acidic interior permits the activity of their intraluminal degradative enzymes, such as acidophilic proteases.", [["lysosomes", "ANATOMY", 191, 200], ["intraluminal", "ANATOMY", 253, 265], ["mTORC1", "GENE_OR_GENE_PRODUCT", 6, 12], ["ULK1", "GENE_OR_GENE_PRODUCT", 98, 102], ["lysosomes", "CELLULAR_COMPONENT", 191, 200], ["mTORC1", "PROTEIN", 6, 12], ["ULK1", "PROTEIN", 98, 102], ["TFEB", "PROTEIN", 138, 142], ["intraluminal degradative enzymes", "PROTEIN", 253, 285], ["acidophilic proteases", "PROTEIN", 295, 316], ["IntroductionAutophagy", "TREATMENT", 144, 165], ["their intraluminal degradative enzymes", "TEST", 247, 285], ["acidophilic proteases", "PROBLEM", 295, 316], ["two distinct", "OBSERVATION_MODIFIER", 37, 49]]], ["Furthermore, mTORC1 is activated on the cytoplasmic surface of lysosomes by two different types of GTPases; Rheb mediates the activation of mTORC1 in response to hormones and growth factors that act via cell surface receptors, while the Rag GTPases relay information about the availability of amino acids, which positively regulate mTORC1 signalling [6] .", [["cytoplasmic surface", "ANATOMY", 40, 59], ["lysosomes", "ANATOMY", 63, 72], ["cell surface", "ANATOMY", 203, 215], ["amino acids", "CHEMICAL", 293, 304], ["amino acids", "CHEMICAL", 293, 304], ["mTORC1", "GENE_OR_GENE_PRODUCT", 13, 19], ["cytoplasmic surface", "CELLULAR_COMPONENT", 40, 59], ["lysosomes", "CELLULAR_COMPONENT", 63, 72], ["GTPases", "GENE_OR_GENE_PRODUCT", 99, 106], ["Rheb", "GENE_OR_GENE_PRODUCT", 108, 112], ["mTORC1", "GENE_OR_GENE_PRODUCT", 140, 146], ["cell", "CELL", 203, 207], ["Rag", "GENE_OR_GENE_PRODUCT", 237, 240], ["amino acids", "AMINO_ACID", 293, 304], ["mTORC1", "GENE_OR_GENE_PRODUCT", 332, 338], ["mTORC1", "PROTEIN", 13, 19], ["GTPases", "PROTEIN", 99, 106], ["Rheb", "PROTEIN", 108, 112], ["mTORC1", "PROTEIN", 140, 146], ["growth factors", "PROTEIN", 175, 189], ["cell surface receptors", "PROTEIN", 203, 225], ["Rag GTPases", "PROTEIN", 237, 248], ["mTORC1", "PROTEIN", 332, 338], ["growth factors", "PROBLEM", 175, 189], ["amino acids", "TREATMENT", 293, 304], ["two different", "OBSERVATION_MODIFIER", 76, 89]]], ["The Rag GTPases are associated with Ragulator complex, which is tethered to the lysosome through the vacuolar type H + -ATPase (v-ATPase) [7] .", [["lysosome", "ANATOMY", 80, 88], ["H +", "CHEMICAL", 115, 118], ["Rag GTPases", "GENE_OR_GENE_PRODUCT", 4, 15], ["Ragulator complex", "GENE_OR_GENE_PRODUCT", 36, 53], ["lysosome", "CELLULAR_COMPONENT", 80, 88], ["H + -ATPase", "GENE_OR_GENE_PRODUCT", 115, 126], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 128, 136], ["Rag GTPases", "PROTEIN", 4, 15], ["Ragulator complex", "PROTEIN", 36, 53], ["vacuolar type H + -ATPase", "PROTEIN", 101, 126], ["v-ATPase", "PROTEIN", 128, 136], ["Rag GTPases", "OBSERVATION", 4, 15]]], ["The significance of lysosomes as the platform on which mTORC1 is regulated may, at least in part, reflect the fact that proteolysis within the lysosome could provide amino acids to help sustain mTORC1 activity [8] [9] [10] .", [["lysosomes", "ANATOMY", 20, 29], ["lysosome", "ANATOMY", 143, 151], ["amino acids", "CHEMICAL", 166, 177], ["amino acids", "CHEMICAL", 166, 177], ["lysosomes", "CELLULAR_COMPONENT", 20, 29], ["mTORC1", "GENE_OR_GENE_PRODUCT", 55, 61], ["lysosome", "CELLULAR_COMPONENT", 143, 151], ["amino acids", "AMINO_ACID", 166, 177], ["mTORC1", "GENE_OR_GENE_PRODUCT", 194, 200], ["mTORC1", "PROTEIN", 55, 61], ["mTORC1", "PROTEIN", 194, 200], ["amino acids", "TREATMENT", 166, 177], ["mTORC1 activity", "TEST", 194, 209]]], ["Given that mTORC1 controls autophagy, another role for the lysosomal association of mTORC1 may be to allow mTORC1 to sense autophagic/lysosomal function and be regulated by it in times of lysosomal dysfunction, such as during reduced clearance of substrates [11] .IntroductionChloroquine (CQ) alkalinises the lumen of the lysosome and thus inhibits its pH-sensitive functions, although its mode of action is yet to be conclusively elucidated.", [["lysosomal", "ANATOMY", 59, 68], ["lysosomal", "ANATOMY", 134, 143], ["lysosomal", "ANATOMY", 188, 197], ["lumen", "ANATOMY", 309, 314], ["lysosome", "ANATOMY", 322, 330], ["Chloroquine", "CHEMICAL", 276, 287], ["CQ", "CHEMICAL", 289, 291], ["Chloroquine", "CHEMICAL", 276, 287], ["CQ", "CHEMICAL", 289, 291], ["mTORC1", "GENE_OR_GENE_PRODUCT", 11, 17], ["lysosomal", "CELLULAR_COMPONENT", 59, 68], ["mTORC1", "GENE_OR_GENE_PRODUCT", 84, 90], ["mTORC1", "GENE_OR_GENE_PRODUCT", 107, 113], ["lysosomal", "CELLULAR_COMPONENT", 134, 143], ["lysosomal", "CELLULAR_COMPONENT", 188, 197], ["Chloroquine", "SIMPLE_CHEMICAL", 276, 287], ["CQ", "SIMPLE_CHEMICAL", 289, 291], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 309, 314], ["lysosome", "CELLULAR_COMPONENT", 322, 330], ["mTORC1", "PROTEIN", 11, 17], ["mTORC1", "PROTEIN", 84, 90], ["mTORC1", "PROTEIN", 107, 113], ["lysosomal dysfunction", "PROBLEM", 188, 209], ["IntroductionChloroquine (CQ)", "TREATMENT", 264, 292], ["its pH", "TEST", 349, 355], ["lysosomal function", "OBSERVATION", 134, 152], ["lysosomal dysfunction", "OBSERVATION", 188, 209], ["lumen", "ANATOMY_MODIFIER", 309, 314], ["lysosome", "OBSERVATION", 322, 330]]], ["The most likely explanation is that CQ enters the lysosome by diffusion, but upon protonation to CQ 2+ , cannot diffuse out of the intralysosomal environment [12] .", [["lysosome", "ANATOMY", 50, 58], ["CQ", "CHEMICAL", 36, 38], ["CQ", "CHEMICAL", 97, 99], ["CQ", "CHEMICAL", 36, 38], ["CQ 2+", "CHEMICAL", 97, 102], ["CQ", "SIMPLE_CHEMICAL", 36, 38], ["lysosome", "CELLULAR_COMPONENT", 50, 58], ["CQ 2+", "SIMPLE_CHEMICAL", 97, 102], ["CQ", "PROBLEM", 36, 38], ["CQ", "TEST", 97, 99], ["most likely explanation", "UNCERTAINTY", 4, 27], ["diffuse", "OBSERVATION_MODIFIER", 112, 119]]], ["By mopping-up protons, this compound increases intralysosomal pH, and inhibits both intralysosomal proteolysis and fusion of the autophagosome with the lysosome (and ultimately autophagy) [12, 13] .", [["autophagosome", "ANATOMY", 129, 142], ["lysosome", "ANATOMY", 152, 160], ["protons", "SIMPLE_CHEMICAL", 14, 21], ["autophagosome", "CELLULAR_COMPONENT", 129, 142], ["lysosome", "CELLULAR_COMPONENT", 152, 160], ["this compound", "PROBLEM", 23, 36], ["intralysosomal pH", "PROBLEM", 47, 64], ["both intralysosomal proteolysis", "PROBLEM", 79, 110], ["increases", "OBSERVATION_MODIFIER", 37, 46], ["intralysosomal pH", "OBSERVATION", 47, 64], ["intralysosomal proteolysis", "OBSERVATION", 84, 110]]], ["Indeed, the utility of CQ as a pharmaceutical agent to treat malaria is based on its acidotropic nature, and its characteristic of entering, but, when protonated, being unable to leave the digestive vacuole of this parasite when they are inside red blood cells.", [["digestive vacuole", "ANATOMY", 189, 206], ["red blood cells", "ANATOMY", 245, 260], ["CQ", "CHEMICAL", 23, 25], ["malaria", "DISEASE", 61, 68], ["CQ", "CHEMICAL", 23, 25], ["CQ", "SIMPLE_CHEMICAL", 23, 25], ["digestive vacuole", "MULTI-TISSUE_STRUCTURE", 189, 206], ["red blood cells", "CELL", 245, 260], ["red blood cells", "CELL_TYPE", 245, 260], ["CQ", "TREATMENT", 23, 25], ["a pharmaceutical agent", "TREATMENT", 29, 51], ["malaria", "PROBLEM", 61, 68], ["red blood cells", "TEST", 245, 260], ["malaria", "OBSERVATION", 61, 68]]], ["In this case, however, CQ forms a complex with haem, which in turn disrupts membrane function to the point of high toxicity to the malarial protozoan [14, 15] .", [["membrane", "ANATOMY", 76, 84], ["CQ", "CHEMICAL", 23, 25], ["toxicity", "DISEASE", 115, 123], ["malarial protozoan", "DISEASE", 131, 149], ["CQ", "CHEMICAL", 23, 25], ["CQ", "SIMPLE_CHEMICAL", 23, 25], ["haem", "SIMPLE_CHEMICAL", 47, 51], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["a complex with haem", "PROBLEM", 32, 51], ["high toxicity", "PROBLEM", 110, 123], ["the malarial protozoan", "TEST", 127, 149]]], ["Recent interest has focused on the utility of CQ derivatives such as hydroxychloroquine in treating infections of the novel coronavirus termed as COVID-19 which have reached pandemic status [16] .", [["CQ", "CHEMICAL", 46, 48], ["hydroxychloroquine", "CHEMICAL", 69, 87], ["infections", "DISEASE", 100, 110], ["coronavirus", "DISEASE", 124, 135], ["CQ", "CHEMICAL", 46, 48], ["hydroxychloroquine", "CHEMICAL", 69, 87], ["CQ derivatives", "SIMPLE_CHEMICAL", 46, 60], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 69, 87], ["coronavirus", "ORGANISM", 124, 135], ["CQ derivatives", "TREATMENT", 46, 60], ["hydroxychloroquine", "TREATMENT", 69, 87], ["infections", "PROBLEM", 100, 110], ["the novel coronavirus", "PROBLEM", 114, 135], ["COVID", "TEST", 146, 151]]], ["Bafilomycin A1 (BafA) de-acidifies the lysosome in an indirect way by inhibiting the v-ATPase [17, 18] , which normally transfers protons into the lysosome to maintain its low pH.IntroductionGiven their very widespread use in diverse studies over many years, we felt it important to examine the possible impact of CQ and BafA on mTORC1 signalling.", [["lysosome", "ANATOMY", 39, 47], ["lysosome", "ANATOMY", 147, 155], ["Bafilomycin A1", "CHEMICAL", 0, 14], ["BafA", "CHEMICAL", 16, 20], ["CQ", "CHEMICAL", 314, 316], ["BafA", "CHEMICAL", 321, 325], ["Bafilomycin A1", "CHEMICAL", 0, 14], ["BafA", "CHEMICAL", 16, 20], ["Bafilomycin A1", "GENE_OR_GENE_PRODUCT", 0, 14], ["BafA", "SIMPLE_CHEMICAL", 16, 20], ["lysosome", "CELLULAR_COMPONENT", 39, 47], ["protons", "SIMPLE_CHEMICAL", 130, 137], ["lysosome", "CELLULAR_COMPONENT", 147, 155], ["CQ", "SIMPLE_CHEMICAL", 314, 316], ["BafA", "SIMPLE_CHEMICAL", 321, 325], ["mTORC1", "GENE_OR_GENE_PRODUCT", 329, 335], ["BafA", "PROTEIN", 16, 20], ["v-ATPase", "PROTEIN", 85, 93], ["mTORC1", "PROTEIN", 329, 335], ["Bafilomycin A1 (BafA)", "TREATMENT", 0, 21], ["the lysosome", "TREATMENT", 143, 155], ["its low pH", "PROBLEM", 168, 178], ["low pH", "OBSERVATION_MODIFIER", 172, 178]]], ["We find that each causes a reduction in mTORC1 activity.", [["mTORC1", "GENE_OR_GENE_PRODUCT", 40, 46], ["mTORC1", "PROTEIN", 40, 46], ["a reduction in mTORC1 activity", "PROBLEM", 25, 55], ["reduction", "OBSERVATION_MODIFIER", 27, 36], ["mTORC1 activity", "OBSERVATION", 40, 55]]], ["Furthermore, our data imply that agents that alkalinise intralysosomal pH should be considered not only inhibitors of autophagy, but rather as mimetics of acute lysosomal storage disorders (LSDs), in which reduced mTORC1 signalling has previously been implicated.", [["lysosomal", "ANATOMY", 161, 170], ["lysosomal storage disorders", "DISEASE", 161, 188], ["LSDs", "DISEASE", 190, 194], ["mTORC1", "GENE_OR_GENE_PRODUCT", 214, 220], ["mTORC1", "PROTEIN", 214, 220], ["alkalinise intralysosomal pH", "PROBLEM", 45, 73], ["autophagy", "PROBLEM", 118, 127], ["acute lysosomal storage disorders", "PROBLEM", 155, 188], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["lysosomal storage", "OBSERVATION", 161, 178], ["mTORC1 signalling", "OBSERVATION", 214, 231]]], ["Therefore, the impact of BafA and CQ on mTORC1 signalling should be taken into account when interpreting the effects of these widely used agents on cellular or organismal physiology.", [["cellular", "ANATOMY", 148, 156], ["BafA", "CHEMICAL", 25, 29], ["CQ", "CHEMICAL", 34, 36], ["CQ", "CHEMICAL", 34, 36], ["BafA", "GENE_OR_GENE_PRODUCT", 25, 29], ["CQ", "SIMPLE_CHEMICAL", 34, 36], ["mTORC1", "GENE_OR_GENE_PRODUCT", 40, 46], ["cellular", "CELL", 148, 156], ["mTORC1", "PROTEIN", 40, 46], ["BafA", "TREATMENT", 25, 29], ["mTORC1 signalling", "TREATMENT", 40, 57], ["organismal physiology", "OBSERVATION", 160, 181]]], ["Furthermore, we also report significant differences in the responses to these two agents on the 5 -AMP activated protein kinase (AMPK), another key regulator of cellular functions.Materials and methodsChemicals AZD8055 (Selleck Chem), bafilomycin A (Sigma-Aldrich), and rapamycin (Sigma-Aldrich) were all dissolved in DMSO, while CQ diphosphate salt (Sigma-Aldrich), leupeptin hydrochloride (Sigma-Aldrich), and sucrose (Sigma-Aldrich) were prepared in Milli-Q water.", [["cellular", "ANATOMY", 161, 169], ["5 -AMP", "CHEMICAL", 96, 102], ["AZD8055", "CHEMICAL", 211, 218], ["bafilomycin A", "CHEMICAL", 235, 248], ["Sigma-Aldrich", "CHEMICAL", 250, 263], ["rapamycin", "CHEMICAL", 270, 279], ["Sigma-Aldrich", "CHEMICAL", 281, 294], ["DMSO", "CHEMICAL", 318, 322], ["CQ diphosphate salt", "CHEMICAL", 330, 349], ["Sigma-Aldrich", "CHEMICAL", 351, 364], ["leupeptin hydrochloride", "CHEMICAL", 367, 390], ["Sigma-Aldrich", "CHEMICAL", 392, 405], ["sucrose", "CHEMICAL", 412, 419], ["5 -AMP", "CHEMICAL", 96, 102], ["AZD8055", "CHEMICAL", 211, 218], ["bafilomycin A", "CHEMICAL", 235, 248], ["Sigma-Aldrich", "CHEMICAL", 250, 263], ["rapamycin", "CHEMICAL", 270, 279], ["DMSO", "CHEMICAL", 318, 322], ["CQ diphosphate", "CHEMICAL", 330, 344], ["leupeptin hydrochloride", "CHEMICAL", 367, 390], ["sucrose", "CHEMICAL", 412, 419], ["5 -AMP activated protein kinase", "GENE_OR_GENE_PRODUCT", 96, 127], ["AMPK", "GENE_OR_GENE_PRODUCT", 129, 133], ["cellular", "CELL", 161, 169], ["AZD8055", "SIMPLE_CHEMICAL", 211, 218], ["Selleck Chem", "SIMPLE_CHEMICAL", 220, 232], ["bafilomycin A", "SIMPLE_CHEMICAL", 235, 248], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 250, 263], ["rapamycin", "SIMPLE_CHEMICAL", 270, 279], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 281, 294], ["DMSO", "SIMPLE_CHEMICAL", 318, 322], ["CQ diphosphate salt", "SIMPLE_CHEMICAL", 330, 349], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 351, 364], ["leupeptin hydrochloride", "SIMPLE_CHEMICAL", 367, 390], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 392, 405], ["sucrose", "SIMPLE_CHEMICAL", 412, 419], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 421, 434], ["Milli-Q water", "SIMPLE_CHEMICAL", 453, 466], ["5 -AMP activated protein kinase", "PROTEIN", 96, 127], ["AMPK", "PROTEIN", 129, 133], ["AMP activated protein kinase", "TREATMENT", 99, 127], ["Chemicals", "TEST", 201, 210], ["bafilomycin A (Sigma-Aldrich)", "TREATMENT", 235, 264], ["rapamycin (Sigma-Aldrich)", "TREATMENT", 270, 295], ["DMSO", "TREATMENT", 318, 322], ["CQ diphosphate salt (Sigma-Aldrich)", "TREATMENT", 330, 365], ["leupeptin hydrochloride", "TREATMENT", 367, 390], ["Sigma-Aldrich)", "TREATMENT", 392, 406], ["sucrose (Sigma-Aldrich)", "TREATMENT", 412, 435], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["cellular functions", "OBSERVATION", 161, 179]]], ["A total of 50\u00d7 MEM essential amino acids and 100\u00d7 MEM non-essential amino acids were supplied by Thermo Fisher.Cell cultureHuman lung carcinoma A549 and cervical cancer HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM, Sigma), supplemented with 10% (v/v) foetal calf serum (Life Technologies), 100 U/ml penicillin/streptomycin (Sigma), and incubated at 37 \u2022 C and 5% ( v / v ) CO 2 .Transient transfectionsiRNA to BECN1 (Santa Cruz) was introduced into cells using Lipofectamine 3000 (Life Technologies) according to the manufacturer's instructions.ImmunoblottingCells were plated on 9-cm 2 wells.", [["Cell cultureHuman lung carcinoma A549", "ANATOMY", 111, 148], ["cervical cancer HeLa cells", "ANATOMY", 153, 179], ["foetal calf serum", "ANATOMY", 272, 289], ["cells", "ANATOMY", 470, 475], ["Cells", "ANATOMY", 580, 585], ["amino acids", "CHEMICAL", 29, 40], ["amino acids", "CHEMICAL", 68, 79], ["lung carcinoma", "DISEASE", 129, 143], ["cervical cancer", "DISEASE", 153, 168], ["penicillin", "CHEMICAL", 320, 330], ["streptomycin", "CHEMICAL", 331, 343], ["amino acids", "CHEMICAL", 29, 40], ["amino acids", "CHEMICAL", 68, 79], ["penicillin", "CHEMICAL", 320, 330], ["streptomycin", "CHEMICAL", 331, 343], ["CO", "CHEMICAL", 394, 396], ["amino acids", "AMINO_ACID", 29, 40], ["amino acids", "AMINO_ACID", 68, 79], ["Cell", "CELL", 111, 115], ["lung carcinoma A549", "CELL", 129, 148], ["cervical cancer HeLa cells", "CELL", 153, 179], ["foetal", "ORGANISM", 272, 278], ["calf", "ORGANISM", 279, 283], ["serum", "ORGANISM_SUBSTANCE", 284, 289], ["penicillin", "SIMPLE_CHEMICAL", 320, 330], ["streptomycin", "SIMPLE_CHEMICAL", 331, 343], ["Sigma", "SIMPLE_CHEMICAL", 345, 350], ["BECN1", "GENE_OR_GENE_PRODUCT", 431, 436], ["cells", "CELL", 470, 475], ["Cells", "CELL", 580, 585], ["Cell cultureHuman lung carcinoma A549", "CELL_LINE", 111, 148], ["cervical cancer HeLa cells", "CELL_LINE", 153, 179], ["BECN1", "PROTEIN", 431, 436], ["Santa Cruz", "PROTEIN", 438, 448], ["calf", "SPECIES", 279, 283], ["A total of 50\u00d7 MEM essential amino acids", "TREATMENT", 0, 40], ["MEM non-essential amino acids", "TREATMENT", 50, 79], ["Cell cultureHuman lung carcinoma A549", "PROBLEM", 111, 148], ["cervical cancer HeLa cells", "PROBLEM", 153, 179], ["Dulbecco", "TEST", 194, 202], ["v/v) foetal calf serum (Life Technologies", "TREATMENT", 267, 308], ["penicillin", "TREATMENT", 320, 330], ["streptomycin", "TREATMENT", 331, 343], ["Lipofectamine", "TREATMENT", 482, 495], ["ImmunoblottingCells", "TREATMENT", 566, 585], ["lung", "ANATOMY", 129, 133], ["carcinoma", "OBSERVATION", 134, 143], ["cervical", "ANATOMY", 153, 161], ["cancer", "OBSERVATION", 162, 168], ["calf", "ANATOMY", 279, 283]]], ["Upon completion of described treatments, the medium was removed, and cells were washed with 2 ml of PBS, after which 250 \u03bcl of RIPA buffer supplemented with 2.5 mM of Na 2 H 2 P 2 O 7 (Sigma-Aldrich), 1 mM \u03b2-glycerophosphate (Sigma-Aldrich), 1 mM Na 3 VO 4 (Sigma-Aldrich), and 1\u00d7 Protease Inhibitor Cocktail (Roche) was added.", [["cells", "ANATOMY", 69, 74], ["Na", "CHEMICAL", 167, 169], ["\u03b2-glycerophosphate", "CHEMICAL", 206, 224], ["Na", "CHEMICAL", 247, 249], ["Na 2 H", "CHEMICAL", 167, 173], ["O 7", "CHEMICAL", 180, 183], ["\u03b2-glycerophosphate", "CHEMICAL", 206, 224], ["Na 3 VO 4", "CHEMICAL", 247, 256], ["cells", "CELL", 69, 74], ["Na 2 H 2 P 2 O 7", "SIMPLE_CHEMICAL", 167, 183], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 185, 198], ["mM \u03b2-glycerophosphate", "SIMPLE_CHEMICAL", 203, 224], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 226, 239], ["Na 3 VO 4", "SIMPLE_CHEMICAL", 247, 256], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 258, 271], ["Protease Inhibitor Cocktail", "GENE_OR_GENE_PRODUCT", 281, 308], ["Roche", "ORGANISM_SUBSTANCE", 310, 315], ["described treatments", "TREATMENT", 19, 39], ["PBS", "TREATMENT", 100, 103], ["RIPA buffer supplemented", "TREATMENT", 127, 151], ["Na", "TEST", 167, 169], ["Sigma-Aldrich)", "TREATMENT", 185, 199], ["glycerophosphate (Sigma-Aldrich)", "TREATMENT", 208, 240], ["Sigma-Aldrich)", "TREATMENT", 258, 272], ["Protease Inhibitor Cocktail (Roche)", "TREATMENT", 281, 316]]], ["Cells were then rocked for 30 min at 4 \u2022 C. Cells were harvested into microfuge tubes and centrifuged at 13000\u00d7g for 30 min at 4 \u2022 C. The supernatant was maintained and transferred to a new microfuge tube.", [["Cells", "ANATOMY", 0, 5], ["Cells", "ANATOMY", 44, 49], ["supernatant", "ANATOMY", 138, 149], ["Cells", "CELL", 0, 5], ["Cells", "CELL", 44, 49], ["tube", "TISSUE", 200, 204], ["microfuge tubes", "TREATMENT", 70, 85], ["a new microfuge tube", "TREATMENT", 184, 204], ["tube", "OBSERVATION", 200, 204]]], ["The protein concentration of each sample was determined via Lowry [19] .", [["sample", "ANATOMY", 34, 40]]], ["Identical amounts of quantified proteins of each were then electrophoresed through a 4-12% (w/v) acrylamide gradient SDS/PAGE gel and transferred to a PVDF membrane.ImmunoblottingMembranes were incubated for 1 h at room temperature in PBS containing 0.1% Tween 20 and 2% bovine serum albumin (BSA) and then rocked overnight at 4 \u2022 C in the same solution supplemented with the primary antibody at a 1/1000 dilution (unless otherwise stated).", [["PVDF membrane", "ANATOMY", 151, 164], ["Membranes", "ANATOMY", 179, 188], ["serum", "ANATOMY", 278, 283], ["acrylamide", "CHEMICAL", 97, 107], ["acrylamide", "CHEMICAL", 97, 107], ["PVDF", "CHEMICAL", 151, 155], ["Tween 20", "CHEMICAL", 255, 263], ["w/v) acrylamide", "SIMPLE_CHEMICAL", 92, 107], ["membrane", "CELLULAR_COMPONENT", 156, 164], ["bovine", "ORGANISM", 271, 277], ["serum", "ORGANISM_SUBSTANCE", 278, 283], ["albumin", "SIMPLE_CHEMICAL", 284, 291], ["BSA", "SIMPLE_CHEMICAL", 293, 296], ["primary antibody", "PROTEIN", 376, 392], ["bovine", "SPECIES", 271, 277], ["bovine", "SPECIES", 271, 277], ["w/v) acrylamide gradient SDS/PAGE gel", "TREATMENT", 92, 129], ["a PVDF membrane", "TREATMENT", 149, 164], ["ImmunoblottingMembranes", "PROBLEM", 165, 188], ["2% bovine serum albumin", "TREATMENT", 268, 291], ["amounts", "OBSERVATION_MODIFIER", 10, 17]]], ["The following day, the membrane was washed three times for 5-10 min at room temperature in PBS containing 0.1% Tween 20, then incubated at room temperature for 1 h in PBS containing 0.1% Tween 20 and 2% BSA plus 1/3000 horseradish peroxidase-linked sheep anti-mouse (GE Healthcare), goat anti-rabbit (Millipore), or 1/5000 mouse anti-human \u03b2-actin (Sigma) IgG.", [["membrane", "ANATOMY", 23, 31], ["BSA", "CHEMICAL", 203, 206], ["Tween 20", "CHEMICAL", 111, 119], ["Tween 20", "CHEMICAL", 187, 195], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["BSA", "SIMPLE_CHEMICAL", 203, 206], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 219, 241], ["sheep", "ORGANISM", 249, 254], ["goat", "ORGANISM", 283, 287], ["mouse", "ORGANISM", 323, 328], ["anti-human", "ORGANISM", 329, 339], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 340, 347], ["horseradish peroxidase", "PROTEIN", 219, 241], ["sheep anti-mouse", "PROTEIN", 249, 265], ["goat anti-rabbit", "PROTEIN", 283, 299], ["1/5000 mouse anti-human \u03b2-actin (Sigma) IgG.", "PROTEIN", 316, 360], ["horseradish", "SPECIES", 219, 230], ["sheep", "SPECIES", 249, 254], ["anti-mouse", "SPECIES", 255, 265], ["goat", "SPECIES", 283, 287], ["anti-rabbit", "SPECIES", 288, 299], ["mouse", "SPECIES", 323, 328], ["anti-human", "SPECIES", 329, 339], ["sheep", "SPECIES", 249, 254], ["goat", "SPECIES", 283, 287], ["mouse", "SPECIES", 323, 328], ["horseradish peroxidase", "TREATMENT", 219, 241], ["sheep anti-mouse (GE Healthcare", "TREATMENT", 249, 280], ["goat anti-rabbit (Millipore)", "TREATMENT", 283, 311]]], ["The membrane was then washed three times for 5-10 min at room temperature in PBS with 0.1% Tween 20, drained, treated with the Supersignal West Pico Plus Chemiluminescent Substrate (Thermo Fisher), developed on an LAS-4000 apparatus (Fujifilm), and analysed using Multigauge 1D software (Fujifilm).", [["membrane", "ANATOMY", 4, 12], ["Tween 20", "CHEMICAL", 91, 99], ["membrane", "CELLULAR_COMPONENT", 4, 12]]], ["In some cases, further densitometric quantification was implemented with ImageJ (NIH).", [["further densitometric quantification", "TEST", 15, 51]]], ["The following primary antibodies were supplied by Cell Signaling Technology: rabbit polyclonal anti-human ribosomal protein S6 (rpS6) P-S240/244, rabbit polyclonal anti-human p70S6K1 P-T389, rabbit polyclonal anti-human p62, rabbit polyclonal anti-human acetyl-CoA carboxylase (ACC), and rabbit polyclonal anti-rat ACC P-S79.", [["Cell", "ANATOMY", 50, 54], ["acetyl", "CHEMICAL", 254, 260], ["acetyl-CoA", "CHEMICAL", 254, 264], ["Cell", "CELL", 50, 54], ["rabbit", "ORGANISM", 77, 83], ["anti-human ribosomal protein S6", "GENE_OR_GENE_PRODUCT", 95, 126], ["rabbit", "ORGANISM", 146, 152], ["rabbit", "ORGANISM", 191, 197], ["p62", "GENE_OR_GENE_PRODUCT", 220, 223], ["rabbit", "ORGANISM", 225, 231], ["acetyl-CoA carboxylase", "GENE_OR_GENE_PRODUCT", 254, 276], ["ACC", "SIMPLE_CHEMICAL", 278, 281], ["rabbit", "ORGANISM", 288, 294], ["primary antibodies", "PROTEIN", 14, 32], ["rabbit polyclonal anti-human ribosomal protein S6 (rpS6) P", "PROTEIN", 77, 135], ["S240/244", "PROTEIN", 136, 144], ["rabbit polyclonal anti-human p70S6K1 P", "PROTEIN", 146, 184], ["T389", "PROTEIN", 185, 189], ["rabbit polyclonal anti-human p62", "PROTEIN", 191, 223], ["rabbit polyclonal anti-human acetyl-CoA carboxylase", "PROTEIN", 225, 276], ["ACC", "PROTEIN", 278, 281], ["rabbit polyclonal anti-rat ACC P-S79", "PROTEIN", 288, 324], ["rabbit", "SPECIES", 77, 83], ["rabbit", "SPECIES", 146, 152], ["anti-human", "SPECIES", 164, 174], ["rabbit", "SPECIES", 191, 197], ["anti-human", "SPECIES", 209, 219], ["rabbit", "SPECIES", 225, 231], ["rabbit", "SPECIES", 288, 294], ["rabbit", "SPECIES", 77, 83], ["rabbit", "SPECIES", 146, 152], ["rabbit", "SPECIES", 191, 197], ["rabbit", "SPECIES", 225, 231], ["rabbit", "SPECIES", 288, 294], ["rabbit polyclonal anti-human ribosomal protein", "TEST", 77, 123], ["rpS6", "TEST", 128, 132], ["P", "TEST", 134, 135], ["rabbit polyclonal anti-human", "TEST", 146, 174], ["P", "TEST", 183, 184], ["rabbit polyclonal anti-human p62", "TEST", 191, 223], ["rabbit polyclonal anti-human acetyl", "TREATMENT", 225, 260], ["CoA carboxylase (ACC)", "TREATMENT", 261, 282], ["rabbit polyclonal anti-rat ACC P", "TREATMENT", 288, 320]]], ["Mouse monoclonal anti-human rpS6, rabbit polyclonal anti-rat p70S6K1, rabbit polyclonal anti-human TSC1 (used at 1/200 dilution) and rabbit polyclonal anti-human TSC2 (used at 1/200 dilution) were purchased from Santa Cruz.", [["Mouse", "ORGANISM", 0, 5], ["rpS6", "GENE_OR_GENE_PRODUCT", 28, 32], ["rabbit", "ORGANISM", 34, 40], ["p70S6K1", "GENE_OR_GENE_PRODUCT", 61, 68], ["rabbit", "ORGANISM", 70, 76], ["TSC1", "GENE_OR_GENE_PRODUCT", 99, 103], ["rabbit", "ORGANISM", 133, 139], ["TSC2", "GENE_OR_GENE_PRODUCT", 162, 166], ["Mouse monoclonal anti-human rpS6", "PROTEIN", 0, 32], ["rabbit polyclonal anti-rat p70S6K1", "PROTEIN", 34, 68], ["rabbit polyclonal anti-human TSC1", "PROTEIN", 70, 103], ["rabbit polyclonal anti-human TSC2", "PROTEIN", 133, 166], ["Santa Cruz", "PROTEIN", 212, 222], ["Mouse", "SPECIES", 0, 5], ["anti-human", "SPECIES", 17, 27], ["rabbit", "SPECIES", 34, 40], ["anti-rat", "SPECIES", 52, 60], ["rabbit", "SPECIES", 70, 76], ["rabbit", "SPECIES", 133, 139], ["anti-human", "SPECIES", 151, 161], ["Mouse", "SPECIES", 0, 5], ["rabbit", "SPECIES", 34, 40], ["rabbit", "SPECIES", 70, 76], ["rabbit", "SPECIES", 133, 139], ["Mouse monoclonal anti-human rpS6", "TREATMENT", 0, 32], ["rabbit polyclonal anti-rat p70S6K1", "TREATMENT", 34, 68], ["rabbit polyclonal anti-human TSC1", "TREATMENT", 70, 103], ["rabbit polyclonal anti-human TSC2", "TREATMENT", 133, 166]]], ["Rabbit polyclonal anti-human microtubule-associated proteins 1A/1B light chain 3B (LC3) and rabbit polyclonal anti-human beclin-1 were provided by Novus Biologicals.", [["microtubule", "ANATOMY", 29, 40], ["Rabbit", "ORGANISM", 0, 6], ["anti-human microtubule-associated proteins 1A/1B light chain 3B", "GENE_OR_GENE_PRODUCT", 18, 81], ["LC3", "GENE_OR_GENE_PRODUCT", 83, 86], ["rabbit", "ORGANISM", 92, 98], ["beclin-1", "GENE_OR_GENE_PRODUCT", 121, 129], ["Novus Biologicals", "ORGANISM", 147, 164], ["Rabbit polyclonal anti-human microtubule-associated proteins 1A/1B light chain 3B", "PROTEIN", 0, 81], ["LC3", "PROTEIN", 83, 86], ["rabbit polyclonal anti-human beclin-1", "PROTEIN", 92, 129], ["Novus Biologicals", "PROTEIN", 147, 164], ["Rabbit", "SPECIES", 0, 6], ["anti-human", "SPECIES", 18, 28], ["rabbit", "SPECIES", 92, 98], ["anti-human", "SPECIES", 110, 120], ["Rabbit", "SPECIES", 0, 6], ["rabbit", "SPECIES", 92, 98], ["Rabbit polyclonal anti-human microtubule", "TEST", 0, 40], ["proteins 1A", "TEST", 52, 63], ["light chain", "TEST", 67, 78], ["LC3", "TEST", 83, 86], ["rabbit polyclonal anti-human beclin", "TREATMENT", 92, 127], ["anti-human microtubule", "OBSERVATION", 18, 40]]], ["Rabbit polyclonal anti-human RAPTOR was custom made by MRC PPU Reagents (University of Dundee) while monoclonal anti-human lysosomal-associated membrane protein 1 (LAMP-1) was raised in-house.Immunofluorescence microscopyCells were plated on four-well Lab-Tek II chamber slides (Thermo Scientific).", [["Cells", "ANATOMY", 221, 226], ["Rabbit", "ORGANISM", 0, 6], ["anti-human lysosomal-associated membrane protein 1", "GENE_OR_GENE_PRODUCT", 112, 162], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 164, 170], ["Cells", "CELL", 221, 226], ["Rabbit polyclonal anti-human RAPTOR", "PROTEIN", 0, 35], ["monoclonal anti-human lysosomal-associated membrane protein 1", "PROTEIN", 101, 162], ["LAMP", "PROTEIN", 164, 168], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit polyclonal anti-human RAPTOR", "TREATMENT", 0, 35], ["monoclonal anti-human lysosomal", "TEST", 101, 132], ["membrane protein", "TEST", 144, 160], ["LAMP", "TEST", 164, 168], ["Immunofluorescence microscopy", "TEST", 192, 221], ["Cells", "TEST", 221, 226]]], ["Upon completion of described treatments, cells were rinsed three times in PBS, then fixed for 15 min in 4% PFA.", [["cells", "ANATOMY", 41, 46], ["PFA", "CHEMICAL", 107, 110], ["cells", "CELL", 41, 46], ["PFA", "SIMPLE_CHEMICAL", 107, 110], ["described treatments", "TREATMENT", 19, 39], ["cells", "TREATMENT", 41, 46]]], ["Fixed cells were washed three times for 5 min at room temperature in PBS and permeabilised for 5 min in PBS containing 0.05% Triton X-100.", [["cells", "ANATOMY", 6, 11], ["Triton X-100", "CHEMICAL", 125, 137], ["cells", "CELL", 6, 11], ["Triton X-100", "SIMPLE_CHEMICAL", 125, 137], ["Fixed cells", "PROBLEM", 0, 11]]], ["Cells were then washed three times for 5 min at room temperature in PBS and blocked for 30 min at room temperature in 10% normal donkey serum (Jackson ImmunoResearch).", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 136, 141], ["Cells", "CELL", 0, 5], ["donkey", "ORGANISM", 129, 135], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["donkey", "SPECIES", 129, 135]]], ["This was replaced with 2% normal donkey serum containing primary antibodies at appropriate concentrations and incubated at room temperature for 1 h.", [["serum", "ANATOMY", 40, 45], ["donkey", "ORGANISM", 33, 39], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["primary antibodies", "PROTEIN", 57, 75], ["donkey", "SPECIES", 33, 39], ["donkey", "SPECIES", 33, 39], ["primary antibodies", "TREATMENT", 57, 75]]], ["Cells were washed three times for 5 min in PBS and secondary antibodies in 2% normal donkey serum were then applied and incubated at room temperature for 1 h.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 92, 97], ["Cells", "CELL", 0, 5], ["donkey", "ORGANISM", 85, 91], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["secondary antibodies", "PROTEIN", 51, 71], ["donkey", "SPECIES", 85, 91], ["donkey", "SPECIES", 85, 91], ["Cells", "TEST", 0, 5], ["PBS", "TREATMENT", 43, 46], ["secondary antibodies", "TEST", 51, 71]]], ["Cells were washed three times for 5 min in PBS and slides mounted in VectaShield with DAPI (Vector Laboratories).", [["Cells", "ANATOMY", 0, 5], ["DAPI", "CHEMICAL", 86, 90], ["Cells", "CELL", 0, 5], ["DAPI", "SIMPLE_CHEMICAL", 86, 90]]], ["The following antibodies were used at 1/200 dilution: sheep anti-human LAMP-1 (raised in-house), rabbit anti-human mTOR (Cell Signaling Technology), donkey anti-rabbit Alexa Fluor 488 (Jackson ImmunoResearch), and donkey anti-sheep Alexa Fluor 594 (Jackson ImmunoResearch).", [["Cell", "ANATOMY", 121, 125], ["Alexa Fluor 594", "CHEMICAL", 232, 247], ["Alexa Fluor 488", "CHEMICAL", 168, 183], ["Alexa Fluor 594", "CHEMICAL", 232, 247], ["sheep", "ORGANISM", 54, 59], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 71, 77], ["rabbit", "ORGANISM", 97, 103], ["mTOR", "GENE_OR_GENE_PRODUCT", 115, 119], ["Cell", "CELL", 121, 125], ["Fluor 488", "SIMPLE_CHEMICAL", 174, 183], ["donkey", "ORGANISM", 214, 220], ["Fluor 594", "SIMPLE_CHEMICAL", 238, 247], ["sheep anti-human LAMP-1", "PROTEIN", 54, 77], ["rabbit anti-human mTOR", "PROTEIN", 97, 119], ["donkey anti-rabbit Alexa Fluor 488", "PROTEIN", 149, 183], ["Jackson ImmunoResearch", "PROTEIN", 185, 207], ["donkey anti-sheep Alexa Fluor 594", "PROTEIN", 214, 247], ["Jackson ImmunoResearch", "PROTEIN", 249, 271], ["sheep", "SPECIES", 54, 59], ["rabbit", "SPECIES", 97, 103], ["donkey", "SPECIES", 149, 155], ["anti-rabbit", "SPECIES", 156, 167], ["donkey", "SPECIES", 214, 220], ["sheep", "SPECIES", 54, 59], ["rabbit", "SPECIES", 97, 103], ["donkey anti-rabbit Alexa Fluor 488 (Jackson ImmunoResearch", "SPECIES", 149, 207], ["donkey anti-sheep Alexa Fluor 594 (Jackson ImmunoResearch", "SPECIES", 214, 271], ["sheep anti-human LAMP", "TREATMENT", 54, 75], ["rabbit anti-human mTOR", "TREATMENT", 97, 119], ["donkey anti-rabbit Alexa Fluor", "TREATMENT", 149, 179]]], ["Slides were examined and imaged on a Leica TCS SP8X confocal microscope.", [["TCS", "CHEMICAL", 43, 46]]], ["Images were analysed using the Fiji package [20] .", [["Images", "TEST", 0, 6]]], ["Mander's coefficients were determined using the JACoP function [21] of ImageJ (NIH).Magic red and lysotracker microscopyCells were plated on four-well Lab-Tek II chamber slides (Thermo Scientific).", [["Cells", "ANATOMY", 120, 125], ["Cells", "CELL", 120, 125], ["the JACoP function", "TEST", 44, 62], ["Magic red", "TREATMENT", 84, 93], ["lysotracker microscopy", "TEST", 98, 120], ["Cells", "TEST", 120, 125]]], ["One hour prior to the completion of described treatments, growth medium was also supplemented with Magic Red Cathepsin L Kit (Bio-Rad) or Lyso-Tracker Red DND-99 (Life Technologies) according to the manufacturers' instructions.", [["DND-99", "CHEMICAL", 155, 161], ["Lyso-Tracker Red DND-99", "SPECIES", 138, 161], ["described treatments", "TREATMENT", 36, 56], ["growth medium", "TREATMENT", 58, 71], ["Magic Red Cathepsin L Kit", "TREATMENT", 99, 124], ["Lyso", "TEST", 138, 142]]], ["Cells were rinsed three times in PBS, then fixed for 15 min in 4% PFA.", [["Cells", "ANATOMY", 0, 5], ["PFA", "CHEMICAL", 66, 69], ["Cells", "CELL", 0, 5], ["PFA", "SIMPLE_CHEMICAL", 66, 69], ["Cells", "TEST", 0, 5]]], ["Fixed cells were washed three times for 5 min at room temperature in PBS and slides mounted in VectaShield with DAPI (Vector Laboratories).", [["cells", "ANATOMY", 6, 11], ["DAPI", "CHEMICAL", 112, 116], ["cells", "CELL", 6, 11], ["DAPI", "SIMPLE_CHEMICAL", 112, 116], ["Fixed cells", "PROBLEM", 0, 11]]], ["Slides were examined and imaged on a Leica TCS SP8X confocal microscope.", [["TCS", "CHEMICAL", 43, 46]]], ["To permit a comparison, the exposure time for the detection of Magic Red or LysoTracker Red DND-99 was maintained at a constant.", [["DND-99", "CHEMICAL", 92, 98], ["Magic Red", "CHEMICAL", 63, 72], ["DND-99", "CHEMICAL", 92, 98], ["LysoTracker Red DND-99", "SIMPLE_CHEMICAL", 76, 98], ["Red DND-99", "SPECIES", 88, 98], ["the detection", "TEST", 46, 59], ["Magic Red", "PROBLEM", 63, 72], ["LysoTracker Red DND", "TREATMENT", 76, 95]]], ["Images were analysed using the Fiji package [20] .Quantitative real-time PCRCells were plated on to 9-cm 2 wells.", [["Images", "TEST", 0, 6]]], ["Upon completion of the described treatments, medium was removed, and cells were washed with 2 ml of PBS, after which 500 \u03bcl of TRIzol reagent (Life Technologies) was added.", [["cells", "ANATOMY", 69, 74], ["cells", "CELL", 69, 74], ["TRIzol", "ORGANISM", 127, 133], ["the described treatments", "TREATMENT", 19, 43], ["PBS", "TREATMENT", 100, 103], ["TRIzol reagent (Life Technologies", "TREATMENT", 127, 160]]], ["Total RNA was subsequently prepared according to the manufacturer's instructions, 500 ng of which provided a template for the preparation of complementary DNA (cDNA) using the SuperScript III First Strand Synthesis System (Life Technologies).", [["DNA", "CELLULAR_COMPONENT", 155, 158], ["complementary DNA", "DNA", 141, 158], ["cDNA", "DNA", 160, 164], ["Total RNA", "TREATMENT", 0, 9], ["a template", "TREATMENT", 107, 117], ["complementary DNA (cDNA", "TREATMENT", 141, 164], ["the SuperScript III First Strand Synthesis System (Life Technologies", "TREATMENT", 172, 240]]], ["The cDNA was then analysed via quantitative real-time PCR (qPCR) employing primers (Table 1 ) designed to amplify fragments of the coding sequences of the lysosomal membrane protein LAMP-1 (Entrez nucleotide accession number NM 005561), the autophagy-related proteins BECN1 (Entrez nucleotide accession number NM 003766.4), and p62/SQSTM1 (Entrez nucleotide accession number NM 003900.4), as well as the internal control \u03b2-actin.", [["lysosomal membrane", "ANATOMY", 155, 173], ["nucleotide", "CHEMICAL", 197, 207], ["nucleotide", "CHEMICAL", 347, 357], ["nucleotide", "CHEMICAL", 197, 207], ["nucleotide", "CHEMICAL", 347, 357], ["lysosomal membrane", "CELLULAR_COMPONENT", 155, 173], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 182, 188], ["BECN1", "GENE_OR_GENE_PRODUCT", 268, 273], ["p62", "GENE_OR_GENE_PRODUCT", 328, 331], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 332, 338], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 421, 428], ["cDNA", "DNA", 4, 8], ["lysosomal membrane protein LAMP-1", "PROTEIN", 155, 188], ["autophagy-related proteins", "PROTEIN", 241, 267], ["BECN1", "PROTEIN", 268, 273], ["p62", "PROTEIN", 328, 331], ["SQSTM1", "PROTEIN", 332, 338], ["\u03b2-actin", "PROTEIN", 421, 428], ["The cDNA", "TEST", 0, 8], ["the lysosomal membrane protein LAMP", "TEST", 151, 186], ["the autophagy", "TEST", 237, 250], ["the internal control \u03b2-actin", "TREATMENT", 400, 428], ["lysosomal membrane", "ANATOMY", 155, 173]]], ["This entailed preparing a mixture containing the equivalent of 25 ng of the original template RNA in 1\u00d7 Fast SYBR Green Mix (Applied Biosystems) and 200 nM of the relevant reverse and forward primer oligonucleotides (Table 1) . qPCRs proceeded as follows on an ABI Step One Plus qPCR instrument (Applied Biosystems): 95 \u2022 C for 20 s, 40\u00d7 (95 \u2022 C for 3 s, 60 \u2022 C for 30 s).", [["template RNA", "RNA", 85, 97], ["a mixture", "TREATMENT", 24, 33], ["the original template RNA", "TREATMENT", 72, 97], ["the relevant reverse and forward primer oligonucleotides", "TREATMENT", 159, 215], ["an ABI Step", "TREATMENT", 258, 269], ["qPCR instrument", "TEST", 279, 294]]], ["The comparative threshold cycle protocol was employed to determine amounts of the target mRNA.StatisticsFor data represented graphically, error bars represent + \u2212 standard error of the mean of the indicated number of independent experiments performed.", [["target mRNA", "RNA", 82, 93], ["The comparative threshold cycle protocol", "TREATMENT", 0, 40]]], ["Statistical significance was determined using unpaired Student's t test.", [["Student's t test", "TEST", 55, 71]]], ["P\u22640.001, ****P\u22640.0001.Agents that cause lysosomal alkalinisation impair mTORC1 signallingBafA interferes with lysosomal function by inhibiting the v-ATPase, thereby promoting alkalinisation of the lysosomal lumen [15, 16] .", [["lysosomal", "ANATOMY", 40, 49], ["lysosomal", "ANATOMY", 110, 119], ["lysosomal lumen", "ANATOMY", 197, 212], ["lysosomal", "CELLULAR_COMPONENT", 40, 49], ["mTORC1", "GENE_OR_GENE_PRODUCT", 72, 78], ["BafA", "GENE_OR_GENE_PRODUCT", 89, 93], ["lysosomal", "CELLULAR_COMPONENT", 110, 119], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 147, 155], ["lysosomal lumen", "CELLULAR_COMPONENT", 197, 212], ["mTORC1", "PROTEIN", 72, 78], ["BafA", "PROTEIN", 89, 93], ["v-ATPase", "PROTEIN", 147, 155], ["Agents", "TREATMENT", 22, 28], ["lysosomal alkalinisation", "PROBLEM", 40, 64], ["lysosomal alkalinisation", "OBSERVATION", 40, 64], ["lysosomal lumen", "OBSERVATION", 197, 212]]], ["We thus first examined whether treating cells with BafA affected mTORC1 signalling by applying the commonly used procedure of assessing the phosphorylation of its downstream effectors in whole cell extracts via immunoblotting [7, 8] , which is more informative regarding intracellular mTORC1 activity than attempting to measure the activity of mTORC1 after isolation from cells which does not yield reliable results.", [["cells", "ANATOMY", 40, 45], ["cell extracts", "ANATOMY", 193, 206], ["intracellular", "ANATOMY", 271, 284], ["cells", "ANATOMY", 372, 377], ["BafA", "CHEMICAL", 51, 55], ["cells", "CELL", 40, 45], ["BafA", "GENE_OR_GENE_PRODUCT", 51, 55], ["mTORC1", "GENE_OR_GENE_PRODUCT", 65, 71], ["cell extracts", "ORGANISM_SUBSTANCE", 193, 206], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 271, 284], ["mTORC1", "GENE_OR_GENE_PRODUCT", 285, 291], ["mTORC1", "GENE_OR_GENE_PRODUCT", 344, 350], ["cells", "CELL", 372, 377], ["BafA", "PROTEIN", 51, 55], ["mTORC1", "PROTEIN", 65, 71], ["downstream effectors", "PROTEIN", 163, 183], ["mTORC1", "PROTEIN", 285, 291], ["mTORC1", "PROTEIN", 344, 350], ["procedure", "TREATMENT", 113, 122]]], ["To this end, human lung carcinoma A549 and cervical cancer HeLa cells were treated with 1 \u03bcM AZD8055 (an inhibitor of mTOR kinase activity, and thus a control that impairs mTOR signalling) or 200 nM BafA (a commonly used concentration [22] and within the range recommended by manufacturers) for 6 or 24 h.", [["lung carcinoma A549", "ANATOMY", 19, 38], ["cervical cancer HeLa cells", "ANATOMY", 43, 69], ["lung carcinoma", "DISEASE", 19, 33], ["cervical cancer", "DISEASE", 43, 58], ["AZD8055", "CHEMICAL", 93, 100], ["BafA", "CHEMICAL", 199, 203], ["AZD8055", "CHEMICAL", 93, 100], ["BafA", "CHEMICAL", 199, 203], ["human", "ORGANISM", 13, 18], ["lung carcinoma A549", "CELL", 19, 38], ["cervical cancer HeLa cells", "CELL", 43, 69], ["AZD8055", "SIMPLE_CHEMICAL", 93, 100], ["mTOR", "GENE_OR_GENE_PRODUCT", 118, 122], ["mTOR", "GENE_OR_GENE_PRODUCT", 172, 176], ["BafA", "SIMPLE_CHEMICAL", 199, 203], ["human lung carcinoma A549", "CELL_LINE", 13, 38], ["cervical cancer HeLa cells", "CELL_LINE", 43, 69], ["mTOR kinase", "PROTEIN", 118, 129], ["mTOR", "PROTEIN", 172, 176], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["human lung carcinoma A549", "PROBLEM", 13, 38], ["cervical cancer HeLa cells", "PROBLEM", 43, 69], ["1 \u03bcM AZD8055", "TREATMENT", 88, 100], ["an inhibitor of mTOR kinase activity", "TREATMENT", 102, 138], ["lung", "ANATOMY", 19, 23], ["carcinoma", "OBSERVATION", 24, 33], ["cervical", "ANATOMY", 43, 51], ["cancer", "OBSERVATION", 52, 58]]], ["Cells were lysed and samples immunoblotted for LC3-II, a protein that is incorporated into the membrane of autophagosomes during their formation upon processing of LC3-I [23] .", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 21, 28], ["membrane", "ANATOMY", 95, 103], ["autophagosomes", "ANATOMY", 107, 121], ["Cells", "CELL", 0, 5], ["LC3-II", "GENE_OR_GENE_PRODUCT", 47, 53], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["autophagosomes", "CELLULAR_COMPONENT", 107, 121], ["LC3-I", "GENE_OR_GENE_PRODUCT", 164, 169], ["LC3-II", "PROTEIN", 47, 53], ["LC3", "PROTEIN", 164, 167], ["Cells", "TEST", 0, 5], ["samples", "TEST", 21, 28], ["LC3", "TEST", 47, 50], ["a protein", "TEST", 55, 64]]], ["It thus serves as a positive control for the efficacy of BafA, as its levels are a marker for the presence of autophagosomes, which accumulate during lysosomal alkalinisation because of the inhibition of fusion of the autophagosome with the lysosome.", [["autophagosomes", "ANATOMY", 110, 124], ["lysosomal", "ANATOMY", 150, 159], ["autophagosome", "ANATOMY", 218, 231], ["lysosome", "ANATOMY", 241, 249], ["BafA", "CHEMICAL", 57, 61], ["BafA", "GENE_OR_GENE_PRODUCT", 57, 61], ["autophagosomes", "CELLULAR_COMPONENT", 110, 124], ["lysosomal", "CELLULAR_COMPONENT", 150, 159], ["autophagosome", "CELLULAR_COMPONENT", 218, 231], ["lysosome", "CELLULAR_COMPONENT", 241, 249], ["BafA", "PROTEIN", 57, 61], ["a positive control", "TREATMENT", 18, 36], ["BafA", "TREATMENT", 57, 61], ["autophagosomes", "PROBLEM", 110, 124], ["lysosomal alkalinisation", "TREATMENT", 150, 174]]], ["As expected, BafA treatment caused LC3-II levels to become detectable after 6 h of treatment and increase markedly after 24 h of treatment ( Figure 1 ).", [["BafA", "CHEMICAL", 13, 17], ["LC3-II", "CHEMICAL", 35, 41], ["BafA", "CHEMICAL", 13, 17], ["BafA", "SIMPLE_CHEMICAL", 13, 17], ["LC3-II", "GENE_OR_GENE_PRODUCT", 35, 41], ["BafA", "PROTEIN", 13, 17], ["LC3", "PROTEIN", 35, 38], ["BafA treatment", "TREATMENT", 13, 27], ["LC3-II levels", "PROBLEM", 35, 48], ["treatment", "TREATMENT", 83, 92], ["treatment", "TREATMENT", 129, 138]]], ["The same samples were also probed for rpS6.", [["samples", "ANATOMY", 9, 16], ["rpS6", "GENE_OR_GENE_PRODUCT", 38, 42], ["rpS6", "PROTEIN", 38, 42], ["rpS6", "TEST", 38, 42]]], ["Its phosphorylation serves as a robust readout of mTORC1 activity, since rpS6 is phosphorylated at Serine 240 and 244 specifically by p70S6K, which is itself activated by direct phosphorylation of Thr 389 by mTORC1 [24] [25] [26] .", [["Thr 389", "CHEMICAL", 197, 204], ["Serine", "CHEMICAL", 99, 105], ["Thr", "CHEMICAL", 197, 200], ["mTORC1", "GENE_OR_GENE_PRODUCT", 50, 56], ["rpS6", "GENE_OR_GENE_PRODUCT", 73, 77], ["Serine 240", "AMINO_ACID", 99, 109], ["244", "AMINO_ACID", 114, 117], ["p70S6K", "GENE_OR_GENE_PRODUCT", 134, 140], ["Thr 389", "AMINO_ACID", 197, 204], ["mTORC1", "GENE_OR_GENE_PRODUCT", 208, 214], ["mTORC1", "PROTEIN", 50, 56], ["rpS6", "PROTEIN", 73, 77], ["p70S6K", "PROTEIN", 134, 140], ["p70S6K", "TEST", 134, 140], ["mTORC1", "TEST", 208, 214]]], ["BafA caused a reduction in the levels of rpS6 P-S240/244 (relative to total rpS6), the effect increasing at the later time point.", [["BafA", "CHEMICAL", 0, 4], ["BafA", "GENE_OR_GENE_PRODUCT", 0, 4], ["rpS6 P-S240/244", "GENE_OR_GENE_PRODUCT", 41, 56], ["rpS6", "GENE_OR_GENE_PRODUCT", 76, 80], ["BafA", "PROTEIN", 0, 4], ["rpS6 P", "PROTEIN", 41, 47], ["S240/244", "PROTEIN", 48, 56], ["rpS6", "PROTEIN", 76, 80], ["a reduction", "PROBLEM", 12, 23], ["rpS6 P", "TEST", 41, 47], ["total rpS6", "TREATMENT", 70, 80], ["reduction", "OBSERVATION_MODIFIER", 14, 23]]], ["This indicates that BafA induces an impairment of mTORC1 signalling.Agents that cause lysosomal alkalinisation impair mTORC1 signallingSince the v-ATPase interacts with Ragulator, which controls mTORC1, it was important to distinguish whether the effects of BafA were due to lysosomal alkalinisation or only to an effect on the v-ATPase/Ragulator axis.", [["lysosomal", "ANATOMY", 86, 95], ["lysosomal", "ANATOMY", 275, 284], ["BafA", "CHEMICAL", 20, 24], ["BafA", "CHEMICAL", 258, 262], ["BafA", "GENE_OR_GENE_PRODUCT", 20, 24], ["mTORC1", "GENE_OR_GENE_PRODUCT", 50, 56], ["lysosomal", "CELLULAR_COMPONENT", 86, 95], ["mTORC1", "GENE_OR_GENE_PRODUCT", 118, 124], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 145, 153], ["Ragulator", "GENE_OR_GENE_PRODUCT", 169, 178], ["mTORC1", "GENE_OR_GENE_PRODUCT", 195, 201], ["BafA", "GENE_OR_GENE_PRODUCT", 258, 262], ["lysosomal", "CELLULAR_COMPONENT", 275, 284], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 328, 336], ["Ragulator", "GENE_OR_GENE_PRODUCT", 337, 346], ["BafA", "PROTEIN", 20, 24], ["mTORC1", "PROTEIN", 50, 56], ["mTORC1", "PROTEIN", 118, 124], ["v-ATPase", "PROTEIN", 145, 153], ["Ragulator", "PROTEIN", 169, 178], ["mTORC1", "PROTEIN", 195, 201], ["BafA", "PROTEIN", 258, 262], ["v-ATPase", "PROTEIN", 328, 336], ["an impairment of mTORC1 signalling", "PROBLEM", 33, 67], ["Agents", "TREATMENT", 68, 74], ["lysosomal alkalinisation", "PROBLEM", 86, 110], ["Ragulator", "TREATMENT", 169, 178], ["BafA", "TREATMENT", 258, 262], ["lysosomal alkalinisation", "PROBLEM", 275, 299], ["impairment", "OBSERVATION", 36, 46], ["mTORC1 signalling", "OBSERVATION", 50, 67], ["lysosomal alkalinisation", "OBSERVATION", 86, 110]]], ["Cells were thus also treated with the regularly used dose of 50 \u03bcM CQ [27] , which directly increases lysosomal pH.", [["Cells", "ANATOMY", 0, 5], ["lysosomal", "ANATOMY", 102, 111], ["CQ", "CHEMICAL", 67, 69], ["CQ", "CHEMICAL", 67, 69], ["Cells", "CELL", 0, 5], ["lysosomal pH", "OBSERVATION", 102, 114]]], ["In addition to the expected increase in LC3-II levels, the phosphorylation of rpS6 was reduced in a manner similar to that seen with BafA ( Figure 1 ).Agents that cause lysosomal alkalinisation impair mTORC1 signallingThere is some controversy with respect to the capacity of CQ to alkalinise lysosomes.", [["lysosomal", "ANATOMY", 169, 178], ["lysosomes", "ANATOMY", 293, 302], ["CQ", "CHEMICAL", 276, 278], ["LC3-II", "GENE_OR_GENE_PRODUCT", 40, 46], ["rpS6", "GENE_OR_GENE_PRODUCT", 78, 82], ["lysosomal", "CELLULAR_COMPONENT", 169, 178], ["mTORC1", "GENE_OR_GENE_PRODUCT", 201, 207], ["CQ", "SIMPLE_CHEMICAL", 276, 278], ["lysosomes", "CELLULAR_COMPONENT", 293, 302], ["LC3", "PROTEIN", 40, 43], ["rpS6", "PROTEIN", 78, 82], ["BafA", "PROTEIN", 133, 137], ["mTORC1", "PROTEIN", 201, 207], ["the phosphorylation of rpS6", "PROBLEM", 55, 82], ["Agents", "TREATMENT", 151, 157], ["lysosomal alkalinisation", "PROBLEM", 169, 193], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["LC3", "OBSERVATION_MODIFIER", 40, 43], ["reduced", "OBSERVATION_MODIFIER", 87, 94], ["lysosomal alkalinisation", "OBSERVATION", 169, 193]]], ["For instance, it has been observed previously that treatment of HeLa cells for 5 h with CQ resulted in no decrease in acidity of the lysosome, as determined by the use of LysoTracker Red DND-99, a fluorescent probe that can permeate cell membranes and label acidic organelles (specifically, the lysosome) [13] .", [["HeLa cells", "ANATOMY", 64, 74], ["lysosome", "ANATOMY", 133, 141], ["cell membranes", "ANATOMY", 233, 247], ["organelles", "ANATOMY", 265, 275], ["lysosome", "ANATOMY", 295, 303], ["CQ", "CHEMICAL", 88, 90], ["LysoTracker Red DND-99", "CHEMICAL", 171, 193], ["CQ", "CHEMICAL", 88, 90], ["DND-99", "CHEMICAL", 187, 193], ["HeLa cells", "CELL", 64, 74], ["CQ", "SIMPLE_CHEMICAL", 88, 90], ["lysosome", "CELLULAR_COMPONENT", 133, 141], ["LysoTracker", "SIMPLE_CHEMICAL", 171, 182], ["DND-99", "SIMPLE_CHEMICAL", 187, 193], ["cell membranes", "CELLULAR_COMPONENT", 233, 247], ["acidic organelles", "CELLULAR_COMPONENT", 258, 275], ["lysosome", "CELLULAR_COMPONENT", 295, 303], ["HeLa cells", "CELL_LINE", 64, 74], ["LysoTracker Red DND-99", "SPECIES", 171, 193], ["HeLa cells", "TREATMENT", 64, 74], ["CQ", "PROBLEM", 88, 90], ["decrease in acidity of the lysosome", "PROBLEM", 106, 141], ["a fluorescent probe", "TREATMENT", 195, 214], ["label acidic organelles", "TEST", 252, 275], ["no", "UNCERTAINTY", 103, 105], ["decrease", "OBSERVATION_MODIFIER", 106, 114], ["cell membranes", "OBSERVATION", 233, 247]]], ["To confirm and assess the ability of CQ or BafA to alkalinise the lysosome, A549 cells were treated for 1, 2, and 6 h with either of these chemicals.", [["lysosome", "ANATOMY", 66, 74], ["A549 cells", "ANATOMY", 76, 86], ["CQ", "CHEMICAL", 37, 39], ["BafA", "CHEMICAL", 43, 47], ["CQ", "CHEMICAL", 37, 39], ["BafA", "CHEMICAL", 43, 47], ["CQ", "SIMPLE_CHEMICAL", 37, 39], ["BafA", "SIMPLE_CHEMICAL", 43, 47], ["lysosome", "CELLULAR_COMPONENT", 66, 74], ["A549 cells", "CELL", 76, 86], ["A549 cells", "CELL_LINE", 76, 86], ["lysosome", "ANATOMY", 66, 74], ["A549 cells", "OBSERVATION", 76, 86]]], ["Prior to fixing the cells, medium was supplemented with LysoTracker Red DND-99.", [["cells", "ANATOMY", 20, 25], ["LysoTracker Red DND-99", "CHEMICAL", 56, 78], ["DND-99", "CHEMICAL", 72, 78], ["cells", "CELL", 20, 25], ["LysoTracker", "SIMPLE_CHEMICAL", 56, 67], ["LysoTracker Red DND-99", "SPECIES", 56, 78], ["LysoTracker", "TREATMENT", 56, 67]]], ["Detection of LysoTracker-stained lysosomes was ablated ( Figure 2 ) as early as the 1 h time-point with either CQ or BafA, indicating that alkalinisation precedes impairment of mTORC1 signalling by several hours.", [["lysosomes", "ANATOMY", 33, 42], ["CQ", "CHEMICAL", 111, 113], ["LysoTracker", "SIMPLE_CHEMICAL", 13, 24], ["lysosomes", "CELLULAR_COMPONENT", 33, 42], ["CQ", "SIMPLE_CHEMICAL", 111, 113], ["BafA", "SIMPLE_CHEMICAL", 117, 121], ["mTORC1", "GENE_OR_GENE_PRODUCT", 177, 183], ["mTORC1", "PROTEIN", 177, 183], ["LysoTracker", "TEST", 13, 24], ["stained lysosomes", "PROBLEM", 25, 42], ["mTORC1 signalling", "PROBLEM", 177, 194], ["alkalinisation", "OBSERVATION", 139, 153], ["mTORC1 signalling", "OBSERVATION", 177, 194]]], ["Indeed, there was no reduction in rpS6 phosphorylation at the 1 and 2 h time points of CQ and BafA treatment (Supplementary Figure S2 ).", [["CQ", "CHEMICAL", 87, 89], ["BafA", "CHEMICAL", 94, 98], ["CQ", "CHEMICAL", 87, 89], ["BafA", "CHEMICAL", 94, 98], ["rpS6", "GENE_OR_GENE_PRODUCT", 34, 38], ["CQ", "SIMPLE_CHEMICAL", 87, 89], ["BafA", "SIMPLE_CHEMICAL", 94, 98], ["rpS6", "PROTEIN", 34, 38], ["rpS6 phosphorylation", "TREATMENT", 34, 54], ["CQ and BafA treatment", "TREATMENT", 87, 108], ["no", "UNCERTAINTY", 18, 20], ["reduction", "OBSERVATION_MODIFIER", 21, 30], ["rpS6 phosphorylation", "OBSERVATION", 34, 54]]], ["This delay in itself implies that reduced mTORC1 activity is not a direct consequence of lysosomal alkalinisation itself and/or (with respect to BafA) inhibition of the v-ATPase, as those effects of the compounds are much more rapid.Agents that cause lysosomal alkalinisation impair mTORC1 signallingFinally, although it was not anticipated that this would be the case, to confirm whether treatment with CQ or BafA affects the levels of expression of components of mTORC1 or proteins that regulate it, extracts from A549 and HeLa cells treated with CQ or BafA for 24 h were immunoblotted with antibodies to mTOR, RAPTOR (the defining component of mTORC1), tuberous sclerosis (TSC) 1 and TSC2 (negative regulators of mTORC1).", [["lysosomal", "ANATOMY", 89, 98], ["lysosomal", "ANATOMY", 251, 260], ["extracts", "ANATOMY", 502, 510], ["A549", "ANATOMY", 516, 520], ["HeLa cells", "ANATOMY", 525, 535], ["CQ", "CHEMICAL", 404, 406], ["BafA", "CHEMICAL", 410, 414], ["CQ", "CHEMICAL", 549, 551], ["BafA", "CHEMICAL", 555, 559], ["tuberous sclerosis", "DISEASE", 656, 674], ["CQ", "CHEMICAL", 404, 406], ["BafA", "CHEMICAL", 410, 414], ["CQ", "CHEMICAL", 549, 551], ["BafA", "CHEMICAL", 555, 559], ["mTORC1", "GENE_OR_GENE_PRODUCT", 42, 48], ["lysosomal", "CELLULAR_COMPONENT", 89, 98], ["BafA", "GENE_OR_GENE_PRODUCT", 145, 149], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 169, 177], ["lysosomal", "CELLULAR_COMPONENT", 251, 260], ["mTORC1", "GENE_OR_GENE_PRODUCT", 283, 289], ["CQ", "SIMPLE_CHEMICAL", 404, 406], ["BafA", "SIMPLE_CHEMICAL", 410, 414], ["mTORC1", "GENE_OR_GENE_PRODUCT", 465, 471], ["extracts", "ORGANISM_SUBSTANCE", 502, 510], ["A549", "CELL", 516, 520], ["HeLa cells", "CELL", 525, 535], ["CQ", "SIMPLE_CHEMICAL", 549, 551], ["BafA", "SIMPLE_CHEMICAL", 555, 559], ["mTOR", "GENE_OR_GENE_PRODUCT", 607, 611], ["RAPTOR", "GENE_OR_GENE_PRODUCT", 613, 619], ["mTORC1", "GENE_OR_GENE_PRODUCT", 647, 653], ["tuberous sclerosis (TSC) 1", "GENE_OR_GENE_PRODUCT", 656, 682], ["TSC2", "GENE_OR_GENE_PRODUCT", 687, 691], ["mTORC1", "GENE_OR_GENE_PRODUCT", 716, 722], ["mTORC1", "PROTEIN", 42, 48], ["BafA", "PROTEIN", 145, 149], ["v-ATPase", "PROTEIN", 169, 177], ["mTORC1", "PROTEIN", 283, 289], ["mTORC1", "PROTEIN", 465, 471], ["A549", "CELL_LINE", 516, 520], ["HeLa cells", "CELL_LINE", 525, 535], ["antibodies", "PROTEIN", 593, 603], ["mTOR", "PROTEIN", 607, 611], ["RAPTOR", "PROTEIN", 613, 619], ["mTORC1", "PROTEIN", 647, 653], ["tuberous sclerosis (TSC) 1", "PROTEIN", 656, 682], ["TSC2", "PROTEIN", 687, 691], ["negative regulators", "PROTEIN", 693, 712], ["mTORC1", "PROTEIN", 716, 722], ["reduced mTORC1 activity", "PROBLEM", 34, 57], ["lysosomal alkalinisation itself", "PROBLEM", 89, 120], ["the v-ATPase", "PROBLEM", 165, 177], ["Agents", "TREATMENT", 233, 239], ["lysosomal alkalinisation", "PROBLEM", 251, 275], ["CQ", "TREATMENT", 404, 406], ["BafA", "TREATMENT", 410, 414], ["mTORC1 or proteins", "PROBLEM", 465, 483], ["HeLa cells", "TREATMENT", 525, 535], ["BafA", "TREATMENT", 555, 559], ["tuberous sclerosis (TSC)", "PROBLEM", 656, 680], ["TSC2", "TEST", 687, 691], ["reduced", "OBSERVATION_MODIFIER", 34, 41], ["mTORC1 activity", "OBSERVATION", 42, 57], ["lysosomal alkalinisation", "OBSERVATION", 89, 113], ["lysosomal alkalinisation", "OBSERVATION", 251, 275], ["HeLa cells", "OBSERVATION_MODIFIER", 525, 535], ["tuberous", "OBSERVATION_MODIFIER", 656, 664], ["sclerosis", "OBSERVATION", 665, 674]]], ["Supplementation of the medium with CQ and BafA expectedly increased LC3-II levels, but there were no significant changes in the levels of the other proteins studied (Figure 3 ).", [["CQ", "CHEMICAL", 35, 37], ["BafA", "CHEMICAL", 42, 46], ["CQ", "CHEMICAL", 35, 37], ["BafA", "CHEMICAL", 42, 46], ["CQ", "SIMPLE_CHEMICAL", 35, 37], ["BafA", "SIMPLE_CHEMICAL", 42, 46], ["LC3-II", "GENE_OR_GENE_PRODUCT", 68, 74], ["LC3", "PROTEIN", 68, 71], ["significant changes in the levels", "PROBLEM", 101, 134], ["no", "UNCERTAINTY", 98, 100], ["significant", "OBSERVATION_MODIFIER", 101, 112], ["changes", "OBSERVATION", 113, 120]]], ["It is thus unlikely that lysosomal alkalinisation impairs mTORC1 signalling by affecting the expression of mTORC1 components mTOR and RAPTOR, or its upstream regulators TSC1/2, but rather impacts the regulation of mTORC1.Agents that cause lysosomal alkalinisation impair mTORC1 signallingThe above data show that raising the intralysosomal pH occurs within a comparable timeframe in response to CQ or BafA, and impacts negatively on mTORC1 signalling.", [["lysosomal", "ANATOMY", 25, 34], ["lysosomal", "ANATOMY", 239, 248], ["intralysosomal", "ANATOMY", 325, 339], ["CQ", "CHEMICAL", 395, 397], ["BafA", "CHEMICAL", 401, 405], ["CQ", "CHEMICAL", 395, 397], ["BafA", "CHEMICAL", 401, 405], ["lysosomal", "CELLULAR_COMPONENT", 25, 34], ["mTORC1", "GENE_OR_GENE_PRODUCT", 58, 64], ["mTORC1", "GENE_OR_GENE_PRODUCT", 107, 113], ["mTOR", "GENE_OR_GENE_PRODUCT", 125, 129], ["RAPTOR", "GENE_OR_GENE_PRODUCT", 134, 140], ["TSC1/2", "GENE_OR_GENE_PRODUCT", 169, 175], ["mTORC1", "GENE_OR_GENE_PRODUCT", 214, 220], ["lysosomal", "CELLULAR_COMPONENT", 239, 248], ["mTORC1", "GENE_OR_GENE_PRODUCT", 271, 277], ["CQ", "SIMPLE_CHEMICAL", 395, 397], ["BafA", "GENE_OR_GENE_PRODUCT", 401, 405], ["mTORC1", "GENE_OR_GENE_PRODUCT", 433, 439], ["mTORC1", "PROTEIN", 58, 64], ["mTORC1 components", "PROTEIN", 107, 124], ["mTOR", "PROTEIN", 125, 129], ["RAPTOR", "PROTEIN", 134, 140], ["upstream regulators", "PROTEIN", 149, 168], ["TSC1/2", "PROTEIN", 169, 175], ["mTORC1", "PROTEIN", 214, 220], ["mTORC1", "PROTEIN", 271, 277], ["mTORC1", "PROTEIN", 433, 439], ["lysosomal alkalinisation", "PROBLEM", 25, 49], ["Agents", "TREATMENT", 221, 227], ["lysosomal alkalinisation", "PROBLEM", 239, 263], ["The above data", "TEST", 288, 302], ["the intralysosomal pH", "PROBLEM", 321, 342], ["thus unlikely", "UNCERTAINTY", 6, 19], ["lysosomal", "OBSERVATION_MODIFIER", 25, 34], ["alkalinisation", "OBSERVATION", 35, 49], ["lysosomal alkalinisation", "OBSERVATION", 239, 263]]], ["Given that these phenomena also result from CQ treatment, this also means that they occur independently of interference with the v-ATPase.", [["CQ", "CHEMICAL", 44, 46], ["CQ", "CHEMICAL", 44, 46], ["CQ", "SIMPLE_CHEMICAL", 44, 46], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 129, 137], ["v-ATPase", "PROTEIN", 129, 137], ["these phenomena", "PROBLEM", 11, 26], ["CQ treatment", "TREATMENT", 44, 56]]], ["However, importantly, the decline in mTORC1 activity appears not to be directly due to either inhibition of the v-ATPase or the change in pH, as these effects are faster than the reduction in mTORC1 signalling.", [["mTORC1", "GENE_OR_GENE_PRODUCT", 37, 43], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 112, 120], ["mTORC1", "GENE_OR_GENE_PRODUCT", 192, 198], ["mTORC1", "PROTEIN", 37, 43], ["v-ATPase", "PROTEIN", 112, 120], ["mTORC1", "PROTEIN", 192, 198], ["the decline in mTORC1 activity", "PROBLEM", 22, 52], ["the v-ATPase", "PROBLEM", 108, 120], ["the change in pH", "PROBLEM", 124, 140], ["mTORC1 activity", "OBSERVATION", 37, 52], ["change", "OBSERVATION_MODIFIER", 128, 134], ["reduction", "OBSERVATION_MODIFIER", 179, 188], ["mTORC1 signalling", "OBSERVATION", 192, 209]]], ["It is thus likely an indirect consequence of altered luminal pH.CQ and BafA treatment results in reduced localisation of mTOR with the lysosomeAs mTORC1 is activated on the cytoplasmic surface of lysosomes [8] , we asked whether CQ or BafA altered its intracellular distribution.", [["luminal", "ANATOMY", 53, 60], ["lysosome", "ANATOMY", 135, 143], ["cytoplasmic surface", "ANATOMY", 173, 192], ["lysosomes", "ANATOMY", 196, 205], ["intracellular", "ANATOMY", 252, 265], ["luminal", "CHEMICAL", 53, 60], ["BafA", "CHEMICAL", 71, 75], ["CQ", "CHEMICAL", 229, 231], ["BafA", "CHEMICAL", 235, 239], ["pH.CQ", "CHEMICAL", 61, 66], ["BafA", "CHEMICAL", 71, 75], ["BafA", "CHEMICAL", 235, 239], ["luminal", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 60], ["pH.CQ", "SIMPLE_CHEMICAL", 61, 66], ["BafA", "SIMPLE_CHEMICAL", 71, 75], ["mTOR", "GENE_OR_GENE_PRODUCT", 121, 125], ["lysosome", "CELLULAR_COMPONENT", 135, 143], ["mTORC1", "GENE_OR_GENE_PRODUCT", 146, 152], ["cytoplasmic surface", "CELLULAR_COMPONENT", 173, 192], ["lysosomes", "CELLULAR_COMPONENT", 196, 205], ["CQ", "SIMPLE_CHEMICAL", 229, 231], ["BafA", "GENE_OR_GENE_PRODUCT", 235, 239], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 252, 265], ["mTOR", "PROTEIN", 121, 125], ["mTORC1", "PROTEIN", 146, 152], ["BafA", "PROTEIN", 235, 239], ["altered luminal pH.CQ", "PROBLEM", 45, 66], ["BafA treatment", "TREATMENT", 71, 85], ["the lysosome", "TREATMENT", 131, 143], ["thus likely", "UNCERTAINTY", 6, 17], ["luminal", "ANATOMY_MODIFIER", 53, 60], ["lysosome", "OBSERVATION", 135, 143], ["intracellular distribution", "OBSERVATION", 252, 278]]], ["We thus evaluated the co-localisation of endogenous mTOR with a marker for lysosomes, lysosomal-associated membrane protein (LAMP)-1.CQ and BafA treatment results in reduced localisation of mTOR with the lysosomeConfocal fluorescence microscopy revealed that CQ or BafA treatment each caused a similar increase in the area of sheep anti-LAMP-1 antibody staining as a result of larger lysosomal volume ( Figure 4A ).", [["lysosomes", "ANATOMY", 75, 84], ["lysosomal", "ANATOMY", 86, 95], ["lysosome", "ANATOMY", 204, 212], ["lysosomal", "ANATOMY", 384, 393], ["CQ", "CHEMICAL", 133, 135], ["BafA", "CHEMICAL", 140, 144], ["CQ", "CHEMICAL", 259, 261], ["BafA", "CHEMICAL", 265, 269], ["CQ", "CHEMICAL", 133, 135], ["BafA", "CHEMICAL", 140, 144], ["CQ", "CHEMICAL", 259, 261], ["BafA", "CHEMICAL", 265, 269], ["mTOR", "GENE_OR_GENE_PRODUCT", 52, 56], ["lysosomes", "CELLULAR_COMPONENT", 75, 84], ["lysosomal-associated membrane protein (LAMP)-1", "GENE_OR_GENE_PRODUCT", 86, 132], ["CQ", "SIMPLE_CHEMICAL", 133, 135], ["BafA", "SIMPLE_CHEMICAL", 140, 144], ["mTOR", "GENE_OR_GENE_PRODUCT", 190, 194], ["lysosome", "CELLULAR_COMPONENT", 204, 212], ["CQ", "SIMPLE_CHEMICAL", 259, 261], ["BafA", "SIMPLE_CHEMICAL", 265, 269], ["sheep", "ORGANISM", 326, 331], ["anti-LAMP-1", "GENE_OR_GENE_PRODUCT", 332, 343], ["endogenous mTOR", "PROTEIN", 41, 56], ["lysosomal-associated membrane protein (LAMP)-1", "PROTEIN", 86, 132], ["mTOR", "PROTEIN", 190, 194], ["sheep anti-LAMP-1 antibody", "PROTEIN", 326, 352], ["sheep", "SPECIES", 326, 331], ["sheep", "SPECIES", 326, 331], ["BafA treatment", "TREATMENT", 140, 154], ["the lysosome", "TREATMENT", 200, 212], ["Confocal fluorescence microscopy", "TEST", 212, 244], ["CQ", "PROBLEM", 259, 261], ["BafA treatment", "TREATMENT", 265, 279], ["sheep anti-LAMP", "TEST", 326, 341], ["1 antibody staining", "PROBLEM", 342, 361], ["endogenous mTOR", "OBSERVATION", 41, 56], ["lysosome", "OBSERVATION", 204, 212], ["similar", "OBSERVATION_MODIFIER", 294, 301], ["increase", "OBSERVATION_MODIFIER", 302, 310], ["larger", "OBSERVATION_MODIFIER", 377, 383], ["lysosomal volume", "OBSERVATION", 384, 400]]], ["This is as expected, because each chemical inhibits lysosomal functions and induces the build-up of undigested macromolecules (or storage material) [28, 29] .", [["lysosomal", "ANATOMY", 52, 61], ["lysosomal", "CELLULAR_COMPONENT", 52, 61], ["undigested macromolecules", "PROBLEM", 100, 125]]], ["Indeed, an increase in LAMP-1 protein was confirmed via immunoblotting ( Figure 4B ).", [["LAMP-1", "GENE_OR_GENE_PRODUCT", 23, 29], ["LAMP-1 protein", "PROTEIN", 23, 37], ["LAMP", "TEST", 23, 27], ["increase", "OBSERVATION_MODIFIER", 11, 19]]], ["Under normal conditions, a proportion of mTOR co-localised with LAMP-1-stained lysosomes ( Figure 4A ).", [["lysosomes", "ANATOMY", 79, 88], ["mTOR", "GENE_OR_GENE_PRODUCT", 41, 45], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 64, 70], ["lysosomes", "CELLULAR_COMPONENT", 79, 88], ["mTOR", "PROTEIN", 41, 45], ["LAMP-1", "PROTEIN", 64, 70], ["LAMP", "TEST", 64, 68], ["normal conditions", "OBSERVATION", 6, 23]]], ["However, treatment with CQ or BafA ablated the punctate staining of mTOR and decreased the fraction of mTOR localised to the lysosome, with CQ causing a greater reduction than BafA ( Figure 4A ,C).", [["lysosome", "ANATOMY", 125, 133], ["CQ", "CHEMICAL", 24, 26], ["BafA", "CHEMICAL", 30, 34], ["CQ", "CHEMICAL", 140, 142], ["CQ", "CHEMICAL", 24, 26], ["BafA", "CHEMICAL", 30, 34], ["CQ", "SIMPLE_CHEMICAL", 24, 26], ["BafA", "SIMPLE_CHEMICAL", 30, 34], ["mTOR", "GENE_OR_GENE_PRODUCT", 68, 72], ["mTOR", "GENE_OR_GENE_PRODUCT", 103, 107], ["lysosome", "CELLULAR_COMPONENT", 125, 133], ["CQ", "SIMPLE_CHEMICAL", 140, 142], ["mTOR", "PROTEIN", 68, 72], ["mTOR", "PROTEIN", 103, 107], ["BafA", "PROTEIN", 176, 180], ["CQ", "TREATMENT", 24, 26], ["BafA", "TREATMENT", 30, 34], ["the punctate staining of mTOR", "PROBLEM", 43, 72], ["CQ", "PROBLEM", 140, 142], ["punctate", "OBSERVATION_MODIFIER", 47, 55], ["decreased", "OBSERVATION_MODIFIER", 77, 86], ["greater", "OBSERVATION_MODIFIER", 153, 160], ["reduction", "OBSERVATION_MODIFIER", 161, 170]]], ["Intriguingly, although the fraction of LAMP-1 localising with mTOR was also significantly reduced when cells were treated with CQ (demonstrating an overall reduction in co-localisation), this was not the case with BafA ( Figure 4C ).", [["cells", "ANATOMY", 103, 108], ["CQ", "CHEMICAL", 127, 129], ["CQ", "CHEMICAL", 127, 129], ["BafA", "CHEMICAL", 214, 218], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 39, 45], ["mTOR", "GENE_OR_GENE_PRODUCT", 62, 66], ["cells", "CELL", 103, 108], ["CQ", "SIMPLE_CHEMICAL", 127, 129], ["BafA", "SIMPLE_CHEMICAL", 214, 218], ["LAMP-1", "PROTEIN", 39, 45], ["mTOR", "PROTEIN", 62, 66], ["BafA", "PROTEIN", 214, 218], ["LAMP", "TEST", 39, 43], ["CQ", "TREATMENT", 127, 129], ["reduction", "OBSERVATION_MODIFIER", 156, 165]]], ["In more detail, staining patterns demonstrate a spatial exclusion of mTOR from LAMP-1 upon CQ treatment and this is confirmed with the respective Mander's coefficients ( Figure 4A ,C).", [["CQ", "CHEMICAL", 91, 93], ["CQ", "CHEMICAL", 91, 93], ["mTOR", "GENE_OR_GENE_PRODUCT", 69, 73], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 79, 85], ["CQ", "SIMPLE_CHEMICAL", 91, 93], ["mTOR", "PROTEIN", 69, 73], ["LAMP", "TEST", 79, 83], ["CQ treatment", "TREATMENT", 91, 103]]], ["In contrast, with BafA treatment, although mTOR is no longer stained in a punctate manner as it is in the control ( Figure 4A ) and there is a statistically significant reduction in the proportion of mTOR associating with LAMP-1, the amount of LAMP-1 localising with mTOR did not change ( Figure 4A ,C).", [["BafA", "CHEMICAL", 18, 22], ["BafA", "CHEMICAL", 18, 22], ["BafA", "SIMPLE_CHEMICAL", 18, 22], ["mTOR", "GENE_OR_GENE_PRODUCT", 43, 47], ["mTOR", "GENE_OR_GENE_PRODUCT", 200, 204], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 222, 228], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 244, 250], ["mTOR", "GENE_OR_GENE_PRODUCT", 267, 271], ["BafA", "PROTEIN", 18, 22], ["mTOR", "PROTEIN", 43, 47], ["mTOR", "PROTEIN", 200, 204], ["LAMP", "PROTEIN", 222, 226], ["LAMP-1", "PROTEIN", 244, 250], ["mTOR", "PROTEIN", 267, 271], ["BafA treatment", "TREATMENT", 18, 32], ["a statistically significant reduction", "PROBLEM", 141, 178], ["LAMP", "TEST", 222, 226], ["LAMP", "TEST", 244, 248], ["no longer", "UNCERTAINTY", 51, 60], ["punctate", "OBSERVATION_MODIFIER", 74, 82], ["statistically", "OBSERVATION_MODIFIER", 143, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["reduction", "OBSERVATION_MODIFIER", 169, 178], ["amount", "OBSERVATION_MODIFIER", 234, 240]]], ["Unlike the situation for CQ, we cannot therefore conclude that BafA reduces mTOR/LAMP-1 co-localisation, when accounting for both Mander's coefficients.", [["CQ", "CHEMICAL", 25, 27], ["BafA", "CHEMICAL", 63, 67], ["BafA", "CHEMICAL", 63, 67], ["CQ", "SIMPLE_CHEMICAL", 25, 27], ["BafA", "SIMPLE_CHEMICAL", 63, 67], ["mTOR", "GENE_OR_GENE_PRODUCT", 76, 80], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 81, 87], ["BafA", "PROTEIN", 63, 67], ["mTOR", "PROTEIN", 76, 80], ["CQ", "PROBLEM", 25, 27]]], ["However, these results might be confounded by the increase in total LAMP-1 ( Figure 4B) .CQ and BafA treatment results in reduced localisation of mTOR with the lysosomeNonetheless, whereas a fraction of mTOR localises with the lysosomal marker LAMP-1 under control conditions, such association is reduced when cells are treated with CQ or BafA.", [["lysosome", "ANATOMY", 160, 168], ["lysosomal", "ANATOMY", 227, 236], ["cells", "ANATOMY", 310, 315], ["CQ", "CHEMICAL", 89, 91], ["BafA", "CHEMICAL", 96, 100], ["CQ", "CHEMICAL", 333, 335], ["CQ", "CHEMICAL", 89, 91], ["BafA", "CHEMICAL", 96, 100], ["CQ", "CHEMICAL", 333, 335], ["BafA", "CHEMICAL", 339, 343], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 68, 74], ["CQ", "SIMPLE_CHEMICAL", 89, 91], ["BafA", "SIMPLE_CHEMICAL", 96, 100], ["mTOR", "GENE_OR_GENE_PRODUCT", 146, 150], ["lysosome", "CELLULAR_COMPONENT", 160, 168], ["mTOR", "GENE_OR_GENE_PRODUCT", 203, 207], ["lysosomal", "CELLULAR_COMPONENT", 227, 236], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 244, 250], ["cells", "CELL", 310, 315], ["CQ", "SIMPLE_CHEMICAL", 333, 335], ["BafA", "SIMPLE_CHEMICAL", 339, 343], ["mTOR", "PROTEIN", 146, 150], ["mTOR", "PROTEIN", 203, 207], ["lysosomal marker LAMP-1", "PROTEIN", 227, 250], ["BafA", "PROTEIN", 339, 343], ["total LAMP", "TEST", 62, 72], ["BafA treatment", "TREATMENT", 96, 110], ["the lysosome", "TREATMENT", 156, 168], ["mTOR localises", "PROBLEM", 203, 217], ["the lysosomal marker LAMP", "TEST", 223, 248], ["BafA", "TREATMENT", 339, 343], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["lysosome", "OBSERVATION", 160, 168], ["reduced", "OBSERVATION_MODIFIER", 297, 304]]], ["Thus, alkalinisation of the lumen of the lysosome leads to the dissociation of mTOR from the lysosomal surface, and, given the importance of lysosomal localisation for the activation of mTORC1 [7, 8, 11] , this may account for the observed impairment of mTORC1 signalling.CQ and BafA treatment results in reduced localisation of mTOR with the lysosomeIncreased amino acid levels fail to rescue the inhibition of mTORC1 signalling induced by lysosomal deacidification mTORC1 activity is sensitive to amino acid availability, and to levels of amino acids within lysosomes [8] , which may originate both from extracellular sources and lysosomal proteolysis.", [["lumen", "ANATOMY", 28, 33], ["lysosome", "ANATOMY", 41, 49], ["lysosomal surface", "ANATOMY", 93, 110], ["lysosomal", "ANATOMY", 141, 150], ["lysosome", "ANATOMY", 343, 351], ["lysosomal", "ANATOMY", 441, 450], ["lysosomes", "ANATOMY", 560, 569], ["extracellular", "ANATOMY", 606, 619], ["lysosomal", "ANATOMY", 632, 641], ["CQ", "CHEMICAL", 272, 274], ["BafA", "CHEMICAL", 279, 283], ["amino acid", "CHEMICAL", 361, 371], ["amino acid", "CHEMICAL", 499, 509], ["amino acids", "CHEMICAL", 541, 552], ["CQ", "CHEMICAL", 272, 274], ["BafA", "CHEMICAL", 279, 283], ["amino acid", "CHEMICAL", 361, 371], ["amino acid", "CHEMICAL", 499, 509], ["amino acids", "CHEMICAL", 541, 552], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 33], ["lysosome", "CELLULAR_COMPONENT", 41, 49], ["mTOR", "GENE_OR_GENE_PRODUCT", 79, 83], ["lysosomal surface", "CELLULAR_COMPONENT", 93, 110], ["lysosomal", "CELLULAR_COMPONENT", 141, 150], ["mTORC1", "GENE_OR_GENE_PRODUCT", 186, 192], ["mTORC1", "GENE_OR_GENE_PRODUCT", 254, 260], ["CQ", "SIMPLE_CHEMICAL", 272, 274], ["BafA", "SIMPLE_CHEMICAL", 279, 283], ["mTOR", "GENE_OR_GENE_PRODUCT", 329, 333], ["lysosome", "CELLULAR_COMPONENT", 343, 351], ["amino acid", "AMINO_ACID", 361, 371], ["mTORC1", "GENE_OR_GENE_PRODUCT", 412, 418], ["lysosomal", "CELLULAR_COMPONENT", 441, 450], ["mTORC1", "GENE_OR_GENE_PRODUCT", 467, 473], ["amino acid", "AMINO_ACID", 499, 509], ["amino acids", "AMINO_ACID", 541, 552], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 606, 619], ["lysosomal", "CELLULAR_COMPONENT", 632, 641], ["mTOR", "PROTEIN", 79, 83], ["mTORC1", "PROTEIN", 186, 192], ["mTORC1", "PROTEIN", 254, 260], ["mTOR", "PROTEIN", 329, 333], ["mTORC1", "PROTEIN", 412, 418], ["mTORC1", "PROTEIN", 467, 473], ["the observed impairment of mTORC1 signalling", "PROBLEM", 227, 271], ["BafA treatment", "TREATMENT", 279, 293], ["the lysosome", "TREATMENT", 339, 351], ["Increased amino acid levels", "PROBLEM", 351, 378], ["mTORC1 signalling", "PROBLEM", 412, 429], ["amino acid availability", "TEST", 499, 522], ["amino acids", "TEST", 541, 552], ["lysosomal proteolysis", "PROBLEM", 632, 653], ["lumen", "ANATOMY_MODIFIER", 28, 33], ["lysosome leads", "OBSERVATION", 41, 55], ["lysosomal", "OBSERVATION_MODIFIER", 93, 102], ["surface", "OBSERVATION_MODIFIER", 103, 110], ["may account for", "UNCERTAINTY", 211, 226], ["mTORC1 signalling", "OBSERVATION", 254, 271], ["lysosome", "OBSERVATION", 343, 351], ["amino acid", "OBSERVATION", 361, 371], ["extracellular sources", "OBSERVATION", 606, 627], ["lysosomal proteolysis", "OBSERVATION", 632, 653]]], ["This raised the possibility that interfering with lysosomal function impaired the supply of intralysosomal amino acids to activate mTORC1.", [["lysosomal", "ANATOMY", 50, 59], ["amino acids", "CHEMICAL", 107, 118], ["amino acids", "CHEMICAL", 107, 118], ["lysosomal", "CELLULAR_COMPONENT", 50, 59], ["amino acids", "AMINO_ACID", 107, 118], ["mTORC1", "GENE_OR_GENE_PRODUCT", 131, 137], ["mTORC1", "PROTEIN", 131, 137], ["lysosomal function", "PROBLEM", 50, 68], ["intralysosomal amino acids", "TREATMENT", 92, 118]]], ["Therefore, we tested the possibility that increasing the supply of extracellular amino acids could restore mTORC1 activity in cells treated with CQ or BafA by compensating for a reduced supply of amino acids from intralysosomal proteolysis, this time by evaluating levels of p70S6K P-T389, which is the direct substrate of mTORC1 [30] .CQ and BafA treatment results in reduced localisation of mTOR with the lysosomeTo examine the effects of increasing amino acid levels in the culture medium, A549 and HeLa cells were first treated with DMSO, CQ, BafA, or AZD8055 for 23 h.", [["extracellular", "ANATOMY", 67, 80], ["cells", "ANATOMY", 126, 131], ["lysosome", "ANATOMY", 407, 415], ["A549", "ANATOMY", 493, 497], ["HeLa cells", "ANATOMY", 502, 512], ["amino acids", "CHEMICAL", 81, 92], ["CQ", "CHEMICAL", 145, 147], ["BafA", "CHEMICAL", 151, 155], ["amino acids", "CHEMICAL", 196, 207], ["BafA", "CHEMICAL", 343, 347], ["amino acid", "CHEMICAL", 452, 462], ["DMSO", "CHEMICAL", 537, 541], ["CQ", "CHEMICAL", 543, 545], ["BafA", "CHEMICAL", 547, 551], ["AZD8055", "CHEMICAL", 556, 563], ["amino acids", "CHEMICAL", 81, 92], ["CQ", "CHEMICAL", 145, 147], ["BafA", "CHEMICAL", 151, 155], ["amino acids", "CHEMICAL", 196, 207], ["BafA", "CHEMICAL", 343, 347], ["amino acid", "CHEMICAL", 452, 462], ["DMSO", "CHEMICAL", 537, 541], ["CQ", "CHEMICAL", 543, 545], ["BafA", "CHEMICAL", 547, 551], ["AZD8055", "CHEMICAL", 556, 563], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 67, 80], ["amino acids", "AMINO_ACID", 81, 92], ["mTORC1", "GENE_OR_GENE_PRODUCT", 107, 113], ["cells", "CELL", 126, 131], ["CQ", "SIMPLE_CHEMICAL", 145, 147], ["BafA", "SIMPLE_CHEMICAL", 151, 155], ["amino acids", "AMINO_ACID", 196, 207], ["p70S6K P-T389", "GENE_OR_GENE_PRODUCT", 275, 288], ["mTORC1 [30] .CQ", "GENE_OR_GENE_PRODUCT", 323, 338], ["BafA", "SIMPLE_CHEMICAL", 343, 347], ["mTOR", "GENE_OR_GENE_PRODUCT", 393, 397], ["lysosome", "CELLULAR_COMPONENT", 407, 415], ["amino acid", "AMINO_ACID", 452, 462], ["A549", "CELL", 493, 497], ["HeLa cells", "CELL", 502, 512], ["DMSO", "SIMPLE_CHEMICAL", 537, 541], ["CQ", "SIMPLE_CHEMICAL", 543, 545], ["BafA", "SIMPLE_CHEMICAL", 547, 551], ["AZD8055", "SIMPLE_CHEMICAL", 556, 563], ["mTORC1", "PROTEIN", 107, 113], ["p70S6K P-T389", "PROTEIN", 275, 288], ["mTOR", "PROTEIN", 393, 397], ["A549", "CELL_LINE", 493, 497], ["HeLa cells", "CELL_LINE", 502, 512], ["extracellular amino acids", "TREATMENT", 67, 92], ["mTORC1 activity in cells", "PROBLEM", 107, 131], ["BafA", "TREATMENT", 151, 155], ["amino acids", "PROBLEM", 196, 207], ["intralysosomal proteolysis", "PROBLEM", 213, 239], ["p70S6K P", "TEST", 275, 283], ["BafA treatment", "TREATMENT", 343, 357], ["the lysosome", "TREATMENT", 403, 415], ["increasing amino acid levels", "TREATMENT", 441, 469], ["the culture medium", "TEST", 473, 491], ["HeLa cells", "TEST", 502, 512], ["DMSO", "TREATMENT", 537, 541], ["BafA", "TREATMENT", 547, 551], ["AZD8055", "TREATMENT", 556, 563], ["lysosome", "OBSERVATION", 407, 415]]], ["In one plate of cells in each treatment set, this was followed by supplementation of the medium for 1 h with essential and non-essential amino acids corresponding to those already present in DMEM to thus provide twice the concentration ( Figure 5A,B) .", [["cells", "ANATOMY", 16, 21], ["amino acids", "CHEMICAL", 137, 148], ["amino acids", "CHEMICAL", 137, 148], ["cells", "CELL", 16, 21], ["amino acids", "AMINO_ACID", 137, 148], ["supplementation of the medium", "TREATMENT", 66, 95], ["non-essential amino acids", "TREATMENT", 123, 148], ["one plate", "ANATOMY_MODIFIER", 3, 12]]], ["Immunoblotting of cell extracts revealed the expected increases in LC3-II levels upon lysosomal deacidification with CQ or BafA, regardless of the addition of amino acids.", [["cell extracts", "ANATOMY", 18, 31], ["lysosomal", "ANATOMY", 86, 95], ["CQ", "CHEMICAL", 117, 119], ["BafA", "CHEMICAL", 123, 127], ["amino acids", "CHEMICAL", 159, 170], ["CQ", "CHEMICAL", 117, 119], ["BafA", "CHEMICAL", 123, 127], ["amino acids", "CHEMICAL", 159, 170], ["cell extracts", "ORGANISM_SUBSTANCE", 18, 31], ["LC3-II", "GENE_OR_GENE_PRODUCT", 67, 73], ["lysosomal", "CELLULAR_COMPONENT", 86, 95], ["CQ", "SIMPLE_CHEMICAL", 117, 119], ["BafA", "SIMPLE_CHEMICAL", 123, 127], ["amino acids", "AMINO_ACID", 159, 170], ["LC3", "PROTEIN", 67, 70], ["Immunoblotting of cell extracts", "TEST", 0, 31], ["BafA", "TREATMENT", 123, 127], ["amino acids", "TREATMENT", 159, 170], ["increases", "OBSERVATION_MODIFIER", 54, 63]]], ["The addition of amino acids to cells that were already in complete medium did not significantly rescue the decreased phospho-S6 or phospho-p70S6K levels caused by CQ or BafA.", [["cells", "ANATOMY", 31, 36], ["amino acids", "CHEMICAL", 16, 27], ["CQ", "CHEMICAL", 163, 165], ["BafA", "CHEMICAL", 169, 173], ["amino acids", "CHEMICAL", 16, 27], ["phospho", "CHEMICAL", 117, 124], ["phospho", "CHEMICAL", 131, 138], ["CQ", "CHEMICAL", 163, 165], ["BafA", "CHEMICAL", 169, 173], ["amino acids", "AMINO_ACID", 16, 27], ["cells", "CELL", 31, 36], ["phospho-S6", "GENE_OR_GENE_PRODUCT", 117, 127], ["phospho-p70S6K", "GENE_OR_GENE_PRODUCT", 131, 145], ["CQ", "SIMPLE_CHEMICAL", 163, 165], ["BafA", "SIMPLE_CHEMICAL", 169, 173], ["S6", "PROTEIN", 125, 127], ["70S6K", "PROTEIN", 140, 145], ["BafA", "PROTEIN", 169, 173], ["amino acids to cells", "TREATMENT", 16, 36], ["phospho", "TEST", 131, 138]]], ["It is therefore unlikely that lysosomal alkalinisation interferes with mTORC1 signalling by a mechanism related to amino acid supply.Inhibition of neither intralysosomal proteolytic activity alone nor autophagosome formation impairs mTORC1 signallingWe next assessed whether CQ and BafA decreased mTORC1 signalling due to their abilities to ablate intralysosomal proteolytic activity (which works optimally at low pH).", [["lysosomal", "ANATOMY", 30, 39], ["autophagosome", "ANATOMY", 201, 214], ["intralysosomal", "ANATOMY", 348, 362], ["amino acid", "CHEMICAL", 115, 125], ["CQ", "CHEMICAL", 275, 277], ["BafA", "CHEMICAL", 282, 286], ["amino acid", "CHEMICAL", 115, 125], ["lysosomal", "CELLULAR_COMPONENT", 30, 39], ["mTORC1", "GENE_OR_GENE_PRODUCT", 71, 77], ["amino acid", "AMINO_ACID", 115, 125], ["autophagosome", "CELLULAR_COMPONENT", 201, 214], ["mTORC1", "GENE_OR_GENE_PRODUCT", 233, 239], ["CQ", "SIMPLE_CHEMICAL", 275, 277], ["BafA", "SIMPLE_CHEMICAL", 282, 286], ["mTORC1", "GENE_OR_GENE_PRODUCT", 297, 303], ["mTORC1", "PROTEIN", 71, 77], ["mTORC1", "PROTEIN", 233, 239], ["mTORC1", "PROTEIN", 297, 303], ["lysosomal alkalinisation", "PROBLEM", 30, 54], ["mTORC1 signalling", "PROBLEM", 71, 88], ["amino acid supply", "TREATMENT", 115, 132], ["neither intralysosomal proteolytic activity", "PROBLEM", 147, 190], ["autophagosome formation", "PROBLEM", 201, 224], ["CQ", "PROBLEM", 275, 277], ["mTORC1 signalling", "PROBLEM", 297, 314], ["intralysosomal proteolytic activity", "PROBLEM", 348, 383], ["therefore unlikely", "UNCERTAINTY", 6, 24], ["lysosomal alkalinisation", "OBSERVATION", 30, 54], ["intralysosomal", "OBSERVATION_MODIFIER", 155, 169], ["proteolytic activity", "OBSERVATION", 170, 190]]], ["To monitor such activity, we used the Magic Red cathepsin L system (manufactured by Bio-Rad).", [["Bio-Rad", "PROTEIN", 84, 91], ["the Magic Red cathepsin L system", "TREATMENT", 34, 66]]], ["After cleavage by cathepsin L, this reagent is excited at 510-560 nm and emits at 570-620 nm, permitting an evaluation of intralysosomal protease cathepsin L activity in cells in culture, and providing a readout for overall intralysosomal activity.Inhibition of neither intralysosomal proteolytic activity alone nor autophagosome formation impairs mTORC1 signallingA549 cells were first treated with the cysteine, serine, and threonine peptidase inhibitor leupeptin (a positive control for inhibition of lysosomal proteolysis [31] ), the vehicle, CQ, BafA, or AZD8055 for 23 h, followed by supplementation of growth medium with Magic Red cathepsin L for a further hour.", [["cells", "ANATOMY", 170, 175], ["intralysosomal", "ANATOMY", 224, 238], ["autophagosome", "ANATOMY", 316, 329], ["A549 cells", "ANATOMY", 365, 375], ["lysosomal", "ANATOMY", 504, 513], ["threonine", "CHEMICAL", 426, 435], ["leupeptin", "CHEMICAL", 456, 465], ["CQ", "CHEMICAL", 547, 549], ["BafA", "CHEMICAL", 551, 555], ["AZD8055", "CHEMICAL", 560, 567], ["cysteine", "CHEMICAL", 404, 412], ["serine", "CHEMICAL", 414, 420], ["threonine", "CHEMICAL", 426, 435], ["leupeptin", "CHEMICAL", 456, 465], ["CQ", "CHEMICAL", 547, 549], ["BafA", "CHEMICAL", 551, 555], ["AZD8055", "CHEMICAL", 560, 567], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 18, 29], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 146, 157], ["cells", "CELL", 170, 175], ["autophagosome", "CELLULAR_COMPONENT", 316, 329], ["mTORC1", "GENE_OR_GENE_PRODUCT", 348, 354], ["A549 cells", "CELL", 365, 375], ["cysteine", "AMINO_ACID", 404, 412], ["serine", "AMINO_ACID", 414, 420], ["threonine", "AMINO_ACID", 426, 435], ["leupeptin", "SIMPLE_CHEMICAL", 456, 465], ["CQ", "SIMPLE_CHEMICAL", 547, 549], ["BafA", "SIMPLE_CHEMICAL", 551, 555], ["AZD8055", "SIMPLE_CHEMICAL", 560, 567], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 638, 649], ["cathepsin L", "PROTEIN", 18, 29], ["intralysosomal protease cathepsin L", "PROTEIN", 122, 157], ["mTORC1", "PROTEIN", 348, 354], ["A549 cells", "CELL_LINE", 365, 375], ["Magic Red cathepsin L", "PROTEIN", 628, 649], ["an evaluation", "TEST", 105, 118], ["intralysosomal protease cathepsin L activity in cells", "TREATMENT", 122, 175], ["culture", "TEST", 179, 186], ["neither intralysosomal proteolytic activity", "PROBLEM", 262, 305], ["autophagosome formation", "PROBLEM", 316, 339], ["mTORC1 signallingA549 cells", "PROBLEM", 348, 375], ["the cysteine", "TREATMENT", 400, 412], ["serine", "TREATMENT", 414, 420], ["threonine peptidase inhibitor leupeptin", "TREATMENT", 426, 465], ["a positive control", "TREATMENT", 467, 485], ["lysosomal proteolysis", "PROBLEM", 504, 525], ["BafA", "TREATMENT", 551, 555], ["AZD8055", "TREATMENT", 560, 567], ["supplementation of growth medium", "TREATMENT", 590, 622], ["Magic Red cathepsin L", "TREATMENT", 628, 649], ["intralysosomal activity", "OBSERVATION", 224, 247], ["A549 cells", "OBSERVATION", 365, 375]]], ["Cells were fixed and visualised by confocal fluorescence microscopy ( Figure 5C ).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["confocal fluorescence microscopy", "TEST", 35, 67]]], ["In control conditions, punctate staining consistent with the expected distribution of lysosomal cathepsin L activity was observed.", [["lysosomal", "ANATOMY", 86, 95], ["lysosomal cathepsin L", "GENE_OR_GENE_PRODUCT", 86, 107], ["lysosomal cathepsin L", "PROTEIN", 86, 107], ["punctate staining", "PROBLEM", 23, 40], ["lysosomal cathepsin L activity", "PROBLEM", 86, 116], ["punctate", "OBSERVATION_MODIFIER", 23, 31], ["staining", "OBSERVATION", 32, 40], ["consistent with", "UNCERTAINTY", 41, 56], ["lysosomal cathepsin", "OBSERVATION", 86, 105], ["L activity", "OBSERVATION", 106, 116]]], ["A similar pattern was also observed in AZD8055-treated cells; also noteworthy was the additional enlargement of the lysosome, which was expected on account of AZD8055's ability to directly inhibit mTORC1 activity and thus promote TFEB transactivation and lysosomal biogenesis.", [["cells", "ANATOMY", 55, 60], ["lysosome", "ANATOMY", 116, 124], ["lysosomal", "ANATOMY", 255, 264], ["AZD8055", "CHEMICAL", 39, 46], ["AZD8055", "CHEMICAL", 159, 166], ["AZD8055", "CHEMICAL", 39, 46], ["AZD8055", "CHEMICAL", 159, 166], ["AZD8055", "SIMPLE_CHEMICAL", 39, 46], ["cells", "CELL", 55, 60], ["lysosome", "CELLULAR_COMPONENT", 116, 124], ["AZD8055", "SIMPLE_CHEMICAL", 159, 166], ["mTORC1", "GENE_OR_GENE_PRODUCT", 197, 203], ["TFEB", "GENE_OR_GENE_PRODUCT", 230, 234], ["lysosomal", "CELLULAR_COMPONENT", 255, 264], ["AZD8055-treated cells", "CELL_LINE", 39, 60], ["mTORC1", "PROTEIN", 197, 203], ["TFEB", "PROTEIN", 230, 234], ["the additional enlargement of the lysosome", "PROBLEM", 82, 124], ["TFEB transactivation", "TREATMENT", 230, 250], ["lysosomal biogenesis", "TREATMENT", 255, 275], ["enlargement", "OBSERVATION", 97, 108], ["lysosome", "OBSERVATION", 116, 124], ["TFEB transactivation", "OBSERVATION", 230, 250], ["lysosomal biogenesis", "OBSERVATION", 255, 275]]], ["Conversely, there was a marked reduction in red fluorescence when cells were exposed to CQ, BafA, or leupeptin, confirming their ability to (indirectly) inhibit intralysosomal proteolysis ( Figure 5C ).", [["cells", "ANATOMY", 66, 71], ["intralysosomal", "ANATOMY", 161, 175], ["CQ", "CHEMICAL", 88, 90], ["BafA", "CHEMICAL", 92, 96], ["leupeptin", "CHEMICAL", 101, 110], ["CQ", "CHEMICAL", 88, 90], ["BafA", "CHEMICAL", 92, 96], ["leupeptin", "CHEMICAL", 101, 110], ["cells", "CELL", 66, 71], ["CQ", "SIMPLE_CHEMICAL", 88, 90], ["BafA", "SIMPLE_CHEMICAL", 92, 96], ["leupeptin", "SIMPLE_CHEMICAL", 101, 110], ["a marked reduction in red fluorescence when cells", "PROBLEM", 22, 71], ["leupeptin", "TREATMENT", 101, 110], ["intralysosomal proteolysis", "PROBLEM", 161, 187], ["marked", "OBSERVATION_MODIFIER", 24, 30], ["reduction", "OBSERVATION_MODIFIER", 31, 40], ["red fluorescence", "OBSERVATION", 44, 60]]], ["Lysates of similarly treated A549 and HeLa cells were then immunoblotted with antibodies for total and phospho-rpS6 and \u03b2-actin.", [["Lysates", "ANATOMY", 0, 7], ["A549", "ANATOMY", 29, 33], ["HeLa cells", "ANATOMY", 38, 48], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["A549", "CELL", 29, 33], ["HeLa cells", "CELL", 38, 48], ["phospho-rpS6", "GENE_OR_GENE_PRODUCT", 103, 115], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 120, 127], ["A549", "CELL_LINE", 29, 33], ["HeLa cells", "CELL_LINE", 38, 48], ["antibodies", "PROTEIN", 78, 88], ["phospho-rpS6", "PROTEIN", 103, 115], ["\u03b2-actin", "PROTEIN", 120, 127], ["Lysates", "TEST", 0, 7], ["HeLa cells", "TEST", 38, 48], ["antibodies", "TEST", 78, 88], ["phospho-rpS6", "TREATMENT", 103, 115], ["\u03b2-actin", "TREATMENT", 120, 127], ["HeLa cells", "OBSERVATION", 38, 48]]], ["In summary, unlike CQ and BafA, leupeptin did not decrease rpS6 phosphorylation, indicating it did not affect mTORC1 signalling.", [["CQ", "CHEMICAL", 19, 21], ["leupeptin", "CHEMICAL", 32, 41], ["BafA", "CHEMICAL", 26, 30], ["leupeptin", "CHEMICAL", 32, 41], ["CQ", "SIMPLE_CHEMICAL", 19, 21], ["BafA", "SIMPLE_CHEMICAL", 26, 30], ["leupeptin", "SIMPLE_CHEMICAL", 32, 41], ["rpS6", "GENE_OR_GENE_PRODUCT", 59, 63], ["mTORC1", "GENE_OR_GENE_PRODUCT", 110, 116], ["rpS6", "PROTEIN", 59, 63], ["mTORC1", "PROTEIN", 110, 116], ["leupeptin", "TREATMENT", 32, 41], ["rpS6 phosphorylation", "TREATMENT", 59, 79]]], ["It is therefore likely that neither CQ nor BafA reduces mTORC1 activity by (indirectly) inhibiting intralysosomal proteolysis and the supply of amino acids, consistent with the conclusions from the amino acid-supplementation experiments.Inhibition of neither intralysosomal proteolytic activity alone nor autophagosome formation impairs mTORC1 signallingFusion of lysosomes with the autophagosome and degradation of the latter's contents permits autophagic flux [31] .", [["intralysosomal", "ANATOMY", 99, 113], ["autophagosome", "ANATOMY", 305, 318], ["lysosomes", "ANATOMY", 364, 373], ["autophagosome", "ANATOMY", 383, 396], ["autophagic", "ANATOMY", 446, 456], ["CQ", "CHEMICAL", 36, 38], ["BafA", "CHEMICAL", 43, 47], ["amino acids", "CHEMICAL", 144, 155], ["CQ", "CHEMICAL", 36, 38], ["BafA", "CHEMICAL", 43, 47], ["amino acids", "CHEMICAL", 144, 155], ["amino", "CHEMICAL", 198, 203], ["CQ", "SIMPLE_CHEMICAL", 36, 38], ["BafA", "SIMPLE_CHEMICAL", 43, 47], ["mTORC1", "GENE_OR_GENE_PRODUCT", 56, 62], ["amino acids", "AMINO_ACID", 144, 155], ["autophagosome", "CELLULAR_COMPONENT", 305, 318], ["mTORC1", "GENE_OR_GENE_PRODUCT", 337, 343], ["lysosomes", "CELLULAR_COMPONENT", 364, 373], ["autophagosome", "CELLULAR_COMPONENT", 383, 396], ["mTORC1", "PROTEIN", 56, 62], ["mTORC1", "PROTEIN", 337, 343], ["CQ", "PROBLEM", 36, 38], ["intralysosomal proteolysis", "PROBLEM", 99, 125], ["amino acids", "TEST", 144, 155], ["the amino acid-supplementation experiments", "TREATMENT", 194, 236], ["neither intralysosomal proteolytic activity", "PROBLEM", 251, 294], ["autophagosome formation", "PROBLEM", 305, 328], ["the autophagosome", "PROBLEM", 379, 396], ["autophagic flux", "PROBLEM", 446, 461], ["therefore likely", "UNCERTAINTY", 6, 22], ["intralysosomal", "OBSERVATION_MODIFIER", 259, 273], ["proteolytic activity", "OBSERVATION", 274, 294], ["autophagic flux", "OBSERVATION", 446, 461]]], ["As mentioned previously, CQ and BafA inhibit this process even under basal conditions, resulting in accumulation of autophagosomes and material within them that would otherwise be degraded [31] .", [["autophagosomes", "ANATOMY", 116, 130], ["CQ", "CHEMICAL", 25, 27], ["BafA", "CHEMICAL", 32, 36], ["CQ", "SIMPLE_CHEMICAL", 25, 27], ["BafA", "SIMPLE_CHEMICAL", 32, 36], ["autophagosomes", "CELLULAR_COMPONENT", 116, 130], ["BafA", "PROTEIN", 32, 36], ["CQ", "PROBLEM", 25, 27], ["this process", "PROBLEM", 45, 57], ["accumulation of autophagosomes and material", "PROBLEM", 100, 143], ["accumulation", "OBSERVATION_MODIFIER", 100, 112], ["autophagosomes", "OBSERVATION", 116, 130]]], ["Another way of inhibiting autophagy involves reducing autophagosome number by depleting the expression of the BECN1 mRNA and thus beclin-1 protein.", [["autophagosome", "ANATOMY", 54, 67], ["autophagosome", "CELLULAR_COMPONENT", 54, 67], ["BECN1", "GENE_OR_GENE_PRODUCT", 110, 115], ["beclin-1", "GENE_OR_GENE_PRODUCT", 130, 138], ["BECN1 mRNA", "RNA", 110, 120], ["beclin-1 protein", "PROTEIN", 130, 146], ["inhibiting autophagy", "PROBLEM", 15, 35], ["beclin", "TEST", 130, 136]]], ["A549 cells were transfected with scrambled siRNA or one directed to BECN1 and, after 72 h, were analysed by immunoblotting with antibodies to LC3-II, p62 (a protein, encoded by SQSTM1, that is targeted to and degraded by the autophagosome), total and phospho-rpS6 and \u03b2-actin ( Figure 6 ).", [["A549 cells", "ANATOMY", 0, 10], ["autophagosome", "ANATOMY", 225, 238], ["A549 cells", "CELL", 0, 10], ["BECN1", "GENE_OR_GENE_PRODUCT", 68, 73], ["LC3-II", "GENE_OR_GENE_PRODUCT", 142, 148], ["p62", "GENE_OR_GENE_PRODUCT", 150, 153], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 177, 183], ["autophagosome", "CELLULAR_COMPONENT", 225, 238], ["phospho-rpS6", "GENE_OR_GENE_PRODUCT", 251, 263], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 268, 275], ["A549 cells", "CELL_LINE", 0, 10], ["BECN1", "PROTEIN", 68, 73], ["antibodies", "PROTEIN", 128, 138], ["LC3-II", "PROTEIN", 142, 148], ["p62", "PROTEIN", 150, 153], ["SQSTM1", "PROTEIN", 177, 183], ["phospho-rpS6", "PROTEIN", 251, 263], ["\u03b2-actin", "PROTEIN", 268, 275], ["Figure 6", "PROTEIN", 278, 286], ["A549 cells", "PROBLEM", 0, 10], ["scrambled siRNA", "TREATMENT", 33, 48], ["BECN1", "TEST", 68, 73], ["immunoblotting", "TEST", 108, 122], ["antibodies", "TEST", 128, 138], ["LC3", "TEST", 142, 145], ["a protein", "TEST", 155, 164], ["SQSTM1", "TEST", 177, 183], ["phospho-rpS6", "TREATMENT", 251, 263]]], ["The inhibition of autophagy was observed upon the knockdown of BECN1 as shown by a statistically significant reduction in LC3-II levels and concomitant increase in p62 protein (P=0.0665).", [["BECN1", "GENE_OR_GENE_PRODUCT", 63, 68], ["LC3-II", "GENE_OR_GENE_PRODUCT", 122, 128], ["p62", "GENE_OR_GENE_PRODUCT", 164, 167], ["BECN1", "PROTEIN", 63, 68], ["LC3", "PROTEIN", 122, 125], ["p62 protein", "PROTEIN", 164, 175], ["a statistically significant reduction in LC3-II levels", "PROBLEM", 81, 135], ["concomitant increase in p62 protein", "PROBLEM", 140, 175], ["P", "TEST", 177, 178], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["reduction", "OBSERVATION_MODIFIER", 109, 118], ["increase", "OBSERVATION_MODIFIER", 152, 160]]], ["However, there was no change in phospho-rpS6 levels.", [["phospho-rpS6", "GENE_OR_GENE_PRODUCT", 32, 44], ["phospho-rpS6", "PROTEIN", 32, 44], ["change in phospho-rpS6 levels", "PROBLEM", 22, 51], ["no", "UNCERTAINTY", 19, 21], ["change", "OBSERVATION_MODIFIER", 22, 28]]], ["Therefore, impairment of autophagy alone in conditions of nutrient abundance does not inhibit mTORC1 activity, and the effects of BafA and CQ on this pathway likely reflect another aspect of their effects on intralysosomal pH.Lysosomal storage of sucrose mimics lysosomal alkalinisationSucrose induces lysosomal stress in a range of primary and immortalised tissue culture lines, due to the combination of the rapid uptake of sucrose into the lysosome, and an inability to metabolise the sucrose on account of a lack of the enzyme invertase [32, 33] .", [["intralysosomal", "ANATOMY", 208, 222], ["Lysosomal", "ANATOMY", 226, 235], ["lysosomal", "ANATOMY", 262, 271], ["lysosomal", "ANATOMY", 302, 311], ["tissue culture lines", "ANATOMY", 358, 378], ["lysosome", "ANATOMY", 443, 451], ["BafA", "CHEMICAL", 130, 134], ["CQ", "CHEMICAL", 139, 141], ["sucrose", "CHEMICAL", 247, 254], ["Sucrose", "CHEMICAL", 286, 293], ["sucrose", "CHEMICAL", 426, 433], ["sucrose", "CHEMICAL", 488, 495], ["CQ", "CHEMICAL", 139, 141], ["sucrose", "CHEMICAL", 247, 254], ["Sucrose", "CHEMICAL", 286, 293], ["sucrose", "CHEMICAL", 426, 433], ["sucrose", "CHEMICAL", 488, 495], ["mTORC1", "GENE_OR_GENE_PRODUCT", 94, 100], ["BafA", "GENE_OR_GENE_PRODUCT", 130, 134], ["CQ", "SIMPLE_CHEMICAL", 139, 141], ["Lysosomal", "CELLULAR_COMPONENT", 226, 235], ["sucrose", "SIMPLE_CHEMICAL", 247, 254], ["lysosomal", "CELLULAR_COMPONENT", 262, 271], ["Sucrose", "SIMPLE_CHEMICAL", 286, 293], ["lysosomal", "CELLULAR_COMPONENT", 302, 311], ["tissue culture lines", "CELL", 358, 378], ["sucrose", "SIMPLE_CHEMICAL", 426, 433], ["lysosome", "CELLULAR_COMPONENT", 443, 451], ["sucrose", "SIMPLE_CHEMICAL", 488, 495], ["mTORC1", "PROTEIN", 94, 100], ["primary and immortalised tissue culture lines", "CELL_LINE", 333, 378], ["enzyme invertase", "PROTEIN", 524, 540], ["impairment of autophagy", "PROBLEM", 11, 34], ["BafA", "TREATMENT", 130, 134], ["intralysosomal pH", "PROBLEM", 208, 225], ["lysosomal stress", "PROBLEM", 302, 318], ["primary and immortalised tissue culture lines", "TREATMENT", 333, 378], ["the rapid uptake of sucrose into the lysosome", "PROBLEM", 406, 451], ["the enzyme invertase", "TEST", 520, 540], ["lysosomal stress", "OBSERVATION", 302, 318]]], ["Therefore, not surprisingly, sucrose treatment results in cellular pathology typical of fibroblasts derived from LSD patients, including the increased nuclear localisation and activity of TFEB (an mTORC1 substrate), the consequent increased expression of the LAMP-1 protein, and up-regulated lysosomal biogenesis [4, 33] .", [["cellular", "ANATOMY", 58, 66], ["fibroblasts", "ANATOMY", 88, 99], ["nuclear", "ANATOMY", 151, 158], ["lysosomal", "ANATOMY", 292, 301], ["sucrose", "CHEMICAL", 29, 36], ["sucrose", "CHEMICAL", 29, 36], ["sucrose", "SIMPLE_CHEMICAL", 29, 36], ["cellular", "CELL", 58, 66], ["fibroblasts", "CELL", 88, 99], ["patients", "ORGANISM", 117, 125], ["nuclear", "CELLULAR_COMPONENT", 151, 158], ["TFEB", "GENE_OR_GENE_PRODUCT", 188, 192], ["mTORC1", "GENE_OR_GENE_PRODUCT", 197, 203], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 259, 265], ["lysosomal", "CELLULAR_COMPONENT", 292, 301], ["fibroblasts", "CELL_TYPE", 88, 99], ["TFEB", "PROTEIN", 188, 192], ["mTORC1 substrate", "PROTEIN", 197, 213], ["LAMP-1 protein", "PROTEIN", 259, 273], ["patients", "SPECIES", 117, 125], ["sucrose treatment", "TREATMENT", 29, 46], ["cellular pathology", "TEST", 58, 76], ["fibroblasts", "PROBLEM", 88, 99], ["the increased nuclear localisation", "PROBLEM", 137, 171], ["an mTORC1 substrate", "TEST", 194, 213], ["the LAMP", "TEST", 255, 263], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["increased", "OBSERVATION_MODIFIER", 231, 240], ["lysosomal biogenesis", "OBSERVATION", 292, 312]]], ["As such, sucrose-treated cells can serve as a model for LSDs, in which one or more metabolic enzymes are deficient, while other functions of the lysosome (such as protease activity) remain uninhibited.Lysosomal storage of sucrose mimics lysosomal alkalinisationGiven that the ability of CQ and BafA to inhibit mTORC1 activity is not associated with their capacity to inhibit autophagy or an impairment of amino acid supply from lysosomal proteolysis, we wished to assess whether decreased lysosomal clearance and thus increased 'storage' of undegraded material within lysosomes might cause the impairment of mTORC1 signalling.", [["cells", "ANATOMY", 25, 30], ["lysosome", "ANATOMY", 145, 153], ["Lysosomal", "ANATOMY", 201, 210], ["lysosomal", "ANATOMY", 237, 246], ["lysosomal", "ANATOMY", 428, 437], ["lysosomal", "ANATOMY", 489, 498], ["lysosomes", "ANATOMY", 568, 577], ["sucrose", "CHEMICAL", 9, 16], ["sucrose", "CHEMICAL", 222, 229], ["CQ", "CHEMICAL", 287, 289], ["BafA", "CHEMICAL", 294, 298], ["amino acid", "CHEMICAL", 405, 415], ["sucrose", "CHEMICAL", 9, 16], ["sucrose", "CHEMICAL", 222, 229], ["BafA", "CHEMICAL", 294, 298], ["amino acid", "CHEMICAL", 405, 415], ["sucrose", "SIMPLE_CHEMICAL", 9, 16], ["cells", "CELL", 25, 30], ["lysosome", "CELLULAR_COMPONENT", 145, 153], ["protease", "GENE_OR_GENE_PRODUCT", 163, 171], ["Lysosomal", "CELLULAR_COMPONENT", 201, 210], ["sucrose", "SIMPLE_CHEMICAL", 222, 229], ["CQ", "SIMPLE_CHEMICAL", 287, 289], ["BafA", "GENE_OR_GENE_PRODUCT", 294, 298], ["mTORC1", "GENE_OR_GENE_PRODUCT", 310, 316], ["amino acid", "AMINO_ACID", 405, 415], ["lysosomal", "CELLULAR_COMPONENT", 489, 498], ["lysosomes", "CELLULAR_COMPONENT", 568, 577], ["mTORC1", "GENE_OR_GENE_PRODUCT", 608, 614], ["sucrose-treated cells", "CELL_LINE", 9, 30], ["metabolic enzymes", "PROTEIN", 83, 100], ["protease", "PROTEIN", 163, 171], ["mTORC1", "PROTEIN", 310, 316], ["mTORC1", "PROTEIN", 608, 614], ["sucrose-treated cells", "TREATMENT", 9, 30], ["LSDs", "PROBLEM", 56, 60], ["the lysosome", "PROBLEM", 141, 153], ["protease activity", "TREATMENT", 163, 180], ["lysosomal alkalinisation", "PROBLEM", 237, 261], ["CQ", "PROBLEM", 287, 289], ["BafA", "TREATMENT", 294, 298], ["mTORC1 activity", "PROBLEM", 310, 325], ["their capacity", "PROBLEM", 349, 363], ["autophagy", "PROBLEM", 375, 384], ["an impairment of amino acid supply", "PROBLEM", 388, 422], ["lysosomal proteolysis", "PROBLEM", 428, 449], ["decreased lysosomal clearance", "PROBLEM", 479, 508], ["undegraded material", "PROBLEM", 541, 560], ["the impairment of mTORC1 signalling", "PROBLEM", 590, 625], ["sucrose mimics", "OBSERVATION", 222, 236], ["lysosomal alkalinisation", "OBSERVATION", 237, 261], ["mTORC1 signalling", "OBSERVATION", 608, 625]]], ["We therefore evaluated whether sucrose mimicked the consequences of lysosomal alkalinisation.", [["lysosomal", "ANATOMY", 68, 77], ["sucrose", "CHEMICAL", 31, 38], ["sucrose", "CHEMICAL", 31, 38], ["sucrose", "SIMPLE_CHEMICAL", 31, 38], ["lysosomal", "CELLULAR_COMPONENT", 68, 77], ["lysosomal alkalinisation", "PROBLEM", 68, 92], ["lysosomal alkalinisation", "OBSERVATION", 68, 92]]], ["To this end, A549 and HeLa cells were treated with sucrose for 24, 48, or 72 h and then analysed by immunoblotting.", [["A549", "ANATOMY", 13, 17], ["HeLa cells", "ANATOMY", 22, 32], ["sucrose", "CHEMICAL", 51, 58], ["sucrose", "CHEMICAL", 51, 58], ["A549", "CELL", 13, 17], ["HeLa cells", "CELL", 22, 32], ["sucrose", "SIMPLE_CHEMICAL", 51, 58], ["A549", "CELL_LINE", 13, 17], ["HeLa cells", "CELL_LINE", 22, 32], ["HeLa cells", "TREATMENT", 22, 32], ["sucrose", "TREATMENT", 51, 58], ["HeLa cells", "OBSERVATION", 22, 32]]], ["In both lines, there was an increase in LAMP-1 protein when compared with untreated cells (Supplementary Figure S5A ,B), indicating increased lysosomal biogenesis [4, 33] .", [["cells", "ANATOMY", 84, 89], ["lysosomal", "ANATOMY", 142, 151], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 40, 46], ["cells", "CELL", 84, 89], ["B", "GENE_OR_GENE_PRODUCT", 117, 118], ["lysosomal", "CELLULAR_COMPONENT", 142, 151], ["LAMP-1 protein", "PROTEIN", 40, 54], ["untreated cells", "CELL_TYPE", 74, 89], ["an increase in LAMP", "PROBLEM", 25, 44], ["untreated cells", "PROBLEM", 74, 89], ["increased lysosomal biogenesis", "PROBLEM", 132, 162], ["both lines", "OBSERVATION", 3, 13], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["lysosomal biogenesis", "OBSERVATION", 142, 162]]], ["Concomitant increases in LC3-II and p62 are typically attributed to inhibition of autophagosome turnover [31] , although these conclusions are complicated by the fact that p62/SQSTM1 is also a TFEB target gene.", [["autophagosome", "ANATOMY", 82, 95], ["LC3-II", "GENE_OR_GENE_PRODUCT", 25, 31], ["p62", "GENE_OR_GENE_PRODUCT", 36, 39], ["autophagosome", "CELLULAR_COMPONENT", 82, 95], ["p62", "GENE_OR_GENE_PRODUCT", 172, 175], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 176, 182], ["TFEB", "GENE_OR_GENE_PRODUCT", 193, 197], ["LC3-II", "PROTEIN", 25, 31], ["p62", "PROTEIN", 36, 39], ["p62", "PROTEIN", 172, 175], ["SQSTM1", "PROTEIN", 176, 182], ["TFEB target gene", "DNA", 193, 209], ["Concomitant increases in LC3-II and p62", "PROBLEM", 0, 39], ["p62/SQSTM1", "TEST", 172, 182], ["increases", "OBSERVATION_MODIFIER", 12, 21], ["LC3", "OBSERVATION_MODIFIER", 25, 28]]], ["Under normal conditions, mTORC1 is tethered to the cytoplasmic side of the lysosomal membrane and displays kinase activity towards Serine 142 and 211 in TFEB, which causes retention of TFEB in the cytoplasm [3] .", [["cytoplasmic", "ANATOMY", 51, 62], ["lysosomal membrane", "ANATOMY", 75, 93], ["cytoplasm", "ANATOMY", 197, 206], ["Serine", "CHEMICAL", 131, 137], ["mTORC1", "GENE_OR_GENE_PRODUCT", 25, 31], ["cytoplasmic", "ORGANISM_SUBSTANCE", 51, 62], ["lysosomal membrane", "CELLULAR_COMPONENT", 75, 93], ["Serine 142", "AMINO_ACID", 131, 141], ["TFEB", "GENE_OR_GENE_PRODUCT", 153, 157], ["TFEB", "GENE_OR_GENE_PRODUCT", 185, 189], ["cytoplasm", "ORGANISM_SUBSTANCE", 197, 206], ["mTORC1", "PROTEIN", 25, 31], ["TFEB", "PROTEIN", 153, 157], ["TFEB", "PROTEIN", 185, 189], ["kinase activity", "TEST", 107, 122], ["Serine", "TEST", 131, 137], ["TFEB", "TEST", 153, 157], ["retention of TFEB in the cytoplasm", "PROBLEM", 172, 206], ["normal conditions", "OBSERVATION", 6, 23], ["lysosomal membrane", "ANATOMY", 75, 93], ["kinase activity", "OBSERVATION", 107, 122], ["retention", "OBSERVATION_MODIFIER", 172, 181], ["TFEB", "OBSERVATION", 185, 189]]], ["Under conditions of cellular stress, such as nutrient starvation or lysosomal stress, mTORC1 is released from the lysosomal membrane and cannot phosphorylate TFEB, thus permitting translocation of TFEB to the nucleus and increased expression of target genes linked to autophagy and lysosomal function [4, 11, [34] [35] [36] [37] [38] .", [["cellular", "ANATOMY", 20, 28], ["lysosomal", "ANATOMY", 68, 77], ["lysosomal membrane", "ANATOMY", 114, 132], ["nucleus", "ANATOMY", 209, 216], ["lysosomal", "ANATOMY", 282, 291], ["4, 11, [34] [35] [36] [37", "CHEMICAL", 302, 327], ["cellular", "CELL", 20, 28], ["lysosomal", "CELLULAR_COMPONENT", 68, 77], ["mTORC1", "GENE_OR_GENE_PRODUCT", 86, 92], ["lysosomal membrane", "CELLULAR_COMPONENT", 114, 132], ["TFEB", "GENE_OR_GENE_PRODUCT", 158, 162], ["TFEB", "GENE_OR_GENE_PRODUCT", 197, 201], ["nucleus", "CELLULAR_COMPONENT", 209, 216], ["lysosomal", "CELLULAR_COMPONENT", 282, 291], ["[34] [35] [36] [37] [38]", "SIMPLE_CHEMICAL", 309, 333], ["mTORC1", "PROTEIN", 86, 92], ["TFEB", "PROTEIN", 158, 162], ["TFEB", "PROTEIN", 197, 201], ["target genes", "DNA", 245, 257], ["cellular stress", "PROBLEM", 20, 35], ["nutrient starvation", "TREATMENT", 45, 64], ["lysosomal stress", "PROBLEM", 68, 84], ["phosphorylate TFEB", "TEST", 144, 162], ["lysosomal function", "TEST", 282, 300], ["cellular stress", "OBSERVATION", 20, 35], ["lysosomal membrane", "ANATOMY", 114, 132], ["nucleus", "ANATOMY", 209, 216]]], ["To evaluate the notion that TFEB is activated, RNA derived from identically treated cells was analysed for p62 transcript levels by qPCR (Supplementary Figure 5C) .Lysosomal storage of sucrose mimics lysosomal alkalinisationIn both cell lines, after 24 h, p62 mRNA was increased and remained at higher levels at 48 and 72 h when compared with the untreated controls.", [["cells", "ANATOMY", 84, 89], ["Lysosomal", "ANATOMY", 164, 173], ["lysosomal", "ANATOMY", 200, 209], ["cell lines", "ANATOMY", 232, 242], ["sucrose", "CHEMICAL", 185, 192], ["sucrose", "CHEMICAL", 185, 192], ["TFEB", "GENE_OR_GENE_PRODUCT", 28, 32], ["cells", "CELL", 84, 89], ["p62", "GENE_OR_GENE_PRODUCT", 107, 110], ["Lysosomal", "CELLULAR_COMPONENT", 164, 173], ["sucrose", "SIMPLE_CHEMICAL", 185, 192], ["cell lines", "CELL", 232, 242], ["p62", "GENE_OR_GENE_PRODUCT", 256, 259], ["TFEB", "PROTEIN", 28, 32], ["p62", "PROTEIN", 107, 110], ["cell lines", "CELL_LINE", 232, 242], ["p62 mRNA", "RNA", 256, 264], ["transcript levels", "TEST", 111, 128], ["lysosomal alkalinisation", "PROBLEM", 200, 224], ["p62 mRNA", "TEST", 256, 264], ["sucrose mimics", "OBSERVATION", 185, 199], ["lysosomal alkalinisation", "OBSERVATION", 200, 224], ["cell lines", "OBSERVATION", 232, 242], ["increased", "OBSERVATION_MODIFIER", 269, 278]]], ["Finally, a statistically significant but transient decrease in rpS6 phosphorylation was observed after 24 h in A549 cells, indicating a reduction in mTORC1 activity, which had returned to control levels by 24 h (Supplementary Figure S5A,B) .", [["A549 cells", "ANATOMY", 111, 121], ["rpS6", "GENE_OR_GENE_PRODUCT", 63, 67], ["A549 cells", "CELL", 111, 121], ["mTORC1", "GENE_OR_GENE_PRODUCT", 149, 155], ["rpS6", "PROTEIN", 63, 67], ["A549 cells", "CELL_LINE", 111, 121], ["mTORC1", "PROTEIN", 149, 155], ["transient decrease in rpS6 phosphorylation", "PROBLEM", 41, 83], ["a reduction in mTORC1 activity", "PROBLEM", 134, 164], ["transient", "OBSERVATION_MODIFIER", 41, 50], ["decrease", "OBSERVATION_MODIFIER", 51, 59], ["rpS6 phosphorylation", "OBSERVATION", 63, 83], ["reduction", "OBSERVATION_MODIFIER", 136, 145], ["mTORC1 activity", "OBSERVATION", 149, 164]]], ["In HeLa cells, however, not only were levels of rpS6 P-S240/244 unchanged at 24 h, but actually increased by 48 and 72 h.Lysosomal storage of sucrose mimics lysosomal alkalinisationWe therefore speculated that whereas lysosomal storage (and consequent mTORC1 inactivation) induced by CQ or BafA would initially require the inhibition of metabolic enzymes and then a gradual accumulation of undegraded macromolecules, the effect of sucrose would be more rapid as the uncleared material (sucrose) is, in this instance, delivered directly to the lysosome.", [["HeLa cells", "ANATOMY", 3, 13], ["lysosomal", "ANATOMY", 157, 166], ["lysosomal", "ANATOMY", 218, 227], ["lysosome", "ANATOMY", 543, 551], ["sucrose", "CHEMICAL", 142, 149], ["CQ", "CHEMICAL", 284, 286], ["BafA", "CHEMICAL", 290, 294], ["sucrose", "CHEMICAL", 431, 438], ["sucrose", "CHEMICAL", 486, 493], ["sucrose", "CHEMICAL", 142, 149], ["CQ", "CHEMICAL", 284, 286], ["BafA", "CHEMICAL", 290, 294], ["sucrose", "CHEMICAL", 431, 438], ["sucrose", "CHEMICAL", 486, 493], ["HeLa cells", "CELL", 3, 13], ["rpS6 P-S240/244", "GENE_OR_GENE_PRODUCT", 48, 63], ["sucrose", "SIMPLE_CHEMICAL", 142, 149], ["lysosomal", "CELLULAR_COMPONENT", 218, 227], ["mTORC1", "GENE_OR_GENE_PRODUCT", 252, 258], ["CQ", "SIMPLE_CHEMICAL", 284, 286], ["BafA", "SIMPLE_CHEMICAL", 290, 294], ["sucrose", "SIMPLE_CHEMICAL", 431, 438], ["sucrose", "SIMPLE_CHEMICAL", 486, 493], ["lysosome", "CELLULAR_COMPONENT", 543, 551], ["HeLa cells", "CELL_LINE", 3, 13], ["P", "DNA", 53, 54], ["mTORC1", "PROTEIN", 252, 258], ["metabolic enzymes", "PROTEIN", 337, 354], ["rpS6 P", "TEST", 48, 54], ["lysosomal storage", "PROBLEM", 218, 235], ["consequent mTORC1 inactivation", "TREATMENT", 241, 271], ["BafA", "TREATMENT", 290, 294], ["metabolic enzymes", "TEST", 337, 354], ["a gradual accumulation of undegraded macromolecules", "PROBLEM", 364, 415], ["sucrose", "TREATMENT", 431, 438], ["HeLa cells", "OBSERVATION", 3, 13], ["undegraded macromolecules", "OBSERVATION", 390, 415]]], ["Indeed, this proposed scenario is consistent with the previously observed rapid translocation of TFEB from the cytoplasm to the nucleus in HeLa cells when similarly treated [4] .", [["cytoplasm", "ANATOMY", 111, 120], ["nucleus", "ANATOMY", 128, 135], ["HeLa cells", "ANATOMY", 139, 149], ["TFEB", "GENE_OR_GENE_PRODUCT", 97, 101], ["cytoplasm", "ORGANISM_SUBSTANCE", 111, 120], ["nucleus", "CELLULAR_COMPONENT", 128, 135], ["HeLa cells", "CELL", 139, 149], ["TFEB", "PROTEIN", 97, 101], ["HeLa cells", "CELL_LINE", 139, 149], ["rapid translocation of TFEB", "PROBLEM", 74, 101], ["consistent with", "UNCERTAINTY", 34, 49], ["TFEB", "OBSERVATION", 97, 101], ["nucleus", "ANATOMY", 128, 135], ["HeLa cells", "OBSERVATION", 139, 149]]], ["Furthermore, since it was possible that the effects of sucrose on mTORC1 signalling were also still transient, but more rapid, in HeLa cells, we treated both HeLa and A549 cells for shorter times (2, 6, as well as 24 h) with sucrose.", [["HeLa cells", "ANATOMY", 130, 140], ["HeLa", "ANATOMY", 158, 162], ["A549 cells", "ANATOMY", 167, 177], ["sucrose", "CHEMICAL", 55, 62], ["sucrose", "CHEMICAL", 225, 232], ["sucrose", "CHEMICAL", 55, 62], ["sucrose", "CHEMICAL", 225, 232], ["sucrose", "SIMPLE_CHEMICAL", 55, 62], ["mTORC1", "GENE_OR_GENE_PRODUCT", 66, 72], ["HeLa cells", "CELL", 130, 140], ["HeLa", "CELL", 158, 162], ["A549 cells", "CELL", 167, 177], ["sucrose", "SIMPLE_CHEMICAL", 225, 232], ["mTORC1", "PROTEIN", 66, 72], ["HeLa cells", "CELL_LINE", 130, 140], ["HeLa", "CELL_LINE", 158, 162], ["A549 cells", "CELL_LINE", 167, 177], ["sucrose on mTORC1 signalling", "PROBLEM", 55, 83], ["sucrose", "TREATMENT", 225, 232]]], ["This treatment ('lysosomal storage') resulted in the inactivation of mTORC1, as indicated by the significant reduction in phosphorylation of rpS6 P-S240/244 (when compared with total rpS6) after 2 or 6 h sucrose treatment in both cell lines ( Figure 7A,B) .", [["lysosomal", "ANATOMY", 17, 26], ["cell lines", "ANATOMY", 230, 240], ["sucrose", "CHEMICAL", 204, 211], ["sucrose", "CHEMICAL", 204, 211], ["mTORC1", "GENE_OR_GENE_PRODUCT", 69, 75], ["rpS6 P-S240/244", "GENE_OR_GENE_PRODUCT", 141, 156], ["sucrose", "SIMPLE_CHEMICAL", 204, 211], ["cell lines", "CELL", 230, 240], ["B", "CELL", 253, 254], ["mTORC1", "PROTEIN", 69, 75], ["rpS6 P", "PROTEIN", 141, 147], ["S240/244", "PROTEIN", 148, 156], ["rpS6", "PROTEIN", 183, 187], ["cell lines", "CELL_LINE", 230, 240], ["This treatment ('lysosomal storage'", "TREATMENT", 0, 35], ["the inactivation of mTORC1", "TREATMENT", 49, 75], ["rpS6 P", "TEST", 141, 147], ["total rpS6", "TREATMENT", 177, 187], ["6 h sucrose treatment", "TREATMENT", 200, 221], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["reduction", "OBSERVATION_MODIFIER", 109, 118], ["cell lines", "OBSERVATION", 230, 240]]], ["Further supporting the notion that mTORC1 is inactivated at these time points, there was a decrease in p62 protein after 2 h of sucrose exposure ( Figure 7A,B) .", [["sucrose", "CHEMICAL", 128, 135], ["sucrose", "CHEMICAL", 128, 135], ["mTORC1", "GENE_OR_GENE_PRODUCT", 35, 41], ["p62", "GENE_OR_GENE_PRODUCT", 103, 106], ["sucrose", "SIMPLE_CHEMICAL", 128, 135], ["mTORC1", "PROTEIN", 35, 41], ["p62 protein", "PROTEIN", 103, 114], ["a decrease in p62 protein", "PROBLEM", 89, 114], ["sucrose exposure", "TREATMENT", 128, 144], ["decrease", "OBSERVATION_MODIFIER", 91, 99]]], ["It is likely that, at this acute stage, mTORC1 inactivity has derepressed ULK1-mediated inhibition of autophagy, but it is still too early for any concomitant TFEB-induced increase in p62 protein to be apparent.", [["TFEB", "CHEMICAL", 159, 163], ["mTORC1", "GENE_OR_GENE_PRODUCT", 40, 46], ["ULK1", "GENE_OR_GENE_PRODUCT", 74, 78], ["TFEB", "SIMPLE_CHEMICAL", 159, 163], ["p62", "GENE_OR_GENE_PRODUCT", 184, 187], ["mTORC1", "PROTEIN", 40, 46], ["ULK1", "PROTEIN", 74, 78], ["TFEB", "PROTEIN", 159, 163], ["p62 protein", "PROTEIN", 184, 195], ["this acute stage", "PROBLEM", 22, 38], ["mTORC1 inactivity", "PROBLEM", 40, 57], ["ULK1", "PROBLEM", 74, 78], ["autophagy", "PROBLEM", 102, 111], ["any concomitant TFEB", "PROBLEM", 143, 163], ["p62 protein", "PROBLEM", 184, 195], ["is likely", "UNCERTAINTY", 3, 12], ["increase", "OBSERVATION_MODIFIER", 172, 180], ["p62 protein", "OBSERVATION", 184, 195]]], ["Nonetheless, provoking storage of material in lysosomes results in a rapid and transient inhibition of mTORC1 signalling in both cell types.", [["lysosomes", "ANATOMY", 46, 55], ["cell", "ANATOMY", 129, 133], ["lysosomes", "CELLULAR_COMPONENT", 46, 55], ["mTORC1", "GENE_OR_GENE_PRODUCT", 103, 109], ["cell", "CELL", 129, 133], ["mTORC1", "PROTEIN", 103, 109], ["material in lysosomes", "PROBLEM", 34, 55], ["a rapid and transient inhibition of mTORC1 signalling", "PROBLEM", 67, 120], ["mTORC1 signalling", "OBSERVATION", 103, 120], ["both cell types", "OBSERVATION", 124, 139]]], ["Finally, to assess whether sucrose treatment caused alkalinisation of the lysosome, we employed LysoTracker Red DND-99.", [["lysosome", "ANATOMY", 74, 82], ["sucrose", "CHEMICAL", 27, 34], ["LysoTracker Red DND-99", "CHEMICAL", 96, 118], ["sucrose", "CHEMICAL", 27, 34], ["DND-99", "CHEMICAL", 112, 118], ["sucrose", "SIMPLE_CHEMICAL", 27, 34], ["lysosome", "CELLULAR_COMPONENT", 74, 82], ["LysoTracker Red DND-99", "SPECIES", 96, 118], ["sucrose treatment", "TREATMENT", 27, 44], ["the lysosome", "PROBLEM", 70, 82]]], ["The extent of detection of LysoTracker-stained lysosomes was unaltered by sucrose treatments at all time points, ruling out that sucrose affects mTORC1 signalling by raising intralysosomal pH ( Figure 7C ).Lysosomal storage of sucrose mimics lysosomal alkalinisationIn summary, the mTORC1 inactivation in response to BafA or CQ is likely due to the accumulation of uncleared material within the lysosome as an indirect consequence of intralysosomal alkalinisation (initially due to impairment of the activity of acidophilic lysosomal enzymes).CQ enhances levels of mRNAs for lysosomal and autophagy-related proteins only in A549 cellsTo further evaluate the effects of CQ and BafA on the function of TFEB, HeLa and A549 cells were treated with DMSO, CQ, or BafA for 6 or 24 h. mRNA was then extracted for qPCR analysis of to the mRNAs for the TFEB targets LAMP-1, BECN1, and p62.", [["lysosomes", "ANATOMY", 47, 56], ["Lysosomal", "ANATOMY", 206, 215], ["lysosomal", "ANATOMY", 242, 251], ["lysosome", "ANATOMY", 395, 403], ["intralysosomal", "ANATOMY", 434, 448], ["lysosomal", "ANATOMY", 524, 533], ["lysosomal", "ANATOMY", 575, 584], ["A549 cells", "ANATOMY", 624, 634], ["TFEB", "ANATOMY", 700, 704], ["HeLa", "ANATOMY", 706, 710], ["A549 cells", "ANATOMY", 715, 725], ["sucrose", "CHEMICAL", 74, 81], ["sucrose", "CHEMICAL", 129, 136], ["sucrose", "CHEMICAL", 227, 234], ["BafA", "CHEMICAL", 317, 321], ["CQ", "CHEMICAL", 325, 327], ["CQ", "CHEMICAL", 543, 545], ["CQ", "CHEMICAL", 669, 671], ["BafA", "CHEMICAL", 676, 680], ["DMSO", "CHEMICAL", 744, 748], ["CQ", "CHEMICAL", 750, 752], ["BafA", "CHEMICAL", 757, 761], ["sucrose", "CHEMICAL", 74, 81], ["sucrose", "CHEMICAL", 129, 136], ["sucrose", "CHEMICAL", 227, 234], ["CQ", "CHEMICAL", 669, 671], ["BafA", "CHEMICAL", 676, 680], ["DMSO", "CHEMICAL", 744, 748], ["CQ", "CHEMICAL", 750, 752], ["BafA", "CHEMICAL", 757, 761], ["LysoTracker", "SIMPLE_CHEMICAL", 27, 38], ["lysosomes", "CELLULAR_COMPONENT", 47, 56], ["sucrose", "SIMPLE_CHEMICAL", 74, 81], ["sucrose", "SIMPLE_CHEMICAL", 129, 136], ["mTORC1", "GENE_OR_GENE_PRODUCT", 145, 151], ["Lysosomal", "CELLULAR_COMPONENT", 206, 215], ["sucrose", "SIMPLE_CHEMICAL", 227, 234], ["mTORC1", "GENE_OR_GENE_PRODUCT", 282, 288], ["BafA", "GENE_OR_GENE_PRODUCT", 317, 321], ["CQ", "SIMPLE_CHEMICAL", 325, 327], ["lysosome", "CELLULAR_COMPONENT", 395, 403], ["acidophilic lysosomal enzymes", "GENE_OR_GENE_PRODUCT", 512, 541], ["CQ", "SIMPLE_CHEMICAL", 543, 545], ["lysosomal", "CELLULAR_COMPONENT", 575, 584], ["A549 cells", "CELL", 624, 634], ["CQ", "SIMPLE_CHEMICAL", 669, 671], ["BafA", "SIMPLE_CHEMICAL", 676, 680], ["TFEB", "GENE_OR_GENE_PRODUCT", 700, 704], ["HeLa", "CELL", 706, 710], ["A549 cells", "CELL", 715, 725], ["DMSO", "SIMPLE_CHEMICAL", 744, 748], ["CQ", "SIMPLE_CHEMICAL", 750, 752], ["BafA", "SIMPLE_CHEMICAL", 757, 761], ["TFEB", "GENE_OR_GENE_PRODUCT", 843, 847], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 856, 862], ["BECN1", "GENE_OR_GENE_PRODUCT", 864, 869], ["p62", "GENE_OR_GENE_PRODUCT", 875, 878], ["mTORC1", "PROTEIN", 145, 151], ["mTORC1", "PROTEIN", 282, 288], ["acidophilic lysosomal enzymes", "PROTEIN", 512, 541], ["mRNAs", "RNA", 565, 570], ["lysosomal and autophagy-related proteins", "PROTEIN", 575, 615], ["A549 cells", "CELL_LINE", 624, 634], ["TFEB", "PROTEIN", 700, 704], ["HeLa", "CELL_LINE", 706, 710], ["A549 cells", "CELL_LINE", 715, 725], ["mRNA", "RNA", 777, 781], ["mRNAs", "RNA", 829, 834], ["TFEB targets LAMP-1", "PROTEIN", 843, 862], ["BECN1", "PROTEIN", 864, 869], ["p62", "PROTEIN", 875, 878], ["LysoTracker-stained lysosomes", "PROBLEM", 27, 56], ["sucrose treatments", "TREATMENT", 74, 92], ["intralysosomal pH", "TEST", 174, 191], ["lysosomal alkalinisation", "PROBLEM", 242, 266], ["the mTORC1 inactivation", "PROBLEM", 278, 301], ["CQ", "PROBLEM", 325, 327], ["the accumulation of uncleared material", "PROBLEM", 345, 383], ["intralysosomal alkalinisation", "PROBLEM", 434, 463], ["acidophilic lysosomal enzymes", "TEST", 512, 541], ["mRNAs", "TEST", 565, 570], ["lysosomal and autophagy", "TEST", 575, 598], ["A549 cells", "PROBLEM", 624, 634], ["CQ", "PROBLEM", 669, 671], ["BafA", "TREATMENT", 676, 680], ["HeLa and A549 cells", "TREATMENT", 706, 725], ["DMSO", "TREATMENT", 744, 748], ["CQ", "TREATMENT", 750, 752], ["BafA", "TREATMENT", 757, 761], ["qPCR analysis", "TEST", 805, 818], ["the TFEB", "TEST", 839, 847], ["LAMP", "TEST", 856, 860], ["BECN1", "TEST", 864, 869], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["stained lysosomes", "OBSERVATION", 39, 56], ["sucrose mimics", "OBSERVATION", 227, 241], ["lysosomal alkalinisation", "OBSERVATION", 242, 266], ["likely due to", "UNCERTAINTY", 331, 344], ["uncleared material", "OBSERVATION", 365, 383], ["intralysosomal alkalinisation", "OBSERVATION", 434, 463], ["A549 cells", "OBSERVATION", 624, 634]]], ["After 24 h, in HeLa cells, BafA treatment resulted in a striking increase in the mRNA levels of all three direct TFEB targets (as a ratio against \u03b2-actin expression) when compared with those of the untreated control, which was also statistically significant for p62 and BECN1 (for LAMP-1, P=0.0604) ( Figure 8A ).", [["HeLa cells", "ANATOMY", 15, 25], ["BafA", "CHEMICAL", 27, 31], ["BafA", "CHEMICAL", 27, 31], ["HeLa cells", "CELL", 15, 25], ["BafA", "SIMPLE_CHEMICAL", 27, 31], ["TFEB", "GENE_OR_GENE_PRODUCT", 113, 117], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 146, 153], ["p62", "GENE_OR_GENE_PRODUCT", 262, 265], ["BECN1", "GENE_OR_GENE_PRODUCT", 270, 275], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 281, 287], ["HeLa cells", "CELL_LINE", 15, 25], ["TFEB targets", "PROTEIN", 113, 125], ["\u03b2-actin", "PROTEIN", 146, 153], ["p62", "PROTEIN", 262, 265], ["BECN1", "PROTEIN", 270, 275], ["BafA treatment", "TREATMENT", 27, 41], ["a striking increase in the mRNA levels", "PROBLEM", 54, 92], ["p62", "TEST", 262, 265], ["BECN1", "TEST", 270, 275], ["LAMP", "TEST", 281, 285], ["increase", "OBSERVATION_MODIFIER", 65, 73]]], ["However, although 24-h CQ treatment significantly increased p62 and BECN1 mRNA levels, it did so more modestly than BafA.", [["CQ", "CHEMICAL", 23, 25], ["CQ", "CHEMICAL", 23, 25], ["CQ", "SIMPLE_CHEMICAL", 23, 25], ["p62", "GENE_OR_GENE_PRODUCT", 60, 63], ["BECN1", "GENE_OR_GENE_PRODUCT", 68, 73], ["BafA", "GENE_OR_GENE_PRODUCT", 116, 120], ["p62", "PROTEIN", 60, 63], ["BECN1", "PROTEIN", 68, 73], ["BafA", "PROTEIN", 116, 120], ["significantly increased p62", "PROBLEM", 36, 63], ["BECN1 mRNA levels", "TEST", 68, 85], ["BECN1 mRNA", "OBSERVATION", 68, 78]]], ["In contrast, in A549 cells, both CQ and BafA treatment caused a similar and significant increase in TFEB target gene expression ( Figure 8B ).", [["A549 cells", "ANATOMY", 16, 26], ["CQ", "CHEMICAL", 33, 35], ["BafA", "CHEMICAL", 40, 44], ["CQ", "CHEMICAL", 33, 35], ["BafA", "CHEMICAL", 40, 44], ["A549 cells", "CELL", 16, 26], ["CQ", "SIMPLE_CHEMICAL", 33, 35], ["BafA", "SIMPLE_CHEMICAL", 40, 44], ["TFEB", "GENE_OR_GENE_PRODUCT", 100, 104], ["A549 cells", "CELL_LINE", 16, 26], ["TFEB", "PROTEIN", 100, 104], ["BafA treatment", "TREATMENT", 40, 54], ["A549 cells", "OBSERVATION", 16, 26], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["TFEB target", "OBSERVATION", 100, 111]]], ["Thus, agents that cause intralysosomal alkalinisation, particularly BafA, activate transcription of TFEB target genes, consistent with the impairment of mTORC1 signalling.BafA enhances AMPK activityIn some cell types, a structural and mechanistic link has been established between AMPK and the v-ATPase [39, 40] .", [["intralysosomal", "ANATOMY", 24, 38], ["cell", "ANATOMY", 206, 210], ["BafA", "CHEMICAL", 171, 175], ["BafA", "GENE_OR_GENE_PRODUCT", 68, 72], ["TFEB", "GENE_OR_GENE_PRODUCT", 100, 104], ["mTORC1", "GENE_OR_GENE_PRODUCT", 153, 159], ["BafA", "GENE_OR_GENE_PRODUCT", 171, 175], ["AMPK", "GENE_OR_GENE_PRODUCT", 185, 189], ["cell", "CELL", 206, 210], ["AMPK", "GENE_OR_GENE_PRODUCT", 281, 285], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 294, 302], ["BafA", "PROTEIN", 68, 72], ["TFEB target genes", "DNA", 100, 117], ["mTORC1", "PROTEIN", 153, 159], ["BafA", "PROTEIN", 171, 175], ["AMPK", "PROTEIN", 185, 189], ["AMPK", "PROTEIN", 281, 285], ["v-ATPase", "PROTEIN", 294, 302], ["agents", "TREATMENT", 6, 12], ["intralysosomal alkalinisation", "PROBLEM", 24, 53], ["the impairment of mTORC1 signalling", "PROBLEM", 135, 170], ["the v-ATPase", "TEST", 290, 302], ["intralysosomal alkalinisation", "OBSERVATION", 24, 53], ["mTORC1 signalling", "OBSERVATION", 153, 170], ["AMPK activity", "OBSERVATION", 185, 198], ["some cell types", "OBSERVATION", 201, 216]]], ["AMPK is activated under conditions of reduced cellular 'energy' (ATP) levels, when AMP concentrations rise.", [["cellular", "ANATOMY", 46, 54], ["ATP", "CHEMICAL", 65, 68], ["AMP", "CHEMICAL", 83, 86], ["ATP", "CHEMICAL", 65, 68], ["AMP", "CHEMICAL", 83, 86], ["AMPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 46, 54], ["ATP", "SIMPLE_CHEMICAL", 65, 68], ["AMP", "SIMPLE_CHEMICAL", 83, 86], ["AMPK", "PROTEIN", 0, 4], ["AMPK", "TREATMENT", 0, 4], ["ATP) levels", "TEST", 65, 76], ["AMP concentrations", "TEST", 83, 101]]], ["AMPK can inhibit mTORC1 both directly (via phosphorylation of Serines 722 and 792 of RAPTOR, a key component of mTORC1) [41] and indirectly (through phosphorylation of Thr 1227 and Ser 1345 of TSC2, which in turn deactivates the mTORC1 activator, Rheb) [42] .", [["Thr", "CHEMICAL", 168, 171], ["Ser", "CHEMICAL", 181, 184], ["AMPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["mTORC1", "GENE_OR_GENE_PRODUCT", 17, 23], ["Serines 722", "GENE_OR_GENE_PRODUCT", 62, 73], ["RAPTOR", "GENE_OR_GENE_PRODUCT", 85, 91], ["mTORC1", "GENE_OR_GENE_PRODUCT", 112, 118], ["Thr 1227", "AMINO_ACID", 168, 176], ["Ser 1345", "AMINO_ACID", 181, 189], ["TSC2", "GENE_OR_GENE_PRODUCT", 193, 197], ["mTORC1", "GENE_OR_GENE_PRODUCT", 229, 235], ["Rheb", "GENE_OR_GENE_PRODUCT", 247, 251], ["AMPK", "PROTEIN", 0, 4], ["mTORC1", "PROTEIN", 17, 23], ["RAPTOR", "PROTEIN", 85, 91], ["mTORC1", "PROTEIN", 112, 118], ["Thr 1227", "PROTEIN", 168, 176], ["TSC2", "PROTEIN", 193, 197], ["mTORC1", "PROTEIN", 229, 235], ["Rheb", "PROTEIN", 247, 251], ["AMPK", "TREATMENT", 0, 4], ["Serines", "TEST", 62, 69], ["TSC2", "TEST", 193, 197]]], ["AMPK also associates with and phosphorylates ULK1 at S317 and S777, thereby activating it [43] [44] [45] [46] .", [["AMPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["ULK1", "GENE_OR_GENE_PRODUCT", 45, 49], ["S317", "GENE_OR_GENE_PRODUCT", 53, 57], ["S777", "AMINO_ACID", 62, 66], ["AMPK", "PROTEIN", 0, 4], ["ULK1", "PROTEIN", 45, 49], ["AMPK", "TEST", 0, 4], ["phosphorylates ULK1", "TEST", 30, 49]]], ["As the function of the v-ATPase is inhibited by BafA, but not CQ, we deemed it relevant to evaluate whether these compounds differed in their ability to promote activation of AMPK, particularly in light of their differing effects on the expression of TFEB target genes in HeLa cells ( Figure 8A) .", [["HeLa cells", "ANATOMY", 272, 282], ["CQ", "CHEMICAL", 62, 64], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 23, 31], ["BafA", "SIMPLE_CHEMICAL", 48, 52], ["CQ", "SIMPLE_CHEMICAL", 62, 64], ["AMPK", "GENE_OR_GENE_PRODUCT", 175, 179], ["TFEB", "GENE_OR_GENE_PRODUCT", 251, 255], ["HeLa cells", "CELL", 272, 282], ["Figure 8A", "CELL", 285, 294], ["v-ATPase", "PROTEIN", 23, 31], ["AMPK", "PROTEIN", 175, 179], ["TFEB target genes", "DNA", 251, 268], ["HeLa cells", "CELL_LINE", 272, 282], ["CQ", "PROBLEM", 62, 64], ["these compounds", "PROBLEM", 108, 123], ["activation of AMPK", "TREATMENT", 161, 179], ["HeLa cells", "OBSERVATION", 272, 282]]], ["First, to assess the possible role of AMPK in CQ-and/or BafA-induced mTORC1 inhibition, HeLa and A549 cells were treated with CQ, BafA, or AZD8055, or starved for amino acids for 30 min (after growth in serum-free medium for 23.5 h).", [["HeLa", "ANATOMY", 88, 92], ["A549 cells", "ANATOMY", 97, 107], ["serum", "ANATOMY", 203, 208], ["CQ", "CHEMICAL", 46, 48], ["BafA", "CHEMICAL", 56, 60], ["CQ", "CHEMICAL", 126, 128], ["BafA", "CHEMICAL", 130, 134], ["AZD8055", "CHEMICAL", 139, 146], ["amino acids", "CHEMICAL", 163, 174], ["CQ", "CHEMICAL", 126, 128], ["BafA", "CHEMICAL", 130, 134], ["AZD8055", "CHEMICAL", 139, 146], ["amino acids", "CHEMICAL", 163, 174], ["AMPK", "GENE_OR_GENE_PRODUCT", 38, 42], ["CQ", "SIMPLE_CHEMICAL", 46, 48], ["BafA", "SIMPLE_CHEMICAL", 56, 60], ["mTORC1", "GENE_OR_GENE_PRODUCT", 69, 75], ["HeLa", "CELL", 88, 92], ["A549 cells", "CELL", 97, 107], ["CQ", "SIMPLE_CHEMICAL", 126, 128], ["BafA", "SIMPLE_CHEMICAL", 130, 134], ["AZD8055", "SIMPLE_CHEMICAL", 139, 146], ["amino acids", "AMINO_ACID", 163, 174], ["serum", "ORGANISM_SUBSTANCE", 203, 208], ["AMPK", "PROTEIN", 38, 42], ["mTORC1", "PROTEIN", 69, 75], ["HeLa", "CELL_LINE", 88, 92], ["A549 cells", "CELL_LINE", 97, 107], ["AMPK", "TEST", 38, 42], ["CQ", "TEST", 46, 48], ["BafA", "TEST", 56, 60], ["HeLa and A549 cells", "TREATMENT", 88, 107], ["BafA", "TREATMENT", 130, 134], ["AZD8055", "TREATMENT", 139, 146], ["amino acids", "TREATMENT", 163, 174], ["serum", "TEST", 203, 208], ["A549 cells", "OBSERVATION", 97, 107]]], ["Furthermore, in both cell lines, BafA caused a significant increase in the phosphorylation of S79 in ACC, an AMPK substrate, indicating activation of AMPK.", [["cell lines", "ANATOMY", 21, 31], ["BafA", "CHEMICAL", 33, 37], ["cell lines", "CELL", 21, 31], ["BafA", "GENE_OR_GENE_PRODUCT", 33, 37], ["S79", "GENE_OR_GENE_PRODUCT", 94, 97], ["ACC", "SIMPLE_CHEMICAL", 101, 104], ["AMPK", "GENE_OR_GENE_PRODUCT", 109, 113], ["AMPK", "GENE_OR_GENE_PRODUCT", 150, 154], ["cell lines", "CELL_LINE", 21, 31], ["BafA", "PROTEIN", 33, 37], ["S79", "PROTEIN", 94, 97], ["ACC", "PROTEIN", 101, 104], ["AMPK substrate", "PROTEIN", 109, 123], ["AMPK", "PROTEIN", 150, 154], ["a significant increase", "PROBLEM", 45, 67], ["the phosphorylation", "TEST", 71, 90], ["an AMPK substrate", "TEST", 106, 123], ["activation of AMPK", "PROBLEM", 136, 154], ["cell lines", "OBSERVATION", 21, 31], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["increase", "OBSERVATION_MODIFIER", 59, 67]]], ["However, CQ did not elicit this effect in HeLa cells, while in A549 cells, the CQ-induced increase in phospho-ACC was smaller than that caused by BafA.", [["HeLa cells", "ANATOMY", 42, 52], ["A549 cells", "ANATOMY", 63, 73], ["CQ", "CHEMICAL", 9, 11], ["CQ", "CHEMICAL", 79, 81], ["CQ", "CHEMICAL", 9, 11], ["CQ", "CHEMICAL", 79, 81], ["CQ", "SIMPLE_CHEMICAL", 9, 11], ["HeLa cells", "CELL", 42, 52], ["A549 cells", "CELL", 63, 73], ["CQ", "SIMPLE_CHEMICAL", 79, 81], ["phospho-ACC", "SIMPLE_CHEMICAL", 102, 113], ["BafA", "GENE_OR_GENE_PRODUCT", 146, 150], ["HeLa cells", "CELL_LINE", 42, 52], ["A549 cells", "CELL_LINE", 63, 73], ["phospho-ACC", "PROTEIN", 102, 113], ["BafA", "PROTEIN", 146, 150], ["CQ", "PROBLEM", 9, 11], ["this effect in HeLa cells", "PROBLEM", 27, 52], ["the CQ", "TEST", 75, 81], ["induced increase in phospho-ACC", "PROBLEM", 82, 113], ["HeLa cells", "OBSERVATION", 42, 52], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["smaller", "OBSERVATION_MODIFIER", 118, 125]]], ["Intriguingly, at shorter durations of treatment (1, 2, or 6 h), neither CQ nor BafA affected ACC phosphorylation (Supplementary Figure S2) .", [["CQ", "CHEMICAL", 72, 74], ["BafA", "CHEMICAL", 79, 83], ["CQ", "CHEMICAL", 72, 74], ["BafA", "CHEMICAL", 79, 83], ["CQ", "SIMPLE_CHEMICAL", 72, 74], ["BafA", "SIMPLE_CHEMICAL", 79, 83], ["ACC", "SIMPLE_CHEMICAL", 93, 96], ["ACC", "PROTEIN", 93, 96], ["treatment", "TREATMENT", 38, 47]]], ["This indicates CQ and BafA have different effects on AMPK activity after 24 h.", [["CQ", "CHEMICAL", 15, 17], ["BafA", "CHEMICAL", 22, 26], ["CQ", "CHEMICAL", 15, 17], ["BafA", "CHEMICAL", 22, 26], ["CQ", "SIMPLE_CHEMICAL", 15, 17], ["BafA", "SIMPLE_CHEMICAL", 22, 26], ["AMPK", "GENE_OR_GENE_PRODUCT", 53, 57], ["AMPK", "PROTEIN", 53, 57], ["CQ", "PROBLEM", 15, 17], ["BafA", "TREATMENT", 22, 26], ["AMPK activity", "TREATMENT", 53, 66]]], ["Given that both compounds impair mTORC1 signalling, mechanisms other than activation of AMPK are likely involved, especially for CQ.DiscussionOur data show CQ and BafA each cause impaired mTORC1 signalling in cells grown in abundant nutrient conditions, which includes extracellular amino acids.", [["cells", "ANATOMY", 209, 214], ["extracellular", "ANATOMY", 269, 282], ["CQ", "CHEMICAL", 129, 131], ["CQ", "CHEMICAL", 156, 158], ["BafA", "CHEMICAL", 163, 167], ["amino acids", "CHEMICAL", 283, 294], ["amino acids", "CHEMICAL", 283, 294], ["mTORC1", "GENE_OR_GENE_PRODUCT", 33, 39], ["AMPK", "GENE_OR_GENE_PRODUCT", 88, 92], ["CQ", "SIMPLE_CHEMICAL", 129, 131], ["CQ", "SIMPLE_CHEMICAL", 156, 158], ["BafA", "SIMPLE_CHEMICAL", 163, 167], ["mTORC1", "GENE_OR_GENE_PRODUCT", 188, 194], ["cells", "CELL", 209, 214], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 269, 282], ["amino acids", "AMINO_ACID", 283, 294], ["mTORC1", "PROTEIN", 33, 39], ["AMPK", "PROTEIN", 88, 92], ["mTORC1", "PROTEIN", 188, 194], ["mTORC1 signalling", "PROBLEM", 33, 50], ["DiscussionOur data", "TEST", 132, 150], ["CQ", "PROBLEM", 156, 158], ["BafA", "TREATMENT", 163, 167], ["impaired mTORC1 signalling in cells", "PROBLEM", 179, 214], ["extracellular amino acids", "TREATMENT", 269, 294], ["impaired", "OBSERVATION_MODIFIER", 179, 187], ["mTORC1 signalling", "OBSERVATION", 188, 205], ["abundant", "OBSERVATION_MODIFIER", 224, 232], ["nutrient conditions", "OBSERVATION", 233, 252], ["amino acids", "OBSERVATION", 283, 294]]], ["However, while de-acidification of the lysosomal lumen occurs rapidly (Figure 2 ), only longer term treatment of human cells with CQ or BafA results in impairment of mTORC1 activity (Figure 1 and Supplementary Figure S2 ), suggesting such inhibition is a consequence of alkalinisation rather than altered pH being the proximal cause.", [["lysosomal lumen", "ANATOMY", 39, 54], ["cells", "ANATOMY", 119, 124], ["CQ", "CHEMICAL", 130, 132], ["BafA", "CHEMICAL", 136, 140], ["CQ", "CHEMICAL", 130, 132], ["BafA", "CHEMICAL", 136, 140], ["lysosomal lumen", "CELLULAR_COMPONENT", 39, 54], ["human", "ORGANISM", 113, 118], ["cells", "CELL", 119, 124], ["CQ", "SIMPLE_CHEMICAL", 130, 132], ["BafA", "GENE_OR_GENE_PRODUCT", 136, 140], ["mTORC1", "GENE_OR_GENE_PRODUCT", 166, 172], ["human cells", "CELL_TYPE", 113, 124], ["BafA", "PROTEIN", 136, 140], ["mTORC1", "PROTEIN", 166, 172], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["the lysosomal lumen", "PROBLEM", 35, 54], ["longer term treatment of human cells", "TREATMENT", 88, 124], ["CQ", "PROBLEM", 130, 132], ["BafA", "TREATMENT", 136, 140], ["mTORC1 activity", "PROBLEM", 166, 181], ["such inhibition", "PROBLEM", 234, 249], ["alkalinisation", "PROBLEM", 270, 284], ["altered pH", "PROBLEM", 297, 307], ["lysosomal lumen", "OBSERVATION", 39, 54], ["mTORC1 activity", "OBSERVATION", 166, 181], ["proximal", "OBSERVATION_MODIFIER", 318, 326]]], ["This is likely at least in part a consequence of the decrease in localisation of mTOR with LAMP1-stained lysosomes, given that the lysosomal surface is a major locus for the activation of mTORC1 [8] (Figure 4) .", [["lysosomes", "ANATOMY", 105, 114], ["lysosomal surface", "ANATOMY", 131, 148], ["mTOR", "GENE_OR_GENE_PRODUCT", 81, 85], ["LAMP1", "GENE_OR_GENE_PRODUCT", 91, 96], ["lysosomes", "CELLULAR_COMPONENT", 105, 114], ["lysosomal surface", "CELLULAR_COMPONENT", 131, 148], ["locus", "CELLULAR_COMPONENT", 160, 165], ["mTORC1 [8]", "GENE_OR_GENE_PRODUCT", 188, 198], ["mTOR", "PROTEIN", 81, 85], ["LAMP1", "PROTEIN", 91, 96], ["mTORC1", "PROTEIN", 188, 194], ["LAMP1-stained lysosomes", "TREATMENT", 91, 114], ["likely", "UNCERTAINTY", 8, 14], ["at least", "OBSERVATION_MODIFIER", 15, 23], ["decrease", "OBSERVATION_MODIFIER", 53, 61], ["lysosomal", "OBSERVATION_MODIFIER", 131, 140], ["surface", "OBSERVATION_MODIFIER", 141, 148]]], ["Additionally, although CQ and BafA each inhibit autophagy by increasing intralysosomal pH, it is unlikely that inhibition of autophagy is itself responsible, as siRNA-mediated knockdown of BECN1 did not affect mTORC1 signalling ( Figure 6 ).", [["CQ", "CHEMICAL", 23, 25], ["BafA", "CHEMICAL", 30, 34], ["CQ", "CHEMICAL", 23, 25], ["BafA", "CHEMICAL", 30, 34], ["CQ", "SIMPLE_CHEMICAL", 23, 25], ["BafA", "SIMPLE_CHEMICAL", 30, 34], ["BECN1", "GENE_OR_GENE_PRODUCT", 189, 194], ["mTORC1", "GENE_OR_GENE_PRODUCT", 210, 216], ["BECN1", "PROTEIN", 189, 194], ["mTORC1", "PROTEIN", 210, 216], ["CQ", "PROBLEM", 23, 25], ["autophagy", "PROBLEM", 48, 57], ["increasing intralysosomal pH", "PROBLEM", 61, 89], ["inhibition of autophagy", "PROBLEM", 111, 134], ["increasing", "OBSERVATION_MODIFIER", 61, 71], ["intralysosomal pH", "OBSERVATION", 72, 89]]], ["Furthermore, as leupeptin (which inhibits cysteine, serine and threonine peptidases without altering lysosomal pH [31] ) did not alter phospho-rpS6 levels ( Figure 5C,D) , it is also unlikely that ablated intralysosomal proteolysis and any associated depletion of intralysosomally generated amino acids impair mTORC1 signalling.", [["lysosomal", "ANATOMY", 101, 110], ["intralysosomal", "ANATOMY", 205, 219], ["leupeptin", "CHEMICAL", 16, 25], ["cysteine", "CHEMICAL", 42, 50], ["threonine", "CHEMICAL", 63, 72], ["amino acids", "CHEMICAL", 291, 302], ["leupeptin", "CHEMICAL", 16, 25], ["cysteine", "CHEMICAL", 42, 50], ["serine", "CHEMICAL", 52, 58], ["threonine", "CHEMICAL", 63, 72], ["phospho", "CHEMICAL", 135, 142], ["amino acids", "CHEMICAL", 291, 302], ["leupeptin", "SIMPLE_CHEMICAL", 16, 25], ["cysteine", "AMINO_ACID", 42, 50], ["serine", "AMINO_ACID", 52, 58], ["threonine", "AMINO_ACID", 63, 72], ["peptidases", "GENE_OR_GENE_PRODUCT", 73, 83], ["phospho-rpS6", "GENE_OR_GENE_PRODUCT", 135, 147], ["amino acids", "AMINO_ACID", 291, 302], ["mTORC1", "GENE_OR_GENE_PRODUCT", 310, 316], ["phospho", "PROTEIN", 135, 142], ["-rpS6", "PROTEIN", 142, 147], ["mTORC1", "PROTEIN", 310, 316], ["leupeptin", "TREATMENT", 16, 25], ["threonine peptidases", "TEST", 63, 83], ["altering lysosomal pH", "TEST", 92, 113], ["phospho-rpS6 levels", "TEST", 135, 154], ["ablated intralysosomal proteolysis", "PROBLEM", 197, 231], ["intralysosomally generated amino acids", "TREATMENT", 264, 302], ["intralysosomal proteolysis", "OBSERVATION", 205, 231]]], ["This conclusion is supported by our observation that increased supply of extracellular amino acids failed to rescue the inhibition of mTORC1 signalling caused by either CQ or BafA ( Figure 5A,B) .DiscussionRather, experiments utilising sucrose treatment (an established model for LSDs) [32, 33] suggest that the accumulation of undegraded substrates within lysosomes is the link between the intralysosomal alkalinisation caused by CQ and BafA and inactivation of mTORC1 (Figure 7 and Supplementary Figure S5 ).", [["extracellular", "ANATOMY", 73, 86], ["lysosomes", "ANATOMY", 357, 366], ["intralysosomal", "ANATOMY", 391, 405], ["amino acids", "CHEMICAL", 87, 98], ["CQ", "CHEMICAL", 169, 171], ["sucrose", "CHEMICAL", 236, 243], ["alkalinisation", "DISEASE", 406, 420], ["CQ", "CHEMICAL", 431, 433], ["BafA", "CHEMICAL", 438, 442], ["amino acids", "CHEMICAL", 87, 98], ["sucrose", "CHEMICAL", 236, 243], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 86], ["amino acids", "AMINO_ACID", 87, 98], ["mTORC1", "GENE_OR_GENE_PRODUCT", 134, 140], ["CQ", "SIMPLE_CHEMICAL", 169, 171], ["B", "GENE_OR_GENE_PRODUCT", 192, 193], ["sucrose", "SIMPLE_CHEMICAL", 236, 243], ["lysosomes", "CELLULAR_COMPONENT", 357, 366], ["CQ", "SIMPLE_CHEMICAL", 431, 433], ["BafA", "GENE_OR_GENE_PRODUCT", 438, 442], ["mTORC1", "GENE_OR_GENE_PRODUCT", 463, 469], ["mTORC1", "PROTEIN", 134, 140], ["BafA", "PROTEIN", 175, 179], ["BafA", "PROTEIN", 438, 442], ["mTORC1", "PROTEIN", 463, 469], ["extracellular amino acids", "TREATMENT", 73, 98], ["mTORC1 signalling", "PROBLEM", 134, 151], ["sucrose treatment", "TREATMENT", 236, 253], ["the accumulation of undegraded substrates within lysosomes", "PROBLEM", 308, 366], ["the intralysosomal alkalinisation", "PROBLEM", 387, 420], ["BafA", "TREATMENT", 438, 442], ["mTORC1 (Figure", "TREATMENT", 463, 477], ["intralysosomal alkalinisation", "OBSERVATION", 391, 420]]], ["Two observations from these data nonetheless require qualification.", [["these data", "TEST", 22, 32]]], ["Firstly, CQ-and BafA-induced inhibition of mTORC1 requires a longer duration of treatment than does exposure to sucrose.", [["CQ", "CHEMICAL", 9, 11], ["BafA", "CHEMICAL", 16, 20], ["sucrose", "CHEMICAL", 112, 119], ["CQ", "CHEMICAL", 9, 11], ["BafA", "CHEMICAL", 16, 20], ["sucrose", "CHEMICAL", 112, 119], ["CQ", "SIMPLE_CHEMICAL", 9, 11], ["BafA", "SIMPLE_CHEMICAL", 16, 20], ["mTORC1", "GENE_OR_GENE_PRODUCT", 43, 49], ["sucrose", "SIMPLE_CHEMICAL", 112, 119], ["mTORC1", "PROTEIN", 43, 49], ["CQ", "TEST", 9, 11], ["BafA", "TREATMENT", 16, 20], ["treatment", "TREATMENT", 80, 89], ["sucrose", "TREATMENT", 112, 119]]], ["This may reflect an indirect effect of CQ and BafA whereby they induce lysosomal storage (and consequent mTORC1 inactivation) secondary to lysosomal alkalinisation and inhibit metabolic enzymes causing the gradual accumulation of undegraded macromolecules, whereas sucrose-induced 'storage' is quicker as the storage material is sucrose itself.", [["lysosomal", "ANATOMY", 71, 80], ["lysosomal", "ANATOMY", 139, 148], ["CQ", "CHEMICAL", 39, 41], ["BafA", "CHEMICAL", 46, 50], ["sucrose", "CHEMICAL", 265, 272], ["sucrose", "CHEMICAL", 329, 336], ["CQ", "CHEMICAL", 39, 41], ["BafA", "CHEMICAL", 46, 50], ["sucrose", "CHEMICAL", 265, 272], ["sucrose", "CHEMICAL", 329, 336], ["CQ", "SIMPLE_CHEMICAL", 39, 41], ["BafA", "SIMPLE_CHEMICAL", 46, 50], ["lysosomal", "CELLULAR_COMPONENT", 71, 80], ["mTORC1", "GENE_OR_GENE_PRODUCT", 105, 111], ["lysosomal", "CELLULAR_COMPONENT", 139, 148], ["sucrose", "SIMPLE_CHEMICAL", 265, 272], ["sucrose", "SIMPLE_CHEMICAL", 329, 336], ["mTORC1", "PROTEIN", 105, 111], ["metabolic enzymes", "PROTEIN", 176, 193], ["BafA", "TREATMENT", 46, 50], ["lysosomal storage", "PROBLEM", 71, 88], ["consequent mTORC1 inactivation", "TREATMENT", 94, 124], ["lysosomal alkalinisation", "PROBLEM", 139, 163], ["metabolic enzymes", "PROBLEM", 176, 193], ["the gradual accumulation of undegraded macromolecules", "PROBLEM", 202, 255], ["may reflect", "UNCERTAINTY", 5, 16], ["lysosomal alkalinisation", "OBSERVATION", 139, 163], ["gradual", "OBSERVATION_MODIFIER", 206, 213], ["accumulation", "OBSERVATION_MODIFIER", 214, 226], ["undegraded macromolecules", "OBSERVATION", 230, 255]]], ["This notion is supported by the observation in in earlier studies [4] that sucrose induces the rapid translocation of TFEB from the cytoplasm to the nucleus.", [["cytoplasm", "ANATOMY", 132, 141], ["nucleus", "ANATOMY", 149, 156], ["sucrose", "CHEMICAL", 75, 82], ["sucrose", "CHEMICAL", 75, 82], ["sucrose", "SIMPLE_CHEMICAL", 75, 82], ["TFEB", "GENE_OR_GENE_PRODUCT", 118, 122], ["cytoplasm", "ORGANISM_SUBSTANCE", 132, 141], ["nucleus", "CELLULAR_COMPONENT", 149, 156], ["TFEB", "PROTEIN", 118, 122], ["the rapid translocation of TFEB", "PROBLEM", 91, 122], ["nucleus", "ANATOMY", 149, 156]]], ["Secondly, at longer time points, there is an increase in p62 and LC3-II proteins (Supplementary Figure S5A,B) , together suggesting an inhibition of autophagy, as well as an increase in the mRNA levels of p62 (Supplementary Figure S5C) , which are typically associated with enhanced TFEB activity and autophagy.", [["p62", "GENE_OR_GENE_PRODUCT", 57, 60], ["LC3-II", "GENE_OR_GENE_PRODUCT", 65, 71], ["Supplementary Figure S5A", "GENE_OR_GENE_PRODUCT", 82, 106], ["B", "GENE_OR_GENE_PRODUCT", 107, 108], ["p62", "GENE_OR_GENE_PRODUCT", 205, 208], ["Supplementary Figure S5C", "GENE_OR_GENE_PRODUCT", 210, 234], ["TFEB", "GENE_OR_GENE_PRODUCT", 283, 287], ["p62", "PROTEIN", 57, 60], ["LC3-II proteins", "PROTEIN", 65, 80], ["Supplementary Figure S5A,B", "PROTEIN", 82, 108], ["p62", "PROTEIN", 205, 208], ["S5C", "PROTEIN", 231, 234], ["TFEB", "PROTEIN", 283, 287], ["an increase in p62", "PROBLEM", 42, 60], ["LC3", "TEST", 65, 68], ["an inhibition of autophagy", "PROBLEM", 132, 158], ["the mRNA levels", "TEST", 186, 201], ["autophagy", "PROBLEM", 301, 310], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["autophagy", "OBSERVATION", 149, 158], ["increase", "OBSERVATION_MODIFIER", 174, 182], ["TFEB activity", "OBSERVATION", 283, 296]]], ["Two contrasting processes thus appear to be occurring: an inhibition of autophagic flux and a transcriptional response associated with increased expression of lysosomal and autophagy genes.", [["lysosomal", "ANATOMY", 159, 168], ["lysosomal", "CELLULAR_COMPONENT", 159, 168], ["lysosomal and autophagy genes", "DNA", 159, 188], ["Two contrasting processes", "PROBLEM", 0, 25], ["autophagic flux", "PROBLEM", 72, 87], ["a transcriptional response", "PROBLEM", 92, 118], ["lysosomal and autophagy genes", "PROBLEM", 159, 188], ["appear to be", "UNCERTAINTY", 31, 43], ["autophagic flux", "OBSERVATION", 72, 87], ["transcriptional response", "OBSERVATION", 94, 118], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["autophagy genes", "OBSERVATION", 173, 188]]], ["Previously, in CA1 pyramidal neurons of the hippocampus from Alzheimer's disease patients, an up-regulation of the network of genes regulated by TFEB was observed, along with a decrease in autophagic flux due to an inability to clear the accumulated substrate [47] .", [["CA1 pyramidal neurons", "ANATOMY", 15, 36], ["hippocampus", "ANATOMY", 44, 55], ["Alzheimer's disease", "DISEASE", 61, 80], ["CA1 pyramidal neurons", "CELL", 15, 36], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 44, 55], ["patients", "ORGANISM", 81, 89], ["TFEB", "GENE_OR_GENE_PRODUCT", 145, 149], ["CA1 pyramidal neurons", "CELL_TYPE", 15, 36], ["TFEB", "PROTEIN", 145, 149], ["patients", "SPECIES", 81, 89], ["Alzheimer's disease", "PROBLEM", 61, 80], ["a decrease in autophagic flux", "PROBLEM", 175, 204], ["an inability", "PROBLEM", 212, 224], ["hippocampus", "ANATOMY", 44, 55], ["Alzheimer", "OBSERVATION_MODIFIER", 61, 70], ["autophagic flux", "OBSERVATION", 189, 204]]], ["Therefore, our data with respect to sucrose treatment of A549 and HeLa cells provide a further similarity between lysosomal alkalinisation and substrate storage caused by reduced lysosomal clearance.DiscussionIn summary, our results using sucrose are consistent with previous observations of a TFEB-induced (and thus mTORC1-regulated) transcriptional response to lysosomal dysfunction [4, 11] .", [["A549", "ANATOMY", 57, 61], ["HeLa cells", "ANATOMY", 66, 76], ["lysosomal", "ANATOMY", 114, 123], ["lysosomal", "ANATOMY", 179, 188], ["lysosomal", "ANATOMY", 363, 372], ["sucrose", "CHEMICAL", 36, 43], ["sucrose", "CHEMICAL", 239, 246], ["TFEB", "CHEMICAL", 294, 298], ["lysosomal dysfunction", "DISEASE", 363, 384], ["sucrose", "CHEMICAL", 36, 43], ["sucrose", "CHEMICAL", 239, 246], ["sucrose", "SIMPLE_CHEMICAL", 36, 43], ["A549", "CELL", 57, 61], ["HeLa cells", "CELL", 66, 76], ["lysosomal", "CELLULAR_COMPONENT", 114, 123], ["lysosomal", "CELLULAR_COMPONENT", 179, 188], ["sucrose", "SIMPLE_CHEMICAL", 239, 246], ["TFEB", "GENE_OR_GENE_PRODUCT", 294, 298], ["mTORC1", "GENE_OR_GENE_PRODUCT", 317, 323], ["lysosomal", "CELLULAR_COMPONENT", 363, 372], ["A549", "CELL_LINE", 57, 61], ["HeLa cells", "CELL_LINE", 66, 76], ["TFEB", "PROTEIN", 294, 298], ["mTORC1", "PROTEIN", 317, 323], ["our data", "TEST", 11, 19], ["sucrose treatment", "TREATMENT", 36, 53], ["A549 and HeLa cells", "TREATMENT", 57, 76], ["lysosomal alkalinisation", "TREATMENT", 114, 138], ["substrate storage", "TREATMENT", 143, 160], ["reduced lysosomal clearance", "PROBLEM", 171, 198], ["sucrose", "TREATMENT", 239, 246], ["a TFEB", "PROBLEM", 292, 298], ["lysosomal dysfunction", "PROBLEM", 363, 384], ["lysosomal alkalinisation", "OBSERVATION", 114, 138], ["reduced", "OBSERVATION_MODIFIER", 171, 178], ["lysosomal clearance", "OBSERVATION", 179, 198], ["lysosomal dysfunction", "OBSERVATION", 363, 384]]], ["This is conceptually novel as we propose that CQ and BafA ultimately exert their effects on the endo-lysosomal network in a similar mechanistic fashion to that of accumulation of substrates within the lysosome.", [["lysosome", "ANATOMY", 201, 209], ["CQ", "CHEMICAL", 46, 48], ["BafA", "CHEMICAL", 53, 57], ["CQ", "SIMPLE_CHEMICAL", 46, 48], ["BafA", "SIMPLE_CHEMICAL", 53, 57], ["lysosome", "CELLULAR_COMPONENT", 201, 209], ["BafA", "TREATMENT", 53, 57], ["the endo-lysosomal network", "TREATMENT", 92, 118], ["accumulation of substrates within the lysosome", "PROBLEM", 163, 209]]], ["Indeed, altered mTORC1 signalling has commonly been demonstrated as a component of diseases associated with lysosomal dysfunction.", [["lysosomal", "ANATOMY", 108, 117], ["lysosomal dysfunction", "DISEASE", 108, 129], ["mTORC1", "GENE_OR_GENE_PRODUCT", 16, 22], ["lysosomal", "CELLULAR_COMPONENT", 108, 117], ["mTORC1", "PROTEIN", 16, 22], ["altered mTORC1 signalling", "PROBLEM", 8, 33], ["diseases", "PROBLEM", 83, 91], ["lysosomal dysfunction", "PROBLEM", 108, 129], ["altered", "OBSERVATION_MODIFIER", 8, 15], ["mTORC1 signalling", "OBSERVATION", 16, 33], ["component", "OBSERVATION_MODIFIER", 70, 79], ["diseases", "OBSERVATION", 83, 91], ["lysosomal dysfunction", "OBSERVATION", 108, 129]]], ["These include (with the mutated gene in parentheses): juvenile neuronal ceroid lipofuscinosis (CLN3) [48] ; Scheie syndrome (IDUA) [49] ; aspartylglucosaminuria (AGA) [49] ; Fabry disease (GLA) [49, 50] ; cystinosis (CTNS) [51] .", [["neuronal", "ANATOMY", 63, 71], ["neuronal ceroid lipofuscinosis", "DISEASE", 63, 93], ["Scheie syndrome", "DISEASE", 108, 123], ["IDUA", "DISEASE", 125, 129], ["aspartylglucosaminuria", "CHEMICAL", 138, 160], ["Fabry disease", "DISEASE", 174, 187], ["cystinosis", "DISEASE", 205, 215], ["CTNS", "DISEASE", 217, 221], ["aspartylglucosaminuria", "CHEMICAL", 138, 160], ["aspartylglucosaminuria", "SIMPLE_CHEMICAL", 138, 160], ["Fabry disease", "CANCER", 174, 187], ["mutated gene", "DNA", 24, 36], ["juvenile neuronal ceroid lipofuscinosis", "PROBLEM", 54, 93], ["Scheie syndrome (IDUA)", "PROBLEM", 108, 130], ["aspartylglucosaminuria (AGA)", "PROBLEM", 138, 166], ["Fabry disease (GLA)", "PROBLEM", 174, 193], ["cystinosis (CTNS)", "PROBLEM", 205, 222], ["neuronal", "ANATOMY", 63, 71], ["ceroid lipofuscinosis", "OBSERVATION", 72, 93]]], ["In the final case, the scenario is complicated by the authors' finding that the product of CTNS interacts with the v-ATPase-Ragulator-RagGTPase complex, so the effect in this example is more likely to be a direct one.", [["CTNS", "GENE_OR_GENE_PRODUCT", 91, 95], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 115, 123], ["RagGTPase", "GENE_OR_GENE_PRODUCT", 134, 143], ["CTNS", "PROTEIN", 91, 95], ["v-ATPase", "PROTEIN", 115, 123], ["Ragulator", "PROTEIN", 124, 133], ["RagGTPase complex", "PROTEIN", 134, 151], ["the v-ATPase", "TEST", 111, 123]]], ["In another recent study, mTORC1 signalling is impaired in myotubes into which a mutation linked to Pompe's disease (a genetic disorder in which lysosomal function is affected by deficiency in the enzyme \u03b1-glucosidase, which normally breaks down glycogen within lysosomes) has been introduced [52] .", [["myotubes", "ANATOMY", 58, 66], ["lysosomal", "ANATOMY", 144, 153], ["lysosomes", "ANATOMY", 261, 270], ["Pompe's disease", "DISEASE", 99, 114], ["genetic disorder", "DISEASE", 118, 134], ["glycogen", "CHEMICAL", 245, 253], ["mTORC1", "GENE_OR_GENE_PRODUCT", 25, 31], ["myotubes", "CELL", 58, 66], ["lysosomal", "CELLULAR_COMPONENT", 144, 153], ["\u03b1-glucosidase", "GENE_OR_GENE_PRODUCT", 203, 216], ["glycogen", "SIMPLE_CHEMICAL", 245, 253], ["lysosomes", "CELLULAR_COMPONENT", 261, 270], ["mTORC1", "PROTEIN", 25, 31], ["myotubes", "CELL_TYPE", 58, 66], ["enzyme \u03b1-glucosidase", "PROTEIN", 196, 216], ["another recent study", "TEST", 3, 23], ["a mutation", "PROBLEM", 78, 88], ["Pompe's disease", "PROBLEM", 99, 114], ["a genetic disorder", "PROBLEM", 116, 134], ["deficiency in the enzyme \u03b1-glucosidase", "PROBLEM", 178, 216], ["impaired", "OBSERVATION_MODIFIER", 46, 54]]], ["However, this is a quite distinct situation as mTOR remains associated with lysosomes (on account of the hyperactivation of the v-ATPase) but instead its negative regulator, TSC2, is recruited to these organelles to inactivate mTORC1.", [["lysosomes", "ANATOMY", 76, 85], ["organelles", "ANATOMY", 202, 212], ["mTOR", "GENE_OR_GENE_PRODUCT", 47, 51], ["lysosomes", "CELLULAR_COMPONENT", 76, 85], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 128, 136], ["TSC2", "GENE_OR_GENE_PRODUCT", 174, 178], ["organelles", "CELLULAR_COMPONENT", 202, 212], ["mTORC1", "GENE_OR_GENE_PRODUCT", 227, 233], ["mTOR", "PROTEIN", 47, 51], ["v-ATPase", "PROTEIN", 128, 136], ["negative regulator", "PROTEIN", 154, 172], ["TSC2", "PROTEIN", 174, 178], ["mTORC1", "PROTEIN", 227, 233], ["lysosomes", "PROBLEM", 76, 85]]], ["Overall, therefore, rather than being described merely as inhibitors of autophagy, it would be more appropriate to consider CQ and BafA, like sucrose, as mimetics of LSDs at the cellular level, as, in addition, they also promote certain aspects of autophagic flux (such as TFEB activation) via mTORC1 inactivation.DiscussionAdditional considerations are raised by our observations of greater inhibition of mTORC1 activity by BafA than CQ, with respect to reduced rpS6 phosphorylation ( Figures 1B, 5B ,D, and 9A) and increased mRNA levels of TFEB target genes ( Figure 8A ) in HeLa cells.", [["cellular", "ANATOMY", 178, 186], ["HeLa cells", "ANATOMY", 577, 587], ["CQ", "CHEMICAL", 124, 126], ["BafA", "CHEMICAL", 131, 135], ["sucrose", "CHEMICAL", 142, 149], ["CQ", "CHEMICAL", 435, 437], ["CQ", "CHEMICAL", 124, 126], ["BafA", "CHEMICAL", 131, 135], ["sucrose", "CHEMICAL", 142, 149], ["CQ", "SIMPLE_CHEMICAL", 124, 126], ["BafA", "SIMPLE_CHEMICAL", 131, 135], ["sucrose", "SIMPLE_CHEMICAL", 142, 149], ["LSDs", "GENE_OR_GENE_PRODUCT", 166, 170], ["cellular", "CELL", 178, 186], ["TFEB", "GENE_OR_GENE_PRODUCT", 273, 277], ["mTORC1", "GENE_OR_GENE_PRODUCT", 294, 300], ["mTORC1", "GENE_OR_GENE_PRODUCT", 406, 412], ["BafA", "GENE_OR_GENE_PRODUCT", 425, 429], ["CQ", "SIMPLE_CHEMICAL", 435, 437], ["rpS6", "GENE_OR_GENE_PRODUCT", 463, 467], ["D", "GENE_OR_GENE_PRODUCT", 502, 503], ["9A", "GENE_OR_GENE_PRODUCT", 509, 511], ["TFEB", "GENE_OR_GENE_PRODUCT", 542, 546], ["Figure 8A", "GENE_OR_GENE_PRODUCT", 562, 571], ["HeLa cells", "CELL", 577, 587], ["TFEB", "PROTEIN", 273, 277], ["mTORC1", "PROTEIN", 294, 300], ["mTORC1", "PROTEIN", 406, 412], ["BafA", "PROTEIN", 425, 429], ["rpS6", "PROTEIN", 463, 467], ["TFEB target genes", "DNA", 542, 559], ["Figure 8A", "DNA", 562, 571], ["HeLa cells", "CELL_LINE", 577, 587], ["autophagy", "PROBLEM", 72, 81], ["BafA", "TREATMENT", 131, 135], ["sucrose", "TREATMENT", 142, 149], ["LSDs", "PROBLEM", 166, 170], ["autophagic flux", "PROBLEM", 248, 263], ["mTORC1 inactivation", "TREATMENT", 294, 313], ["reduced rpS6 phosphorylation", "PROBLEM", 455, 483], ["Figures", "TEST", 486, 493], ["5B", "TEST", 498, 500], ["increased mRNA levels of TFEB target genes", "PROBLEM", 517, 559], ["autophagic flux", "OBSERVATION", 248, 263], ["HeLa cells", "OBSERVATION", 577, 587]]], ["The fact that CQ impairs mTORC1 signalling indicates that lysosomal alkalinisation itself impacts on mTORC1 signalling, while the somewhat greater effect of BafA might indicate that interference with the v-ATPase, a partner for Ragulator, exerts additional effects on mTORC1 [8] .", [["lysosomal", "ANATOMY", 58, 67], ["CQ", "CHEMICAL", 14, 16], ["BafA", "CHEMICAL", 157, 161], ["CQ", "CHEMICAL", 14, 16], ["CQ", "SIMPLE_CHEMICAL", 14, 16], ["mTORC1", "GENE_OR_GENE_PRODUCT", 25, 31], ["lysosomal", "CELLULAR_COMPONENT", 58, 67], ["mTORC1", "GENE_OR_GENE_PRODUCT", 101, 107], ["BafA", "GENE_OR_GENE_PRODUCT", 157, 161], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 204, 212], ["Ragulator", "GENE_OR_GENE_PRODUCT", 228, 237], ["mTORC1 [8]", "GENE_OR_GENE_PRODUCT", 268, 278], ["mTORC1", "PROTEIN", 25, 31], ["mTORC1", "PROTEIN", 101, 107], ["BafA", "PROTEIN", 157, 161], ["v-ATPase", "PROTEIN", 204, 212], ["Ragulator", "PROTEIN", 228, 237], ["mTORC1", "PROTEIN", 268, 274], ["lysosomal alkalinisation", "PROBLEM", 58, 82], ["Ragulator", "TREATMENT", 228, 237], ["lysosomal alkalinisation", "OBSERVATION", 58, 82]]], ["Furthermore, while 24-h BafA treatment also caused a significant increase in AMPK activity (seen as phosphorylation of ACC S79) in both cell lines (Figure 9 ), a similar effect for CQ (albeit modest, when compared with that elicited by BafA) was only evident in A549 cells ( Figure 9 ).", [["cell lines", "ANATOMY", 136, 146], ["A549 cells", "ANATOMY", 262, 272], ["BafA", "CHEMICAL", 24, 28], ["CQ", "CHEMICAL", 181, 183], ["BafA", "CHEMICAL", 24, 28], ["BafA", "SIMPLE_CHEMICAL", 24, 28], ["AMPK", "GENE_OR_GENE_PRODUCT", 77, 81], ["ACC S79", "GENE_OR_GENE_PRODUCT", 119, 126], ["cell lines", "CELL", 136, 146], ["CQ", "SIMPLE_CHEMICAL", 181, 183], ["BafA", "GENE_OR_GENE_PRODUCT", 236, 240], ["A549 cells", "CELL", 262, 272], ["AMPK", "PROTEIN", 77, 81], ["ACC S79", "PROTEIN", 119, 126], ["cell lines", "CELL_LINE", 136, 146], ["BafA", "PROTEIN", 236, 240], ["A549 cells", "CELL_LINE", 262, 272], ["BafA treatment", "TREATMENT", 24, 38], ["a significant increase in AMPK activity", "PROBLEM", 51, 90], ["CQ", "PROBLEM", 181, 183], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["AMPK activity", "OBSERVATION", 77, 90], ["cell lines", "OBSERVATION", 136, 146], ["A549 cells", "OBSERVATION", 262, 272]]], ["In HeLa cells it appears that inhibition of the v-ATPase itself, rather than lysosomal alkalinisation, is a trigger for AMPK activation in this line.", [["HeLa cells", "ANATOMY", 3, 13], ["lysosomal", "ANATOMY", 77, 86], ["HeLa cells", "CELL", 3, 13], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 48, 56], ["lysosomal", "CELLULAR_COMPONENT", 77, 86], ["AMPK", "GENE_OR_GENE_PRODUCT", 120, 124], ["HeLa cells", "CELL_LINE", 3, 13], ["v-ATPase", "PROTEIN", 48, 56], ["AMPK", "PROTEIN", 120, 124], ["HeLa cells", "TREATMENT", 3, 13], ["lysosomal alkalinisation", "PROBLEM", 77, 101], ["AMPK activation in this line", "PROBLEM", 120, 148], ["HeLa cells", "OBSERVATION", 3, 13], ["alkalinisation", "OBSERVATION", 87, 101]]], ["As BafA quickly promotes lysosomal de-acidification (Figure 2) , it was surprising that shorter durations of treatment with BafA (1-6 h) failed to alter ACC phosphorylation and thus AMPK activation (Supplementary Figure S2) , because a more rapid response to BafA would be consistent with recent observations that link the v-ATPase to activation of AMPK [39] .", [["lysosomal", "ANATOMY", 25, 34], ["BafA", "CHEMICAL", 3, 7], ["BafA", "CHEMICAL", 124, 128], ["BafA", "CHEMICAL", 259, 263], ["BafA", "CHEMICAL", 124, 128], ["BafA", "CHEMICAL", 259, 263], ["BafA", "GENE_OR_GENE_PRODUCT", 3, 7], ["lysosomal", "CELLULAR_COMPONENT", 25, 34], ["BafA", "SIMPLE_CHEMICAL", 124, 128], ["ACC", "SIMPLE_CHEMICAL", 153, 156], ["AMPK", "GENE_OR_GENE_PRODUCT", 182, 186], ["BafA", "GENE_OR_GENE_PRODUCT", 259, 263], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 323, 331], ["AMPK [39]", "GENE_OR_GENE_PRODUCT", 349, 358], ["BafA", "PROTEIN", 3, 7], ["ACC", "PROTEIN", 153, 156], ["AMPK", "PROTEIN", 182, 186], ["BafA", "PROTEIN", 259, 263], ["v-ATPase", "PROTEIN", 323, 331], ["AMPK", "PROTEIN", 349, 353], ["treatment with BafA", "TREATMENT", 109, 128], ["ACC phosphorylation", "PROBLEM", 153, 172], ["lysosomal de-acidification", "OBSERVATION", 25, 51]]], ["During nutrient stress, a complex consisting of AXIN and LKB1 interacts with the v-ATPase, promoting the phosphorylation of AMPK by LKB1 and thus the activation of AMPK [39] .", [["AXIN", "GENE_OR_GENE_PRODUCT", 48, 52], ["LKB1", "GENE_OR_GENE_PRODUCT", 57, 61], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 81, 89], ["AMPK", "GENE_OR_GENE_PRODUCT", 124, 128], ["LKB1", "GENE_OR_GENE_PRODUCT", 132, 136], ["AMPK [39]", "GENE_OR_GENE_PRODUCT", 164, 173], ["AXIN", "PROTEIN", 48, 52], ["LKB1", "PROTEIN", 57, 61], ["v-ATPase", "PROTEIN", 81, 89], ["AMPK", "PROTEIN", 124, 128], ["LKB1", "PROTEIN", 132, 136], ["AMPK", "PROTEIN", 164, 168], ["AXIN and LKB1", "PROBLEM", 48, 61]]], ["However, as A549 and HeLa cells do not express detectable levels of LKB1 [53, 54] , this mechanism cannot operate in them, perhaps explaining why longer BafA treatment is required to activate AMPK.", [["A549", "ANATOMY", 12, 16], ["HeLa cells", "ANATOMY", 21, 31], ["BafA", "CHEMICAL", 153, 157], ["BafA", "CHEMICAL", 153, 157], ["A549", "CELL", 12, 16], ["HeLa cells", "CELL", 21, 31], ["LKB1", "GENE_OR_GENE_PRODUCT", 68, 72], ["BafA", "SIMPLE_CHEMICAL", 153, 157], ["AMPK", "GENE_OR_GENE_PRODUCT", 192, 196], ["A549", "CELL_LINE", 12, 16], ["HeLa cells", "CELL_LINE", 21, 31], ["LKB1", "PROTEIN", 68, 72], ["BafA", "PROTEIN", 153, 157], ["AMPK", "PROTEIN", 192, 196], ["HeLa cells", "TEST", 21, 31], ["LKB1", "TEST", 68, 72], ["longer BafA treatment", "TREATMENT", 146, 167]]], ["The reason that BafA activates AMPK, while CQ only does so to a much more limited extent, probably reflects the fact the former affects the v-ATPase directly, while CQ does not [39] .", [["BafA", "CHEMICAL", 16, 20], ["CQ", "CHEMICAL", 43, 45], ["CQ", "CHEMICAL", 165, 167], ["BafA", "GENE_OR_GENE_PRODUCT", 16, 20], ["AMPK", "GENE_OR_GENE_PRODUCT", 31, 35], ["CQ", "SIMPLE_CHEMICAL", 43, 45], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 140, 148], ["CQ", "SIMPLE_CHEMICAL", 165, 167], ["BafA", "PROTEIN", 16, 20], ["AMPK", "PROTEIN", 31, 35], ["v-ATPase", "PROTEIN", 140, 148]]], ["At any rate, independent of the exact mechanism, the chronic effect of BafA to inhibit mTORC1 may ultimately involve both activation of AMPK and lysosomal alkalinisation, while CQ, by exerting only the latter effect, impairs mTORC1 signalling more modestly.", [["lysosomal", "ANATOMY", 145, 154], ["BafA", "CHEMICAL", 71, 75], ["CQ", "CHEMICAL", 177, 179], ["BafA", "CHEMICAL", 71, 75], ["BafA", "GENE_OR_GENE_PRODUCT", 71, 75], ["mTORC1", "GENE_OR_GENE_PRODUCT", 87, 93], ["AMPK", "GENE_OR_GENE_PRODUCT", 136, 140], ["lysosomal", "CELLULAR_COMPONENT", 145, 154], ["CQ", "SIMPLE_CHEMICAL", 177, 179], ["mTORC1", "GENE_OR_GENE_PRODUCT", 225, 231], ["BafA", "PROTEIN", 71, 75], ["mTORC1", "PROTEIN", 87, 93], ["AMPK", "PROTEIN", 136, 140], ["mTORC1", "PROTEIN", 225, 231], ["BafA", "TREATMENT", 71, 75], ["mTORC1", "TREATMENT", 87, 93], ["lysosomal alkalinisation", "PROBLEM", 145, 169], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["lysosomal alkalinisation", "OBSERVATION", 145, 169]]], ["A similar pattern was seen for the abilities of CQ and BafA to up-regulate known TFEB targets; in HeLa cells, BafA treatment for 24 h led to increased levels of three known direct TFEB targets (LAMP-1, BECN, and p62), whereas CQ caused only a modest up-regulation of p62 and BECN1 ( Figure 8A ).", [["HeLa cells", "ANATOMY", 98, 108], ["CQ", "CHEMICAL", 48, 50], ["BafA", "CHEMICAL", 55, 59], ["BafA", "CHEMICAL", 110, 114], ["CQ", "CHEMICAL", 226, 228], ["BafA", "CHEMICAL", 110, 114], ["CQ", "CHEMICAL", 226, 228], ["CQ", "SIMPLE_CHEMICAL", 48, 50], ["BafA", "GENE_OR_GENE_PRODUCT", 55, 59], ["TFEB", "GENE_OR_GENE_PRODUCT", 81, 85], ["HeLa cells", "CELL", 98, 108], ["BafA", "GENE_OR_GENE_PRODUCT", 110, 114], ["TFEB", "GENE_OR_GENE_PRODUCT", 180, 184], ["LAMP-1", "GENE_OR_GENE_PRODUCT", 194, 200], ["BECN", "GENE_OR_GENE_PRODUCT", 202, 206], ["p62", "GENE_OR_GENE_PRODUCT", 212, 215], ["CQ", "SIMPLE_CHEMICAL", 226, 228], ["p62", "GENE_OR_GENE_PRODUCT", 267, 270], ["BECN1 ( Figure 8A", "GENE_OR_GENE_PRODUCT", 275, 292], ["BafA", "PROTEIN", 55, 59], ["TFEB", "PROTEIN", 81, 85], ["HeLa cells", "CELL_LINE", 98, 108], ["TFEB targets", "PROTEIN", 180, 192], ["LAMP-1", "PROTEIN", 194, 200], ["BECN", "PROTEIN", 202, 206], ["p62", "PROTEIN", 212, 215], ["p62", "PROTEIN", 267, 270], ["BECN1", "PROTEIN", 275, 280], ["Figure 8A", "PROTEIN", 283, 292], ["BafA", "TREATMENT", 55, 59], ["BafA treatment", "TREATMENT", 110, 124], ["LAMP", "TEST", 194, 198], ["BECN", "TEST", 202, 206], ["TFEB targets", "OBSERVATION", 81, 93], ["HeLa cells", "OBSERVATION_MODIFIER", 98, 108]]], ["There may also be differences between cell lines (Figures 8B and 9 ).", [["cell lines", "ANATOMY", 38, 48], ["cell lines", "CELL", 38, 48], ["cell lines", "CELL_LINE", 38, 48], ["cell lines", "TEST", 38, 48], ["may also be", "UNCERTAINTY", 6, 17], ["cell lines", "OBSERVATION", 38, 48]]], ["In summary, lysosomal alkalinisation is sufficient to inhibit mTORC1 activity, although additional signalling mechanisms likely contribute to the stronger responses to BafA.", [["lysosomal", "ANATOMY", 12, 21], ["BafA", "CHEMICAL", 168, 172], ["BafA", "CHEMICAL", 168, 172], ["lysosomal", "CELLULAR_COMPONENT", 12, 21], ["mTORC1", "GENE_OR_GENE_PRODUCT", 62, 68], ["BafA", "GENE_OR_GENE_PRODUCT", 168, 172], ["mTORC1", "PROTEIN", 62, 68], ["BafA", "PROTEIN", 168, 172], ["lysosomal alkalinisation", "TEST", 12, 36], ["additional signalling mechanisms", "PROBLEM", 88, 120], ["lysosomal alkalinisation", "OBSERVATION", 12, 36]]], ["Indeed, it should be noted that other differences have been seen between the effects of CQ and BafA, such as on the organisation of certain organelles, e.g., the Golgi [13] .", [["organelles", "ANATOMY", 140, 150], ["Golgi", "ANATOMY", 162, 167], ["CQ", "CHEMICAL", 88, 90], ["BafA", "CHEMICAL", 95, 99], ["CQ", "SIMPLE_CHEMICAL", 88, 90], ["BafA", "SIMPLE_CHEMICAL", 95, 99], ["organelles", "CELLULAR_COMPONENT", 140, 150], ["Golgi", "CELLULAR_COMPONENT", 162, 167], ["BafA", "TREATMENT", 95, 99]]], ["However, the common means by which both compounds act as mimetics of acute LSDs is via their shared capacity to induce the alkalinisation of the lumen of the lysosome, the accumulation of intralysosomal storage material (the defining characteristic of LSDs) and subsequently also the impairment of mTORC1 activity.DiscussionAlthough, an inhibitory effect of lysosomal alkalinisation on mTORC1 signalling has been previously reported [55] , those authors proposed that impeding autophagy itself inhibits mTORC1 in an attempt to compensate by promoting autophagy, in a type of 'homoeostatic' feedback mechanism; this scenario is not supported by our data, as the inhibition of autophagy by siRNA-mediated knockdown of BECN1 did not influence mTORC1 signalling ( Figure 6 ).", [["lumen", "ANATOMY", 145, 150], ["lysosome", "ANATOMY", 158, 166], ["lysosomal", "ANATOMY", 358, 367], ["LSDs", "DISEASE", 75, 79], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 145, 150], ["lysosome", "CELLULAR_COMPONENT", 158, 166], ["LSDs", "GENE_OR_GENE_PRODUCT", 252, 256], ["mTORC1", "GENE_OR_GENE_PRODUCT", 298, 304], ["lysosomal", "CELLULAR_COMPONENT", 358, 367], ["mTORC1", "GENE_OR_GENE_PRODUCT", 386, 392], ["mTORC1", "GENE_OR_GENE_PRODUCT", 503, 509], ["BECN1", "GENE_OR_GENE_PRODUCT", 716, 721], ["mTORC1", "GENE_OR_GENE_PRODUCT", 740, 746], ["mTORC1", "PROTEIN", 298, 304], ["mTORC1", "PROTEIN", 386, 392], ["mTORC1", "PROTEIN", 503, 509], ["BECN1", "PROTEIN", 716, 721], ["mTORC1", "PROTEIN", 740, 746], ["acute LSDs", "PROBLEM", 69, 79], ["the lysosome", "PROBLEM", 154, 166], ["intralysosomal storage material", "PROBLEM", 188, 219], ["LSDs", "PROBLEM", 252, 256], ["lysosomal alkalinisation", "PROBLEM", 358, 382], ["mTORC1", "TREATMENT", 503, 509], ["BECN1", "PROBLEM", 716, 721], ["lumen", "ANATOMY_MODIFIER", 145, 150], ["lysosome", "ANATOMY", 158, 166], ["accumulation", "OBSERVATION_MODIFIER", 172, 184], ["intralysosomal storage material", "OBSERVATION", 188, 219], ["impairment", "OBSERVATION_MODIFIER", 284, 294], ["mTORC1 activity", "OBSERVATION", 298, 313], ["lysosomal alkalinisation", "OBSERVATION", 358, 382]]], ["We note that there is also a contrasting report that, in osteoclasts, alkalinisation of the lysosome (via exposure to CQ or ammonium chloride) increases mTORC1 activity, an effect which was associated with increased mTOR protein levels [56] .", [["osteoclasts", "ANATOMY", 57, 68], ["lysosome", "ANATOMY", 92, 100], ["CQ", "CHEMICAL", 118, 120], ["ammonium chloride", "CHEMICAL", 124, 141], ["CQ", "CHEMICAL", 118, 120], ["ammonium chloride", "CHEMICAL", 124, 141], ["osteoclasts", "CELL", 57, 68], ["lysosome", "CELLULAR_COMPONENT", 92, 100], ["CQ", "SIMPLE_CHEMICAL", 118, 120], ["ammonium chloride", "SIMPLE_CHEMICAL", 124, 141], ["mTORC1", "GENE_OR_GENE_PRODUCT", 153, 159], ["mTOR", "GENE_OR_GENE_PRODUCT", 216, 220], ["osteoclasts", "CELL_TYPE", 57, 68], ["mTORC1", "PROTEIN", 153, 159], ["mTOR", "PROTEIN", 216, 220], ["osteoclasts", "PROBLEM", 57, 68], ["the lysosome", "PROBLEM", 88, 100], ["ammonium chloride", "TREATMENT", 124, 141], ["mTORC1 activity", "PROBLEM", 153, 168], ["increased mTOR protein levels", "PROBLEM", 206, 235], ["osteoclasts", "ANATOMY", 57, 68], ["mTORC1 activity", "OBSERVATION", 153, 168]]], ["Enhanced mTORC1 activity resulting from increased lysosomal pH caused by treatment with CQ and (more potently) BafA has also been observed in chondrocytes (but without an increased level of mTOR protein) [57] .", [["lysosomal", "ANATOMY", 50, 59], ["chondrocytes", "ANATOMY", 142, 154], ["CQ", "CHEMICAL", 88, 90], ["BafA", "CHEMICAL", 111, 115], ["CQ", "CHEMICAL", 88, 90], ["mTORC1", "GENE_OR_GENE_PRODUCT", 9, 15], ["lysosomal", "CELLULAR_COMPONENT", 50, 59], ["CQ", "SIMPLE_CHEMICAL", 88, 90], ["BafA", "GENE_OR_GENE_PRODUCT", 111, 115], ["chondrocytes", "CELL", 142, 154], ["mTOR", "GENE_OR_GENE_PRODUCT", 190, 194], ["mTORC1", "PROTEIN", 9, 15], ["BafA", "PROTEIN", 111, 115], ["chondrocytes", "CELL_TYPE", 142, 154], ["mTOR protein", "PROTEIN", 190, 202], ["Enhanced mTORC1 activity", "PROBLEM", 0, 24], ["increased lysosomal pH", "PROBLEM", 40, 62], ["treatment with CQ", "TREATMENT", 73, 90], ["an increased level of mTOR protein", "PROBLEM", 168, 202], ["mTORC1 activity", "OBSERVATION", 9, 24], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["lysosomal pH", "OBSERVATION", 50, 62]]], ["These findings may reflect a specific feature of cells that are related to bone growth.DiscussionIn conclusion, future studies using BafA or CQ (for example, to manipulate lysosomal function/autophagy) must take into account their abilities to modulate mTORC1 signalling and to acutely mimic LSDs (and in the case of BafA, to further activate AMPK), since these pathways exert diverse effects on cell physiology [1] .", [["cells", "ANATOMY", 49, 54], ["bone", "ANATOMY", 75, 79], ["lysosomal", "ANATOMY", 172, 181], ["cell", "ANATOMY", 396, 400], ["BafA", "CHEMICAL", 133, 137], ["CQ", "CHEMICAL", 141, 143], ["LSDs", "DISEASE", 292, 296], ["cells", "CELL", 49, 54], ["bone", "TISSUE", 75, 79], ["BafA", "GENE_OR_GENE_PRODUCT", 133, 137], ["CQ", "SIMPLE_CHEMICAL", 141, 143], ["lysosomal", "CELLULAR_COMPONENT", 172, 181], ["mTORC1", "GENE_OR_GENE_PRODUCT", 253, 259], ["LSDs", "PATHOLOGICAL_FORMATION", 292, 296], ["BafA", "GENE_OR_GENE_PRODUCT", 317, 321], ["AMPK", "GENE_OR_GENE_PRODUCT", 343, 347], ["cell", "CELL", 396, 400], ["mTORC1", "PROTEIN", 253, 259], ["BafA", "PROTEIN", 317, 321], ["AMPK", "PROTEIN", 343, 347], ["a specific feature of cells", "PROBLEM", 27, 54], ["bone growth", "PROBLEM", 75, 86], ["BafA", "TREATMENT", 133, 137], ["BafA", "TREATMENT", 317, 321], ["may reflect", "UNCERTAINTY", 15, 26], ["bone", "ANATOMY", 75, 79], ["growth", "OBSERVATION_MODIFIER", 80, 86]]], ["This is becoming more relevant medically, given that recent research implicates impaired v-ATPase activity (due to genetic defects) and increased intralysosomal pH in more highly prevalent conditions such as late-onset neurodegenerative disorders [58] .", [["intralysosomal", "ANATOMY", 146, 160], ["neurodegenerative disorders", "DISEASE", 219, 246], ["v-ATPase", "GENE_OR_GENE_PRODUCT", 89, 97], ["v-ATPase", "PROTEIN", 89, 97], ["impaired v-ATPase activity", "PROBLEM", 80, 106], ["genetic defects", "PROBLEM", 115, 130], ["increased intralysosomal pH", "PROBLEM", 136, 163], ["late-onset neurodegenerative disorders", "PROBLEM", 208, 246], ["v-ATPase activity", "OBSERVATION", 89, 106], ["defects", "OBSERVATION", 123, 130], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["intralysosomal pH", "OBSERVATION", 146, 163], ["highly prevalent", "OBSERVATION_MODIFIER", 172, 188], ["neurodegenerative", "OBSERVATION_MODIFIER", 219, 236]]]], "e9c971f80258e83c52a7e490ae2bf8af0e59e232": [["Yam (Dioscorea spp.) is a popular vegetatively propagated staple crop cultivated for its starchy tubers in West Africa.", [["Yam", "CHEMICAL", 0, 3], ["Yam", "ORGANISM", 0, 3], ["Dioscorea spp.", "ORGANISM", 5, 19], ["Dioscorea spp.", "SPECIES", 5, 19], ["Dioscorea spp.", "SPECIES", 5, 19], ["staple crop", "TREATMENT", 58, 69], ["staple crop", "OBSERVATION", 58, 69], ["starchy tubers", "OBSERVATION", 89, 103]]], ["Yam mosaic virus (YMV, genus Potyvirus, family Potyviridae) causes \"mosaic disease\", the most economically important viral disease of yams, which can reduce yields by up to 40% [6, 17] .", [["mosaic disease", "DISEASE", 68, 82], ["Yam mosaic virus", "ORGANISM", 0, 16], ["YMV", "ORGANISM", 18, 21], ["genus Potyvirus", "ORGANISM", 23, 38], ["Yam mosaic virus", "SPECIES", 0, 16], ["Yam mosaic virus", "SPECIES", 0, 16], ["YMV", "SPECIES", 18, 21], ["Yam mosaic virus", "PROBLEM", 0, 16], ["genus Potyvirus", "TREATMENT", 23, 38], ["Potyviridae", "TREATMENT", 47, 58], ["mosaic disease\"", "PROBLEM", 68, 83], ["viral disease of yams", "PROBLEM", 117, 138], ["mosaic virus", "OBSERVATION", 4, 16], ["mosaic disease", "OBSERVATION", 68, 82]]], ["YMV is endemic in the West African \"yam belt\" stretching from western Cameroon to C\u00f4te d'Ivoire, which is known to be the largest edible-yam production region in the world [2] .", [["YMV", "CHEMICAL", 0, 3], ["yam", "SPECIES", 36, 39], ["yam", "SPECIES", 137, 140], ["YMV", "SPECIES", 0, 3], ["endemic", "OBSERVATION_MODIFIER", 7, 14]]], ["YMV is most frequently detected in D. rotundata, the dominant yam species cultivated in the yam belt [2, 4, 6] .", [["YMV", "CHEMICAL", 0, 3], ["YMV", "GENE_OR_GENE_PRODUCT", 0, 3], ["D. rotundata", "ORGANISM", 35, 47], ["YMV", "PROTEIN", 0, 3], ["D. rotundata", "SPECIES", 35, 47], ["yam", "SPECIES", 62, 65], ["yam", "SPECIES", 92, 95], ["YMV", "SPECIES", 0, 3], ["D. rotundata", "SPECIES", 35, 47], ["the dominant yam species", "PROBLEM", 49, 73], ["most frequently", "OBSERVATION_MODIFIER", 7, 22]]], ["Since yams are clonally propagated using whole tubers, portions of the tubers (setts), or vine cuttings, the virus perpetuates from season to season and spreads to new areas along with the infected planting material [6] .", [["yams", "ANATOMY", 6, 10], ["tubers", "ANATOMY", 47, 53], ["tubers", "ANATOMY", 71, 77], ["setts", "ANATOMY", 79, 84], ["tubers", "ORGANISM_SUBDIVISION", 47, 53], ["tubers", "ORGANISM_SUBDIVISION", 71, 77], ["whole tubers", "TREATMENT", 41, 53], ["vine cuttings", "TREATMENT", 90, 103], ["the virus", "PROBLEM", 105, 114], ["the infected planting material", "TREATMENT", 185, 215], ["new", "OBSERVATION_MODIFIER", 164, 167], ["infected", "OBSERVATION_MODIFIER", 189, 197]]]], "9fa3ead39adfb6028f3586e0f4bf109c94357e20": [["IntroductionDuring the outbreak of the Middle East Respiratory Syndrome coronavirus (MERS-CoV) in South Korea in 2015, 186 confirmed cases were reported, including one patient with maintenance hemodialysis (HD); 36 (19.4%) of the patients died.", [["Middle East Respiratory Syndrome coronavirus", "DISEASE", 39, 83], ["Middle East Respiratory Syndrome coronavirus", "ORGANISM", 39, 83], ["MERS-CoV", "ORGANISM", 85, 93], ["patient", "ORGANISM", 168, 175], ["patients", "ORGANISM", 230, 238], ["patient", "SPECIES", 168, 175], ["patients", "SPECIES", 230, 238], ["Middle East Respiratory Syndrome coronavirus", "SPECIES", 39, 83], ["MERS-CoV", "SPECIES", 85, 93], ["the Middle East Respiratory Syndrome coronavirus", "PROBLEM", 35, 83], ["maintenance hemodialysis (HD)", "TREATMENT", 181, 210], ["Middle", "ANATOMY_MODIFIER", 39, 45], ["Respiratory Syndrome", "OBSERVATION", 51, 71]]], ["In the course of coping with MERS-CoV, 16 ,752 people were quarantined.", [["MERS-CoV", "ORGANISM", 29, 37], ["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["MERS-CoV", "SPECIES", 29, 37]]], ["Some dialysis patients in three HD units were incidentally exposed to patients or healthcare workers with confirmed MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 116, 134], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 70, 78], ["MERS-CoV", "ORGANISM", 116, 124], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 70, 78], ["MERS-CoV", "SPECIES", 116, 124], ["Some dialysis", "TREATMENT", 0, 13], ["three HD units", "TREATMENT", 26, 40], ["CoV infection", "PROBLEM", 121, 134], ["dialysis", "OBSERVATION", 5, 13], ["CoV", "ANATOMY", 121, 124], ["infection", "OBSERVATION", 125, 134]]], ["To interrupt the spread of MERS-CoV, these individuals were isolated from the community during the outbreak.IntroductionA life-threatening physical illness can lead to various psychological symptoms after recovery.", [["physical illness", "DISEASE", 139, 155], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["individuals", "ORGANISM", 43, 54], ["MERS-CoV", "SPECIES", 27, 35], ["various psychological symptoms", "PROBLEM", 168, 198]]], ["In 2003, severe acute respiratory syndrome (SARS) spread across 30 countries, and those who were infected experienced social stigma and reported mental health problems such as anxiety, depression, and post-traumatic stress disorder (PTSD) [1] [2] [3] [4] .", [["acute respiratory syndrome", "DISEASE", 16, 42], ["SARS", "DISEASE", 44, 48], ["anxiety", "DISEASE", 176, 183], ["depression", "DISEASE", 185, 195], ["post-traumatic stress disorder", "DISEASE", 201, 231], ["PTSD", "DISEASE", 233, 237], ["severe acute respiratory syndrome", "PROBLEM", 9, 42], ["SARS", "PROBLEM", 44, 48], ["mental health problems", "PROBLEM", 145, 167], ["anxiety", "PROBLEM", 176, 183], ["depression", "PROBLEM", 185, 195], ["post-traumatic stress disorder", "PROBLEM", 201, 231], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["respiratory syndrome", "OBSERVATION", 22, 42]]], ["In Hong Kong, the mental health of 1394 SARS survivors was assessed; 47.8% of the sampled participants experienced PTSD symptoms after recovery, and 25.6% of those who had PTSD symptoms continued experiencing mental health issues up to 30 months after the outbreak [5] .IntroductionPatients with HD have a high risk of accompanying psychiatric illnesses such as depression, anxiety, and stress symptoms [6] [7] [8] , and previous exposure to trauma indicates a greater risk of stress symptoms from a subsequent trauma [9] .", [["SARS", "DISEASE", 40, 44], ["PTSD", "DISEASE", 115, 119], ["PTSD", "DISEASE", 172, 176], ["HD", "DISEASE", 296, 298], ["psychiatric illnesses", "DISEASE", 332, 353], ["depression", "DISEASE", 362, 372], ["anxiety", "DISEASE", 374, 381], ["trauma", "DISEASE", 442, 448], ["trauma", "DISEASE", 511, 517], ["participants", "ORGANISM", 90, 102], ["participants", "SPECIES", 90, 102], ["PTSD symptoms", "PROBLEM", 115, 128], ["PTSD symptoms", "PROBLEM", 172, 185], ["mental health issues", "PROBLEM", 209, 229], ["HD", "TREATMENT", 296, 298], ["accompanying psychiatric illnesses", "PROBLEM", 319, 353], ["depression", "PROBLEM", 362, 372], ["anxiety", "PROBLEM", 374, 381], ["stress symptoms", "PROBLEM", 387, 402], ["trauma", "PROBLEM", 442, 448], ["stress symptoms", "PROBLEM", 477, 492], ["a subsequent trauma", "PROBLEM", 498, 517]]], ["In the outbreak of MERS-CoV in South Korea, some HD patients were quarantined irrespective of their own will to prevent secondary MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 130, 148], ["MERS-CoV", "ORGANISM", 19, 27], ["patients", "ORGANISM", 52, 60], ["MERS-CoV", "ORGANISM", 130, 138], ["patients", "SPECIES", 52, 60], ["MERS-CoV", "SPECIES", 19, 27], ["MERS-CoV", "SPECIES", 130, 138], ["some HD patients", "TREATMENT", 44, 60], ["secondary MERS", "PROBLEM", 120, 134], ["CoV infection", "PROBLEM", 135, 148], ["CoV infection", "OBSERVATION", 135, 148]]], ["Fortunately, no further patients were infected by MERS-CoV; however, the possibility of a life-threatening infection and quarantine can be more traumatic to patients with chronic kidney disease than to the general population.", [["kidney", "ANATOMY", 179, 185], ["infection", "DISEASE", 107, 116], ["traumatic", "DISEASE", 144, 153], ["chronic kidney disease", "DISEASE", 171, 193], ["patients", "ORGANISM", 24, 32], ["MERS-CoV", "ORGANISM", 50, 58], ["patients", "ORGANISM", 157, 165], ["kidney", "ORGAN", 179, 185], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 157, 165], ["MERS-CoV", "SPECIES", 50, 58], ["a life-threatening infection", "PROBLEM", 88, 116], ["quarantine", "TREATMENT", 121, 131], ["chronic kidney disease", "PROBLEM", 171, 193], ["no", "UNCERTAINTY", 13, 15], ["infected", "OBSERVATION", 38, 46], ["infection", "OBSERVATION", 107, 116], ["kidney", "ANATOMY", 179, 185], ["disease", "OBSERVATION", 186, 193]]], ["The experience of those placed under quarantine in terms of compliance, emotional response, and psychological impact remains under-researched in HD patients.", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156]]], ["This study examined post-traumatic stress symptoms and associated factors among HD patients who were exposed to MERS-CoVinfected patients and isolated for a certain period.ParticipantsA total of 116 HD patients were isolated in Kyung Hee University at Kangdong, Gangeung Medical Center and Kangdong Sacred Heart Hospital during the outbreak of MERS in Korea.", [["post-traumatic stress symptoms", "DISEASE", 20, 50], ["MERS", "DISEASE", 344, 348], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 202, 210], ["This study", "TEST", 0, 10], ["post-traumatic stress symptoms", "PROBLEM", 20, 50], ["Heart", "ANATOMY", 306, 311]]], ["Among those, 89 patients were included in this study because 27 were lost to follow-up at 12 months after quarantine.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["this study", "TEST", 42, 52]]], ["One HD patient and a head nurse in the HD room at the first two hospitals were confirmed to be MERS-CoV-infected.", [["head", "ANATOMY", 21, 25], ["MERS-CoV-infected", "DISEASE", 95, 112], ["patient", "ORGANISM", 7, 14], ["head", "ORGANISM_SUBDIVISION", 21, 25], ["MERS-CoV", "ORGANISM", 95, 103], ["patient", "SPECIES", 7, 14], ["MERS-CoV", "SPECIES", 95, 103], ["infected", "PROBLEM", 104, 112], ["head", "ANATOMY", 21, 25], ["infected", "OBSERVATION", 104, 112]]], ["As a result, 107 HD patients at these two hospitals were suspected to have been exposed to the confirmed cases.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["In the third hospital, 9 HD patients were exposed to MERS-CoV from a confirmed case outside HD units.", [["patients", "ORGANISM", 28, 36], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["patients", "SPECIES", 28, 36], ["MERS-CoV", "SPECIES", 53, 61], ["HD units", "TREATMENT", 92, 100]]], ["All three HD units performed isolation practice to prevent the further spread of MERS-CoV among maintenance HD patients.Isolation practiceAccording to the \"Middle East respiratory syndrome clinical practice guideline for HD facilities\" by the Korean Society of Nephrology during the MERS-CoV outbreak in 2015, a patient in close contact with a MERS patient, without fever or respiratory symptoms, would be subjected to hospitalized quarantine for 14 days since last exposure [10] .", [["respiratory", "ANATOMY", 375, 386], ["respiratory syndrome", "DISEASE", 168, 188], ["fever", "DISEASE", 366, 371], ["respiratory symptoms", "DISEASE", 375, 395], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 81, 89], ["patients", "ORGANISM", 111, 119], ["patient", "ORGANISM", 312, 319], ["patient", "ORGANISM", 349, 356], ["patients", "SPECIES", 111, 119], ["patient", "SPECIES", 312, 319], ["patient", "SPECIES", 349, 356], ["MERS-CoV", "SPECIES", 81, 89], ["MERS-CoV", "SPECIES", 283, 291], ["All three HD units", "TREATMENT", 0, 18], ["isolation practice", "TREATMENT", 29, 47], ["MERS", "PROBLEM", 81, 85], ["maintenance HD patients", "TREATMENT", 96, 119], ["Isolation practiceAccording", "TREATMENT", 120, 147], ["HD facilities", "TREATMENT", 221, 234], ["fever", "PROBLEM", 366, 371], ["respiratory symptoms", "PROBLEM", 375, 395], ["Middle", "ANATOMY_MODIFIER", 156, 162]]], ["Close contact refers to a receiver of dialysis who was in the same place, at the same time as a suspected or confirmed MERS patient in the symptomatic period [11] .", [["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["dialysis", "TREATMENT", 38, 46]]], ["Asymptomatic casual contacts should be subjected to cohort isolation for 14 days after exposure and closely monitored for any suspicious symptoms.", [["cohort isolation", "TREATMENT", 52, 68], ["any suspicious symptoms", "PROBLEM", 122, 145]]], ["Casual contact refers to those who received dialysis on the same day, in the same room as a patient with suspected or confirmed MERS-CoV infection, but at different times and on different beds during the symptomatic period, without having worn appropriate personal protective equipment.", [["MERS-CoV infection", "DISEASE", 128, 146], ["patient", "ORGANISM", 92, 99], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 128, 136], ["patient", "SPECIES", 92, 99], ["MERS-CoV", "SPECIES", 128, 136], ["dialysis", "TREATMENT", 44, 52], ["CoV infection", "PROBLEM", 133, 146], ["CoV", "OBSERVATION_MODIFIER", 133, 136], ["infection", "OBSERVATION", 137, 146]]], ["Hospitalized quarantine was defined as single room or cohort isolation.", [["cohort isolation", "TREATMENT", 54, 70]]], ["Patients isolated in a single room received dialysis in their own rooms installed with dialysis machines.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["dialysis", "TREATMENT", 44, 52], ["dialysis machines", "TREATMENT", 87, 104]]], ["\"Cohort isolation\" is a method of hospitalized quarantine during HD treatment, in a shared HD room.", [["HD treatment", "TREATMENT", 65, 77]]], ["Self-quarantine applied to a patient who received dialysis on a different day from dialysis date of MERS-CoV confirmed case or to patients who were exposed to MERS-CoV from a confirmed case outside HD units and had no respiratory symptoms.", [["respiratory", "ANATOMY", 218, 229], ["respiratory symptoms", "DISEASE", 218, 238], ["patient", "ORGANISM", 29, 36], ["patients", "ORGANISM", 130, 138], ["MERS-CoV", "ORGANISM", 159, 167], ["patient", "SPECIES", 29, 36], ["patients", "SPECIES", 130, 138], ["MERS-CoV", "SPECIES", 100, 108], ["MERS-CoV", "SPECIES", 159, 167], ["Self-quarantine", "TREATMENT", 0, 15], ["dialysis", "TREATMENT", 50, 58], ["HD units", "TREATMENT", 198, 206], ["respiratory symptoms", "PROBLEM", 218, 238], ["no", "UNCERTAINTY", 215, 217], ["respiratory", "ANATOMY", 218, 229], ["symptoms", "OBSERVATION", 230, 238]]], ["The patient was monitored for the development of fever or respiratory symptoms during quarantine.Clinical data and measuresDemographic information including age, gender, HD duration, history of diabetes mellitus, and previous cardiovascular diseaselaboratory data including hemoglobin, albumin, and hsCRP were collected at the time of enrollment.Clinical data and measuresA survey was conducted at 12 months after the isolation period.", [["respiratory", "ANATOMY", 58, 69], ["cardiovascular", "ANATOMY", 226, 240], ["fever", "DISEASE", 49, 54], ["respiratory symptoms", "DISEASE", 58, 78], ["diabetes mellitus", "DISEASE", 194, 211], ["patient", "ORGANISM", 4, 11], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 274, 284], ["albumin", "GENE_OR_GENE_PRODUCT", 286, 293], ["hsCRP", "GENE_OR_GENE_PRODUCT", 299, 304], ["hemoglobin", "PROTEIN", 274, 284], ["albumin", "PROTEIN", 286, 293], ["hsCRP", "PROTEIN", 299, 304], ["patient", "SPECIES", 4, 11], ["fever", "PROBLEM", 49, 54], ["respiratory symptoms", "PROBLEM", 58, 78], ["Clinical data", "TEST", 97, 110], ["diabetes mellitus", "PROBLEM", 194, 211], ["previous cardiovascular diseaselaboratory data", "PROBLEM", 217, 263], ["hemoglobin", "TEST", 274, 284], ["albumin", "TEST", 286, 293], ["hsCRP", "TEST", 299, 304], ["Clinical data", "TEST", 346, 359], ["the isolation period", "TREATMENT", 414, 434], ["fever", "OBSERVATION", 49, 54], ["diabetes mellitus", "OBSERVATION", 194, 211]]], ["Post-traumatic stress symptoms were assessed with the Impact of Event Scale-Revised-Korean (IES-R-K), which showed good reliability and validity for the assessment of PTSD symptom severity [12] .", [["PTSD", "DISEASE", 167, 171], ["traumatic stress symptoms", "PROBLEM", 5, 30], ["Event Scale", "TEST", 64, 75], ["the assessment", "TEST", 149, 163], ["PTSD symptom severity", "PROBLEM", 167, 188]]], ["The scale consisted of the following four factors: intrusion; avoidance; hyperarousal; and sleep disturbance, emotional numbing, and dissociation.", [["hyperarousal", "DISEASE", 73, 85], ["sleep disturbance", "DISEASE", 91, 108], ["hyperarousal", "PROBLEM", 73, 85], ["sleep disturbance", "PROBLEM", 91, 108], ["emotional numbing", "PROBLEM", 110, 127], ["dissociation", "PROBLEM", 133, 145]]], ["A high total score represented high severity of the symptoms; so, a total score of 18 or more was used as a cut-off [12] .", [["A high total score", "PROBLEM", 0, 18], ["the symptoms", "PROBLEM", 48, 60], ["a total score", "TEST", 66, 79], ["high severity", "OBSERVATION_MODIFIER", 31, 44]]], ["The alpha coefficient for this sample was 0.873.StatisticsThe data are expressed as mean \u00b1 standard deviation.", [["this sample", "TEST", 26, 37], ["alpha coefficient", "OBSERVATION_MODIFIER", 4, 21]]], ["Comparisons of continuous variables were performed using t-tests and paired t-tests.", [["continuous variables", "TEST", 15, 35], ["t-tests", "TEST", 57, 64], ["paired t-tests", "TEST", 69, 83]]], ["Categorical variables, expressed as percentages, were analyzed using the chisquare test.", [["Categorical variables", "TEST", 0, 21], ["the chisquare test", "TEST", 69, 87]]], ["Univariate linear regression analyses were performed to analyze contributing factors towards high IES-R-K score.", [["Univariate linear regression analyses", "TEST", 0, 37]]], ["All calculations were performed using SPSS 18.0 (SPSS Inc. Armonk, NY).", [["All calculations", "TEST", 0, 16], ["SPSS", "TEST", 38, 42]]], ["P < 0.05 was considered significant.ResultsOf the 89 HD patients, 67 (75.3%) completed the questionnaires.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["the questionnaires", "TEST", 87, 105]]], ["There was no significant difference between the two groups.", [["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35]]], ["The participants' mean age was 62.6 years; 46 (68.7%) were men, 31 (46.3%) had diabetes, and 3 (4.4%) had a history of cardiovascular disease.", [["cardiovascular", "ANATOMY", 119, 133], ["diabetes", "DISEASE", 79, 87], ["cardiovascular disease", "DISEASE", 119, 141], ["men", "ORGANISM", 59, 62], ["cardiovascular", "ANATOMICAL_SYSTEM", 119, 133], ["participants", "SPECIES", 4, 16], ["men", "SPECIES", 59, 62], ["diabetes", "PROBLEM", 79, 87], ["cardiovascular disease", "PROBLEM", 119, 141], ["cardiovascular", "ANATOMY", 119, 133], ["disease", "OBSERVATION", 134, 141]]], ["The mean isolation period following exposure was 14.8 days.", [["mean isolation", "OBSERVATION", 4, 18]]], ["Single room isolation was implemented for 40 (58.8%) subjects; cohort isolation, for 20 (29.4%); and self-imposed quarantine, for 8 (11.8%) subjects.", [["Single room isolation", "TREATMENT", 0, 21], ["cohort isolation", "TEST", 63, 79]]], ["Figure 1 shows the prevalence of IES-R-K\u226718 by isolation method.", [["IES", "DNA", 33, 36], ["K\u226718", "DNA", 39, 43], ["IES", "TEST", 33, 36]]], ["A total of 12 (17.9%) participants reported stress symptoms with IES-R-K scores exceeding cut-off point.", [["participants", "ORGANISM", 22, 34], ["participants", "SPECIES", 22, 34], ["stress symptoms", "PROBLEM", 44, 59], ["IES", "TEST", 65, 68], ["K scores", "TEST", 71, 79]]], ["Nine out of 40 patients (22.5%) in a single-room isolation group, 3 of 19 patients (15.8%) in a cohort-isolation group and none of the subjects in the self-imposed quarantine group were shown to have post-traumatic stress with IES-R-K\u226718.", [["IES-R-K", "CHEMICAL", 227, 234], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 74, 82], ["post-traumatic stress", "PROBLEM", 200, 221], ["IES", "TEST", 227, 230]]], ["The prevalence rate of IES-R-K\u226718 did not differ significantly (P = 0.3) between the single-room and cohortisolation groups.", [["IES", "DNA", 23, 26], ["The prevalence rate", "TEST", 0, 19], ["IES", "TEST", 23, 26], ["K\u2267", "TEST", 29, 31], ["P", "TEST", 64, 65]]], ["Table 1 shows a comparison of participants by IES-R-K cutoff point.", [["participants", "SPECIES", 30, 42], ["IES", "TEST", 46, 49]]], ["Women and patients who had a shorter duration of isolation were more likely to develop symptoms of IES-R-K\u226718.ResultsWe performed linear regression analysis to identify associated factors with high IES-R-K score ( Table 2) .", [["IES-R-K\u226718", "CHEMICAL", 99, 109], ["Women", "ORGANISM", 0, 5], ["patients", "ORGANISM", 10, 18], ["IES", "DNA", 198, 201], ["Women", "SPECIES", 0, 5], ["patients", "SPECIES", 10, 18], ["symptoms", "PROBLEM", 87, 95], ["IES", "TEST", 99, 102], ["linear regression analysis", "TEST", 130, 156], ["associated factors", "PROBLEM", 169, 187]]], ["Shorter isolation period was associated with high IES-R-K score (standardized \u03b2 coefficient \u2212 0.272, P = 0.026).", [["IES", "DNA", 50, 53], ["K score", "TEST", 56, 63], ["P", "TEST", 101, 102]]], ["We compared the total IES-R-K and subscale scores according to isolation duration in Table 3 .", [["IES", "DNA", 22, 25], ["subscale scores", "TEST", 34, 49]]], ["The total scores did not differ significantly between male and female subjects (8.46 \u00b1 9.59 vs. 12.38 \u00b1 12.09, P = 0.158).", [["The total scores", "TEST", 0, 16], ["P", "TEST", 111, 112]]], ["However, the sleep disturbance subscale score was higher among female, compared to male subjects (1.57 \u00b1 2.79 vs. 0.46 \u00b1 1.17, P = 0.024).", [["sleep disturbance", "DISEASE", 13, 30], ["the sleep disturbance subscale score", "PROBLEM", 9, 45], ["P", "TEST", 127, 128]]], ["We divided the participants by median isolation duration.", [["participants", "SPECIES", 15, 27]]], ["Participants isolated for less than 16 days showed a higher total score than those isolated for more than 16 days (13.47 \u00b1 12.69 vs. 6.23 \u00b1 6.45, P = 0.004).", [["Participants", "SPECIES", 0, 12], ["a higher total score", "PROBLEM", 51, 71], ["P", "TEST", 146, 147]]], ["At a subscale level, avoidance (4.94 \u00b1 5.94 vs. 2.34 \u00b1 3.12, P = 0.027) and sleep disturbance, emotional numbing, and dissociation (4.75 \u00b1 3.25 vs. 2.09 \u00b1 2.28, P < 0.001) subscale scores were higher in participants who had been isolated for less than 16 days.", [["sleep disturbance", "DISEASE", 76, 93], ["participants", "SPECIES", 203, 215], ["avoidance", "TEST", 21, 30], ["P", "TEST", 61, 62], ["sleep disturbance", "PROBLEM", 76, 93], ["emotional numbing", "PROBLEM", 95, 112], ["dissociation", "TEST", 118, 130], ["P", "TEST", 161, 162], ["subscale scores", "TEST", 172, 187]]], ["With regard to the sleep disturbance, emotional numbing, and dissociation subscale scores, emotional numbing (2.22 \u00b1 1.50 vs. 1.0 \u00b1 1.16, P < 0.001) and dissociation (1.50 \u00b1 1.59 vs. 0.49 \u00b1 0.92, P = 0.002) scores were higher in that group.", [["sleep disturbance", "DISEASE", 19, 36], ["the sleep disturbance", "PROBLEM", 15, 36], ["emotional numbing", "PROBLEM", 38, 55], ["dissociation subscale scores", "TEST", 61, 89], ["emotional numbing", "PROBLEM", 91, 108], ["P", "TEST", 138, 139], ["dissociation", "TEST", 153, 165], ["P", "TEST", 196, 197], ["scores", "TEST", 207, 213]]], ["Before the outbreak of MERS, 5.9% of the participants (n = 4) had scores exceeding the cutoff point of the IES-R-K.", [["MERS", "DISEASE", 23, 27], ["participants", "SPECIES", 41, 53]]], ["Therefore, a paired-samples t-test was conducted to compare pre-and post-MERS IES-R-K scores in only 44 respondents (Table 4 ).", [["a paired-samples t-test", "TEST", 11, 34], ["MERS IES", "TEST", 73, 81], ["K scores", "TEST", 84, 92]]], ["Participants' post-traumatic stress symptoms increased at 1 year after the MERS outbreak.", [["post-traumatic stress symptoms", "DISEASE", 14, 44], ["Participants", "SPECIES", 0, 12], ["post-traumatic stress symptoms", "PROBLEM", 14, 44], ["the MERS outbreak", "PROBLEM", 71, 88]]], ["There was a significant difference in the total scores on the IES-R-K pre-and post-MERS (3.16 \u00b1 9.02 vs. 9.69 \u00b1 10.50, P < 0.001).", [["a significant difference", "PROBLEM", 10, 34], ["the IES", "TEST", 58, 65], ["P", "TEST", 119, 120], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34]]], ["At the subscale level, sleep disturbance, emotional numbing, and dissociation at post-MERS (2.52 \u00b1 2.61) was significantly higher than that at pre-MERS (0.82 \u00b1 2.40, P < 0.001).", [["sleep disturbance", "DISEASE", 23, 40], ["sleep disturbance", "PROBLEM", 23, 40], ["emotional numbing", "PROBLEM", 42, 59], ["dissociation", "PROBLEM", 65, 77], ["P", "TEST", 166, 167], ["sleep disturbance", "OBSERVATION", 23, 40]]], ["However, there was no significant difference in avoidance, intrusion, and hyperarousal at pre-MERS and post-MERS.", [["hyperarousal", "DISEASE", 74, 86], ["intrusion", "PROBLEM", 59, 68], ["hyperarousal", "PROBLEM", 74, 86], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["difference", "OBSERVATION_MODIFIER", 34, 44]]], ["When the fourth factor, which consists of three different symptoms, is broken down, there was a significant difference in emotional numbing (0.27 \u00b1 0.85 vs. 1.16 \u00b1 1.18, P < 0.001) and dissociation (0.20 \u00b1 0.67 vs. 0.55 \u00b1 0.93, P = 0.01) at pre-and post-MERS.", [["fourth factor", "PROTEIN", 9, 22], ["three different symptoms", "PROBLEM", 42, 66], ["a significant difference in emotional numbing", "PROBLEM", 94, 139], ["P", "TEST", 170, 171], ["dissociation", "TEST", 185, 197], ["P", "TEST", 228, 229], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["difference", "OBSERVATION_MODIFIER", 108, 118]]], ["However, sleep disturbance showed no significant difference (0.34 \u00b1 1.36 vs. 0.82 \u00b1 7.80, P = 0.07).DiscussionThe present study examined post-traumatic stress symptoms from the quarantine experience of HD patients during the outbreak of MERS-CoV in Korea.", [["sleep disturbance", "DISEASE", 9, 26], ["post-traumatic stress symptoms", "DISEASE", 137, 167], ["HD", "DISEASE", 202, 204], ["patients", "ORGANISM", 205, 213], ["MERS-CoV", "ORGANISM", 237, 245], ["patients", "SPECIES", 205, 213], ["MERS-CoV", "SPECIES", 237, 245], ["sleep disturbance", "PROBLEM", 9, 26], ["significant difference", "PROBLEM", 37, 59], ["P", "TEST", 90, 91], ["The present study", "TEST", 110, 127], ["post-traumatic stress symptoms", "PROBLEM", 137, 167], ["HD patients", "TREATMENT", 202, 213], ["no", "UNCERTAINTY", 34, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48]]], ["In total, 17.9% of the patients developed stress symptoms with scores over the IES-R-K cut-off.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["stress symptoms", "PROBLEM", 42, 57], ["scores", "TEST", 63, 69], ["the IES", "TEST", 75, 82]]], ["Several studies have reported the psychological impact of the quarantine experience [13, 14] .", [["Several studies", "TEST", 0, 15]]], ["Reynolds et al. showed that of the feelings experienced during SARS quarantine, boredom (62.2%), isolation (60.6%), and frustration (58.5%) were most commonly reported.", [["SARS", "DISEASE", 63, 67], ["boredom", "DISEASE", 80, 87], ["isolation", "TEST", 97, 106], ["frustration", "TEST", 120, 131]]], ["In that study, an IES-R score of at least 20 was obtained by 14.6% of respondents [14] .", [["that study", "TEST", 3, 13], ["an IES-R score", "TEST", 15, 29]]], ["In a study on the psychological effects of SARS quarantine in Toronto, the 129 quarantined persons who responded to a Web-based survey exhibited a high prevalence of psychological distress [13] .", [["SARS", "DISEASE", 43, 47], ["psychological distress", "DISEASE", 166, 188], ["persons", "ORGANISM", 91, 98], ["persons", "SPECIES", 91, 98], ["a study", "TEST", 3, 10], ["psychological distress", "PROBLEM", 166, 188]]], ["Symptoms of PTSD and depression were observed in 28.9 and 31.2% of respondents, respectively.", [["PTSD", "DISEASE", 12, 16], ["depression", "DISEASE", 21, 31], ["Symptoms", "PROBLEM", 0, 8], ["PTSD", "PROBLEM", 12, 16], ["depression", "PROBLEM", 21, 31], ["PTSD", "OBSERVATION", 12, 16]]], ["In these studies, quarantine type was home or work.", [["these studies", "TEST", 3, 16]]], ["Subjects were not hospitalized.DiscussionThe results of this study revealed that isolation duration is negatively associated with IES-R-K score.", [["Subjects", "ORGANISM", 0, 8], ["this study", "TEST", 56, 66], ["IES", "TEST", 130, 133]]], ["This result is contrary to those of previous studies that showed a positive correlation between quarantine duration and post-traumatic stress symptoms [13, 14] .", [["post-traumatic stress symptoms", "DISEASE", 120, 150], ["previous studies", "TEST", 36, 52], ["post-traumatic stress symptoms", "PROBLEM", 120, 150]]], ["However, isolation duration does not mean duration only, but also represents participants' cooperativeness with the mandatory quarantine request.", [["participants", "SPECIES", 77, 89]]], ["When HD patients who were exposed to MERS-CoV were asked to undergo mandatory quarantine, some were cooperative, such that they were admitted immediately following instructions by medical staff.", [["patients", "ORGANISM", 8, 16], ["MERS-CoV", "ORGANISM", 37, 45], ["patients", "SPECIES", 8, 16], ["MERS-CoV", "SPECIES", 37, 45]]], ["Others resisted the isolation, dragging on until, finally, they were forcibly hospitalized at a later stage.", [["isolation", "OBSERVATION_MODIFIER", 20, 29]]], ["Since all participants were later released from quarantine on the same day, the isolation duration indicated their cooperativeness with the mandatory quarantine and their trust in the prevention system of epidemics.", [["participants", "ORGANISM", 10, 22], ["participants", "SPECIES", 10, 22], ["epidemics", "PROBLEM", 205, 214]]], ["Therefore, the results of this study indicated that participants who cooperated with the isolation request and received longer support reported fewer posttraumatic stress symptoms.", [["posttraumatic stress symptoms", "DISEASE", 150, 179], ["participants", "SPECIES", 52, 64], ["this study", "TEST", 26, 36], ["longer support", "TREATMENT", 120, 134], ["posttraumatic stress symptoms", "PROBLEM", 150, 179]]], ["At the subscale level, patients quarantined for less than 16 days showed higher avoidance, emotional numbing, and dissociation, compared to those quarantined for more than 16 days.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["emotional numbing", "PROBLEM", 91, 108], ["dissociation", "PROBLEM", 114, 126]]], ["Psychological trauma causes not only post-traumatic stress symptoms such as intrusion, avoidance, and hyperarousal, but also many other somatic and psychiatric symptoms due to its complexity and the diversity of symptoms, showing high levels of comorbidity with other problems [15] .", [["trauma", "DISEASE", 14, 20], ["hyperarousal", "DISEASE", 102, 114], ["psychiatric", "DISEASE", 148, 159], ["Psychological trauma", "PROBLEM", 0, 20], ["post-traumatic stress symptoms", "PROBLEM", 37, 67], ["hyperarousal", "PROBLEM", 102, 114], ["many other somatic and psychiatric symptoms", "PROBLEM", 125, 168], ["symptoms", "PROBLEM", 212, 220], ["high levels of comorbidity", "PROBLEM", 230, 256]]], ["Based on Lee [16] suggestion regarding posttraumatic growth, trauma-related symptoms occur in sequential order, as follows: catatonia, emotional numbing, dissociation, fear, intrusion, paranoid ideation, avoidance, obsession, hyperarousal, anxiety, depression, existential emptiness, searching for meaning, and posttraumatic growth.", [["posttraumatic growth", "DISEASE", 39, 59], ["trauma", "DISEASE", 61, 67], ["catatonia", "DISEASE", 124, 133], ["emotional numbing", "DISEASE", 135, 152], ["paranoid ideation", "DISEASE", 185, 202], ["hyperarousal", "DISEASE", 226, 238], ["anxiety", "DISEASE", 240, 247], ["depression", "DISEASE", 249, 259], ["posttraumatic growth", "DISEASE", 311, 331], ["posttraumatic growth", "PROBLEM", 39, 59], ["trauma", "PROBLEM", 61, 67], ["related symptoms", "PROBLEM", 68, 84], ["catatonia", "PROBLEM", 124, 133], ["emotional numbing", "PROBLEM", 135, 152], ["dissociation", "PROBLEM", 154, 166], ["intrusion", "PROBLEM", 174, 183], ["paranoid ideation", "PROBLEM", 185, 202], ["obsession", "PROBLEM", 215, 224], ["hyperarousal", "PROBLEM", 226, 238], ["anxiety", "PROBLEM", 240, 247], ["depression", "PROBLEM", 249, 259], ["existential emptiness", "PROBLEM", 261, 282], ["posttraumatic growth", "PROBLEM", 311, 331], ["catatonia", "OBSERVATION", 124, 133], ["posttraumatic", "OBSERVATION_MODIFIER", 311, 324]]], ["The results of the current study, indicating that participants showed emotional numbing and dissociation more often, compared to intrusion, avoidance, and hyperarousal, in turn indicated that participants did not process the trauma and the isolation experience, so that their symptoms remained at the very early stage of processing trauma.", [["hyperarousal", "DISEASE", 155, 167], ["trauma", "DISEASE", 225, 231], ["trauma", "DISEASE", 332, 338], ["participants", "SPECIES", 50, 62], ["participants", "SPECIES", 192, 204], ["the current study", "TEST", 15, 32], ["emotional numbing", "PROBLEM", 70, 87], ["dissociation", "PROBLEM", 92, 104], ["hyperarousal", "PROBLEM", 155, 167], ["the trauma", "PROBLEM", 221, 231], ["their symptoms", "PROBLEM", 270, 284], ["processing trauma", "PROBLEM", 321, 338]]], ["This indicates that participants can experience subsequent symptoms of hyperarousal.", [["hyperarousal", "DISEASE", 71, 83], ["participants", "SPECIES", 20, 32], ["subsequent symptoms", "PROBLEM", 48, 67], ["hyperarousal", "PROBLEM", 71, 83]]], ["Thus, psychological intervention and follow-up are needed.DiscussionIn this study, being female was associated with posttraumatic stress symptoms.", [["posttraumatic stress symptoms", "DISEASE", 116, 145], ["psychological intervention", "TREATMENT", 6, 32], ["this study", "TEST", 71, 81], ["posttraumatic stress symptoms", "PROBLEM", 116, 145]]], ["This is consistent with previous research that found gender differences in traumatized populations [17] [18] [19] [20] .", [["traumatized populations", "PROBLEM", 75, 98], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Specifically, the score on the sleep disturbance subscale was higher among female subjects.", [["the sleep disturbance subscale", "PROBLEM", 27, 57]]], ["Before the outbreak of MERS, 5.9% of participants (n = 4) reported that they had pre-existing posttraumatic stress symptoms exceeding the cutoff point of the IES-R-K.", [["MERS", "DISEASE", 23, 27], ["posttraumatic stress symptoms", "DISEASE", 94, 123], ["participants", "SPECIES", 37, 49], ["pre-existing posttraumatic stress symptoms", "PROBLEM", 81, 123]]], ["This is higher than the current prevalence in the general population of a city in Korea (2.12%) [21] .", [["higher", "OBSERVATION_MODIFIER", 8, 14]]], ["This seems to be because the study sample comprised patients with HD, who are going through a lifethreatening chronic disease.DiscussionThere are several limitations in this study.", [["HD", "DISEASE", 66, 68], ["chronic disease", "DISEASE", 110, 125], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["the study", "TEST", 25, 34], ["HD", "TREATMENT", 66, 68], ["a lifethreatening chronic disease", "PROBLEM", 92, 125], ["this study", "TEST", 169, 179], ["chronic", "OBSERVATION_MODIFIER", 110, 117], ["disease", "OBSERVATION", 118, 125]]], ["First, this study had a low response rate and a small sample size.", [["this study", "TEST", 7, 17], ["a low response rate", "PROBLEM", 22, 41], ["a small sample size", "PROBLEM", 46, 65], ["small", "OBSERVATION_MODIFIER", 48, 53], ["sample", "OBSERVATION_MODIFIER", 54, 60], ["size", "OBSERVATION_MODIFIER", 61, 65]]], ["Therefore, the present findings may not be readily generalized to all isolated HD patients.", [["HD", "DISEASE", 79, 81], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["may not be", "UNCERTAINTY", 32, 42]]], ["Second, the IES-R-K is a self-report instrument tested 12 months after subjects' exposure to MERS-CoV.", [["MERS-CoV", "ORGANISM", 93, 101], ["IES", "DNA", 12, 15], ["MERS-CoV", "SPECIES", 93, 101]]], ["Furthermore, other factors in addition to isolation experience might affect psychological stress in quarantined HD patients.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["psychological stress", "PROBLEM", 76, 96], ["quarantined HD patients", "TREATMENT", 100, 123]]], ["Fourth, we did not measure other psychological and medical factors that could affect post-traumatic stress symptoms 12 months after isolation.", [["post-traumatic stress symptoms", "PROBLEM", 85, 115]]], ["Fifth, we didn't investigate stress symptoms on HD patients without isolation as a control.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["stress symptoms", "PROBLEM", 29, 44], ["HD", "TREATMENT", 48, 50], ["isolation", "TREATMENT", 68, 77]]], ["Despite these limitations, the results of this study show that quarantine can result in considerable psychological distress..", [["this study", "TEST", 42, 52], ["considerable psychological distress", "PROBLEM", 88, 123]]], ["A shorter duration of quarantine was associated with high IES-R-K scores.", [["IES", "DNA", 58, 61], ["A shorter duration of quarantine", "PROBLEM", 0, 32]]], ["Public health officials, infectious disease physicians, and psychologists must be aware of this result.", [["infectious disease", "DISEASE", 25, 43]]], ["Further research is needed to determine factors that influence the success of quarantine and in relation to the provision of additional support to patients who are at an increased risk of the adverse psychological effects of quarantine.Supplementary informationSupplementary information accompanies this paper at https://doi.org/10.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["quarantine", "TREATMENT", 78, 88], ["additional support", "TREATMENT", 125, 143]]], ["1186/s13030-020-00181-z.Supplementary informationAdditional file 1: Table S1 .", [["S1", "ANATOMY", 74, 76]]], ["Comparison of study respondents with non-respondents.", [["Comparison of study", "TEST", 0, 19]]]], "7de0d0ac71e79cba5b50ed89303cae6d89bb0130": [["IntroductionInfection by the human immunodeficiency virus (HIV) is characterized by a dramatic and progressive depletion of CD4+ T cells and a sustained state of chronic inflammation and immune activation.", [["T cells", "ANATOMY", 129, 136], ["IntroductionInfection", "DISEASE", 0, 21], ["human immunodeficiency virus (HIV)", "DISEASE", 29, 63], ["inflammation", "DISEASE", 170, 182], ["human immunodeficiency virus", "ORGANISM", 29, 57], ["HIV", "ORGANISM", 59, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 124, 127], ["T cells", "CELL", 129, 136], ["CD4", "PROTEIN", 124, 127], ["T cells", "CELL_TYPE", 129, 136], ["human immunodeficiency virus (HIV", "SPECIES", 29, 62], ["human immunodeficiency virus", "SPECIES", 29, 57], ["HIV", "SPECIES", 59, 62], ["IntroductionInfection", "TREATMENT", 0, 21], ["the human immunodeficiency virus", "PROBLEM", 25, 57], ["a dramatic and progressive depletion of CD4", "PROBLEM", 84, 127], ["T cells", "PROBLEM", 129, 136], ["chronic inflammation", "PROBLEM", 162, 182], ["immune activation", "PROBLEM", 187, 204], ["dramatic", "OBSERVATION_MODIFIER", 86, 94], ["progressive", "OBSERVATION_MODIFIER", 99, 110], ["depletion", "OBSERVATION", 111, 120], ["CD4", "OBSERVATION", 124, 127], ["sustained", "OBSERVATION_MODIFIER", 143, 152], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["inflammation", "OBSERVATION", 170, 182], ["immune activation", "OBSERVATION", 187, 204]]], ["Disease progression appears to be directly related to early events during acute infection, including an intense and coordinated production of plasma cytokines (\"cytokine storm\") that is not observed in other chronic viral infections, such as Hepatitis type B and C [1] .", [["plasma", "ANATOMY", 142, 148], ["infection", "DISEASE", 80, 89], ["viral infections", "DISEASE", 216, 232], ["Hepatitis type B", "DISEASE", 242, 258], ["plasma", "ORGANISM_SUBSTANCE", 142, 148], ["plasma cytokines", "PROTEIN", 142, 158], ["cytokine", "PROTEIN", 161, 169], ["Hepatitis type B", "SPECIES", 242, 258], ["Disease progression", "PROBLEM", 0, 19], ["early events", "PROBLEM", 54, 66], ["acute infection", "PROBLEM", 74, 89], ["plasma cytokines", "PROBLEM", 142, 158], ["other chronic viral infections", "PROBLEM", 202, 232], ["Hepatitis type B", "PROBLEM", 242, 258], ["early", "OBSERVATION_MODIFIER", 54, 59], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["infection", "OBSERVATION", 80, 89], ["intense", "OBSERVATION_MODIFIER", 104, 111], ["not observed", "UNCERTAINTY", 186, 198], ["chronic", "OBSERVATION_MODIFIER", 208, 215], ["viral", "OBSERVATION_MODIFIER", 216, 221], ["infections", "OBSERVATION", 222, 232]]], ["Studies using macaques infected with simian immunodeficiency virus (SIV) corroborate these findings (S1 Information), and provide insights on the complex network of immune regulatory genes that is triggered in response against the virus [2, 3] .", [["simian immunodeficiency virus", "DISEASE", 37, 66], ["macaques", "ORGANISM", 14, 22], ["simian immunodeficiency virus", "ORGANISM", 37, 66], ["SIV", "ORGANISM", 68, 71], ["immune regulatory genes", "DNA", 165, 188], ["macaques", "SPECIES", 14, 22], ["simian immunodeficiency virus", "SPECIES", 37, 66], ["simian immunodeficiency virus", "SPECIES", 37, 66], ["SIV", "SPECIES", 68, 71], ["Studies", "TEST", 0, 7], ["macaques infected", "PROBLEM", 14, 31], ["simian immunodeficiency virus", "PROBLEM", 37, 66], ["immune regulatory genes", "PROBLEM", 165, 188], ["the virus", "PROBLEM", 227, 236]]], ["Because of the difficulties in establishing the precise time when an individual is infected by HIV, unravelling the effect of genes and their level of significance during acute SIV infection is key in understanding the mechanisms by which these viruses interact with the immune system.", [["immune system", "ANATOMY", 271, 284], ["infection", "DISEASE", 181, 190], ["SIV", "ORGANISM", 177, 180], ["HIV", "SPECIES", 95, 98], ["HIV", "SPECIES", 95, 98], ["SIV", "SPECIES", 177, 180], ["the difficulties", "PROBLEM", 11, 27], ["HIV", "PROBLEM", 95, 98], ["acute SIV infection", "PROBLEM", 171, 190], ["infected", "OBSERVATION", 83, 91], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["SIV infection", "OBSERVATION", 177, 190]]], ["Using an SIV macaque model for AIDS and CNS disease, our group has been assessing how the expression of genes associated with immune and inflammatory responses are longitudinally changed in different organs or cells during SIV infection.", [["CNS", "ANATOMY", 40, 43], ["organs", "ANATOMY", 200, 206], ["cells", "ANATOMY", 210, 215], ["AIDS", "DISEASE", 31, 35], ["CNS disease", "DISEASE", 40, 51], ["SIV infection", "DISEASE", 223, 236], ["SIV", "ORGANISM", 9, 12], ["CNS", "ANATOMICAL_SYSTEM", 40, 43], ["organs", "ORGAN", 200, 206], ["cells", "CELL", 210, 215], ["SIV", "ORGANISM", 223, 226], ["SIV macaque", "SPECIES", 9, 20], ["SIV macaque", "SPECIES", 9, 20], ["SIV", "SPECIES", 223, 226], ["an SIV macaque model", "TREATMENT", 6, 26], ["AIDS", "PROBLEM", 31, 35], ["CNS disease", "PROBLEM", 40, 51], ["immune and inflammatory responses", "PROBLEM", 126, 159], ["cells during SIV infection", "PROBLEM", 210, 236], ["SIV macaque", "OBSERVATION", 9, 20], ["CNS", "ANATOMY", 40, 43], ["disease", "OBSERVATION", 44, 51], ["inflammatory", "OBSERVATION", 137, 149], ["SIV infection", "OBSERVATION", 223, 236]]], ["Because of the large number of tissue samples and to be cost effective, we designed a set of Nanostring probes to measure the expression of 88 immune-related genes that are routinely analyzed in several diseases.", [["tissue samples", "ANATOMY", 31, 45], ["tissue samples", "TISSUE", 31, 45], ["Nanostring probes", "DNA", 93, 110], ["Nanostring probes", "TREATMENT", 93, 110], ["several diseases", "PROBLEM", 195, 211], ["large", "OBSERVATION_MODIFIER", 15, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["tissue", "ANATOMY", 31, 37]]], ["These include genes from different families such as chemokines, chemokine receptors, interferons, type I interferon receptors, interleukins, cytokine receptors, interferon regulatory factors, and interferon-stimulated genes (S1 Table) .", [["type I interferon receptors", "GENE_OR_GENE_PRODUCT", 98, 125], ["interleukins", "GENE_OR_GENE_PRODUCT", 127, 139], ["interferon regulatory factors", "GENE_OR_GENE_PRODUCT", 161, 190], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 196, 223], ["chemokines", "PROTEIN", 52, 62], ["chemokine receptors", "PROTEIN", 64, 83], ["interferons", "PROTEIN", 85, 96], ["type I interferon receptors", "PROTEIN", 98, 125], ["interleukins", "PROTEIN", 127, 139], ["cytokine receptors", "PROTEIN", 141, 159], ["interferon regulatory factors", "PROTEIN", 161, 190], ["interferon-stimulated genes", "DNA", 196, 223], ["S1 Table", "DNA", 225, 233], ["chemokines, chemokine receptors", "TREATMENT", 52, 83], ["interferons", "TREATMENT", 85, 96], ["type I interferon receptors", "TREATMENT", 98, 125], ["interleukins", "TREATMENT", 127, 139], ["cytokine receptors", "TREATMENT", 141, 159], ["interferon regulatory factors", "TREATMENT", 161, 190], ["interferon", "TREATMENT", 196, 206]]], ["In this paper, we propose to use a novel multivariate analysis method to identify significant genes affecting immune responses in three different lymphoid compartments during acute SIV infection.IntroductionUnivariate analysis of the gene expressions alone or studying the correlation between gene expressions and output variables such as time since infection and SIV RNA in plasma provides limited success in interpreting the data.", [["lymphoid compartments", "ANATOMY", 146, 167], ["plasma", "ANATOMY", 375, 381], ["SIV infection", "DISEASE", 181, 194], ["infection", "DISEASE", 350, 359], ["lymphoid compartments", "MULTI-TISSUE_STRUCTURE", 146, 167], ["SIV", "ORGANISM", 181, 184], ["SIV", "ORGANISM", 364, 367], ["plasma", "ORGANISM_SUBSTANCE", 375, 381], ["SIV RNA", "RNA", 364, 371], ["SIV", "SPECIES", 181, 184], ["SIV", "SPECIES", 364, 367], ["a novel multivariate analysis method", "TREATMENT", 33, 69], ["significant genes affecting immune responses", "PROBLEM", 82, 126], ["acute SIV infection", "PROBLEM", 175, 194], ["the gene expressions", "TREATMENT", 230, 250], ["gene expressions and output variables", "PROBLEM", 293, 330], ["infection", "PROBLEM", 350, 359], ["SIV RNA in plasma", "PROBLEM", 364, 381], ["three different", "OBSERVATION_MODIFIER", 130, 145], ["lymphoid compartments", "OBSERVATION", 146, 167], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["SIV infection", "OBSERVATION", 181, 194], ["SIV RNA", "OBSERVATION", 364, 371]]], ["This may be due to several reasons.", [["may be due to", "UNCERTAINTY", 5, 18]]], ["First, the changes in gene expressions are essentially caused by SIV infection.", [["SIV infection", "DISEASE", 65, 78], ["SIV", "ORGANISM", 65, 68], ["SIV", "SPECIES", 65, 68], ["the changes in gene expressions", "PROBLEM", 7, 38], ["SIV infection", "PROBLEM", 65, 78], ["SIV infection", "OBSERVATION", 65, 78]]], ["This suggests that the mRNA measurements, regardless of the biological functions of genes, should be correlated with time since infection or SIV RNA in plasma, leading to many \"hits\" that are not biologically significant.", [["plasma", "ANATOMY", 152, 158], ["infection", "DISEASE", 128, 137], ["SIV", "ORGANISM", 141, 144], ["plasma", "ORGANISM_SUBSTANCE", 152, 158], ["SIV RNA", "RNA", 141, 148], ["SIV", "SPECIES", 141, 144], ["the mRNA measurements", "TEST", 19, 40], ["infection", "PROBLEM", 128, 137], ["SIV RNA in plasma", "PROBLEM", 141, 158], ["many \"hits\"", "PROBLEM", 171, 182], ["SIV RNA", "OBSERVATION", 141, 148]]], ["Second, it is generally thought that multiple genes work together to orchestrate the immune response during acute SIV infection.", [["SIV infection", "DISEASE", 114, 127], ["SIV", "ORGANISM", 114, 117], ["SIV", "SPECIES", 114, 117], ["multiple genes work", "PROBLEM", 37, 56], ["acute SIV infection", "PROBLEM", 108, 127], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["SIV infection", "OBSERVATION", 114, 127]]], ["Therefore, we use multivariate analysis techniques, which can compensate for the correlations between multiple genes, to study all the genes simultaneously.", [["multivariate analysis techniques", "TEST", 18, 50]]], ["These techniques, including principal component analysis (PCA), independent component analysis (ICA), and partial least squares (PLS) regression, have been used in various biological applications such as tumor classification [4] , biomarker identification in traumatic brain injury [5] , predicting age of cytotoxic T cells [6] , and classification of yeast gene expression data into biologically meaningful groups [7] .", [["tumor", "ANATOMY", 204, 209], ["brain", "ANATOMY", 269, 274], ["cytotoxic T cells", "ANATOMY", 306, 323], ["tumor", "DISEASE", 204, 209], ["traumatic brain injury", "DISEASE", 259, 281], ["tumor", "CANCER", 204, 209], ["brain", "ORGAN", 269, 274], ["cytotoxic T cells", "CELL", 306, 323], ["cytotoxic T cells", "CELL_TYPE", 306, 323], ["yeast", "SPECIES", 352, 357], ["yeast", "SPECIES", 352, 357], ["These techniques", "TEST", 0, 16], ["principal component analysis", "TEST", 28, 56], ["independent component analysis (ICA), and partial least squares (PLS) regression", "PROBLEM", 64, 144], ["biomarker identification", "TEST", 231, 255], ["traumatic brain injury", "PROBLEM", 259, 281], ["cytotoxic T cells", "PROBLEM", 306, 323], ["brain", "ANATOMY", 269, 274]]], ["The main differences between univariate and multivariate analysis methods are addressed in a recent review by Saccenti et al. [8] .", [["multivariate analysis methods", "TEST", 44, 73], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Note that prior quantitative knowledge of how the changes in expression of each gene impact the immune response during acute SIV infection is not available.", [["SIV infection", "DISEASE", 125, 138], ["SIV", "ORGANISM", 125, 128], ["SIV", "SPECIES", 125, 128], ["acute SIV infection", "PROBLEM", 119, 138], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["SIV infection", "OBSERVATION", 125, 138]]], ["For example, the system may be more sensitive to changes in the absolute values of mRNA measurement for some genes, but more sensitive to relative changes for other genes.", [["mRNA", "RNA", 83, 87], ["mRNA measurement", "TEST", 83, 99]]], ["Previous multivariate analysis studies emphasize only one of these possibilities, and therefore selects preferentially for genes that satisfy the assumption-for example, selects for genes with high absolute changes, or only genes with high relative changes.", [["Previous multivariate analysis studies", "TEST", 0, 38], ["high absolute changes", "PROBLEM", 193, 214], ["high relative changes", "PROBLEM", 235, 256]]], ["Therefore, preprocessing the data to take into account various initial assumptions is a necessary step for performing a thorough study of the effect of genes on the immune response.", [["a thorough study", "TEST", 118, 134]]], ["Various normalization methods including mean-centering [9, 10] , autoscaling or unit-variance scaling [10, 11] , pareto scaling [12, 13] , maximum scaling [14] , range scaling [14, 15] , vast scaling [16] , and maximum likelihood scaling [17, 18] have been used prior to multivariate analysis methods.", [["Various normalization methods", "TEST", 0, 29], ["mean", "TEST", 40, 44], ["autoscaling", "TEST", 65, 76], ["unit-variance scaling", "TEST", 80, 101], ["pareto scaling", "TEST", 113, 127], ["maximum scaling", "TEST", 139, 154], ["range scaling", "TEST", 162, 175], ["vast scaling", "TEST", 187, 199], ["maximum likelihood scaling", "TEST", 211, 237], ["multivariate analysis methods", "TEST", 271, 300]]], ["The advantages and disadvantages of these different normalization strategies were discussed in detail in [13, 19] .IntroductionIn this work, we present a multiplexed component analysis (MCA) technique in which we combine a variety of preprocessing techniques with two popular multivariate analysis methods to develop a set of twelve \"judges\" (Fig 1A) .", [["these different normalization strategies", "TREATMENT", 36, 76], ["a multiplexed component analysis", "TEST", 152, 184], ["preprocessing techniques", "TREATMENT", 234, 258]]], ["Preprocessing emphasizes specific features of a dataset by using an array of methods such as mean-centering, unit-variance scaling, or coefficient of variation scaling (CV), applied on the original or log-transformed data.", [["an array of methods", "TREATMENT", 65, 84], ["unit-variance scaling", "TREATMENT", 109, 130], ["variation scaling", "PROBLEM", 150, 167]]], ["Using a multiplexed set of preprocessing techniques ensures that we incorporate multiple possibilities for how gene expression changes affect the immune response, and therefore do not artificially Since there is no prior information on how the changes in gene expressions affect the immune response during acute SIV infection, we use an array of mathematical techniques to be able to observe the data from different viewpoints.", [["SIV infection", "DISEASE", 312, 325], ["SIV", "ORGANISM", 312, 315], ["SIV", "SPECIES", 312, 315], ["preprocessing techniques", "TREATMENT", 27, 51], ["how gene expression changes", "PROBLEM", 107, 134], ["acute SIV infection", "PROBLEM", 306, 325], ["mathematical techniques", "TREATMENT", 346, 369], ["acute", "OBSERVATION_MODIFIER", 306, 311], ["SIV infection", "OBSERVATION", 312, 325]]], ["A \"judge\" is defined as the combination of a transformation, a normalization technique and a multivariate analysis method.", [["a transformation", "PROBLEM", 43, 59], ["a normalization technique", "TREATMENT", 61, 86], ["a multivariate analysis method", "TEST", 91, 121]]], ["Each dataset is analyzed by 12 different judges, forming a Multiplexed Component Analysis (MCA).", [["a Multiplexed Component Analysis", "TEST", 57, 89], ["MCA", "ANATOMY", 91, 94]]], ["Each judge provides a model consisting of a set of principal components (PCs), which are used to classify datasets based on one of the two output variables: time since infection or SIV RNA in plasma (classification schemes).", [["plasma", "ANATOMY", 192, 198], ["infection", "DISEASE", 168, 177], ["SIV", "ORGANISM", 181, 184], ["plasma", "ORGANISM_SUBSTANCE", 192, 198], ["SIV RNA", "RNA", 181, 188], ["SIV", "SPECIES", 181, 184], ["infection", "PROBLEM", 168, 177], ["SIV RNA", "PROBLEM", 181, 188], ["infection", "OBSERVATION", 168, 177], ["SIV RNA", "OBSERVATION", 181, 188]]], ["For each judge, the two PCs that provide the most accurate and robust classification are chosen for further analysis.", [["further analysis", "TEST", 100, 116]]], ["(B) Normalization methods include mean-centering (MC), unit-variance scaling (UV), and coefficient of variation scaling (CV); each method results in a different representation of the data, emphasizing different characteristics of the original data set.", [["Normalization methods", "TEST", 4, 25], ["mean", "TEST", 34, 38], ["variation scaling", "PROBLEM", 102, 119], ["each method", "TEST", 126, 137], ["the data", "TEST", 179, 187]]], ["The MC normalization method emphasizes the genes with the highest absolute variations; the UV normalization method gives equal weight to each gene in the dataset; the CV normalization method emphasizes the genes with the highest relative changes. include or exclude potentially significant genes.", [["the UV normalization method", "TREATMENT", 87, 114], ["the CV normalization method", "TEST", 163, 190], ["significant genes", "PROBLEM", 278, 295]]], ["We use PCA [10, [20] [21] [22] [23] and PLS [24, 25] as multivariate analysis techniques, which are powerful tools in studying datasets where the variables (88 genes) outnumber the observations (24 animals).", [["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 16, 35], ["PCA", "TREATMENT", 7, 10], ["multivariate analysis techniques", "TEST", 56, 88]]], ["We identify top contributing genes in each tissue by ranking the overall weights (loadings) of genes on the top two classifier PCs.", [["tissue", "ANATOMY", 43, 49], ["tissue", "TISSUE", 43, 49]]], ["Finally, we calculate the contribution of each gene to the classification in each tissue to evaluate whether mRNA measurements in PBMC can act as a possible surrogate of measurements in spleen and MLN.ResultsData collection, preprocessing, and the twelve judgesResultsIn this study, we analyzed the RNA expression levels of 88 genes in spleen, mesenteric lymph node and PBMCs of macaques acutely infected with SIV. mRNA levels were quantified using Nanostring, a probe-based technique, and values were normalized by the geometric mean of four housekeeping genes (see S1 Method).", [["tissue", "ANATOMY", 82, 88], ["PBMC", "ANATOMY", 130, 134], ["spleen", "ANATOMY", 186, 192], ["MLN", "ANATOMY", 197, 200], ["spleen", "ANATOMY", 336, 342], ["mesenteric lymph node", "ANATOMY", 344, 365], ["PBMCs", "ANATOMY", 370, 375], ["tissue", "TISSUE", 82, 88], ["PBMC", "CELL", 130, 134], ["spleen", "ORGAN", 186, 192], ["MLN", "MULTI-TISSUE_STRUCTURE", 197, 200], ["spleen", "ORGAN", 336, 342], ["mesenteric lymph node", "MULTI-TISSUE_STRUCTURE", 344, 365], ["PBMCs", "CELL", 370, 375], ["macaques", "ORGANISM", 379, 387], ["SIV", "ORGANISM", 410, 413], ["PBMC", "CELL_TYPE", 130, 134], ["MLN", "CELL_TYPE", 197, 200], ["88 genes", "DNA", 324, 332], ["PBMCs", "CELL_TYPE", 370, 375], ["mRNA", "RNA", 415, 419], ["housekeeping genes", "DNA", 543, 561], ["macaques", "SPECIES", 379, 387], ["SIV", "SPECIES", 410, 413], ["mRNA measurements", "TEST", 109, 126], ["Data collection", "TEST", 208, 223], ["preprocessing", "TEST", 225, 238], ["this study", "TEST", 271, 281], ["the RNA expression levels", "TEST", 295, 320], ["mesenteric lymph node", "TREATMENT", 344, 365], ["mRNA levels", "TEST", 415, 426], ["a probe-based technique", "TEST", 461, 484], ["spleen", "ANATOMY", 186, 192], ["MLN", "ANATOMY", 197, 200], ["spleen", "ANATOMY", 336, 342], ["mesenteric", "ANATOMY", 344, 354], ["lymph node", "OBSERVATION", 355, 365], ["macaques", "OBSERVATION_MODIFIER", 379, 387]]], ["The final counts were preprocessed as described next (and in more detail in S2 Method), and the preprocessed data were analyzed using PCA or PLS (more detail in S3 Method and S4 Method).ResultsPreprocessing the data had two steps: transformation and normalization.", [["The final counts", "TEST", 0, 16], ["the preprocessed data", "TEST", 92, 113], ["PLS", "TEST", 141, 144]]], ["The outliers may exert a large impact on the model and overshadow other measurements.", [["large", "OBSERVATION_MODIFIER", 25, 30], ["impact", "OBSERVATION", 31, 37]]], ["For datasets with non-zero values, one method to alleviate the non-normality of the data is to perform logtransformation [26] .", [["non-zero values", "TEST", 18, 33]]], ["In this manuscript, we either use the original raw data (Orig) or perform log 2 -transformation on the data (Log2).ResultsNormalization of the data is common because the typical amount and the range of expression for each gene in the datasets can vary substantially.", [["the data", "TEST", 99, 107], ["the data", "TEST", 139, 147]]], ["This can significantly affect analyses attempting to identify which genes are key during the acute SIV infection.", [["SIV infection", "DISEASE", 99, 112], ["SIV", "ORGANISM", 99, 102], ["SIV", "SPECIES", 99, 102], ["the acute SIV infection", "PROBLEM", 89, 112], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["SIV infection", "OBSERVATION", 99, 112]]], ["The type of normalization used alters the type of gene expression changes that are assumed to be significant, which in turn is related to how these gene expression changes can affect the immune response.", [["gene expression changes", "PROBLEM", 50, 73], ["these gene expression changes", "PROBLEM", 142, 171], ["normalization", "OBSERVATION", 12, 25], ["assumed to be", "UNCERTAINTY", 83, 96], ["significant", "OBSERVATION_MODIFIER", 97, 108]]], ["The MC normalization method emphasizes the genes with the highest absolute variations in mRNA measurements across animals; (2) Unit-variance scaling (UV) divides the mean-centered variables by their standard deviation, resulting in unit variance variables (Fig 1B) .", [["mRNA measurements", "TEST", 89, 106], ["Unit-variance scaling (UV)", "TREATMENT", 127, 153], ["unit variance variables", "TEST", 232, 255], ["standard deviation", "OBSERVATION", 199, 217]]], ["The UV normalization method is a popular method that gives equal weight to each variable in the dataset; (3) Coefficient of variation scaling (CV) divides each variable by its mean and subtracts one (Fig 1B) .", [["The UV normalization method", "TREATMENT", 0, 27], ["variation scaling", "PROBLEM", 124, 141], ["UV", "OBSERVATION_MODIFIER", 4, 6], ["normalization", "OBSERVATION", 7, 20]]], ["This method emphasizes the genes with the highest relative changes in mRNA measurements.", [["mRNA measurements", "TEST", 70, 87]]], ["For a worked example illustrating the difference between the types of gene changes to which each normalization method is responsive, see S2 Method.ResultsEach of our 12 judges is a combination of a preprocessing method (transformation and normalization) and a multivariate analysis technique, i.e. a judge can be represented by an ordered triple (x, y, z) where x takes its value from {Orig, Log2}, y takes its value from {MC, UV, CV}, and z takes its value from {PCA, PLS} ( Fig 1A) .", [["gene changes", "PROBLEM", 70, 82], ["a preprocessing method", "TREATMENT", 196, 218], ["a multivariate analysis technique", "TEST", 258, 291], ["an ordered triple (x, y, z)", "TREATMENT", 328, 355], ["PCA", "TEST", 464, 467], ["PLS", "TEST", 469, 472]]], ["Therefore, there are 12 distinct judges in our analysis.", [["our analysis", "TEST", 43, 55], ["12 distinct", "OBSERVATION_MODIFIER", 21, 32]]], ["We use \u00c3 to denote all the possible options for a particular triple element; for example, (Log2, \u00c3 , PCA) defines all the judges that use log 2 -transformation and the PCA analysis method.", [["a particular triple element", "TREATMENT", 48, 75], ["log 2 -transformation", "TREATMENT", 138, 159], ["the PCA analysis method", "TEST", 164, 187]]], ["In this work, the dataset for each tissue (spleen, MLN, PBMC) was analyzed by all 12 judges, forming the Multiplexed Component Analysis algorithm.Animals cluster into separate groups in the score plotAfter PCA or PLS is performed on the preproccesed data, observations are projected onto a low dimensional space and are assigned new coordinates, called scores.", [["tissue", "ANATOMY", 35, 41], ["spleen", "ANATOMY", 43, 49], ["MLN", "ANATOMY", 51, 54], ["PBMC", "ANATOMY", 56, 60], ["tissue", "TISSUE", 35, 41], ["spleen", "ORGAN", 43, 49], ["MLN", "CELL", 51, 54], ["PBMC", "CELL", 56, 60], ["MLN", "CELL_TYPE", 51, 54], ["PBMC", "CELL_TYPE", 56, 60], ["spleen", "ANATOMY", 43, 49], ["MLN", "ANATOMY", 51, 54]]], ["Fig 2A shows a PC1-PC2 score plot of 24 observations (animals) in the spleen dataset analyzed by judge 2-J2: (Orig, UV, PCA).", [["spleen", "ANATOMY", 70, 76], ["spleen", "ORGAN", 70, 76], ["PC1", "PROTEIN", 15, 18], ["PC2", "PROTEIN", 19, 22], ["a PC1", "TEST", 13, 18], ["PC2 score plot", "TEST", 19, 33], ["spleen", "ANATOMY", 70, 76], ["J2", "ANATOMY", 105, 107], ["PCA", "ANATOMY", 120, 123]]], ["Together, these two principal components capture 57.5% of the variation in the dataset.", [["two", "OBSERVATION_MODIFIER", 16, 19], ["principal", "OBSERVATION_MODIFIER", 20, 29]]], ["Although PCA is an unsupervised method with no information on the time since infection, it is seen that dots with the same color (animals with the same time of infection) grouped together.", [["infection", "DISEASE", 77, 86], ["infection", "DISEASE", 160, 169], ["infection", "PROBLEM", 77, 86], ["infection", "PROBLEM", 160, 169], ["infection", "OBSERVATION", 77, 86], ["infection", "OBSERVATION", 160, 169]]], ["The red dashed ellipse is drawn using Hotelling's T 2 statistic [27] to determine the 95% confidence interval, which contains all the dots except animal #18.", [["The red dashed ellipse", "TREATMENT", 0, 22]]], ["A circular pattern is seen in Fig 2A: uninfected animals (red dots) lie in the top left quadrant but they move to the top right quadrant 4 days after infection (green dots), and the bottom right quadrant at 7 days (blue dots), and settle in the bottom left quadrant (brown and black dots), possibly demonstrating a new steady state at 14-21 days.", [["left quadrant", "ANATOMY", 83, 96], ["left quadrant", "ANATOMY", 252, 265], ["infection", "DISEASE", 150, 159], ["brown", "ORGANISM_SUBDIVISION", 267, 272], ["red dots)", "TREATMENT", 58, 67], ["infection", "PROBLEM", 150, 159], ["circular", "OBSERVATION_MODIFIER", 2, 10], ["Fig 2A", "OBSERVATION_MODIFIER", 30, 36], ["uninfected", "OBSERVATION", 38, 48], ["top", "ANATOMY_MODIFIER", 79, 82], ["left", "ANATOMY_MODIFIER", 83, 87], ["quadrant", "ANATOMY_MODIFIER", 88, 96], ["top", "ANATOMY_MODIFIER", 118, 121], ["right", "ANATOMY_MODIFIER", 122, 127], ["quadrant", "ANATOMY_MODIFIER", 128, 136], ["infection", "OBSERVATION", 150, 159], ["bottom", "ANATOMY_MODIFIER", 182, 188], ["right", "ANATOMY_MODIFIER", 189, 194], ["quadrant", "ANATOMY", 195, 203], ["bottom", "ANATOMY_MODIFIER", 245, 251], ["left", "ANATOMY_MODIFIER", 252, 256], ["quadrant", "ANATOMY", 257, 265], ["brown", "ANATOMY", 267, 272], ["new", "OBSERVATION_MODIFIER", 315, 318]]], ["Fig 2B is the corresponding loading plot, where the weight of each gene on PC1 and PC2 is shown.", [["PC1", "GENE_OR_GENE_PRODUCT", 75, 78], ["PC2", "GENE_OR_GENE_PRODUCT", 83, 86], ["PC1", "DNA", 75, 78], ["PC2", "DNA", 83, 86], ["PC1", "TEST", 75, 78], ["PC2", "TEST", 83, 86]]], ["The loading and score plots are closely linked such that genes that are highly loaded in a specific direction in the loading plot contribute more to the observations that are located in that direction in the score plot.", [["The loading and score plots", "PROBLEM", 0, 27], ["loading", "OBSERVATION_MODIFIER", 4, 11]]], ["For example, type I interferons (IFN\u03b11 and IFN\u03b2) and interferon-stimulated genes (MxA, OAS1, OAS2) are rapidly and significantly upregulated during the first days of SIV infection and they share similar location with the 4-day group in the score plot.", [["SIV infection", "DISEASE", 166, 179], ["type I interferons", "GENE_OR_GENE_PRODUCT", 13, 31], ["IFN\u03b11", "GENE_OR_GENE_PRODUCT", 33, 38], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 43, 47], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 53, 80], ["MxA", "GENE_OR_GENE_PRODUCT", 82, 85], ["OAS1", "GENE_OR_GENE_PRODUCT", 87, 91], ["OAS2", "GENE_OR_GENE_PRODUCT", 93, 97], ["SIV", "ORGANISM", 166, 169], ["type I interferons", "PROTEIN", 13, 31], ["IFN\u03b11", "PROTEIN", 33, 38], ["IFN\u03b2", "PROTEIN", 43, 47], ["interferon-stimulated genes", "DNA", 53, 80], ["MxA", "DNA", 82, 85], ["OAS1", "DNA", 87, 91], ["OAS2", "DNA", 93, 97], ["SIV", "SPECIES", 166, 169], ["type I interferons (IFN\u03b1", "TREATMENT", 13, 37], ["IFN\u03b2", "TEST", 43, 47], ["interferon", "TREATMENT", 53, 63], ["SIV infection", "PROBLEM", 166, 179], ["infection", "OBSERVATION", 170, 179]]], ["In general, genes that are far from the origin point (0, 0) in the loading plot, i.e. highly loaded on PC1 and PC2, contribute more to the scores in the score plots.", [["PC1", "GENE_OR_GENE_PRODUCT", 103, 106], ["PC2", "GENE_OR_GENE_PRODUCT", 111, 114], ["PC1", "DNA", 103, 106], ["PC2", "DNA", 111, 114], ["the loading plot", "TEST", 63, 79], ["PC1", "TREATMENT", 103, 106], ["PC2", "TREATMENT", 111, 114]]], ["The loading plots are used to find correlated genes through clustering genes that are located in a particular direction, provided that the two PCs constructing the loading plots satisfactorily approximate the matrix of the data [28] .", [["The loading plots", "TREATMENT", 0, 17]]], ["For example, functionally related inflammatory genes such as type I interferons are located in the top right quadrant, which indicates the correlation between their expression profiles.The judges have distinct interpretations of the spleenIn this section, we focus in detail on the spleen dataset analyzed by all the 12 judges, as described in the methods; we applied the methods to the other tissues as well.", [["right quadrant", "ANATOMY", 103, 117], ["spleen", "ANATOMY", 233, 239], ["spleen", "ANATOMY", 282, 288], ["tissues", "ANATOMY", 393, 400], ["type I interferons", "GENE_OR_GENE_PRODUCT", 61, 79], ["spleen", "ORGAN", 233, 239], ["spleen", "ORGAN", 282, 288], ["tissues", "TISSUE", 393, 400], ["inflammatory genes", "DNA", 34, 52], ["type I interferons", "PROTEIN", 61, 79], ["functionally related inflammatory genes", "PROBLEM", 13, 52], ["type I interferons", "PROBLEM", 61, 79], ["the methods", "TREATMENT", 368, 379], ["inflammatory genes", "OBSERVATION", 34, 52], ["top", "ANATOMY_MODIFIER", 99, 102], ["right", "ANATOMY_MODIFIER", 103, 108], ["quadrant", "ANATOMY_MODIFIER", 109, 117], ["distinct", "OBSERVATION_MODIFIER", 201, 209], ["spleen", "ANATOMY", 233, 239], ["spleen", "ANATOMY", 282, 288]]], ["Each judge emphasizes a unique type of change in gene expression, and hence the shapes of the gene clouds calculated by each judge are different, showing that different genes could be predicted to be significant depending on the underlying assumptions, which are different for each judge.The judges have distinct interpretations of the spleenIn Fig 3, the loading plots for the first two components are shown for the 12 judges.", [["change in gene expression", "PROBLEM", 39, 64], ["the gene clouds", "PROBLEM", 90, 105], ["the spleenIn Fig", "TREATMENT", 332, 348], ["the loading plots", "TREATMENT", 352, 369], ["gene expression", "OBSERVATION", 49, 64], ["distinct", "OBSERVATION_MODIFIER", 304, 312]]], ["The loading plot constructed by J1: (Orig, MC, PCA) shows both MxA and CXCL10 are loaded higher than other genes.", [["MxA", "GENE_OR_GENE_PRODUCT", 63, 66], ["CXCL10", "GENE_OR_GENE_PRODUCT", 71, 77], ["MxA", "PROTEIN", 63, 66], ["CXCL10", "PROTEIN", 71, 77], ["The loading plot", "TEST", 0, 16], ["MxA", "TEST", 63, 66], ["CXCL10", "TEST", 71, 77]]], ["For J7: (Orig, MC, PLS), where PCA is replaced by PLS, we see that, the gene cloud is approximately mirrored compared to the gene cloud of judge 1.", [["PCA", "TREATMENT", 31, 34], ["PLS", "TEST", 50, 53]]], ["Other highloading genes for these two judges include OAS1, OAS2, CXCL11, and IDO1.", [["OAS1", "GENE_OR_GENE_PRODUCT", 53, 57], ["OAS2", "GENE_OR_GENE_PRODUCT", 59, 63], ["CXCL11", "GENE_OR_GENE_PRODUCT", 65, 71], ["IDO1", "GENE_OR_GENE_PRODUCT", 77, 81], ["highloading genes", "DNA", 6, 23], ["OAS1", "PROTEIN", 53, 57], ["OAS2", "DNA", 59, 63], ["CXCL11", "PROTEIN", 65, 71], ["IDO1", "PROTEIN", 77, 81], ["OAS1", "TEST", 53, 57], ["OAS2", "TEST", 59, 63], ["CXCL11", "TEST", 65, 71], ["IDO1", "TEST", 77, 81]]], ["Comparing no transformation (Orig) with log 2 -transformation (Log2) in judges 1 and 4, we observe that judge 4 is less dominated by a small number of highly-loaded genes than judge 1 (the scales on the axes are different).", [["transformation", "PROBLEM", 13, 27], ["no", "UNCERTAINTY", 10, 12], ["transformation", "OBSERVATION_MODIFIER", 13, 27], ["less dominated", "OBSERVATION_MODIFIER", 115, 129], ["small", "OBSERVATION_MODIFIER", 135, 140], ["number", "OBSERVATION_MODIFIER", 141, 147]]], ["A common feature of judges 1, 4, 7, and 10 is that the MC is the normalization method.", [["normalization", "OBSERVATION", 65, 78]]], ["Thus, if we assume that changes in the absolute value of gene expressions have significant impacts on the immune response, genes such as MxA, CCL8, and CXCL10 are highly contributing to the immunological events observed during acute SIV infection.", [["SIV infection", "DISEASE", 233, 246], ["MxA", "GENE_OR_GENE_PRODUCT", 137, 140], ["CCL8", "GENE_OR_GENE_PRODUCT", 142, 146], ["CXCL10", "GENE_OR_GENE_PRODUCT", 152, 158], ["SIV", "ORGANISM", 233, 236], ["MxA", "PROTEIN", 137, 140], ["CCL8", "PROTEIN", 142, 146], ["CXCL10", "PROTEIN", 152, 158], ["SIV", "SPECIES", 233, 236], ["gene expressions", "PROBLEM", 57, 73], ["MxA", "TEST", 137, 140], ["CCL8", "TEST", 142, 146], ["CXCL10", "TEST", 152, 158], ["the immunological events", "PROBLEM", 186, 210], ["acute SIV infection", "PROBLEM", 227, 246], ["acute", "OBSERVATION_MODIFIER", 227, 232], ["SIV infection", "OBSERVATION", 233, 246]]], ["Indeed, MxA is one of the most reliable surrogates for the measurement of type I interferon response both in Although the PCA method is given no information on the time since infection, clearly animals cluster with their time points.", [["infection", "DISEASE", 175, 184], ["MxA", "GENE_OR_GENE_PRODUCT", 8, 11], ["type I interferon", "GENE_OR_GENE_PRODUCT", 74, 91], ["MxA", "PROTEIN", 8, 11], ["type I interferon", "PROTEIN", 74, 91], ["type I interferon response", "PROBLEM", 74, 100], ["the PCA method", "TREATMENT", 118, 132], ["infection", "PROBLEM", 175, 184], ["infection", "OBSERVATION", 175, 184]]], ["The red dashed ellipse determines the 95% confidence interval, which is drawn using Hotelling's T 2 statistic.", [["The red dashed ellipse", "TREATMENT", 0, 22]]], ["(B) Gene loadings (weights) for the top two PCs.", [["PCs", "ANATOMY", 44, 47], ["Gene loadings (weights", "TREATMENT", 4, 26]]], ["Genes that are highly loaded on PC1 and PC2 (i.e. far from the origin) contribute more to the scores in the score plot than other genes.", [["PC1", "GENE_OR_GENE_PRODUCT", 32, 35], ["PC2", "GENE_OR_GENE_PRODUCT", 40, 43], ["PC1", "DNA", 32, 35], ["PC2", "DNA", 40, 43], ["PC1 and PC2", "TREATMENT", 32, 43]]], ["The results for other judges testing the spleen dataset are shown in S3 Information (score plots) and Fig 3 (loading plots) .", [["spleen", "ANATOMY", 41, 47], ["spleen", "ORGAN", 41, 47], ["other judges testing", "TEST", 16, 36], ["Fig 3 (loading plots", "TREATMENT", 102, 122], ["spleen", "ANATOMY", 41, 47]]], ["The 12 judges identify both consensus and judge-specific genes: loading plots of 12 judges for the spleen dataset.", [["spleen", "ANATOMY", 99, 105], ["spleen", "ORGAN", 99, 105], ["spleen", "ANATOMY", 99, 105]]], ["In our analysis, we either use the original data (the 1st and 3rd rows) or log 2 -transformed data (the 2nd and 4th rows).", [["the original data", "TEST", 31, 48], ["the 1st and 3rd rows", "TREATMENT", 50, 70]]], ["Before performing PCA (top two rows) or PLS (bottom two rows), preprocessing methods are applied on the data to make it mean-centered (MC), unit variance (UV)-scaled, or coefficient of variation (CV)-scaled (columns).", [["PLS", "DNA", 40, 43], ["PCA (top two rows)", "TREATMENT", 18, 36], ["PLS (bottom two rows)", "TREATMENT", 40, 61], ["preprocessing methods", "TREATMENT", 63, 84]]], ["For this figure, we use time since infection as the output variable for PLS.", [["infection", "DISEASE", 35, 44], ["infection", "PROBLEM", 35, 44], ["the output", "TEST", 48, 58], ["PLS", "TEST", 72, 75], ["infection", "OBSERVATION", 35, 44]]], ["The loading plots on PC1 and PC2 are shown for each judge.", [["PC2", "GENE_OR_GENE_PRODUCT", 29, 32], ["PC1", "DNA", 21, 24], ["PC2", "DNA", 29, 32], ["The loading plots", "TEST", 0, 17], ["PC1 and PC2", "TREATMENT", 21, 32]]], ["In the first column (MC), we observe that there are a few highly loaded genes in each plot and the rest of genes are located in a dense cloud.", [["a few highly loaded genes in each plot", "PROBLEM", 52, 90], ["a dense cloud", "PROBLEM", 128, 141], ["few", "OBSERVATION_MODIFIER", 54, 57], ["highly", "OBSERVATION_MODIFIER", 58, 64], ["loaded genes", "OBSERVATION", 65, 77], ["dense", "OBSERVATION_MODIFIER", 130, 135], ["cloud", "OBSERVATION", 136, 141]]], ["In the second column (UV), there is no single gene with a significantly high loading and the cloud of genes is more spread out.", [["single gene", "PROBLEM", 39, 50], ["a significantly high loading", "PROBLEM", 56, 84], ["second column", "ANATOMY_MODIFIER", 7, 20], ["no", "UNCERTAINTY", 36, 38], ["significantly", "OBSERVATION_MODIFIER", 58, 71], ["high loading", "OBSERVATION", 72, 84], ["cloud", "OBSERVATION_MODIFIER", 93, 98], ["more", "OBSERVATION_MODIFIER", 111, 115], ["spread", "OBSERVATION_MODIFIER", 116, 122]]], ["In the third column (CV), we see a combination of the main features of the previous columns: a few highly loaded genes are observed and the gene clouds are more spread.", [["a few highly loaded genes", "PROBLEM", 93, 118], ["the gene clouds", "PROBLEM", 136, 151], ["third", "ANATOMY_MODIFIER", 7, 12], ["column", "ANATOMY", 13, 19], ["main", "OBSERVATION_MODIFIER", 54, 58], ["few", "OBSERVATION_MODIFIER", 95, 98], ["highly", "OBSERVATION_MODIFIER", 99, 105], ["loaded genes", "OBSERVATION", 106, 118], ["clouds", "OBSERVATION_MODIFIER", 145, 151], ["more", "OBSERVATION_MODIFIER", 156, 160], ["spread", "OBSERVATION_MODIFIER", 161, 167]]], ["The score and loading plots for the 12 judges in other datasets (and other classification schemes) are available in S3 Information.The judges have distinct interpretations of the spleenvitro and in vivo [29] , and CCL8 and CXCL10 are important chemoattractants for monocytes and activated lymphocytes, respectively [30] .The judges have distinct interpretations of the spleenUnlike ( \u00c3 , MC, \u00c3 ) in the 1st column, no single gene with a significantly high loading is seen in the 2nd column, constructed by ( \u00c3 , UV, \u00c3 ).", [["monocytes", "ANATOMY", 265, 274], ["lymphocytes", "ANATOMY", 289, 300], ["CCL8", "GENE_OR_GENE_PRODUCT", 214, 218], ["CXCL10", "GENE_OR_GENE_PRODUCT", 223, 229], ["monocytes", "CELL", 265, 274], ["lymphocytes", "CELL", 289, 300], ["CCL8", "PROTEIN", 214, 218], ["CXCL10", "PROTEIN", 223, 229], ["chemoattractants", "PROTEIN", 244, 260], ["monocytes", "CELL_TYPE", 265, 274], ["activated lymphocytes", "CELL_TYPE", 279, 300], ["The score", "TEST", 0, 9], ["loading plots", "TEST", 14, 27], ["the spleenvitro", "TEST", 175, 190], ["CCL8", "TEST", 214, 218], ["CXCL10", "TEST", 223, 229], ["monocytes", "TEST", 265, 274], ["activated lymphocytes", "TEST", 279, 300], ["the spleenUnlike", "TEST", 365, 381], ["a significantly high loading", "PROBLEM", 435, 463], ["distinct", "OBSERVATION_MODIFIER", 337, 345], ["1st column", "ANATOMY", 403, 413], ["no", "UNCERTAINTY", 415, 417], ["significantly", "OBSERVATION_MODIFIER", 437, 450], ["high loading", "OBSERVATION", 451, 463], ["2nd column", "ANATOMY", 479, 489]]], ["This is somewhat expected since all the genes have equal variance when the UV scaling is performed.", [["the UV scaling", "TEST", 71, 85]]], ["Comparing J2: (Orig, UV, PCA) and J5: (Log2, UV, PCA), we observe that there is a slight rotation between the two gene clouds, while they are similar in terms of the distance of genes from the origin and their relative location.", [["Log2, UV, PCA", "TREATMENT", 39, 52], ["a slight rotation between the two gene clouds", "PROBLEM", 80, 125], ["PCA", "ANATOMY", 25, 28], ["PCA", "ANATOMY", 49, 52], ["slight", "OBSERVATION_MODIFIER", 82, 88], ["rotation", "OBSERVATION_MODIFIER", 89, 97], ["clouds", "OBSERVATION_MODIFIER", 119, 125], ["similar", "OBSERVATION_MODIFIER", 142, 149], ["origin", "ANATOMY_MODIFIER", 193, 199]]], ["If PC2 in judge 8 is multiplied by -1, the same scenario will be observed between judges 8 and 11, both of which use the UV normalization method.", [["PC2", "PROTEIN", 3, 6], ["PC2", "TEST", 3, 6], ["the UV normalization method", "TREATMENT", 117, 144]]], ["This indicates that UV scaling may alleviate the issue of nonnormality and therefore log 2 -transformation has a lesser effect in this case.The judges have distinct interpretations of the spleenThe CV scaling method, used in the 3rd column, preprocesses genes to have their variance equal to the square of the coefficient of variation of the original genes.", [["spleen", "ANATOMY", 188, 194], ["spleen", "ORGAN", 188, 194], ["UV scaling", "PROBLEM", 20, 30], ["nonnormality", "PROBLEM", 58, 70], ["log 2 -transformation", "PROBLEM", 85, 106], ["The CV scaling method", "TREATMENT", 194, 215], ["UV scaling", "OBSERVATION", 20, 30], ["nonnormality", "OBSERVATION", 58, 70], ["lesser effect", "OBSERVATION_MODIFIER", 113, 126], ["distinct", "OBSERVATION_MODIFIER", 156, 164], ["spleen", "ANATOMY", 188, 194], ["3rd column", "ANATOMY", 229, 239], ["original genes", "OBSERVATION", 342, 356]]], ["Therefore, it lies somewhere between the UV scaling method, which gives equal variance to each variable, and the MC normalization method, which does not modify the variance of variables at all.", [["the MC normalization method", "TEST", 109, 136], ["UV", "OBSERVATION_MODIFIER", 41, 43], ["scaling", "OBSERVATION_MODIFIER", 44, 51], ["equal variance", "OBSERVATION", 72, 86]]], ["Here, we also observe that the 3rd column of judges, ( \u00c3 , CV, \u00c3 ), shares features with both the first and second columns, i.e., a few highly loaded genes as well as a spread cloud of genes.", [["judges", "TEST", 45, 51], ["a few highly loaded genes", "PROBLEM", 130, 155], ["few", "OBSERVATION_MODIFIER", 132, 135], ["highly", "OBSERVATION_MODIFIER", 136, 142], ["loaded genes", "OBSERVATION", 143, 155]]], ["The preprocessing methods clearly impact the shape of the gene clouds constructed by PC1 and PC2, and hence changing the loading (importance) of genes under each assumption.", [["PC1", "GENE_OR_GENE_PRODUCT", 85, 88], ["PC2", "GENE_OR_GENE_PRODUCT", 93, 96], ["PC1", "DNA", 85, 88], ["PC2", "DNA", 93, 96], ["The preprocessing methods", "TREATMENT", 0, 25], ["the gene clouds", "TREATMENT", 54, 69], ["PC2", "TREATMENT", 93, 96]]], ["In the next section, we define metrics to select the best pair of PCs for each judge to perform further analysis.The choice of top classifier PCs varies between the judgesThe score plots provided by the PCA and PLS methods are used to cluster observations into separate groups based on the information on time since infection or SIV RNA in plasma.", [["plasma", "ANATOMY", 340, 346], ["infection", "DISEASE", 316, 325], ["SIV", "ORGANISM", 329, 332], ["plasma", "ORGANISM_SUBSTANCE", 340, 346], ["SIV RNA", "RNA", 329, 336], ["SIV", "SPECIES", 329, 332], ["further analysis", "TEST", 96, 112], ["The score plots", "TEST", 171, 186], ["the PCA", "TREATMENT", 199, 206], ["PLS methods", "TREATMENT", 211, 222], ["infection", "PROBLEM", 316, 325], ["SIV RNA in plasma", "PROBLEM", 329, 346], ["SIV RNA", "OBSERVATION", 329, 336]]], ["For each judge, dataset (tissue) and classification scheme (time since infection or SIV RNA in plasma), our goal is to find a score plot that provides the most accurate and robust classification of observations and to study the gene loadings in the corresponding loading plot.", [["tissue", "ANATOMY", 25, 31], ["plasma", "ANATOMY", 95, 101], ["infection", "DISEASE", 71, 80], ["tissue", "TISSUE", 25, 31], ["SIV", "ORGANISM", 84, 87], ["plasma", "ORGANISM_SUBSTANCE", 95, 101], ["SIV RNA", "RNA", 84, 91], ["SIV", "SPECIES", 84, 87], ["classification scheme", "TEST", 37, 58], ["infection", "PROBLEM", 71, 80], ["a score plot", "TEST", 124, 136]]], ["For each judge, we look at 28 score plots generated by all the combinations of two of the top eight PCs.", [["the top eight PCs", "TREATMENT", 86, 103]]], ["This is because in all cases a high degree of variability, at least 76% and on average 87%, is captured by the top eight PCs (S2 Information).", [["high degree", "OBSERVATION_MODIFIER", 31, 42], ["variability", "OBSERVATION_MODIFIER", 46, 57]]], ["Next, we perform centroid-based classification and cross validation to obtain classification and LOOCV rates, indicative of the accuracy and the robustness of the classification on a given score plot, respectively.", [["cross validation", "TEST", 51, 67], ["LOOCV rates", "TEST", 97, 108]]], ["The PCs representing the highest accuracy and robustness are chosen as the top two classifier PCs for that judge (S2 Table) .", [["PCs", "CELL_TYPE", 4, 7], ["The PCs", "TEST", 0, 7], ["highest", "OBSERVATION_MODIFIER", 25, 32]]], ["PC1 and PC2 are the most commonly chosen classifier PCs, comprising 75% and 51% of all pairs, respectively.", [["PC1", "GENE_OR_GENE_PRODUCT", 0, 3], ["PC2", "GENE_OR_GENE_PRODUCT", 8, 11], ["PC1", "DNA", 0, 3], ["PC2", "DNA", 8, 11], ["PC1", "TEST", 0, 3], ["PC2", "TEST", 8, 11], ["PCs", "TEST", 52, 55]]], ["This is expected, as PC1 and PC2 capture the highest amount of variability among PCs.", [["PCs", "ANATOMY", 81, 84], ["PC1", "GENE_OR_GENE_PRODUCT", 21, 24], ["PC2", "GENE_OR_GENE_PRODUCT", 29, 32], ["PCs", "CELL", 81, 84], ["PC1", "PROTEIN", 21, 24], ["PC2", "PROTEIN", 29, 32], ["PCs", "CELL_TYPE", 81, 84], ["PC1", "TEST", 21, 24], ["PC2", "TEST", 29, 32], ["highest", "OBSERVATION_MODIFIER", 45, 52], ["amount", "OBSERVATION_MODIFIER", 53, 59], ["variability", "OBSERVATION_MODIFIER", 63, 74]]], ["The PC1-PC2 pair is chosen in 25 out of 72 cases, followed by PC1-PC3 and PC1-PC4, each chosen in 9 cases.The choice of top classifier PCs varies between the judgesThe results of clustering for both classification schemes are shown in the score plots in S3 Information and summarized in Fig 4.", [["PC1-PC3", "ANATOMY", 62, 69], ["PC1-PC2", "GENE_OR_GENE_PRODUCT", 4, 11], ["PC1-PC3", "CELL", 62, 69], ["PC1-PC4", "CELL", 74, 81], ["PC1", "DNA", 4, 7], ["PC2", "DNA", 8, 11], ["PC1", "DNA", 62, 65], ["PC1", "DNA", 74, 77], ["PC4", "DNA", 78, 81], ["The PC1-PC2 pair", "TEST", 0, 16], ["PC1", "TEST", 62, 65], ["PC1", "TEST", 74, 77], ["PC4", "TREATMENT", 78, 81]]], ["In most cases for time since infection (Fig 4A) , the classification rates are higher than 75% (mean = 83.9%) and the LOOCV rates are higher than 60% (mean = 70.9%).", [["infection", "DISEASE", 29, 38], ["infection", "PROBLEM", 29, 38], ["the classification rates", "TEST", 50, 74], ["mean", "TEST", 96, 100], ["the LOOCV rates", "TEST", 114, 129], ["mean", "TEST", 151, 155], ["higher", "OBSERVATION_MODIFIER", 134, 140]]], ["For SIV RNA in plasma in most cases (Fig 4B) , classification rates are higher than 60% (mean = 69.2%) and the LOOCV rates are higher than 54% (mean = 61.9%).", [["plasma", "ANATOMY", 15, 21], ["SIV", "ORGANISM", 4, 7], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["SIV RNA", "RNA", 4, 11], ["SIV", "SPECIES", 4, 7], ["classification rates", "TEST", 47, 67], ["the LOOCV rates", "TEST", 107, 122], ["mean", "TEST", 144, 148], ["SIV RNA", "OBSERVATION", 4, 11], ["higher", "OBSERVATION_MODIFIER", 127, 133]]], ["We observe that clustering based on SIV RNA in plasma is generally less accurate and less robust than the classification based on time since infection.", [["plasma", "ANATOMY", 47, 53], ["infection", "DISEASE", 141, 150], ["SIV", "ORGANISM", 36, 39], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["SIV RNA", "RNA", 36, 43], ["SIV", "SPECIES", 36, 39], ["SIV RNA", "TEST", 36, 43], ["infection", "PROBLEM", 141, 150], ["SIV RNA", "OBSERVATION", 36, 43], ["infection", "OBSERVATION", 141, 150]]], ["This may suggest that measuring SIV RNA in plasma alone does not provide a good indicator for the changes in immunological events during SIV infection due to the complex interactions between the virus and the immune system.", [["plasma", "ANATOMY", 43, 49], ["immune system", "ANATOMY", 209, 222], ["SIV infection", "DISEASE", 137, 150], ["SIV", "ORGANISM", 32, 35], ["plasma", "ORGANISM_SUBSTANCE", 43, 49], ["SIV", "ORGANISM", 137, 140], ["immune system", "ANATOMICAL_SYSTEM", 209, 222], ["SIV RNA", "RNA", 32, 39], ["SIV", "SPECIES", 32, 35], ["SIV", "SPECIES", 137, 140], ["measuring SIV RNA in plasma", "PROBLEM", 22, 49], ["immunological events", "PROBLEM", 109, 129], ["SIV infection", "PROBLEM", 137, 150], ["the complex interactions between the virus", "PROBLEM", 158, 200], ["may suggest", "UNCERTAINTY", 5, 16], ["SIV RNA", "OBSERVATION", 32, 39]]], ["Indeed, during HIV infection, markers for cellular activation are better predictors of disease outcome than plasma viral load [31] .The choice of top classifier PCs varies between the judgesIn order to find whether there is a particular transformation, or preprocessing, or multivariate analysis that systematically provides more accurate and robust results than others, we calculated the average classification and LOOCV rates for judges that have a common feature, i.e. Orig vs. Log2, MC vs. UV vs. CV, and PCA vs. PLS (Fig 4C-4H ).", [["cellular", "ANATOMY", 42, 50], ["plasma", "ANATOMY", 108, 114], ["HIV infection", "DISEASE", 15, 28], ["HIV", "ORGANISM", 15, 18], ["cellular", "CELL", 42, 50], ["plasma", "ORGANISM_SUBSTANCE", 108, 114], ["HIV", "SPECIES", 15, 18], ["HIV", "SPECIES", 15, 18], ["HIV infection", "PROBLEM", 15, 28], ["cellular activation", "PROBLEM", 42, 61], ["disease outcome", "PROBLEM", 87, 102], ["plasma viral load", "TEST", 108, 125], ["a particular transformation", "PROBLEM", 224, 251], ["multivariate analysis", "TEST", 274, 295], ["infection", "OBSERVATION", 19, 28], ["PCA", "ANATOMY", 509, 512]]], ["It would be difficult to argue that one judge is clearly better than others when we consider both classification and LOOCV rates.", [["LOOCV rates", "TEST", 117, 128]]], ["Since each judge observes the data from a distinct viewpoint and we want to consider various assumptions on how the immune response is affected by the changes in gene expressions, we combine their opinions to identify significant genes during acute SIV infection.The choice of top classifier PCs varies between the judgesIn general, after the classification and cross validation are performed, the judges need to be evaluated based on their accuracy and robustness.", [["SIV infection", "DISEASE", 249, 262], ["SIV", "ORGANISM", 249, 252], ["SIV", "SPECIES", 249, 252], ["acute SIV infection", "PROBLEM", 243, 262], ["cross validation", "TEST", 362, 378], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["SIV infection", "OBSERVATION", 249, 262]]], ["If a judge has a low accuracy compared to others, that judge can be removed from further analysis.", [["a low accuracy", "PROBLEM", 15, 29], ["further analysis", "TEST", 81, 97]]], ["In this application, all the judges have high and approximately similar accuracy and robustness and hence we give them equal weights when we combine the results.", [["high", "OBSERVATION_MODIFIER", 41, 45]]], ["Note that although the judges have similar accuracy, each of them analyzes data differently and assigns distinguishably different loadings to the genes (loading plots in S3 Information).The choice of top classifier PCs varies between the judgesCCL8 is identified as the top \"contributing\" gene by all the judges Genes that are highly loaded (distant from the origin) contribute more to the scores that were used for classification, and hence are considered as top \"contributing\" genes.", [["judgesCCL8", "GENE_OR_GENE_PRODUCT", 238, 248], ["judgesCCL8", "DNA", 238, 248], ["top \"contributing\" gene", "DNA", 270, 293], ["top \"contributing\" genes", "DNA", 460, 484]]], ["To find these genes, we calculate the distance of each gene from the origin in the loading plots (loading plots in S3 Information) and rank the values with the highest rank equivalent to the maximum distance, i.e. the highest contribution.", [["highest contribution", "OBSERVATION", 218, 238]]], ["To answer this, we create a 88\u00d712 gene ranking table where rows and columns correspond to genes and judges, respectively.", [["88\u00d712 gene ranking table", "DNA", 28, 52]]], ["Using the Friedman test, we obtained extremely small p-values (S3 Table) , suggesting that in all three tissues and for both classification schemes there is at least one gene that is consistently ranked higher or lower than others.", [["tissues", "ANATOMY", 104, 111], ["tissues", "TISSUE", 104, 111], ["the Friedman test", "TEST", 6, 23], ["three tissues", "ANATOMY", 98, 111]]], ["The genes are sorted based on the average of their 12 ranks in Fig 5A-5C (time since infection) and panels A-C in S4 Information (SIV RNA in plasma).", [["plasma", "ANATOMY", 141, 147], ["infection", "DISEASE", 85, 94], ["A-C", "GENE_OR_GENE_PRODUCT", 107, 110], ["SIV", "ORGANISM", 130, 133], ["plasma", "ORGANISM_SUBSTANCE", 141, 147], ["SIV", "SPECIES", 130, 133], ["infection", "PROBLEM", 85, 94]]], ["CCL8 is ranked as the highest contributing gene in both classification schemes.", [["CCL8", "GENE_OR_GENE_PRODUCT", 0, 4], ["CCL8", "DNA", 0, 4], ["both classification", "OBSERVATION", 51, 70]]], ["Albeit with a different order of contribution, CCL8 is followed by CXCL10, CXCL11, MxA, OAS2, and OAS1 in the two classification schemes.", [["CCL8", "GENE_OR_GENE_PRODUCT", 47, 51], ["CXCL10", "GENE_OR_GENE_PRODUCT", 67, 73], ["CXCL11", "GENE_OR_GENE_PRODUCT", 75, 81], ["MxA", "GENE_OR_GENE_PRODUCT", 83, 86], ["OAS2", "GENE_OR_GENE_PRODUCT", 88, 92], ["OAS1", "GENE_OR_GENE_PRODUCT", 98, 102], ["CCL8", "PROTEIN", 47, 51], ["CXCL10", "PROTEIN", 67, 73], ["CXCL11", "PROTEIN", 75, 81], ["MxA", "PROTEIN", 83, 86], ["OAS2", "PROTEIN", 88, 92], ["OAS1", "PROTEIN", 98, 102], ["CXCL11", "TEST", 75, 81], ["MxA", "TEST", 83, 86], ["OAS2", "TEST", 88, 92]]], ["These genes always appear among the top eleven contributing genes in all tissues and for both classification schemes.", [["tissues", "ANATOMY", 73, 80], ["tissues", "TISSUE", 73, 80], ["all tissues", "ANATOMY", 69, 80]]], ["These genes are all stimulated by type I interferon, suggesting that the cytokine storm we here identify in lymphoid tissues-and that is also observed in the plasma of patients during acute HIV infection-reflects a systemic innate immune response against viral replication [1, 32] .", [["lymphoid tissues", "ANATOMY", 108, 124], ["plasma", "ANATOMY", 158, 164], ["HIV infection", "DISEASE", 190, 203], ["type I interferon", "GENE_OR_GENE_PRODUCT", 34, 51], ["lymphoid tissues", "TISSUE", 108, 124], ["plasma", "ORGANISM_SUBSTANCE", 158, 164], ["patients", "ORGANISM", 168, 176], ["HIV", "ORGANISM", 190, 193], ["type I interferon", "PROTEIN", 34, 51], ["cytokine", "PROTEIN", 73, 81], ["patients", "SPECIES", 168, 176], ["HIV", "SPECIES", 190, 193], ["HIV", "SPECIES", 190, 193], ["the cytokine storm", "PROBLEM", 69, 87], ["acute HIV infection", "PROBLEM", 184, 203], ["viral replication", "PROBLEM", 255, 272], ["lymphoid tissues", "OBSERVATION", 108, 124], ["infection", "OBSERVATION", 194, 203]]], ["While there are genes that contribute highly to all three tissues, among the transcripts analyzed in this project we cannot identify a single gene that consistently appears in the lowest eleven contributing genes.The choice of top classifier PCs varies between the judgesTo evaluate our MCA method, we compared its ranking results with those of other methods including the Pearson correlation (S5 Information), the Spearman correlation [33, 34] (S6 Information), One-way analysis of variance (ANOVA) (S7 Information), and the significance analysis of microarrays (SAM) [35] (S8 Information) methods, all of which are used to rank the genes.", [["tissues", "ANATOMY", 58, 65], ["tissues", "TISSUE", 58, 65], ["our MCA method", "TEST", 283, 297]]], ["Note that t-statistics and fold-change methods are also used in literature, but they are limited to classifications based on two groups.", [["t-statistics and fold-change methods", "TREATMENT", 10, 46]]], ["In most cases, the generated trees overfitted the dataset, and hence we pruned the trees and chose the sub-tree with the lowest cross validation error rate.", [["tree", "ANATOMY_MODIFIER", 107, 111]]], ["The results indicate that, in 11 out of 12 cases, the top genes selected by MCA have substantially better classification power than those selected by the Pearson or Spearman correlation methods (panels A and C in S9 Information).", [["MCA", "MULTI-TISSUE_STRUCTURE", 76, 79], ["top genes", "DNA", 54, 63], ["MCA", "DNA", 76, 79], ["MCA", "ANATOMY", 76, 79]]], ["The classification results of the SAM and ANOVA methods are similar to those of the MCA method.", [["the SAM and ANOVA methods", "PROBLEM", 30, 55], ["MCA", "ANATOMY", 84, 87]]], ["Furthermore, the Spearman's rank correlation coefficients, measuring the degree of similarity between the rankings of the MCA and other methods, indicate high correlations between the MCA and SAM methods (panels B and D in S9 Information).", [["MCA", "DNA", 122, 125], ["the Spearman's rank correlation coefficients", "TEST", 13, 57], ["SAM methods", "TEST", 192, 203], ["MCA", "ANATOMY", 122, 125], ["high", "OBSERVATION", 154, 158], ["MCA", "ANATOMY", 184, 187]]], ["We also showed that in most cases the classification power top 5 average-ranked genes selected by all the judges is equally well or better than that of the top 5 genes selected by each individual judge (S10 Information) or that top 5 average-ranked genes selected by the judges with log2-transformation (S11 Information).", [["5 genes", "DNA", 160, 167]]], ["Identification of tissue-specific and global genes: gene rankings across judges and datasets (tissues).", [["tissue", "ANATOMY", 18, 24], ["tissues", "ANATOMY", 94, 101], ["tissue", "TISSUE", 18, 24], ["tissues", "TISSUE", 94, 101], ["global genes", "DNA", 38, 50], ["tissue", "ANATOMY", 18, 24]]], ["The highly loaded genes contribute more to the scores that are used for classification, and hence are considered as the top \"contributing\" genes.", [["top \"contributing\" genes", "DNA", 120, 144]]], ["To study genes based on their contribution, we calculate the distance of each gene from the origin in the loading plots and rank the distance values in a descending order with the highest rank equivalent to the maximum distance, i.e. the highest contribution.", [["origin", "ANATOMY_MODIFIER", 92, 98], ["loading plots", "OBSERVATION", 106, 119], ["descending", "ANATOMY_MODIFIER", 154, 164], ["maximum", "OBSERVATION_MODIFIER", 211, 218], ["highest contribution", "OBSERVATION", 238, 258]]], ["Then, we calculate the average of twelve ranks for each gene and sort the results from the high-ranking genes (dark blue) to the low-ranking genes (dark red) in the (A) spleen, (B) MLN and (C) PBMC datasets.", [["spleen", "ANATOMY", 169, 175], ["MLN", "ANATOMY", 181, 184], ["PBMC", "ANATOMY", 193, 197], ["spleen", "ORGAN", 169, 175], ["PBMC", "CELL", 193, 197], ["low-ranking genes", "DNA", 129, 146], ["PBMC", "CELL_TYPE", 193, 197], ["dark blue", "PROBLEM", 111, 120], ["spleen", "ANATOMY", 169, 175], ["MLN", "ANATOMY", 181, 184]]], ["This leads to an overall rank for each gene in each of the datasets.", [["overall", "OBSERVATION_MODIFIER", 17, 24], ["rank", "OBSERVATION", 25, 29]]], ["(D) We calculate the average value of the three overall ranks and sort the results in a descending order of contribution.", [["descending", "ANATOMY", 88, 98]]], ["We observe that CCL8, followed by MxA, CXCL10, CXCL11, OAS2, and OAS1 are ranked as the top contributing genes in all datasets.", [["CCL8", "GENE_OR_GENE_PRODUCT", 16, 20], ["MxA", "GENE_OR_GENE_PRODUCT", 34, 37], ["CXCL10", "GENE_OR_GENE_PRODUCT", 39, 45], ["CXCL11", "GENE_OR_GENE_PRODUCT", 47, 53], ["OAS2", "GENE_OR_GENE_PRODUCT", 55, 59], ["OAS1", "GENE_OR_GENE_PRODUCT", 65, 69], ["CCL8", "PROTEIN", 16, 20], ["MxA", "PROTEIN", 34, 37], ["CXCL10", "PROTEIN", 39, 45], ["CXCL11", "PROTEIN", 47, 53], ["OAS2", "PROTEIN", 55, 59], ["OAS1", "PROTEIN", 65, 69], ["CCL8", "TEST", 16, 20], ["MxA", "TEST", 34, 37], ["CXCL10", "TEST", 39, 45], ["CXCL11", "TEST", 47, 53]]], ["S4 Information shows the equivalent results for SIV RNA in plasma as the classifier.The choice of top classifier PCs varies between the judgesThe level of agreement between judges on the gene contributions varies substantially among genes.", [["plasma", "ANATOMY", 59, 65], ["SIV", "ORGANISM", 48, 51], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["SIV RNA", "RNA", 48, 55], ["SIV", "SPECIES", 48, 51]]], ["Similar colors across a row, such as CXCL11 and CCL2 in Fig 5B, show a high degree of consensus among judges, while there is a significant amount of disagreement between judges on rows with mixed colors, such as CCL24 in Fig 5A.", [["CXCL11", "GENE_OR_GENE_PRODUCT", 37, 43], ["CCL2", "GENE_OR_GENE_PRODUCT", 48, 52], ["CXCL11", "PROTEIN", 37, 43], ["CCL2", "PROTEIN", 48, 52], ["CCL24", "PROTEIN", 212, 217], ["CXCL11", "TEST", 37, 43], ["CCL2 in Fig 5B", "TEST", 48, 62], ["mixed colors", "PROBLEM", 190, 202], ["high degree", "OBSERVATION_MODIFIER", 71, 82], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["amount", "OBSERVATION_MODIFIER", 139, 145], ["disagreement", "OBSERVATION", 149, 161], ["mixed colors", "OBSERVATION", 190, 202]]], ["Typically, the high contributing genes tend to be located in the left bottom corner of figures in S12 Information, suggesting that there is a high degree of agreement between judges on the contribution of these genes.", [["left", "ANATOMY_MODIFIER", 65, 69], ["bottom", "ANATOMY_MODIFIER", 70, 76], ["high degree", "OBSERVATION_MODIFIER", 142, 153]]], ["For both classification schemes, we observe that there is a greater degree of agreement between judges in the MLN dataset than in spleen and PBMC.", [["spleen", "ANATOMY", 130, 136], ["PBMC", "ANATOMY", 141, 145], ["spleen", "ORGAN", 130, 136], ["PBMC", "CELL", 141, 145], ["PBMC", "CELL_TYPE", 141, 145], ["greater degree", "OBSERVATION_MODIFIER", 60, 74], ["MLN", "ANATOMY", 110, 113], ["spleen", "ANATOMY", 130, 136], ["PBMC", "ANATOMY", 141, 145]]], ["This can be visually seen in Fig 5 and the figure in S4 Information, where the gene rankings in the MLN dataset show the most consistency.", [["MLN", "ANATOMY", 100, 103]]], ["Furthermore, we evaluated how genes were assigned differential rankings by the judges with a common feature, specifically, MC-vs.", [["MC", "TEST", 123, 125]]], ["UV-vs.", [["UV", "TEST", 0, 2]]], ["The proximity of a gene to a vertex indicates that the gene has more importance to the class or classes of the judges noted at that vertex.", [["vertex", "ANATOMY_MODIFIER", 132, 138]]], ["The inner color of each dot represents the average of the ranks, whereas the outer color represents the minimum of the three ranks.", [["inner", "OBSERVATION_MODIFIER", 4, 9], ["color", "OBSERVATION_MODIFIER", 10, 15], ["average", "OBSERVATION_MODIFIER", 43, 50]]], ["The congested region in the center of the hexagon houses In each hexagonal plot, three main vertices represent MC-, UV-, and CV-based judges.", [["The congested region", "PROBLEM", 0, 20], ["MC", "TEST", 111, 113], ["UV", "TEST", 116, 118], ["congested", "OBSERVATION", 4, 13], ["hexagon", "ANATOMY_MODIFIER", 42, 49], ["hexagonal plot", "OBSERVATION", 65, 79], ["main", "OBSERVATION_MODIFIER", 87, 91], ["vertices", "OBSERVATION_MODIFIER", 92, 100], ["MC", "OBSERVATION_MODIFIER", 111, 113]]], ["Genes close to one of these vertices are relatively more important to that class of judge.", [["vertices", "OBSERVATION", 28, 36]]], ["For example, genes that are close to CV&MC have equal importance to both CV-and MC-based judges.", [["CV&MC", "GENE_OR_GENE_PRODUCT", 37, 42], ["CV&MC", "DNA", 37, 42], ["CV", "TEST", 73, 75]]], ["The coordinates are formatted as the relative gene importance, C UV , C MC , C CV , taking values in the range [-1/3, 1] and satisfy C UV + C MC + C CV = 1 (see S6 Method for further explanation of coordinates).", [["C UV", "TEST", 133, 137], ["MC", "TEST", 142, 144]]], ["The inner color of each dot represents the average of the three ranks given by each class of the judges (obtained from Fig 5B) , whereas the outer color represents the minimum (best) of the three ranks.", [["inner", "OBSERVATION_MODIFIER", 4, 9], ["color", "OBSERVATION_MODIFIER", 10, 15]]], ["The congested regions in the center of the left hexagonal plots are shown in greater detail on the right.", [["congested", "OBSERVATION", 4, 13], ["center", "ANATOMY_MODIFIER", 29, 35], ["left", "ANATOMY_MODIFIER", 43, 47], ["hexagonal", "ANATOMY_MODIFIER", 48, 57], ["plots", "OBSERVATION", 58, 63], ["greater", "OBSERVATION_MODIFIER", 77, 84], ["right", "ANATOMY_MODIFIER", 99, 104]]], ["Results for all tissues and classification schemes are shown in S13 Information. most of the genes and is amplified on the right-hand plot.", [["tissues", "ANATOMY", 16, 23], ["right-hand", "ANATOMY", 123, 133], ["tissues", "TISSUE", 16, 23], ["right", "ANATOMY_MODIFIER", 123, 128], ["hand", "ANATOMY", 129, 133]]], ["For example, genes in the center such as CXCL11, CCL8, CXCL10, and MxA have approximately the same blue color for the inner and outer circles, showing that these genes are important to all three classes and the level of importance to each class is the same.", [["inner", "ANATOMY", 118, 123], ["CXCL11", "GENE_OR_GENE_PRODUCT", 41, 47], ["CCL8", "GENE_OR_GENE_PRODUCT", 49, 53], ["CXCL10", "GENE_OR_GENE_PRODUCT", 55, 61], ["MxA", "GENE_OR_GENE_PRODUCT", 67, 70], ["inner", "TISSUE", 118, 123], ["CXCL11", "PROTEIN", 41, 47], ["CCL8", "PROTEIN", 49, 53], ["CXCL10", "PROTEIN", 55, 61], ["MxA", "PROTEIN", 67, 70], ["CXCL11", "TEST", 41, 47], ["CCL8", "TEST", 49, 53], ["CXCL10", "TEST", 55, 61], ["MxA", "TEST", 67, 70], ["CXCL11", "ANATOMY_MODIFIER", 41, 47], ["inner", "ANATOMY_MODIFIER", 118, 123]]], ["On the other hand, CCL24 has moderate importance when the decision of all the judges are combined, but it has a relatively high importance to CVbased judges.", [["CCL24", "CHEMICAL", 19, 24], ["CCL24", "GENE_OR_GENE_PRODUCT", 19, 24], ["CCL24", "PROTEIN", 19, 24], ["moderate", "OBSERVATION_MODIFIER", 29, 37]]], ["This suggests that CCL24 is one of the genes with the highest amount of change relative to the mean value.", [["CCL24", "GENE_OR_GENE_PRODUCT", 19, 24], ["CCL24", "DNA", 19, 24], ["CCL24", "TEST", 19, 24], ["highest", "OBSERVATION_MODIFIER", 54, 61], ["amount", "OBSERVATION_MODIFIER", 62, 68]]], ["Note that if a gene is only important to CV-based judges, then it is likely to be biologically relevant only if high relative changes are the trigger for downstream effect.", [["high relative changes", "PROBLEM", 112, 133], ["downstream effect", "PROBLEM", 154, 171]]], ["Such a gene would be ignored if only UV-or MC-based methods were used.The choice of top classifier PCs varies between the judgesGene rankings are more statistically significant in the MLN datasetThe choice of top classifier PCs varies between the judgesWe study the statistical significance of the gene contributions by running a paired t-test for every two rows (genes) of the 88\u00d712 table to evaluate the null hypothesis that the two genes have equal contribution against the alternative hypothesis that one gene contributes significantly higher than the other one.", [["88\u00d712 table", "DNA", 378, 389], ["UV", "TREATMENT", 37, 39], ["MC-based methods", "TREATMENT", 43, 59], ["a paired t-test", "TEST", 328, 343], ["the null hypothesis", "PROBLEM", 402, 421], ["MLN", "ANATOMY", 184, 187], ["significantly", "OBSERVATION_MODIFIER", 526, 539], ["higher", "OBSERVATION_MODIFIER", 540, 546]]], ["If the p-value of the test takes sufficiently small values, it shows that one of the genes has a significantly higher contribution (Fig 7) .", [["the test", "TEST", 18, 26], ["significantly", "OBSERVATION_MODIFIER", 97, 110], ["higher", "OBSERVATION_MODIFIER", 111, 117]]], ["Using linkage analysis (dendrograms), we identified clusters of genes that are statistically ranked higher than other succeeding gene clusters (\u03b1 = 0.05).", [["linkage analysis", "TEST", 6, 22]]], ["For example in Fig 7A, the highest contributing group of genes consists of MxA, OAS2, OAS1, and CCL8.", [["MxA", "GENE_OR_GENE_PRODUCT", 75, 78], ["OAS2", "GENE_OR_GENE_PRODUCT", 80, 84], ["OAS1", "GENE_OR_GENE_PRODUCT", 86, 90], ["CCL8", "GENE_OR_GENE_PRODUCT", 96, 100], ["MxA", "PROTEIN", 75, 78], ["OAS2", "PROTEIN", 80, 84], ["OAS1", "PROTEIN", 86, 90], ["CCL8", "PROTEIN", 96, 100], ["MxA", "TEST", 75, 78], ["OAS2", "TEST", 80, 84], ["OAS1", "TEST", 86, 90], ["CCL8", "TEST", 96, 100]]], ["In this group, the sharpest statistical difference is between MxA and OAS1 with a p-value of 0.55, suggesting that none of the genes in this group are significantly more contributing than others.", [["MxA", "GENE_OR_GENE_PRODUCT", 62, 65], ["OAS1", "GENE_OR_GENE_PRODUCT", 70, 74], ["MxA", "PROTEIN", 62, 65], ["OAS1", "PROTEIN", 70, 74], ["MxA", "TEST", 62, 65], ["a p-value", "TEST", 80, 89]]], ["Similarly, in the second top contributing gene cluster, the lowest p-value, 0.23, belongs to the paired t-test between CXCL11 and IRF7, meaning that the genes in this group are also not statistically significantly different.", [["CXCL11", "GENE_OR_GENE_PRODUCT", 119, 125], ["IRF7", "GENE_OR_GENE_PRODUCT", 130, 134], ["top contributing gene cluster", "DNA", 25, 54], ["CXCL11", "PROTEIN", 119, 125], ["IRF7", "PROTEIN", 130, 134], ["the lowest p-value", "TEST", 56, 74], ["CXCL11", "TEST", 119, 125], ["IRF7", "TEST", 130, 134], ["gene cluster", "OBSERVATION", 42, 54]]], ["Instead, when we compare these two top gene clusters, we obtain a p-value of 0.012, meaning that the first gene cluster is significantly more contributing than the second gene cluster.", [["top gene clusters", "DNA", 35, 52], ["first gene cluster", "DNA", 101, 119], ["second gene cluster", "DNA", 164, 183], ["a p-value", "TEST", 64, 73]]], ["For both classification schemes, the diagonal dark region for the MLN dataset is narrower than the other panels and the transition from the dark color to the light copper color is the sharpest.", [["copper", "CHEMICAL", 164, 170], ["copper", "CHEMICAL", 164, 170], ["diagonal dark region", "DNA", 37, 57], ["the MLN dataset", "TEST", 62, 77], ["the other panels", "TEST", 95, 111], ["diagonal", "ANATOMY_MODIFIER", 37, 45], ["MLN", "ANATOMY", 66, 69], ["narrower", "OBSERVATION_MODIFIER", 81, 89], ["dark color", "OBSERVATION", 140, 150]]], ["In agreement with our previous observations (compare Fig 5A-5C ), this suggests that the gene rankings in the MLN dataset are more statistically significant than in the other two datasets.", [["MLN", "ANATOMY", 110, 113]]], ["We note that p-values of paired t-tests between consecutive single genes did not take sufficiently small values to show statistically significant difference among them.", [["p-values", "TEST", 13, 21], ["paired t-tests", "TEST", 25, 39]]], ["Instead, we were able to identify gene clusters that were statistically different compared to each other. mRNA measurements from more animals could lead to lower p-values, smaller gene clusters and more statistically significant gene rankings.", [["mRNA", "RNA", 106, 110], ["mRNA measurements", "TEST", 106, 123], ["lower p-values", "PROBLEM", 156, 170], ["smaller gene clusters", "PROBLEM", 172, 193], ["smaller", "OBSERVATION_MODIFIER", 172, 179], ["gene clusters", "OBSERVATION", 180, 193], ["significant", "OBSERVATION_MODIFIER", 217, 228], ["gene rankings", "OBSERVATION", 229, 242]]], ["High resolution images of the panels of Fig 7 are shown in S14 Information.Polar plots provide a complete picture of the genes in the datasetsIn the loading plots, we assign a vector to each gene from the origin to its location and study the correlation between genes using the cosine of the angle between their vectors, resulting in a matrix of size 88\u00d788 (loading plots in S3 Information).", [["Polar plots", "TEST", 75, 86], ["the cosine of the angle between their vectors", "TREATMENT", 274, 319], ["a matrix of size", "TEST", 334, 350], ["angle", "ANATOMY_MODIFIER", 292, 297], ["size", "OBSERVATION_MODIFIER", 346, 350]]], ["This is possible because the columns of the score matrix are orthonormal and the top two classifier PCs provide an accurate and robust classification of the observations, and hence sufficiently approximate the dataset [28] .", [["matrix", "CELLULAR_COMPONENT", 50, 56]]], ["The angular correlation coefficients obtained this way do not necessarily match the pairwise correlation coefficients calculated using mRNA measurements in the dataset.", [["The angular correlation coefficients", "TEST", 0, 36], ["mRNA measurements", "TEST", 135, 152], ["angular", "OBSERVATION_MODIFIER", 4, 11]]], ["The average of 12 correlation coefficient matrices (one for each judge) for a given dataset and a classification scheme is shown in Fig 8, where each row or column shows the correlation coefficients between a specific gene and other genes.", [["a classification scheme", "TEST", 96, 119]]], ["The mean of these values is calculated for each gene and shown in the bar chart on the right hand side of each correlation matrix.", [["right hand", "ANATOMY", 87, 97], ["matrix", "CELLULAR_COMPONENT", 123, 129], ["these values", "TEST", 12, 24], ["right", "ANATOMY_MODIFIER", 87, 92]]], ["Smaller values of the mean for a gene imply higher degrees of agreement between judges on the correlation of that gene with other genes.", [["Smaller values", "PROBLEM", 0, 14], ["higher degrees", "OBSERVATION_MODIFIER", 44, 58]]], ["For example in Fig 8A, the judges have the lowest degree of consensus about the correlation of IL11 with other genes.", [["IL11", "GENE_OR_GENE_PRODUCT", 95, 99], ["IL11", "PROTEIN", 95, 99], ["lowest degree", "OBSERVATION_MODIFIER", 43, 56]]], ["For both classification schemes, the judges have a high degree of agreement on the gene correlations in the spleen dataset (Fig 8A and Fig 8D) .", [["spleen", "ANATOMY", 108, 114], ["spleen", "ORGAN", 108, 114], ["high degree", "OBSERVATION_MODIFIER", 51, 62], ["spleen", "ANATOMY", 108, 114]]], ["This is followed by the MLN and PBMC datasets, respectively.", [["MLN", "ANATOMY", 24, 27], ["PBMC", "CELL", 32, 36], ["MLN", "CELL_TYPE", 24, 27], ["PBMC", "CELL_TYPE", 32, 36], ["MLN", "ANATOMY", 24, 27]]], ["Using linkage analysis (dendrograms), we identified 20 clusters comprising genes with approximately similar correlation patterns in the dataset.", [["linkage analysis", "TEST", 6, 22]]], ["Interestingly, interferon-stimulated genes (MxA, OAS1, OAS2) always appear in the same group and in close proximity to type I interferon genes (IFN\u03b11 and IFN\u03b2), suggesting correlated behavior during acute SIV infection.", [["SIV infection", "DISEASE", 205, 218], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 15, 42], ["MxA", "GENE_OR_GENE_PRODUCT", 44, 47], ["OAS1", "GENE_OR_GENE_PRODUCT", 49, 53], ["OAS2", "GENE_OR_GENE_PRODUCT", 55, 59], ["type I interferon", "GENE_OR_GENE_PRODUCT", 119, 136], ["IFN\u03b11", "GENE_OR_GENE_PRODUCT", 144, 149], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 154, 158], ["SIV", "ORGANISM", 205, 208], ["interferon-stimulated genes", "DNA", 15, 42], ["MxA", "DNA", 44, 47], ["OAS1", "DNA", 49, 53], ["OAS2", "DNA", 55, 59], ["type I interferon genes", "DNA", 119, 142], ["IFN\u03b11", "DNA", 144, 149], ["IFN\u03b2", "DNA", 154, 158], ["SIV", "SPECIES", 205, 208], ["interferon", "TREATMENT", 15, 25], ["acute SIV infection", "PROBLEM", 199, 218], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["SIV infection", "OBSERVATION", 205, 218]]], ["High resolution images of the panels of Fig 8 are shown in S15 Information.Polar plots provide a complete picture of the genes in the datasetsTo visualize the relative position of each gene compared to the other genes, we next perform PCA on the average correlation coefficient matrix and construct the loading plot using the first two PCs scaled by the square root of their eigenvalues (S16 Information).", [["S15", "GENE_OR_GENE_PRODUCT", 59, 62], ["matrix", "CELLULAR_COMPONENT", 278, 284], ["S15", "PROTEIN", 59, 62], ["Polar plots", "TEST", 75, 86], ["the loading plot", "TEST", 299, 315], ["position", "OBSERVATION_MODIFIER", 168, 176]]], ["Since the first two PCs capture more than 70% of the variance, they can create a plane that closely approximates the matrix, and hence the cosine of the angle between any two genes is approximately equal to the corresponding correlation coefficient in the matrix [28] .", [["matrix", "CELLULAR_COMPONENT", 117, 123], ["matrix", "CELLULAR_COMPONENT", 256, 262], ["angle", "OBSERVATION_MODIFIER", 153, 158]]], ["To validate this assumption, we calculated the angular correlation coefficients matrices from these plots, which provide a good approximation of the average correlation coefficient matrices with differences between some genes (compare Fig 8 and the figure in S17 Information) .", [["these plots", "TEST", 94, 105]]], ["We measured the confidence on the angular position of a gene relative to others by calculating the mean-square-difference (MSD) between rows of the average correlation coefficient matrices in Fig 8 and their corresponding matrices in S17 Information.", [["angular", "OBSERVATION_MODIFIER", 34, 41]]], ["If the MSD of a gene takes small values, it suggests there is high confidence on the angular position of that gene in the loading plot.Polar plots provide a complete picture of the genes in the datasetsPolar plots summarize correlation information, MSD values and gene rankings in one place (Fig 9) .", [["Polar plots", "TEST", 135, 146], ["Polar plots", "TEST", 202, 213], ["MSD values", "TEST", 249, 259], ["high", "OBSERVATION_MODIFIER", 62, 66], ["angular", "OBSERVATION_MODIFIER", 85, 92], ["loading plot", "OBSERVATION", 122, 134]]], ["The distance from the origin indicates the overall contribution of the genes in the dataset, obtained from Fig 5 and the figure in S4 Information.", [["distance", "OBSERVATION_MODIFIER", 4, 12], ["origin", "ANATOMY_MODIFIER", 22, 28], ["overall", "OBSERVATION_MODIFIER", 43, 50]]], ["The angular position of genes is extracted from the loading plots constructed by the first two eigenvectors of the average correlation coefficient matrices (S16 Information).", [["angular", "OBSERVATION_MODIFIER", 4, 11], ["position", "OBSERVATION_MODIFIER", 12, 20], ["genes", "OBSERVATION_MODIFIER", 24, 29], ["loading plots", "OBSERVATION", 52, 65]]], ["The radial grid lines define the clusters obtained in Fig 7, each of which contains genes that are significantly more contributing than the genes in the lower neighboring cluster.", [["radial grid lines", "ANATOMY", 4, 21], ["radial grid lines", "CELL", 4, 21], ["radial grid lines", "CELL_LINE", 4, 21], ["The radial grid lines", "TREATMENT", 0, 21], ["radial", "ANATOMY_MODIFIER", 4, 10], ["grid lines", "OBSERVATION", 11, 21], ["clusters", "OBSERVATION_MODIFIER", 33, 41], ["genes", "OBSERVATION", 84, 89], ["significantly", "OBSERVATION_MODIFIER", 99, 112], ["lower", "ANATOMY_MODIFIER", 153, 158]]], ["We plotted the expression profiles of representative genes from these clusters, showing the dynamic mRNA expression profiles as we move around the plot.", [["the dynamic mRNA expression profiles", "PROBLEM", 88, 124]]], ["Finally, the radius of each dot is linearly inversely proportional to the square root of MSD (rMSD), i.e. there is more confidence on the angular position of larger dots.", [["larger dots", "PROBLEM", 158, 169], ["radius", "ANATOMY_MODIFIER", 13, 19], ["linearly", "OBSERVATION_MODIFIER", 35, 43], ["inversely", "OBSERVATION_MODIFIER", 44, 53], ["proportional", "OBSERVATION_MODIFIER", 54, 66], ["square", "OBSERVATION_MODIFIER", 74, 80], ["root", "OBSERVATION_MODIFIER", 81, 85], ["MSD", "OBSERVATION_MODIFIER", 89, 92], ["more", "OBSERVATION_MODIFIER", 115, 119], ["angular", "OBSERVATION_MODIFIER", 138, 145], ["position", "OBSERVATION_MODIFIER", 146, 154], ["larger", "OBSERVATION_MODIFIER", 158, 164], ["dots", "OBSERVATION_MODIFIER", 165, 169]]], ["We generally observe that the dots in the spleen dataset for classification based on time since infection have a larger size compared to other cases.", [["spleen", "ANATOMY", 42, 48], ["infection", "DISEASE", 96, 105], ["spleen", "ORGAN", 42, 48], ["infection", "PROBLEM", 96, 105], ["spleen", "ANATOMY", 42, 48], ["infection", "OBSERVATION", 96, 105], ["larger", "OBSERVATION_MODIFIER", 113, 119], ["size", "OBSERVATION_MODIFIER", 120, 124]]], ["This is because the first and second PCs capture more than 96% of the variance in the average correlation coefficient matrix (panel A in S16 Information).", [["second PCs capture", "TEST", 30, 48], ["the variance", "TEST", 66, 78]]], ["For example, we observe that in the Spleen, MLN, and PBMC datasets, CCL8, MxA, CXCL10, CXCL11, OAS2 and OAS1 are located close to the perimeter in the top two clusters, meaning that they are all top contributing genes and their contribution is statistically significantly higher than that of other genes; they are clearly grouped in the same angular direction, suggesting strong correlations exist among them; they are all represented by large dots, implying high confidence on their locations relative to the other genes; Correlations among genes simplified on a polar plot, illustrating MSD values and the ranking information.", [["Spleen", "ANATOMY", 36, 42], ["MLN", "ANATOMY", 44, 47], ["MLN", "GENE_OR_GENE_PRODUCT", 44, 47], ["PBMC", "CELL", 53, 57], ["CCL8", "GENE_OR_GENE_PRODUCT", 68, 72], ["MxA", "GENE_OR_GENE_PRODUCT", 74, 77], ["CXCL10", "GENE_OR_GENE_PRODUCT", 79, 85], ["CXCL11", "GENE_OR_GENE_PRODUCT", 87, 93], ["OAS2", "GENE_OR_GENE_PRODUCT", 95, 99], ["OAS1", "GENE_OR_GENE_PRODUCT", 104, 108], ["PBMC", "CELL_TYPE", 53, 57], ["CCL8", "PROTEIN", 68, 72], ["MxA", "PROTEIN", 74, 77], ["CXCL10", "PROTEIN", 79, 85], ["CXCL11", "PROTEIN", 87, 93], ["OAS2", "PROTEIN", 95, 99], ["OAS1", "PROTEIN", 104, 108], ["MLN", "TEST", 44, 47], ["PBMC datasets", "TEST", 53, 66], ["CCL8", "TEST", 68, 72], ["MxA", "TEST", 74, 77], ["CXCL10", "TEST", 79, 85], ["CXCL11", "TEST", 87, 93], ["OAS2", "TEST", 95, 99], ["a polar plot", "TEST", 562, 574], ["Spleen", "ANATOMY", 36, 42], ["MLN", "ANATOMY", 44, 47], ["PBMC datasets", "OBSERVATION", 53, 66], ["significantly", "OBSERVATION_MODIFIER", 258, 271], ["higher", "OBSERVATION_MODIFIER", 272, 278], ["large", "OBSERVATION_MODIFIER", 438, 443]]], ["The distance from the origin indicates the overall contribution of the genes in the dataset, obtained from Fig 5 and the figure in S4 Information.", [["distance", "OBSERVATION_MODIFIER", 4, 12], ["origin", "ANATOMY_MODIFIER", 22, 28], ["overall", "OBSERVATION_MODIFIER", 43, 50]]], ["Therefore the high-ranking genes are located close to the perimeter while low ranking genes are located at the center.", [["low ranking genes", "DNA", 74, 91], ["high", "OBSERVATION_MODIFIER", 14, 18]]], ["The radial grid lines define the cluster of genes that consist of significantly more (less) contributing genes than their lower (upper) neighboring clusters.", [["radial grid lines", "ANATOMY", 4, 21], ["radial grid lines", "CELL", 4, 21], ["radial grid lines", "CELL_LINE", 4, 21], ["The radial grid lines", "TREATMENT", 0, 21], ["radial", "ANATOMY_MODIFIER", 4, 10], ["grid lines", "OBSERVATION", 11, 21], ["cluster", "OBSERVATION_MODIFIER", 33, 40], ["significantly", "OBSERVATION_MODIFIER", 66, 79], ["upper", "ANATOMY_MODIFIER", 129, 134]]], ["These clusters are the dark and light blue clusters shown in Fig 7.", [["dark", "OBSERVATION_MODIFIER", 23, 27]]], ["The angular position of genes is extracted from the loading plots constructed by the first two eigenvectors of the average correlation coefficient matrix (S16 Information).", [["angular", "OBSERVATION_MODIFIER", 4, 11], ["position", "OBSERVATION_MODIFIER", 12, 20], ["genes", "OBSERVATION_MODIFIER", 24, 29], ["loading plots", "OBSERVATION", 52, 65]]], ["To make the comparisons easier, the clouds of genes are rotated such that CCL8, the top contributing gene, is located at zero degrees.", [["CCL8", "GENE_OR_GENE_PRODUCT", 74, 78], ["CCL8", "DNA", 74, 78], ["top contributing gene", "DNA", 84, 105], ["CCL8", "TREATMENT", 74, 78]]], ["The genes are color-and they are upregulated during the first days of SIV infection and their expression goes down after 4 days p.i.Polar plots provide a complete picture of the genes in the datasetsNote that we could not directly combine the information on the angular position of genes in the loading plots provided by the judges.", [["infection", "DISEASE", 74, 83], ["SIV", "ORGANISM", 70, 73], ["SIV", "SPECIES", 70, 73], ["SIV infection", "PROBLEM", 70, 83], ["color", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 74, 83]]], ["This is because if a PC is multiplied by -1, the new vector is still a principal component; however, all the relative positions of genes change in the loading plot.", [["PC", "CANCER", 21, 23], ["a PC", "TEST", 19, 23], ["genes change", "PROBLEM", 131, 143], ["the loading plot", "TEST", 147, 163], ["principal", "OBSERVATION_MODIFIER", 71, 80], ["component", "OBSERVATION_MODIFIER", 81, 90], ["genes change", "OBSERVATION", 131, 143], ["loading plot", "OBSERVATION", 151, 163]]], ["To avoid this problem, we converted the information on the angular position of genes to the correlation coefficients for each judge, took the average of the correlation coefficient matrices and converted it back using PCA to visualize positions of genes relative to each other.", [["this problem", "PROBLEM", 9, 21], ["the correlation coefficient matrices", "TREATMENT", 153, 189], ["PCA", "TREATMENT", 218, 221]]], ["A schematic of the algorithm for obtaining polar plots is given in S19 Information.Top contributing genes have approximately equal contributions to all tissuesSince genes contribute differently to each tissue, we measure the relative contribution of each gene to identify tissue-specific genes (see S6 Method).", [["tissues", "ANATOMY", 152, 159], ["tissue", "ANATOMY", 202, 208], ["tissue", "ANATOMY", 272, 278], ["tissues", "TISSUE", 152, 159], ["tissue", "TISSUE", 202, 208], ["tissue", "TISSUE", 272, 278], ["tissue-specific genes", "DNA", 272, 293], ["polar plots", "TREATMENT", 43, 54], ["all tissues", "OBSERVATION_MODIFIER", 148, 159]]], ["The results are shown in hexagonal plots (Fig 10) , where genes in the center contribute equally to all tissues.", [["tissues", "ANATOMY", 104, 111], ["tissues", "TISSUE", 104, 111], ["all tissues", "ANATOMY", 100, 111]]], ["The proximity of a gene to a vertex indicates that the gene contributes more to the tissue(s) noted at that vertex than to other tissues.", [["tissue", "ANATOMY", 84, 90], ["tissues", "ANATOMY", 129, 136], ["tissue", "TISSUE", 84, 90], ["tissues", "TISSUE", 129, 136]]], ["The inner color of each dot represents the average contribution of the gene, whereas the outer color represents the highest contribution (lowest rank) of that gene.", [["inner", "OBSERVATION_MODIFIER", 4, 9], ["color", "OBSERVATION_MODIFIER", 10, 15], ["average", "OBSERVATION_MODIFIER", 43, 50], ["highest contribution", "OBSERVATION", 116, 136]]], ["The common genes are seen close to the center of the hexagon, while the tissue-specific genes are located close to the vertices and near the edges.", [["tissue", "ANATOMY", 72, 78], ["tissue", "TISSUE", 72, 78], ["hexagon", "DNA", 53, 60], ["tissue-specific genes", "DNA", 72, 93], ["common genes", "ANATOMY", 4, 16], ["hexagon", "OBSERVATION_MODIFIER", 53, 60], ["specific genes", "OBSERVATION", 79, 93], ["vertices", "ANATOMY_MODIFIER", 119, 127], ["edges", "OBSERVATION_MODIFIER", 141, 146]]], ["The congested region in the center of the hexagon houses most of the genes.", [["hexagon", "DNA", 42, 49], ["The congested region", "PROBLEM", 0, 20], ["congested", "OBSERVATION", 4, 13], ["region", "OBSERVATION_MODIFIER", 14, 20], ["hexagon", "ANATOMY_MODIFIER", 42, 49]]], ["To see this region more clearly, it is amplified on the right-hand plot.", [["right-hand", "ANATOMY", 56, 66], ["right", "ANATOMY_MODIFIER", 56, 61]]], ["For both classification schemes, we observe the top contributing genes such as CCL8, MxA, CXCL10, CXCL11, OAS2, and OAS1 lie in the center of the plot with approximately the same blue color for the inner and outer circles, indicating their equal contribution to all tissues (Fig 10) .", [["inner", "ANATOMY", 198, 203], ["tissues", "ANATOMY", 266, 273], ["CCL8", "GENE_OR_GENE_PRODUCT", 79, 83], ["MxA", "GENE_OR_GENE_PRODUCT", 85, 88], ["CXCL10", "GENE_OR_GENE_PRODUCT", 90, 96], ["CXCL11", "GENE_OR_GENE_PRODUCT", 98, 104], ["OAS2", "GENE_OR_GENE_PRODUCT", 106, 110], ["OAS1", "GENE_OR_GENE_PRODUCT", 116, 120], ["inner", "TISSUE", 198, 203], ["tissues", "TISSUE", 266, 273], ["CCL8", "DNA", 79, 83], ["MxA", "DNA", 85, 88], ["CXCL10", "DNA", 90, 96], ["CXCL11", "DNA", 98, 104], ["OAS2", "DNA", 106, 110], ["OAS1", "DNA", 116, 120], ["CCL8", "TEST", 79, 83], ["MxA", "TEST", 85, 88], ["CXCL10", "TEST", 90, 96], ["CXCL11", "TEST", 98, 104], ["OAS2", "TEST", 106, 110], ["inner", "ANATOMY_MODIFIER", 198, 203], ["outer circles", "ANATOMY", 208, 221], ["equal contribution", "OBSERVATION", 240, 258]]], ["This suggests that type I interferon responses are quite similar in the three compartments and that these genes could be used as biomarkers to be measured in PBMCs instead of spleen and MLNs during acute SIV infection.", [["PBMCs", "ANATOMY", 158, 163], ["spleen", "ANATOMY", 175, 181], ["MLNs", "ANATOMY", 186, 190], ["SIV infection", "DISEASE", 204, 217], ["type I interferon", "GENE_OR_GENE_PRODUCT", 19, 36], ["PBMCs", "CELL", 158, 163], ["spleen", "ORGAN", 175, 181], ["MLNs", "MULTI-TISSUE_STRUCTURE", 186, 190], ["SIV", "ORGANISM", 204, 207], ["PBMCs", "CELL_TYPE", 158, 163], ["MLNs", "CELL_TYPE", 186, 190], ["SIV", "SPECIES", 204, 207], ["type I interferon responses", "PROBLEM", 19, 46], ["spleen", "PROBLEM", 175, 181], ["MLNs", "PROBLEM", 186, 190], ["acute SIV infection", "PROBLEM", 198, 217], ["spleen", "ANATOMY", 175, 181], ["MLNs", "ANATOMY", 186, 190], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["SIV infection", "OBSERVATION", 204, 217]]], ["This can be tested by classifying the observations using the mRNA measurements of these genes in PBMCs and by evaluating whether that classification is as accurate as the classifications using measurements in spleen or MLN.", [["PBMCs", "ANATOMY", 97, 102], ["spleen", "ANATOMY", 209, 215], ["MLN", "ANATOMY", 219, 222], ["PBMCs", "CELL", 97, 102], ["spleen", "ORGAN", 209, 215], ["MLN", "MULTI-TISSUE_STRUCTURE", 219, 222], ["PBMCs", "CELL_TYPE", 97, 102], ["MLN", "CELL_TYPE", 219, 222], ["the mRNA measurements", "TEST", 57, 78], ["spleen", "ANATOMY", 209, 215], ["MLN", "ANATOMY", 219, 222]]], ["To this end, we built decision trees using the top seven highly contributing genes and chose the subtrees with the lowest cross validation error rates in all tissues and for both classification schemes (S4 Table) .", [["tissues", "ANATOMY", 158, 165], ["tissues", "TISSUE", 158, 165]]], ["For time since infection and SIV RNA in plasma, the classification rates in the PBMC dataset are 87.5% and 83.3%, greater than or equal to the classification rates in spleen and MLN.", [["plasma", "ANATOMY", 40, 46], ["PBMC", "ANATOMY", 80, 84], ["spleen", "ANATOMY", 167, 173], ["MLN", "ANATOMY", 178, 181], ["infection", "DISEASE", 15, 24], ["SIV", "ORGANISM", 29, 32], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["PBMC", "CELL", 80, 84], ["spleen", "ORGAN", 167, 173], ["MLN", "MULTI-TISSUE_STRUCTURE", 178, 181], ["SIV RNA", "RNA", 29, 36], ["PBMC", "CELL_TYPE", 80, 84], ["MLN", "CELL_TYPE", 178, 181], ["SIV", "SPECIES", 29, 32], ["infection", "PROBLEM", 15, 24], ["SIV RNA in plasma", "PROBLEM", 29, 46], ["the classification rates", "TEST", 48, 72], ["the PBMC dataset", "TEST", 76, 92], ["infection", "OBSERVATION", 15, 24], ["SIV RNA", "OBSERVATION", 29, 36], ["PBMC", "ANATOMY", 80, 84], ["spleen", "ANATOMY", 167, 173], ["MLN", "ANATOMY", 178, 181]]], ["This suggests that an analysis of gene expression in the more accessible PBMC can be used as a surrogate to understand the immunological events happening in the less accessible spleen and lymph nodes during acute SIV infection.", [["PBMC", "ANATOMY", 73, 77], ["spleen", "ANATOMY", 177, 183], ["lymph nodes", "ANATOMY", 188, 199], ["SIV infection", "DISEASE", 213, 226], ["PBMC", "CELL", 73, 77], ["spleen", "ORGAN", 177, 183], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 188, 199], ["SIV", "ORGANISM", 213, 216], ["PBMC", "CELL_TYPE", 73, 77], ["SIV", "SPECIES", 213, 216], ["an analysis", "TEST", 19, 30], ["gene expression", "PROBLEM", 34, 49], ["the immunological events", "PROBLEM", 119, 143], ["lymph nodes", "PROBLEM", 188, 199], ["acute SIV infection", "PROBLEM", 207, 226], ["gene expression", "OBSERVATION", 34, 49], ["spleen", "ANATOMY", 177, 183], ["lymph nodes", "OBSERVATION", 188, 199], ["acute", "OBSERVATION_MODIFIER", 207, 212], ["SIV infection", "OBSERVATION", 213, 226]]], ["However, each tissue has unique expression profiles, e.g. XCL1, a relatively high-contributing gene, contributes highly to spleen and MLN compared to PBMC, and hence analysis of selected top contributing tissuespecific genes could greatly inform about the mechanisms related to SIV infection in those tissues.Discussion and ConclusionsAcute HIV infection is characterized by an exponential increase in plasma viremia with subsequent viral dissemination to lymphoid and non-lymphoid organs.", [["tissue", "ANATOMY", 14, 20], ["spleen", "ANATOMY", 123, 129], ["MLN", "ANATOMY", 134, 137], ["PBMC", "ANATOMY", 150, 154], ["tissues", "ANATOMY", 301, 308], ["plasma", "ANATOMY", 402, 408], ["lymphoid", "ANATOMY", 456, 464], ["non-lymphoid organs", "ANATOMY", 469, 488], ["SIV infection", "DISEASE", 278, 291], ["HIV infection", "DISEASE", 341, 354], ["viremia", "DISEASE", 409, 416], ["tissue", "TISSUE", 14, 20], ["XCL1", "GENE_OR_GENE_PRODUCT", 58, 62], ["spleen", "ORGAN", 123, 129], ["MLN", "CELL", 134, 137], ["PBMC", "CELL", 150, 154], ["SIV", "ORGANISM", 278, 281], ["tissues", "TISSUE", 301, 308], ["HIV", "ORGANISM", 341, 344], ["plasma", "ORGANISM_SUBSTANCE", 402, 408], ["lymphoid", "CELL", 456, 464], ["non-lymphoid organs", "TISSUE", 469, 488], ["XCL1", "PROTEIN", 58, 62], ["MLN", "CELL_TYPE", 134, 137], ["PBMC", "CELL_TYPE", 150, 154], ["tissuespecific genes", "DNA", 204, 224], ["SIV", "SPECIES", 278, 281], ["HIV", "SPECIES", 341, 344], ["unique expression profiles", "PROBLEM", 25, 51], ["XCL1", "TEST", 58, 62], ["PBMC", "TEST", 150, 154], ["SIV infection in those tissues", "PROBLEM", 278, 308], ["Acute HIV infection", "PROBLEM", 335, 354], ["an exponential increase in plasma viremia", "PROBLEM", 375, 416], ["subsequent viral dissemination to lymphoid and non-lymphoid organs", "PROBLEM", 422, 488], ["expression profiles", "OBSERVATION", 32, 51], ["spleen", "ANATOMY", 123, 129], ["MLN", "ANATOMY", 134, 137], ["SIV", "OBSERVATION_MODIFIER", 278, 281], ["infection", "OBSERVATION", 282, 291], ["Acute", "OBSERVATION_MODIFIER", 335, 340], ["HIV", "OBSERVATION", 341, 344], ["exponential", "OBSERVATION_MODIFIER", 378, 389], ["increase", "OBSERVATION_MODIFIER", 390, 398], ["plasma viremia", "OBSERVATION", 402, 416], ["viral dissemination", "OBSERVATION", 433, 452], ["lymphoid", "OBSERVATION", 456, 464], ["non-lymphoid organs", "OBSERVATION", 469, 488]]], ["As the innate immune system responds to viral replication, the expression of inflammatory cytokines in the plasma also rapidly increases, leading to a positive feedback where newly-induced activated cells allow for Tissue-specificity of genes: relative contribution of each gene to each tissue.", [["plasma", "ANATOMY", 107, 113], ["cells", "ANATOMY", 199, 204], ["Tissue", "ANATOMY", 215, 221], ["tissue", "ANATOMY", 287, 293], ["plasma", "ORGANISM_SUBSTANCE", 107, 113], ["cells", "CELL", 199, 204], ["Tissue", "TISSUE", 215, 221], ["tissue", "TISSUE", 287, 293], ["inflammatory cytokines", "PROTEIN", 77, 99], ["activated cells", "CELL_TYPE", 189, 204], ["viral replication", "TREATMENT", 40, 57], ["inflammatory cytokines", "PROBLEM", 77, 99], ["the plasma", "TEST", 103, 113], ["a positive feedback", "PROBLEM", 149, 168], ["activated cells", "PROBLEM", 189, 204], ["viral replication", "OBSERVATION", 40, 57], ["inflammatory", "OBSERVATION_MODIFIER", 77, 89]]], ["In each hexagonal plot, three main vertices represent Spleen, MLN, and PBMC.", [["Spleen", "ANATOMY", 54, 60], ["MLN", "ANATOMY", 62, 65], ["PBMC", "ANATOMY", 71, 75], ["Spleen", "MULTI-TISSUE_STRUCTURE", 54, 60], ["MLN", "MULTI-TISSUE_STRUCTURE", 62, 65], ["PBMC", "CELL", 71, 75], ["Spleen, MLN", "CELL_TYPE", 54, 65], ["PBMC", "CELL_TYPE", 71, 75], ["hexagonal plot", "OBSERVATION", 8, 22], ["three", "OBSERVATION_MODIFIER", 24, 29], ["main", "OBSERVATION_MODIFIER", 30, 34], ["vertices", "ANATOMY_MODIFIER", 35, 43], ["Spleen", "ANATOMY", 54, 60], ["MLN", "ANATOMY", 62, 65], ["PBMC", "ANATOMY", 71, 75]]], ["Genes close to one of these vertices show a strong contribution to the corresponding tissue.", [["tissue", "ANATOMY", 85, 91], ["tissue", "TISSUE", 85, 91], ["strong", "OBSERVATION_MODIFIER", 44, 50]]], ["Genes at the center contribute approximately equally to each tissue.", [["tissue", "ANATOMY", 61, 67], ["tissue", "TISSUE", 61, 67]]], ["The inner color of each gene shows its overall rank in all tissues (Fig 5D-5E ), while the outer color represents the minimum of each gene's three ranks in the tissues.", [["tissues", "ANATOMY", 59, 66], ["tissues", "ANATOMY", 160, 167], ["inner color", "MULTI-TISSUE_STRUCTURE", 4, 15], ["tissues", "TISSUE", 59, 66], ["Fig 5D-5E", "CELL", 68, 77], ["tissues", "TISSUE", 160, 167], ["inner", "ANATOMY_MODIFIER", 4, 9], ["overall", "OBSERVATION_MODIFIER", 39, 46], ["rank", "OBSERVATION_MODIFIER", 47, 51], ["all tissues", "ANATOMY", 55, 66], ["tissues", "ANATOMY", 160, 167]]], ["Analysis of Gene Expression in Acute SIV Infection more viral infection.", [["viral infection", "DISEASE", 56, 71], ["SIV", "ORGANISM", 37, 40], ["Gene Expression", "PROBLEM", 12, 27], ["Acute SIV Infection more viral infection", "PROBLEM", 31, 71], ["Gene Expression", "OBSERVATION", 12, 27], ["Acute", "OBSERVATION_MODIFIER", 31, 36], ["SIV Infection", "OBSERVATION", 37, 50], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["infection", "OBSERVATION", 62, 71]]], ["This hypercytokinemia is known as \"cytokine storm\", and it is not unique to HIV [36] .", [["hypercytokinemia", "DISEASE", 5, 21], ["cytokine", "PROTEIN", 35, 43], ["HIV", "SPECIES", 76, 79], ["HIV", "SPECIES", 76, 79], ["This hypercytokinemia", "PROBLEM", 0, 21]]], ["Other pathogens may also cause strong immune responses that lead to tissue damage, organ dysfunction and death.", [["tissue", "ANATOMY", 68, 74], ["organ", "ANATOMY", 83, 88], ["tissue damage", "DISEASE", 68, 81], ["organ dysfunction", "DISEASE", 83, 100], ["death", "DISEASE", 105, 110], ["tissue", "TISSUE", 68, 74], ["organ", "ORGAN", 83, 88], ["Other pathogens", "PROBLEM", 0, 15], ["strong immune responses", "PROBLEM", 31, 54], ["tissue damage", "PROBLEM", 68, 81], ["organ dysfunction", "PROBLEM", 83, 100], ["death", "PROBLEM", 105, 110], ["may also cause", "UNCERTAINTY", 16, 30]]], ["For instance, severe acute lung injury with respiratory failure can be observed after SARS-CoV and influenza infections, and are caused by cytokine storms in the lung alveoli and peripheral blood [36] .", [["lung", "ANATOMY", 27, 31], ["respiratory", "ANATOMY", 44, 55], ["lung alveoli", "ANATOMY", 162, 174], ["peripheral blood", "ANATOMY", 179, 195], ["lung injury", "DISEASE", 27, 38], ["respiratory failure", "DISEASE", 44, 63], ["SARS-CoV", "DISEASE", 86, 94], ["influenza infections", "DISEASE", 99, 119], ["lung", "ORGAN", 27, 31], ["SARS-CoV", "ORGANISM", 86, 94], ["lung alveoli", "MULTI-TISSUE_STRUCTURE", 162, 174], ["peripheral blood", "ORGANISM_SUBSTANCE", 179, 195], ["cytokine", "PROTEIN", 139, 147], ["SARS-CoV", "SPECIES", 86, 94], ["severe acute lung injury", "PROBLEM", 14, 38], ["respiratory failure", "PROBLEM", 44, 63], ["SARS", "PROBLEM", 86, 90], ["CoV", "PROBLEM", 91, 94], ["influenza infections", "PROBLEM", 99, 119], ["cytokine storms in the lung alveoli", "PROBLEM", 139, 174], ["peripheral blood", "TEST", 179, 195], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["lung", "ANATOMY", 27, 31], ["injury", "OBSERVATION", 32, 38], ["respiratory failure", "OBSERVATION", 44, 63], ["influenza infections", "OBSERVATION", 99, 119], ["cytokine storms", "OBSERVATION", 139, 154], ["lung", "ANATOMY", 162, 166], ["alveoli", "ANATOMY_MODIFIER", 167, 174], ["peripheral", "ANATOMY_MODIFIER", 179, 189], ["blood", "ANATOMY", 190, 195]]], ["In HIV infection, this inflammatory response is not fatal but may cause irreparable impairment to the immune system, leading to massive CD4 + T cell depletion and chronic immune activation [1] .", [["immune system", "ANATOMY", 102, 115], ["CD4 + T cell", "ANATOMY", 136, 148], ["HIV infection", "DISEASE", 3, 16], ["HIV", "ORGANISM", 3, 6], ["CD4", "GENE_OR_GENE_PRODUCT", 136, 139], ["CD4", "PROTEIN", 136, 139], ["HIV", "SPECIES", 3, 6], ["HIV", "SPECIES", 3, 6], ["HIV infection", "PROBLEM", 3, 16], ["this inflammatory response", "PROBLEM", 18, 44], ["irreparable impairment to the immune system", "PROBLEM", 72, 115], ["massive CD4 + T cell depletion", "PROBLEM", 128, 158], ["chronic immune activation", "PROBLEM", 163, 188], ["HIV", "OBSERVATION_MODIFIER", 3, 6], ["infection", "OBSERVATION", 7, 16], ["inflammatory", "OBSERVATION_MODIFIER", 23, 35], ["massive", "OBSERVATION_MODIFIER", 128, 135], ["CD4", "OBSERVATION", 136, 139], ["T cell depletion", "OBSERVATION", 142, 158], ["chronic", "OBSERVATION_MODIFIER", 163, 170], ["immune activation", "OBSERVATION", 171, 188]]], ["A similar cytokine storm is observed during acute infection in the brain of SIV-infected macaques [2] , indicating that even immuneprivileged organs are not shielded from the damage that such responses may cause during HIV and SIV infection.", [["brain", "ANATOMY", 67, 72], ["organs", "ANATOMY", 142, 148], ["infection", "DISEASE", 50, 59], ["SIV-infected", "DISEASE", 76, 88], ["HIV and SIV infection", "DISEASE", 219, 240], ["brain", "ORGAN", 67, 72], ["SIV", "ORGANISM", 76, 79], ["macaques", "ORGANISM", 89, 97], ["organs", "ORGAN", 142, 148], ["HIV", "ORGANISM", 219, 222], ["SIV", "ORGANISM", 227, 230], ["cytokine", "PROTEIN", 10, 18], ["SIV-infected macaques", "SPECIES", 76, 97], ["HIV", "SPECIES", 219, 222], ["HIV", "SPECIES", 219, 222], ["SIV", "SPECIES", 227, 230], ["A similar cytokine storm", "PROBLEM", 0, 24], ["acute infection in the brain", "PROBLEM", 44, 72], ["the damage", "PROBLEM", 171, 181], ["HIV and SIV infection", "PROBLEM", 219, 240], ["cytokine storm", "OBSERVATION", 10, 24], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["infection", "OBSERVATION", 50, 59], ["brain", "ANATOMY", 67, 72], ["SIV", "ANATOMY", 76, 79], ["infected macaques", "OBSERVATION", 80, 97], ["SIV infection", "OBSERVATION", 227, 240]]], ["Understanding the pathways and components of these immunological events is essential for the development of therapeutic strategies aimed at reducing their harmful effects.", [["these immunological events", "PROBLEM", 45, 71], ["therapeutic strategies", "TREATMENT", 108, 130]]], ["Similar acute phase studies cannot be performed in HIV-infected patients for several reasons, including lack of precision regarding the exact time of transmission, limited access to organ biopsies, and HIV genotypical diversity [37] .", [["organ", "ANATOMY", 182, 187], ["HIV-infected", "DISEASE", 51, 63], ["HIV", "ORGANISM", 51, 54], ["patients", "ORGANISM", 64, 72], ["organ biopsies", "MULTI-TISSUE_STRUCTURE", 182, 196], ["HIV", "SPECIES", 51, 54], ["patients", "SPECIES", 64, 72], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 202, 205], ["Similar acute phase studies", "TEST", 0, 27], ["organ biopsies", "TEST", 182, 196], ["HIV genotypical diversity", "PROBLEM", 202, 227], ["acute", "OBSERVATION_MODIFIER", 8, 13]]], ["Therefore, SIV macaque models represent a viable and efficient alternative to human studies, despite the biological differences between HIV and SIV [3, 38] .Discussion and ConclusionsIn this study we used an accelerated and consistent macaque model of AIDS and HIV-associated neurocognitive disorders to analyze the expression of immune-related genes in three different lymphoid compartments during acute SIV infection. mRNA levels were quantitated by Nanostring, a novel technology that allows for the measurement of a large number of transcripts without reverse transcription or DNA amplification.", [["lymphoid compartments", "ANATOMY", 370, 391], ["AIDS", "DISEASE", 252, 256], ["neurocognitive disorders", "DISEASE", 276, 300], ["SIV infection", "DISEASE", 405, 418], ["SIV macaque", "ORGANISM", 11, 22], ["human", "ORGANISM", 78, 83], ["HIV", "ORGANISM", 136, 139], ["SIV", "ORGANISM", 144, 147], ["macaque", "ORGANISM", 235, 242], ["HIV", "ORGANISM", 261, 264], ["lymphoid compartments", "MULTI-TISSUE_STRUCTURE", 370, 391], ["SIV", "ORGANISM", 405, 408], ["DNA", "CELLULAR_COMPONENT", 581, 584], ["immune-related genes", "DNA", 330, 350], ["human", "SPECIES", 78, 83], ["HIV", "SPECIES", 136, 139], ["HIV", "SPECIES", 261, 264], ["SIV macaque", "SPECIES", 11, 22], ["human", "SPECIES", 78, 83], ["HIV", "SPECIES", 136, 139], ["SIV", "SPECIES", 144, 147], ["HIV", "SPECIES", 261, 264], ["SIV", "SPECIES", 405, 408], ["human studies", "TEST", 78, 91], ["this study", "TEST", 186, 196], ["AIDS", "PROBLEM", 252, 256], ["HIV", "PROBLEM", 261, 264], ["neurocognitive disorders", "PROBLEM", 276, 300], ["immune-related genes", "PROBLEM", 330, 350], ["acute SIV infection", "PROBLEM", 399, 418], ["mRNA levels", "TEST", 420, 431], ["reverse transcription", "TREATMENT", 556, 577], ["DNA amplification", "TREATMENT", 581, 598], ["SIV macaque", "OBSERVATION", 11, 22], ["three different", "OBSERVATION_MODIFIER", 354, 369], ["lymphoid compartments", "OBSERVATION", 370, 391], ["acute", "OBSERVATION_MODIFIER", 399, 404], ["SIV infection", "OBSERVATION", 405, 418]]], ["Fluorescent bar-coded probes specifically hybridize with mRNAs that are then counted by a powerful scanner.", [["Fluorescent bar-coded probes", "DNA", 0, 28], ["mRNAs", "RNA", 57, 62], ["Fluorescent bar", "TEST", 0, 15]]], ["The technique involves little sample manipulation and generates results faster, presented in a simple spreadsheet format.", [["The technique", "TREATMENT", 0, 13]]], ["The Nanostring panel in this study was designed to understand how immune responses are longitudinally developed in different organs or cells during SIV infection.", [["organs", "ANATOMY", 125, 131], ["cells", "ANATOMY", 135, 140], ["SIV infection", "DISEASE", 148, 161], ["organs", "ORGAN", 125, 131], ["cells", "CELL", 135, 140], ["SIV", "ORGANISM", 148, 151], ["SIV", "SPECIES", 148, 151], ["The Nanostring panel", "TEST", 0, 20], ["this study", "TEST", 24, 34], ["SIV infection", "PROBLEM", 148, 161], ["SIV infection", "OBSERVATION", 148, 161]]], ["The panel includes genes that are commonly analyzed during inflammation and viral infection, and has been used to evaluate the longitudinal level variances in individual cytokines during SIV infection.", [["inflammation", "DISEASE", 59, 71], ["viral infection", "DISEASE", 76, 91], ["SIV infection", "DISEASE", 187, 200], ["SIV", "ORGANISM", 187, 190], ["cytokines", "PROTEIN", 170, 179], ["SIV", "SPECIES", 187, 190], ["The panel", "TEST", 0, 9], ["inflammation", "PROBLEM", 59, 71], ["viral infection", "PROBLEM", 76, 91], ["individual cytokines", "PROBLEM", 159, 179], ["SIV infection", "PROBLEM", 187, 200], ["viral", "OBSERVATION_MODIFIER", 76, 81], ["infection", "OBSERVATION", 82, 91], ["SIV infection", "OBSERVATION", 187, 200]]], ["Thus, the panel gives us insight into the host response to acute infection.Discussion and ConclusionsStudies that attempt to analyze changes of gene expressions over time or only examine bivariate correlations between two genes or a gene and a clinical parameter such as SIV RNA in plasma can result in limited (and often flawed) conclusions.", [["plasma", "ANATOMY", 282, 288], ["infection", "DISEASE", 65, 74], ["SIV", "ORGANISM", 271, 274], ["plasma", "ORGANISM_SUBSTANCE", 282, 288], ["SIV RNA", "RNA", 271, 278], ["SIV", "SPECIES", 271, 274], ["the panel", "TEST", 6, 15], ["acute infection", "PROBLEM", 59, 74], ["gene expressions", "PROBLEM", 144, 160], ["a clinical parameter", "TEST", 242, 262], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["infection", "OBSERVATION", 65, 74]]], ["This can be due to several reasons including lack of prior information on how changes in gene expressions affect the immune response, noisy measurements, and contribution of many genes, each of which has a minor impact but when considered together can create a significant response.", [["noisy measurements", "TEST", 134, 152]]], ["In addition, after animals are infected by SIV, the changes in gene expressions are presumably caused by SIV infection.", [["SIV infection", "DISEASE", 105, 118], ["SIV", "ORGANISM", 43, 46], ["SIV", "ORGANISM", 105, 108], ["SIV", "SPECIES", 43, 46], ["SIV", "SPECIES", 105, 108], ["infected", "PROBLEM", 31, 39], ["the changes in gene expressions", "PROBLEM", 48, 79], ["SIV infection", "PROBLEM", 105, 118], ["infected", "OBSERVATION", 31, 39], ["gene expressions", "OBSERVATION", 63, 79], ["presumably caused", "UNCERTAINTY", 84, 101], ["SIV infection", "OBSERVATION", 105, 118]]], ["One can expect the mRNA measurements, regardless of their biological functions, to be correlated with SIV clinical parameters.", [["SIV", "ORGANISM", 102, 105], ["SIV", "SPECIES", 102, 105], ["the mRNA measurements", "TEST", 15, 36], ["SIV clinical parameters", "TEST", 102, 125]]], ["Therefore, multivariate analysis techniques are more appropriate tools to study a set of genes simultaneously.Discussion and ConclusionsHere, we introduced a novel multiplexed component analysis (MCA) technique to simultaneously analyze mRNA measurements under different assumptions for how the gene expression changes affect the immune response during acute SIV infection.", [["SIV infection", "DISEASE", 359, 372], ["SIV", "ORGANISM", 359, 362], ["SIV", "SPECIES", 359, 362], ["multivariate analysis techniques", "TEST", 11, 43], ["a novel multiplexed component analysis (MCA) technique", "TREATMENT", 156, 210], ["mRNA measurements", "TEST", 237, 254], ["the gene expression changes", "PROBLEM", 291, 318], ["acute SIV infection", "PROBLEM", 353, 372], ["acute", "OBSERVATION_MODIFIER", 353, 358], ["SIV infection", "OBSERVATION", 359, 372]]], ["In this method, mRNA measurements were studied by 12 judges, each of which consists of three successive modules: 1) transformation (Log2 or Orig), 2) preprocessing (MC, UV, or CV) and 3) multivariate analysis (PCA or PLS).", [["mRNA measurements", "TEST", 16, 33], ["preprocessing (MC, UV", "TEST", 150, 171], ["multivariate analysis", "TEST", 187, 208], ["PLS", "TEST", 217, 220]]], ["The preprocessing module aims to emphasize specific features of the dataset, e.g. the MC normalization method emphasizes biological responses in which the immune response is affected by the genes with the highest absolute variations in expression across animals, whereas the CV normalization method puts emphasis on responses in which the relative changes in gene expressions are more important.", [["the CV normalization method", "TEST", 271, 298]]], ["Note that other normalizations, transformations and multivariate techniques could be combined to create more judges; however, the goal in this method is to have unique judges that observe the data from distinct viewpoints and hence the techniques that have similar effects on the data should not be included in the same analysis.Discussion and ConclusionsEach of the twelve judges provides a distinct set of uncorrelated principal components (PCs), capturing the directions in the data with maximum variance.", [["multivariate techniques", "TEST", 52, 75], ["the data", "TEST", 188, 196], ["the techniques", "TEST", 232, 246], ["the data", "TEST", 276, 284]]], ["From each set, we select two PCs that provide the most accurate and robust classification of the data in each of the classification schemes: time since infection and SIV RNA in plasma.", [["plasma", "ANATOMY", 177, 183], ["infection", "DISEASE", 152, 161], ["SIV", "ORGANISM", 166, 169], ["plasma", "ORGANISM_SUBSTANCE", 177, 183], ["SIV RNA", "RNA", 166, 173], ["SIV", "SPECIES", 166, 169], ["infection", "PROBLEM", 152, 161], ["SIV RNA in plasma", "PROBLEM", 166, 183], ["infection", "OBSERVATION", 152, 161], ["SIV RNA", "OBSERVATION", 166, 173]]], ["These selection criteria result in PCs with gene loadings that robustly classify the animals at different stages of the disease.", [["These selection criteria", "TEST", 0, 24], ["gene loadings", "PROBLEM", 44, 57], ["the disease", "PROBLEM", 116, 127], ["disease", "OBSERVATION", 120, 127]]], ["Our hypothesis is that highly loaded genes, which contribute the most to the classification, are those whose levels of expression are most profoundly affected during acute SIV infection and therefore warrant further study.", [["SIV infection", "DISEASE", 172, 185], ["SIV", "ORGANISM", 172, 175], ["SIV", "SPECIES", 172, 175], ["acute SIV infection", "PROBLEM", 166, 185], ["further study", "TEST", 208, 221], ["highly", "OBSERVATION_MODIFIER", 23, 29], ["loaded genes", "OBSERVATION", 30, 42], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["SIV infection", "OBSERVATION", 172, 185]]], ["While the MCA technique does not by itself provide mechanistic insight into how these genes function in the immune system, it provides an impartial platform to compare genes and highlight those with the highest level of contribution during acute SIV infection, globally in the immune system or locally in specific tissues; and it can further be combined with mechanistic information about the immune response dependence on specific gene expression changes.", [["immune system", "ANATOMY", 108, 121], ["immune system", "ANATOMY", 277, 290], ["tissues", "ANATOMY", 314, 321], ["SIV infection", "DISEASE", 246, 259], ["immune system", "ANATOMICAL_SYSTEM", 108, 121], ["SIV", "ORGANISM", 246, 249], ["immune system", "ANATOMICAL_SYSTEM", 277, 290], ["tissues", "TISSUE", 314, 321], ["SIV", "SPECIES", 246, 249], ["acute SIV infection", "PROBLEM", 240, 259], ["the immune response dependence", "PROBLEM", 389, 419], ["specific gene expression changes", "PROBLEM", 423, 455], ["MCA", "ANATOMY", 10, 13], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["SIV infection", "OBSERVATION", 246, 259]]], ["Also, the MCA method can be used in genome-wide studies, where the number of genes is significantly higher.", [["MCA", "DNA", 10, 13], ["the MCA method", "TREATMENT", 6, 20], ["genome-wide studies", "TEST", 36, 55], ["MCA", "ANATOMY", 10, 13], ["significantly", "OBSERVATION_MODIFIER", 86, 99], ["higher", "OBSERVATION_MODIFIER", 100, 106]]], ["The transformation and normalization modules do not change in such applications.", [["The transformation", "PROBLEM", 0, 18], ["normalization modules", "PROBLEM", 23, 44]]], ["Also, the PCA and PLS methods are essentially dimension reduction algorithms and hence can be readily applied to large datasets to identify genes with significant contributions.", [["the PCA", "TREATMENT", 6, 13], ["PLS methods", "TEST", 18, 29], ["essentially dimension reduction algorithms", "TREATMENT", 34, 76], ["PCA", "ANATOMY", 10, 13]]], ["One should note that the sets of significant genes selected by individual judges might be different when the number of genes is high, and hence extra attention should be paid when the gene ranking results from the judges are combined.", [["significant", "OBSERVATION_MODIFIER", 33, 44], ["high", "OBSERVATION_MODIFIER", 128, 132]]], ["This suggests that the specific way that gene expression changes are translated to the immune response matters, and that these genes can hold less or more significance, which in turn generates new hypotheses for future experiments.", [["gene expression changes", "PROBLEM", 41, 64]]], ["The results also demonstrate differential ranking of some genes according to specific lymphoid compartments.", [["lymphoid compartments", "ANATOMY", 86, 107], ["lymphoid compartments", "MULTI-TISSUE_STRUCTURE", 86, 107], ["some genes", "PROBLEM", 53, 63], ["some genes", "OBSERVATION", 53, 63], ["lymphoid compartments", "OBSERVATION", 86, 107]]], ["IFN\u03b11, for instance, is highly ranked in MLN but not in PBMCs or spleen.", [["MLN", "ANATOMY", 41, 44], ["PBMCs", "ANATOMY", 56, 61], ["spleen", "ANATOMY", 65, 71], ["IFN\u03b11", "GENE_OR_GENE_PRODUCT", 0, 5], ["MLN", "CELL", 41, 44], ["PBMCs", "CELL", 56, 61], ["spleen", "ORGAN", 65, 71], ["IFN\u03b11", "PROTEIN", 0, 5], ["MLN", "CELL_TYPE", 41, 44], ["PBMCs", "CELL_TYPE", 56, 61], ["MLN", "ANATOMY", 41, 44], ["spleen", "ANATOMY", 65, 71]]], ["We hypothesize that this is due to the highly abundant population of IFN\u03b1-producing dendritic cells, which are responsible for antigen presentation and T cell activation in lymph nodes [39] .", [["dendritic cells", "ANATOMY", 84, 99], ["T cell", "ANATOMY", 152, 158], ["lymph nodes", "ANATOMY", 173, 184], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 69, 73], ["dendritic cells", "CELL", 84, 99], ["T cell", "CELL", 152, 158], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 173, 184], ["IFN\u03b1-producing dendritic cells", "CELL_TYPE", 69, 99], ["IFN\u03b1", "PROBLEM", 69, 73], ["dendritic cells", "PROBLEM", 84, 99], ["antigen presentation", "PROBLEM", 127, 147], ["T cell activation in lymph nodes", "PROBLEM", 152, 184], ["highly", "OBSERVATION_MODIFIER", 39, 45], ["abundant", "OBSERVATION_MODIFIER", 46, 54], ["population", "OBSERVATION", 55, 65], ["dendritic cells", "OBSERVATION", 84, 99], ["responsible for", "UNCERTAINTY", 111, 126], ["lymph nodes", "OBSERVATION", 173, 184]]], ["Similarly, CD68, a bona fide marker for macrophage activation ranks higher in spleen, an organ rich in macrophages [40] .", [["macrophage", "ANATOMY", 40, 50], ["spleen", "ANATOMY", 78, 84], ["organ", "ANATOMY", 89, 94], ["macrophages", "ANATOMY", 103, 114], ["CD68", "GENE_OR_GENE_PRODUCT", 11, 15], ["macrophage", "CELL", 40, 50], ["spleen", "ORGAN", 78, 84], ["organ", "ORGAN", 89, 94], ["macrophages", "CELL", 103, 114], ["CD68", "PROTEIN", 11, 15], ["macrophages", "CELL_TYPE", 103, 114], ["CD68", "TEST", 11, 15], ["macrophage activation", "TEST", 40, 61], ["CD68", "OBSERVATION", 11, 15], ["spleen", "ANATOMY", 78, 84], ["organ", "ANATOMY", 89, 94], ["macrophages", "OBSERVATION", 103, 114]]], ["An important point to make is that all three tissues here analyzed comprise mobile cell types, and therefore are subject to numerical changes in cell subpopulations during infection.", [["tissues", "ANATOMY", 45, 52], ["cell", "ANATOMY", 83, 87], ["cell", "ANATOMY", 145, 149], ["infection", "DISEASE", 172, 181], ["tissues", "TISSUE", 45, 52], ["cell", "CELL", 83, 87], ["cell", "CELL", 145, 149], ["numerical changes in cell subpopulations during infection", "PROBLEM", 124, 181], ["cell subpopulations", "OBSERVATION", 145, 164], ["infection", "OBSERVATION", 172, 181]]], ["Thus, changes in gene expressions do not reflect only transcription modulation, but also cell trafficking.", [["cell", "ANATOMY", 89, 93], ["cell", "CELL", 89, 93], ["changes in gene expressions", "PROBLEM", 6, 33], ["transcription modulation", "PROBLEM", 54, 78]]], ["Interestingly, three of the highest-ranking genes, CCL8, CXCL10 and CXCL11, are chemoattractants of cells susceptible to SIV infection (CCL8 for monocytes and CXCL10 and CXCL11 for activated lymphocytes) [41, 42] , and may be directly responsible for the trafficking of SIV-infected cells to organs and subsequent establishment of viral reservoirs during acute infection.", [["cells", "ANATOMY", 100, 105], ["monocytes", "ANATOMY", 145, 154], ["lymphocytes", "ANATOMY", 191, 202], ["cells", "ANATOMY", 283, 288], ["organs", "ANATOMY", 292, 298], ["SIV infection", "DISEASE", 121, 134], ["acute infection", "DISEASE", 355, 370], ["CCL8", "GENE_OR_GENE_PRODUCT", 51, 55], ["CXCL10", "GENE_OR_GENE_PRODUCT", 57, 63], ["CXCL11", "GENE_OR_GENE_PRODUCT", 68, 74], ["cells", "CELL", 100, 105], ["SIV", "ORGANISM", 121, 124], ["CCL8", "GENE_OR_GENE_PRODUCT", 136, 140], ["monocytes", "CELL", 145, 154], ["CXCL10", "GENE_OR_GENE_PRODUCT", 159, 165], ["CXCL11", "GENE_OR_GENE_PRODUCT", 170, 176], ["lymphocytes", "CELL", 191, 202], ["SIV", "ORGANISM", 270, 273], ["cells", "CELL", 283, 288], ["organs", "ORGAN", 292, 298], ["CCL8", "DNA", 51, 55], ["CXCL10", "DNA", 57, 63], ["CXCL11", "PROTEIN", 68, 74], ["monocytes", "CELL_TYPE", 145, 154], ["CXCL10", "PROTEIN", 159, 165], ["CXCL11", "PROTEIN", 170, 176], ["activated lymphocytes", "CELL_TYPE", 181, 202], ["SIV-infected cells", "CELL_TYPE", 270, 288], ["SIV", "SPECIES", 121, 124], ["SIV", "SPECIES", 270, 273], ["CCL8", "TEST", 51, 55], ["CXCL10", "TEST", 57, 63], ["CXCL11", "TEST", 68, 74], ["chemoattractants of cells", "PROBLEM", 80, 105], ["SIV infection", "PROBLEM", 121, 134], ["monocytes", "TEST", 145, 154], ["CXCL10", "TEST", 159, 165], ["CXCL11", "TEST", 170, 176], ["activated lymphocytes", "TEST", 181, 202], ["SIV", "PROBLEM", 270, 273], ["infected cells", "PROBLEM", 274, 288], ["viral reservoirs", "PROBLEM", 331, 347], ["acute infection", "PROBLEM", 355, 370], ["SIV infection", "OBSERVATION", 121, 134], ["viral reservoirs", "OBSERVATION", 331, 347], ["acute", "OBSERVATION_MODIFIER", 355, 360], ["infection", "OBSERVATION", 361, 370]]], ["Similar multi-gene analyses of cell type-specific transcripts may lead to methods for the precise quantitation of leukocytes in lymphoid compartments, and their contribution to inflammatory responses during pathological conditions.Discussion and ConclusionsOne of the main advantages of our methodology is to provide a diverse set of perspectives on the evaluation of cellular and molecular events during infection in different tissues.", [["cell", "ANATOMY", 31, 35], ["leukocytes", "ANATOMY", 114, 124], ["lymphoid compartments", "ANATOMY", 128, 149], ["cellular", "ANATOMY", 368, 376], ["tissues", "ANATOMY", 428, 435], ["infection", "DISEASE", 405, 414], ["cell", "CELL", 31, 35], ["leukocytes", "CELL", 114, 124], ["lymphoid compartments", "MULTI-TISSUE_STRUCTURE", 128, 149], ["cellular", "CELL", 368, 376], ["tissues", "TISSUE", 428, 435], ["leukocytes", "CELL_TYPE", 114, 124], ["cell type-specific transcripts", "PROBLEM", 31, 61], ["leukocytes in lymphoid compartments", "PROBLEM", 114, 149], ["inflammatory responses during pathological conditions", "PROBLEM", 177, 230], ["the evaluation", "TEST", 350, 364], ["cellular and molecular events", "PROBLEM", 368, 397], ["infection in different tissues", "PROBLEM", 405, 435], ["cell", "OBSERVATION", 31, 35], ["type-specific transcripts", "OBSERVATION", 36, 61], ["leukocytes", "OBSERVATION", 114, 124], ["lymphoid compartments", "OBSERVATION", 128, 149], ["inflammatory", "OBSERVATION_MODIFIER", 177, 189], ["infection", "OBSERVATION", 405, 414], ["different tissues", "OBSERVATION_MODIFIER", 418, 435]]], ["For instance, gene-ranking analysis informs about the overall aspects of the immune response, but also identifies signature genes that are singularly relevant to cellular mechanisms in specific lymphoid compartments.", [["cellular", "ANATOMY", 162, 170], ["lymphoid compartments", "ANATOMY", 194, 215], ["cellular", "CELL", 162, 170], ["lymphoid compartments", "MULTI-TISSUE_STRUCTURE", 194, 215], ["signature genes", "DNA", 114, 129], ["signature genes", "OBSERVATION", 114, 129], ["lymphoid compartments", "OBSERVATION", 194, 215]]], ["In this report, similar high ranking genes in spleen, MLN and PBMC reveal a systemic and concomitant type I interferon response during acute SIV infection, despite the diversity in cell populations in each tissue and the particular pathways by which cell phenotypes respond to viral infection.", [["spleen", "ANATOMY", 46, 52], ["MLN", "ANATOMY", 54, 57], ["PBMC", "ANATOMY", 62, 66], ["cell", "ANATOMY", 181, 185], ["tissue", "ANATOMY", 206, 212], ["cell", "ANATOMY", 250, 254], ["SIV infection", "DISEASE", 141, 154], ["viral infection", "DISEASE", 277, 292], ["spleen", "ORGAN", 46, 52], ["MLN", "CELL", 54, 57], ["PBMC", "CELL", 62, 66], ["type I interferon", "GENE_OR_GENE_PRODUCT", 101, 118], ["SIV", "ORGANISM", 141, 144], ["cell populations", "CELL", 181, 197], ["tissue", "TISSUE", 206, 212], ["cell", "CELL", 250, 254], ["MLN", "CELL_TYPE", 54, 57], ["PBMC", "CELL_TYPE", 62, 66], ["interferon", "PROTEIN", 108, 118], ["SIV", "SPECIES", 141, 144], ["PBMC", "TEST", 62, 66], ["a systemic and concomitant type I interferon response", "PROBLEM", 74, 127], ["acute SIV infection", "PROBLEM", 135, 154], ["cell phenotypes", "PROBLEM", 250, 265], ["viral infection", "PROBLEM", 277, 292], ["spleen", "ANATOMY", 46, 52], ["MLN", "ANATOMY", 54, 57], ["systemic", "OBSERVATION_MODIFIER", 76, 84], ["interferon response", "OBSERVATION", 108, 127], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["SIV infection", "OBSERVATION", 141, 154], ["diversity", "OBSERVATION_MODIFIER", 168, 177], ["cell populations", "OBSERVATION", 181, 197], ["each tissue", "OBSERVATION_MODIFIER", 201, 212], ["cell phenotypes", "OBSERVATION", 250, 265], ["viral", "OBSERVATION_MODIFIER", 277, 282], ["infection", "OBSERVATION", 283, 292]]], ["Therefore, the synchronous changes in gene expressions appear to be driven mostly by the crosstalk between cells and cytokines that are constantly trafficking through tissues than by viral replication per se [32] .Discussion and ConclusionsNonetheless, ranking gives somewhat limited information on how genes relate to each other and how transcription is longitudinally modulated in each tissue.", [["cells", "ANATOMY", 107, 112], ["tissues", "ANATOMY", 167, 174], ["tissue", "ANATOMY", 388, 394], ["cells", "CELL", 107, 112], ["tissues", "TISSUE", 167, 174], ["tissue", "TISSUE", 388, 394], ["cytokines", "PROTEIN", 117, 126], ["the synchronous changes in gene expressions", "PROBLEM", 11, 54], ["cytokines", "TREATMENT", 117, 126], ["synchronous", "OBSERVATION_MODIFIER", 15, 26]]], ["Therefore, by combining the information on the angular position of genes provided by all the judges and depicting the results in polar plots (Fig 9) , it is possible to identify genes with similar regulation patterns and evaluate whether these same genes are equally regulated in other lymphoid compartments.", [["lymphoid compartments", "ANATOMY", 286, 307], ["lymphoid compartments", "MULTI-TISSUE_STRUCTURE", 286, 307], ["lymphoid compartments", "OBSERVATION", 286, 307]]], ["As an example, all putative interferon-stimulated genes (ISG) are grouped together in all three compartments, indicating a common regulatory process.", [["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 28, 55], ["ISG", "GENE_OR_GENE_PRODUCT", 57, 60], ["interferon-stimulated genes", "DNA", 28, 55], ["ISG", "DNA", 57, 60], ["a common regulatory process", "PROBLEM", 121, 148], ["interferon", "OBSERVATION", 28, 38]]], ["On the other hand, based on the spleen results alone, it could be suggested that the transcription activator STAT5A is directly involved in the regulation of IL4, but this is not observed in the other two tissues, suggesting either tissue-specific regulation or an aliasing effect, and these are computationally-derived hypotheses for further study.Discussion and ConclusionsFinally, this methodology allows for the combination of results from three related but independent analyses into one cogent hexagonal plot (Fig 10) , displaying the relative contribution of each gene to the overall changes in each compartment.", [["spleen", "ANATOMY", 32, 38], ["tissues", "ANATOMY", 205, 212], ["tissue", "ANATOMY", 232, 238], ["spleen", "ORGAN", 32, 38], ["STAT5A", "GENE_OR_GENE_PRODUCT", 109, 115], ["IL4", "GENE_OR_GENE_PRODUCT", 158, 161], ["tissues", "TISSUE", 205, 212], ["tissue", "TISSUE", 232, 238], ["transcription activator", "PROTEIN", 85, 108], ["STAT5A", "PROTEIN", 109, 115], ["IL4", "PROTEIN", 158, 161], ["the transcription activator STAT5A", "PROBLEM", 81, 115], ["an aliasing effect", "PROBLEM", 262, 280], ["further study", "TEST", 335, 348], ["spleen", "ANATOMY", 32, 38], ["aliasing effect", "OBSERVATION", 265, 280], ["overall", "OBSERVATION_MODIFIER", 582, 589], ["changes", "OBSERVATION", 590, 597]]], ["This powerful visualization tool can be used to identify genes that uniquely and significantly contribute to immune responses in specific tissues, and also genes that could be selected as general inflammatory markers to be investigated during acute infection.", [["tissues", "ANATOMY", 138, 145], ["acute infection", "DISEASE", 243, 258], ["tissues", "TISSUE", 138, 145], ["immune responses in specific tissues", "PROBLEM", 109, 145], ["general inflammatory markers", "PROBLEM", 188, 216], ["acute infection", "PROBLEM", 243, 258], ["inflammatory", "OBSERVATION", 196, 208], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["infection", "OBSERVATION", 249, 258]]], ["The model suggests that evaluation of a small selected panel of ISGs and chemokines in PBMCs may be sufficient to assess systemic inflammatory responses triggered by viral infection in secondary lymphoid tissues.", [["PBMCs", "ANATOMY", 87, 92], ["lymphoid tissues", "ANATOMY", 195, 211], ["viral infection", "DISEASE", 166, 181], ["PBMCs", "CELL", 87, 92], ["lymphoid tissues", "TISSUE", 195, 211], ["ISGs", "PROTEIN", 64, 68], ["chemokines", "PROTEIN", 73, 83], ["PBMCs", "CELL_TYPE", 87, 92], ["evaluation", "TEST", 24, 34], ["a small selected panel of ISGs", "PROBLEM", 38, 68], ["chemokines in PBMCs", "TEST", 73, 92], ["systemic inflammatory responses", "PROBLEM", 121, 152], ["viral infection in secondary lymphoid tissues", "PROBLEM", 166, 211], ["small", "OBSERVATION_MODIFIER", 40, 45], ["inflammatory", "OBSERVATION", 130, 142], ["viral", "OBSERVATION_MODIFIER", 166, 171], ["infection", "OBSERVATION", 172, 181], ["secondary lymphoid tissues", "OBSERVATION", 185, 211]]], ["On the other hand, IL10 and XCL1 appear to be highly significant in spleen and MLN but not in PBMCs, and therefore examining the levels of these cytokines in the blood may not provide accurate information regarding immunological events in lymphoid organs.", [["spleen", "ANATOMY", 68, 74], ["MLN", "ANATOMY", 79, 82], ["PBMCs", "ANATOMY", 94, 99], ["blood", "ANATOMY", 162, 167], ["lymphoid organs", "ANATOMY", 239, 254], ["IL10", "GENE_OR_GENE_PRODUCT", 19, 23], ["XCL1", "GENE_OR_GENE_PRODUCT", 28, 32], ["spleen", "ORGAN", 68, 74], ["MLN", "CELL", 79, 82], ["PBMCs", "CELL", 94, 99], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 239, 254], ["IL10", "PROTEIN", 19, 23], ["XCL1", "PROTEIN", 28, 32], ["MLN", "CELL_TYPE", 79, 82], ["PBMCs", "CELL_TYPE", 94, 99], ["cytokines", "PROTEIN", 145, 154], ["PBMCs", "TEST", 94, 99], ["these cytokines", "TEST", 139, 154], ["immunological events in lymphoid organs", "PROBLEM", 215, 254], ["hand", "ANATOMY", 13, 17], ["IL10", "ANATOMY", 19, 23], ["appear to be", "UNCERTAINTY", 33, 45], ["highly", "OBSERVATION_MODIFIER", 46, 52], ["significant", "OBSERVATION", 53, 64], ["spleen", "ANATOMY", 68, 74], ["MLN", "ANATOMY", 79, 82], ["lymphoid organs", "OBSERVATION", 239, 254]]], ["The expression profiles of these genes in spleen and MLNs are strongly correlated, while they have little to no correlation with the expression profiles in PBMCs.Discussion and ConclusionsNote that mRNA samples in our study were isolated from different animals euthanized at 4, 7, 14, and 21 days post infection.", [["spleen", "ANATOMY", 42, 48], ["MLNs", "ANATOMY", 53, 57], ["PBMCs", "ANATOMY", 156, 161], ["samples", "ANATOMY", 203, 210], ["infection", "DISEASE", 302, 311], ["spleen", "ORGAN", 42, 48], ["MLNs", "MULTI-TISSUE_STRUCTURE", 53, 57], ["PBMCs", "CELL", 156, 161], ["MLNs", "CELL_TYPE", 53, 57], ["PBMCs", "CELL_TYPE", 156, 161], ["mRNA samples", "TEST", 198, 210], ["our study", "TEST", 214, 223], ["infection", "PROBLEM", 302, 311], ["spleen", "ANATOMY", 42, 48], ["MLNs", "ANATOMY", 53, 57], ["infection", "OBSERVATION", 302, 311]]], ["Therefore, the obtained measurements at various time points do not constitute a longitudinal study.", [["a longitudinal study", "TEST", 78, 98]]], ["For example, the gene expression data points at days 4 and 7 are not inherently connected, but instead represent samples from populations of animals infected with SIV for 4 and 7 days, respectively.", [["samples", "ANATOMY", 113, 120], ["animals", "ORGANISM", 141, 148], ["SIV", "ORGANISM", 163, 166], ["SIV", "SPECIES", 163, 166]]], ["In addition, there is a fundamentally different relationship between the input variables (mRNA measurements) and each of the two classification schemes.", [["mRNA", "RNA", 90, 94], ["mRNA measurements", "TEST", 90, 107]]], ["While time since infection as an output variable is intrinsically independent of the mRNA measurements, SIV RNA in plasma is completely dependent on the changes in gene expressions, as both inflammatory response genes and SIV are constantly in direct or indirect interactions in the immune system and hence cause changes in mRNA counts and SIV RNA in plasma.", [["plasma", "ANATOMY", 115, 121], ["immune system", "ANATOMY", 283, 296], ["plasma", "ANATOMY", 351, 357], ["infection", "DISEASE", 17, 26], ["SIV", "ORGANISM", 104, 107], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["SIV", "ORGANISM", 222, 225], ["SIV", "ORGANISM", 340, 343], ["plasma", "ORGANISM_SUBSTANCE", 351, 357], ["SIV RNA", "RNA", 104, 111], ["inflammatory response genes", "DNA", 190, 217], ["SIV RNA", "RNA", 340, 347], ["plasma", "CELL_TYPE", 351, 357], ["SIV", "SPECIES", 104, 107], ["SIV", "SPECIES", 222, 225], ["SIV", "SPECIES", 340, 343], ["infection", "PROBLEM", 17, 26], ["an output", "TEST", 30, 39], ["the mRNA measurements", "TEST", 81, 102], ["SIV RNA in plasma", "PROBLEM", 104, 121], ["the changes in gene expressions", "PROBLEM", 149, 180], ["both inflammatory response genes", "PROBLEM", 185, 217], ["SIV", "PROBLEM", 222, 225], ["mRNA counts", "TEST", 324, 335], ["SIV RNA in plasma", "TEST", 340, 357], ["infection", "OBSERVATION", 17, 26], ["dependent", "OBSERVATION_MODIFIER", 136, 145], ["inflammatory", "OBSERVATION_MODIFIER", 190, 202], ["SIV RNA", "OBSERVATION", 340, 347]]], ["This, in addition to other factors, may partially explain why classification based on time since infection is more accurate than classification based on SIV RNA in plasma.Discussion and ConclusionsFor most viral infections, the acute phase is a time of drastic physiological and immunological changes, especially at the beginning of adaptive immune responses.", [["plasma", "ANATOMY", 164, 170], ["infection", "DISEASE", 97, 106], ["viral infections", "DISEASE", 206, 222], ["SIV", "ORGANISM", 153, 156], ["plasma", "ORGANISM_SUBSTANCE", 164, 170], ["SIV RNA", "RNA", 153, 160], ["SIV", "SPECIES", 153, 156], ["infection", "PROBLEM", 97, 106], ["most viral infections", "PROBLEM", 201, 222], ["drastic physiological and immunological changes", "PROBLEM", 253, 300], ["acute", "OBSERVATION_MODIFIER", 228, 233]]], ["Further similar studies performed in samples collected at later time points, when infection is already established, would help to evaluate the relationship between cytokine expression and viral replication.Animals and ethics statementAll animal studies were approved by the Johns Hopkins University Institutional Care and Use Committee (IACUC protocol #PR12M310), and all procedures followed the guidelines of the Weatherall Report, the USDA Animal Welfare Act, and the Guide for the Care and Use of Laboratory Animals.", [["samples", "ANATOMY", 37, 44], ["infection", "DISEASE", 82, 91], ["samples", "CANCER", 37, 44], ["cytokine", "PROTEIN", 164, 172], ["Further similar studies", "TEST", 0, 23], ["infection", "PROBLEM", 82, 91], ["cytokine expression", "TREATMENT", 164, 183], ["viral replication", "TREATMENT", 188, 205], ["All animal studies", "TEST", 234, 252], ["infection", "OBSERVATION", 82, 91], ["viral replication", "OBSERVATION", 188, 205]]], ["Twenty-four juvenile pigtailed macaques (Macaca nemestrina) were studied before and during acute SIV infection.", [["SIV infection", "DISEASE", 97, 110], ["macaques", "ORGANISM", 31, 39], ["Macaca", "ORGANISM", 41, 47], ["nemestrina", "ORGANISM", 48, 58], ["SIV", "ORGANISM", 97, 100], ["macaques", "SPECIES", 31, 39], ["Macaca nemestrina", "SPECIES", 41, 58], ["Macaca nemestrina", "SPECIES", 41, 58], ["SIV", "SPECIES", 97, 100], ["four juvenile pigtailed macaques (Macaca nemestrina", "TREATMENT", 7, 58], ["acute SIV infection", "PROBLEM", 91, 110], ["juvenile", "OBSERVATION_MODIFIER", 12, 20], ["pigtailed macaques", "OBSERVATION", 21, 39], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["SIV infection", "OBSERVATION", 97, 110]]], ["Twenty of these animals were dual-inoculated with the molecular clone SIV/17E-Fr and the immunosuppressive swarm SIV/DeltaB670, as previously described [43] .", [["animals", "ORGANISM", 16, 23], ["SIV", "ORGANISM", 70, 73], ["17E-Fr", "ORGANISM", 74, 80], ["SIV", "ORGANISM", 113, 116], ["Delta", "GENE_OR_GENE_PRODUCT", 117, 122], ["DeltaB670", "PROTEIN", 117, 126], ["SIV/DeltaB670", "SPECIES", 113, 126], ["clone SIV", "OBSERVATION", 64, 73], ["immunosuppressive", "OBSERVATION_MODIFIER", 89, 106], ["swarm SIV", "OBSERVATION", 107, 116]]], ["Groups of six infected macaque were euthanized at 4, 7, and 14 days post infection (p.i.), and two animals were euthanized at 21 days p.i.", [["infection", "DISEASE", 73, 82], ["macaque", "ORGANISM", 23, 30], ["macaque", "SPECIES", 23, 30], ["six infected macaque", "PROBLEM", 10, 30], ["infection", "PROBLEM", 73, 82], ["infected macaque", "OBSERVATION", 14, 30], ["infection", "OBSERVATION", 73, 82]]], ["Four animals were mock-inoculated and used as uninfected controls.", [["animals", "ORGANISM", 5, 12]]], ["The 4-day time point is included as the earliest time point that the virus could be found in the brain of infected macaques.", [["brain", "ANATOMY", 97, 102], ["brain", "ORGAN", 97, 102], ["macaques", "ORGANISM", 115, 123], ["macaques", "SPECIES", 115, 123], ["the virus", "PROBLEM", 65, 74], ["virus", "OBSERVATION", 69, 74], ["brain", "ANATOMY", 97, 102], ["infected macaques", "OBSERVATION", 106, 123]]], ["All animals were considered SPF (specific pathogen free) before enrolling in our study, and were tested negative for SIV, Simian type D retrovirus, Herpesvirus simiae (B virus), Simian foamy virus and simian T-cell leukemia virus.", [["Herpesvirus simiae", "DISEASE", 148, 166], ["simian T-cell leukemia virus", "DISEASE", 201, 229], ["SIV", "ORGANISM", 117, 120], ["Simian type D retrovirus", "ORGANISM", 122, 146], ["Herpesvirus simiae (B virus", "ORGANISM", 148, 175], ["Simian foamy virus", "ORGANISM", 178, 196], ["simian T-cell leukemia virus", "ORGANISM", 201, 229], ["Herpesvirus simiae", "SPECIES", 148, 166], ["B virus", "SPECIES", 168, 175], ["Simian foamy virus", "SPECIES", 178, 196], ["simian T-cell leukemia virus", "SPECIES", 201, 229], ["SIV", "SPECIES", 117, 120], ["Simian type D retrovirus", "SPECIES", 122, 146], ["Herpesvirus simiae", "SPECIES", 148, 166], ["B virus", "SPECIES", 168, 175], ["Simian foamy virus", "SPECIES", 178, 196], ["simian T-cell leukemia virus", "SPECIES", 201, 229], ["SPF", "PROBLEM", 28, 31], ["our study", "TEST", 77, 86], ["SIV", "PROBLEM", 117, 120], ["Simian type D retrovirus", "PROBLEM", 122, 146], ["Herpesvirus simiae (B virus", "PROBLEM", 148, 175], ["Simian foamy virus", "PROBLEM", 178, 196], ["simian T-cell leukemia virus", "PROBLEM", 201, 229], ["foamy virus", "OBSERVATION", 185, 196], ["cell leukemia virus", "OBSERVATION", 210, 229]]], ["Uninfected and infected macaques were housed in different rooms to prevent cross-contamination.", [["macaques", "ORGANISM", 24, 32], ["macaques", "SPECIES", 24, 32], ["macaques", "SPECIES", 24, 32], ["infected macaques", "TREATMENT", 15, 32], ["cross-contamination", "PROBLEM", 75, 94], ["infected", "OBSERVATION_MODIFIER", 15, 23], ["macaques", "OBSERVATION", 24, 32], ["cross-contamination", "OBSERVATION", 75, 94]]], ["Assigned veterinarians and trained technicians monitored the animals twice daily for signs of distress, including diarrhea, weight loss, and opportunistic infections, in order that early humane endpoints could be performed if necessary.", [["distress", "DISEASE", 94, 102], ["diarrhea", "DISEASE", 114, 122], ["weight loss", "DISEASE", 124, 135], ["opportunistic infections", "DISEASE", 141, 165], ["distress", "PROBLEM", 94, 102], ["diarrhea", "PROBLEM", 114, 122], ["weight loss", "PROBLEM", 124, 135], ["opportunistic infections", "PROBLEM", 141, 165], ["distress", "OBSERVATION", 94, 102], ["opportunistic", "OBSERVATION_MODIFIER", 141, 154], ["infections", "OBSERVATION", 155, 165]]], ["Macaques were housed in facilities that are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International (AAALAC), and fed a balanced commercial macaque chow (Purina Mills).", [["macaque", "ORGANISM", 198, 205], ["chow", "ORGANISM_SUBDIVISION", 206, 210], ["the Assessment", "TEST", 84, 98], ["International (AAALAC)", "TREATMENT", 144, 166]]], ["Throughout the experiments, animals were housed in cages providing 6 square feet of space with visual and auditory contact of conspecifics, and received environmental enrichment, such as manipulanda and novel foodstuffs.", [["environmental enrichment", "TREATMENT", 153, 177], ["manipulanda", "TREATMENT", 187, 198]]], ["Before euthanasia, all macaques were perfused with sterile saline solution.", [["macaques", "ORGANISM", 23, 31], ["macaques", "SPECIES", 23, 31], ["euthanasia", "TREATMENT", 7, 17], ["all macaques", "TREATMENT", 19, 31], ["sterile saline solution", "TREATMENT", 51, 74]]], ["Euthanasia was performed under veterinary supervision using an overdose of intravenous sodium pentobarbital while under deep ketamine sedation (10 mg/kg intramuscular), followed by perfusion with 1X PBS prior to tissue harvest.", [["intravenous", "ANATOMY", 75, 86], ["tissue", "ANATOMY", 212, 218], ["overdose", "DISEASE", 63, 71], ["sodium pentobarbital", "CHEMICAL", 87, 107], ["ketamine", "CHEMICAL", 125, 133], ["sodium pentobarbital", "CHEMICAL", 87, 107], ["ketamine", "CHEMICAL", 125, 133], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["sodium", "SIMPLE_CHEMICAL", 87, 93], ["pentobarbital", "SIMPLE_CHEMICAL", 94, 107], ["ketamine", "SIMPLE_CHEMICAL", 125, 133], ["tissue", "TISSUE", 212, 218], ["intravenous sodium pentobarbital", "TREATMENT", 75, 107], ["deep ketamine sedation", "TREATMENT", 120, 142], ["1X PBS", "TREATMENT", 196, 202], ["tissue harvest", "TREATMENT", 212, 226], ["tissue", "ANATOMY", 212, 218], ["harvest", "OBSERVATION", 219, 226]]], ["Organs, including spleen and mesenteric lymph node (MLN), were harvested, sectioned, and frozen at -80\u00b0C. Blood was collected for the isolation of peripheral blood mononuclear cells (PBMC) using a Percoll protocol (GE Healthcare Life Sciences, Pittsburgh, USA), and cell pellets were frozen and stored at -80\u00b0C.RNA isolation from spleen, MLN, and PBMCTotal RNA was isolated from frozen spleen, MLN, and PBMCs using the RNeasy kit (Qiagen, Valencia, CA, USA), according to the manufacturer's protocol.", [["Organs", "ANATOMY", 0, 6], ["spleen", "ANATOMY", 18, 24], ["mesenteric lymph node", "ANATOMY", 29, 50], ["MLN", "ANATOMY", 52, 55], ["Blood", "ANATOMY", 106, 111], ["peripheral blood mononuclear cells", "ANATOMY", 147, 181], ["PBMC", "ANATOMY", 183, 187], ["cell", "ANATOMY", 266, 270], ["spleen", "ANATOMY", 330, 336], ["MLN", "ANATOMY", 338, 341], ["spleen", "ANATOMY", 386, 392], ["MLN", "ANATOMY", 394, 397], ["PBMCs", "ANATOMY", 403, 408], ["Organs", "ORGAN", 0, 6], ["spleen", "ORGAN", 18, 24], ["mesenteric lymph node", "MULTI-TISSUE_STRUCTURE", 29, 50], ["MLN", "MULTI-TISSUE_STRUCTURE", 52, 55], ["Blood", "ORGANISM_SUBSTANCE", 106, 111], ["peripheral blood mononuclear cells", "CELL", 147, 181], ["PBMC", "CELL", 183, 187], ["cell", "CELL", 266, 270], ["spleen", "ORGAN", 330, 336], ["MLN", "CELL", 338, 341], ["PBMCTotal", "GENE_OR_GENE_PRODUCT", 347, 356], ["spleen", "ORGAN", 386, 392], ["MLN", "CELL", 394, 397], ["PBMCs", "CELL", 403, 408], ["peripheral blood mononuclear cells", "CELL_TYPE", 147, 181], ["PBMC", "CELL_TYPE", 183, 187], ["MLN", "CELL_TYPE", 338, 341], ["PBMCTotal RNA", "RNA", 347, 360], ["MLN", "CELL_TYPE", 394, 397], ["PBMCs", "CELL_TYPE", 403, 408], ["mesenteric lymph node", "TREATMENT", 29, 50], ["Blood", "TEST", 106, 111], ["peripheral blood mononuclear cells", "TREATMENT", 147, 181], ["a Percoll protocol", "TREATMENT", 195, 213], ["cell pellets", "TREATMENT", 266, 278], ["RNA isolation", "TEST", 311, 324], ["PBMCTotal RNA", "PROBLEM", 347, 360], ["PBMCs", "TREATMENT", 403, 408], ["the RNeasy kit", "TREATMENT", 415, 429], ["the manufacturer's protocol", "TREATMENT", 472, 499], ["spleen", "ANATOMY", 18, 24], ["mesenteric", "ANATOMY", 29, 39], ["lymph node", "OBSERVATION", 40, 50], ["MLN", "ANATOMY", 52, 55], ["harvested", "OBSERVATION", 63, 72], ["peripheral", "ANATOMY_MODIFIER", 147, 157], ["blood", "ANATOMY", 158, 163], ["mononuclear cells", "OBSERVATION", 164, 181], ["spleen", "ANATOMY", 330, 336], ["MLN", "ANATOMY", 338, 341], ["spleen", "ANATOMY", 386, 392], ["MLN", "ANATOMY", 394, 397]]], ["Samples were eluted in 60 \u03bcL of RNase-free water and frozen at -80\u00b0C until time to be analyzed.Quantification of SIV virions in plasmaPlasma was collected during euthanasia, and SIV RNA was isolated using the QIAamp Viral RNA Mini Kit (Qiagen).", [["Samples", "ANATOMY", 0, 7], ["plasmaPlasma", "ANATOMY", 128, 140], ["RNase", "GENE_OR_GENE_PRODUCT", 32, 37], ["SIV", "ORGANISM", 113, 116], ["plasmaPlasma", "CANCER", 128, 140], ["SIV", "ORGANISM", 178, 181], ["RNase", "PROTEIN", 32, 37], ["SIV RNA", "RNA", 178, 185], ["SIV", "SPECIES", 113, 116], ["SIV", "SPECIES", 178, 181], ["Samples", "TEST", 0, 7], ["RNase", "TREATMENT", 32, 37], ["SIV virions in plasmaPlasma", "PROBLEM", 113, 140], ["euthanasia", "PROBLEM", 162, 172], ["SIV RNA", "PROBLEM", 178, 185], ["the QIAamp Viral RNA", "TREATMENT", 205, 225], ["SIV virions", "OBSERVATION", 113, 124]]], ["Analysis was performed by qPCR as previously described [44] .NanoString nCounter gene expression systemNanostring technology uses molecular \"barcodes\" (a string of fluorescent dyes that uniquely identify a specific transcript) and potent microscopic imaging to quantify genes of interest after a hybridization protocol.", [["Analysis", "TEST", 0, 8], ["qPCR", "TEST", 26, 30], ["NanoString nCounter gene expression systemNanostring technology", "TREATMENT", 61, 124], ["fluorescent dyes", "TREATMENT", 164, 180], ["potent microscopic imaging", "TEST", 231, 257], ["a hybridization protocol", "TREATMENT", 294, 318]]], ["The technique does not require reverse transcription or DNA amplification, and provides high reproducibility and sensitivity for the detection of multiple transcripts [45] .", [["DNA", "CELLULAR_COMPONENT", 56, 59], ["reverse transcription", "TREATMENT", 31, 52], ["DNA amplification", "TEST", 56, 73]]], ["CodeSets for 92 macaque genes (S1 Table) , including four housekeeping genes, were designed according to the company's specifications, based on rhesus macaques (Macaca mulata) annotated sequences.", [["macaque", "ORGANISM", 16, 23], ["rhesus", "ORGANISM", 144, 150], ["macaques", "ORGANISM", 151, 159], ["Macaca mulata", "ORGANISM", 161, 174], ["92 macaque genes", "DNA", 13, 29], ["S1 Table", "DNA", 31, 39], ["housekeeping genes", "DNA", 58, 76], ["rhesus macaques", "SPECIES", 144, 159], ["Macaca mulata", "SPECIES", 161, 174], ["rhesus macaques", "SPECIES", 144, 159], ["Macaca mulata", "SPECIES", 161, 174], ["CodeSets", "TREATMENT", 0, 8]]], ["In addition to the target-specific CodeSets, the kit also includes six positive probes for quality control and seven negative controls whose sequences were obtained from the External RNA Controls Consortium and are confirmed to not hybridize with mammalian genes.", [["CodeSets", "DNA", 35, 43], ["mammalian genes", "DNA", 247, 262], ["the kit", "TEST", 45, 52]]], ["Isolated RNA was quantitated by spectrophotometry, and 250 ng of each sample was sent for hybridization and consecutive quantitation to the Johns Hopkins Deep Sequencing and Microarray Core.", [["sample", "ANATOMY", 70, 76], ["Isolated RNA", "PROBLEM", 0, 12], ["spectrophotometry", "TEST", 32, 49], ["each sample", "TEST", 65, 76], ["hybridization", "TEST", 90, 103], ["RNA", "OBSERVATION", 9, 12]]], ["RNA counts were normalized by the geometric mean of four housekeeping genes: actin, GAPDH, HPRT, and PBGD.", [["actin", "GENE_OR_GENE_PRODUCT", 77, 82], ["GAPDH", "GENE_OR_GENE_PRODUCT", 84, 89], ["HPRT", "GENE_OR_GENE_PRODUCT", 91, 95], ["PBGD", "GENE_OR_GENE_PRODUCT", 101, 105], ["housekeeping genes", "DNA", 57, 75], ["actin", "PROTEIN", 77, 82], ["GAPDH", "PROTEIN", 84, 89], ["HPRT", "PROTEIN", 91, 95], ["PBGD", "PROTEIN", 101, 105], ["RNA counts", "TEST", 0, 10], ["HPRT", "TEST", 91, 95], ["PBGD", "TEST", 101, 105]]], ["Therefore, we used mRNA measurements from 88 genes as input variables in our analysis (for additional information see S1 Method).", [["mRNA measurements", "TEST", 19, 36], ["our analysis", "TEST", 73, 85]]], ["The data sets supporting the results of this article are available in the NCBI Gene Expression Omnibus (GEO) database, [ID: GSE51488, http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE51488].NanoString nCounter gene expression systemPreprocessing of data, multivariate analysis methods, and the judges The gene expression datasets are first preprocessed using a transformation and a normalization method (as described in the Results section and in S2 Method).", [["multivariate analysis methods", "TEST", 260, 289], ["The gene expression datasets", "PROBLEM", 306, 334], ["a normalization method", "TEST", 385, 407]]], ["For PCA, we use the princomp function in Matlab.", [["PCA", "TREATMENT", 4, 7]]], ["The two important outputs of this function are: 1) the loadings of genes onto each PC, which are the coefficients (weights) of the genes that comprise the PC; and 2) the scores of each PC for each observation, which are the projected data points in the new space created by PCs.", [["PC", "CANCER", 185, 187], ["PCs", "CELL", 274, 277], ["PCs", "CELL_TYPE", 274, 277], ["the loadings of genes onto each PC", "TREATMENT", 51, 85], ["each observation", "TEST", 192, 208], ["new", "OBSERVATION_MODIFIER", 253, 256]]], ["We impose orthonormality on the columns of the score matrix obtained by the princomp function and scale the columns of the loading matrix accordingly such that the score matrix multiplied by the transposed loading matrix still results in the original matrix of the data.", [["matrix", "CELLULAR_COMPONENT", 53, 59], ["matrix", "CELLULAR_COMPONENT", 131, 137], ["matrix", "CELLULAR_COMPONENT", 214, 220], ["matrix", "CELLULAR_COMPONENT", 251, 257], ["the loading matrix", "TREATMENT", 119, 137], ["the score matrix", "PROBLEM", 160, 176], ["the transposed loading matrix", "TREATMENT", 191, 220]]], ["This is necessary to study the correlation between genes in the dataset in a loading plot, provided that the two constructing PCs closely approximate the matrix of the data [28] .NanoString nCounter gene expression systemPLS regression is a method to find fundamental relations between input variables (mRNA measurements) and output variables (time since infection or SIV RNA in plasma) by means of latent variables called components [24, 25] .", [["plasma", "ANATOMY", 379, 385], ["infection", "DISEASE", 355, 364], ["matrix", "CELLULAR_COMPONENT", 154, 160], ["SIV", "ORGANISM", 368, 371], ["plasma", "ORGANISM_SUBSTANCE", 379, 385], ["mRNA", "RNA", 303, 307], ["SIV RNA", "RNA", 368, 375], ["plasma", "CELL_TYPE", 379, 385], ["SIV", "SPECIES", 368, 371], ["NanoString nCounter gene expression systemPLS regression", "TREATMENT", 179, 235], ["mRNA measurements", "TEST", 303, 320], ["output variables", "TEST", 326, 342], ["infection", "PROBLEM", 355, 364], ["SIV RNA", "PROBLEM", 368, 375]]], ["In this work, we use the plsregress function in Matlab to perform PLS regression.", [["PLS regression", "TEST", 66, 80]]], ["This function returns PCs (loadings), the amount of variability captured by each PC, and scores for both the input and output variables.", [["output variables", "TEST", 119, 135], ["amount", "OBSERVATION_MODIFIER", 42, 48], ["variability", "OBSERVATION_MODIFIER", 52, 63]]], ["The columns of the score matrix returned by the plsregress function are orthonormal.", [["matrix", "CELLULAR_COMPONENT", 25, 31], ["columns", "OBSERVATION_MODIFIER", 4, 11]]], ["Therefore one can study the correlation between genes in the dataset using the gene loadings in the loading plots.", [["the gene loadings", "TREATMENT", 75, 92]]], ["Additional information about PCA and PLS can be found in S3 Method and S4 Method.NanoString nCounter gene expression systemWe define a judge as the combination of a preprocessing method (transformation and normalization) and a multivariate analysis technique (Fig 1A) , as described in the Results section.", [["NanoString nCounter gene expression systemWe", "DNA", 81, 125], ["PCA", "TREATMENT", 29, 32], ["PLS", "TEST", 37, 40], ["a preprocessing method", "TREATMENT", 163, 185], ["a multivariate analysis technique", "TEST", 225, 258]]], ["In this work, each dataset, i.e. spleen, MLN, or PBMC, was analyzed by all 12 judges, forming a Multiplexed Component Analysis algorithm.", [["spleen", "ANATOMY", 33, 39], ["MLN", "ANATOMY", 41, 44], ["PBMC", "ANATOMY", 49, 53], ["spleen", "ORGAN", 33, 39], ["MLN", "MULTI-TISSUE_STRUCTURE", 41, 44], ["PBMC", "CELL", 49, 53], ["MLN", "CELL_TYPE", 41, 44], ["PBMC", "CELL_TYPE", 49, 53], ["PBMC", "TREATMENT", 49, 53], ["a Multiplexed Component Analysis algorithm", "TEST", 94, 136], ["spleen", "ANATOMY", 33, 39], ["MLN", "ANATOMY", 41, 44]]], ["Instructions on how to download the Matlab files for visualization and the MCA method can be found in S5 Method.Classification and cross validationIn our analysis, we use a centroid-based clustering technique.", [["visualization", "TEST", 53, 66], ["the MCA method", "TEST", 71, 85], ["cross validation", "TEST", 131, 147], ["a centroid-based clustering technique", "TREATMENT", 171, 208], ["MCA", "ANATOMY", 75, 78]]], ["We use two variables to cluster the animals into distinct groups: (1) time since infection; and (2) SIV RNA in plasma (copies/ ml) (panel D in S1 Information).", [["plasma", "ANATOMY", 111, 117], ["infection", "DISEASE", 81, 90], ["SIV", "ORGANISM", 100, 103], ["plasma", "ORGANISM_SUBSTANCE", 111, 117], ["SIV RNA", "RNA", 100, 107], ["SIV", "SPECIES", 100, 103], ["infection", "PROBLEM", 81, 90], ["infection", "OBSERVATION", 81, 90]]], ["The true class information for each observation is known prior to the analysis, and if the cluster is assigned correctly, the classification is successful; otherwise it has failed.", [["the analysis", "TEST", 66, 78]]], ["We perform the classification for all the 24 observations and calculate the classification rate.Classification and cross validationFor classification, all the data is used to train the model and the same data is classified into clusters.", [["the classification rate", "TEST", 72, 95], ["cross validation", "TEST", 115, 131]]], ["We use leave-one-out cross validation (LOOCV), in which a single observation from the dataset is selected as the test dataset.", [["the test dataset", "TEST", 109, 125]]], ["The remaining observations are used as the training dataset to build the model and to calculate the centroid for each cluster.", [["the training dataset", "TREATMENT", 39, 59]]], ["Then, the test observation is projected onto the low-dimensional space created by the model and assigned to the nearest cluster.", [["the test observation", "TEST", 6, 26]]], ["We perform the cross validation for all 24 observations and calculate the estimated LOOCV rate.Classification and cross validationSupporting Information S1 Method.", [["the cross validation", "TEST", 11, 31], ["the estimated LOOCV rate", "TEST", 70, 94]]], ["NanoString nCounter gene expression system.", [["expression system", "OBSERVATION", 25, 42]]], ["(DOCX) S13 Information.", [["(DOCX) S13", "GENE_OR_GENE_PRODUCT", 0, 10]]], ["Judge-specificity of genes: relative importance of each gene using each normalization method.", [["each normalization method", "TREATMENT", 67, 92]]], ["(DOCX) S14 Information. p-value heatmap of the paired t-tests of gene rankings in all datasets and for both classification schemes (high-resolution images of the panels of Fig 7) .", [["(DOCX) S14", "GENE_OR_GENE_PRODUCT", 0, 10], ["p-value heatmap", "TEST", 24, 39], ["the paired t-tests", "TEST", 43, 61]]], ["(DOCX) S15 Information.", [["(DOCX) S15", "GENE_OR_GENE_PRODUCT", 0, 10]]], ["Average correlation coefficient matrices in all datasets, for both classification schemes (high-resolution images of the panels of Fig 8) .Classification and cross validation(DOCX) S16 Information.", [["both classification schemes", "TEST", 62, 89]]], ["The loading plots of average correlation coefficient matrices shown in Fig 8.", [["The loading plots", "TREATMENT", 0, 17]]], ["(DOCX) S18 Information.", [["(DOCX) S18", "GENE_OR_GENE_PRODUCT", 0, 10]]], ["Gene expression profiles in all datasets and for both classification schemes.", [["Gene expression profiles", "PROBLEM", 0, 24]]], ["(DOCX) S19 Information.", [["(DOCX) S19", "GENE_OR_GENE_PRODUCT", 0, 10]]], ["Schematic of algorithm to plot polar plots in Fig 9.", [["plot polar plots", "TEST", 26, 42]]], ["(DOCX) S1Author ContributionsConceived and designed the experiments: LG.", [["LG", "OBSERVATION", 69, 71]]], ["Performed the experiments: LG.", [["LG", "ANATOMY", 27, 29]]]], "50f64351365ea2088d49216d598ba04d078e46dc": [["IntroductionMembers of the Coronaviridae are assigned to a small number of serological groups.", [["the Coronaviridae", "TREATMENT", 23, 40], ["small", "OBSERVATION_MODIFIER", 59, 64]]], ["Human coronavirus (HCV-OC43), haemagglutinating encephalomyelitis virus (HEV) and bovine coronavirus (BCV) form one such group [2, 9, 17] .", [["haemagglutinating encephalomyelitis", "DISEASE", 30, 65], ["bovine coronavirus", "DISEASE", 82, 100], ["Human coronavirus", "ORGANISM", 0, 17], ["HCV-OC43)", "ORGANISM", 19, 28], ["haemagglutinating encephalomyelitis virus", "ORGANISM", 30, 71], ["HEV", "ORGANISM", 73, 76], ["bovine coronavirus", "ORGANISM", 82, 100], ["BCV", "ORGANISM", 102, 105], ["Human", "SPECIES", 0, 5], ["coronavirus", "SPECIES", 6, 17], ["haemagglutinating encephalomyelitis virus", "SPECIES", 30, 71], ["bovine", "SPECIES", 82, 88], ["coronavirus", "SPECIES", 89, 100], ["Human coronavirus", "SPECIES", 0, 17], ["HCV", "SPECIES", 19, 22], ["OC43", "SPECIES", 23, 27], ["haemagglutinating encephalomyelitis virus", "SPECIES", 30, 71], ["HEV", "SPECIES", 73, 76], ["bovine coronavirus", "SPECIES", 82, 100], ["BCV", "SPECIES", 102, 105], ["Human coronavirus (HCV-OC43", "PROBLEM", 0, 27], ["haemagglutinating encephalomyelitis virus", "PROBLEM", 30, 71], ["bovine coronavirus", "PROBLEM", 82, 100]]], ["There has been no extensive serological comparison of BCV strains or investigations into the extent of their relationship with other members of this group.", [["BCV", "ORGANISM", 54, 57], ["BCV", "SPECIES", 54, 57], ["BCV strains", "PROBLEM", 54, 65], ["no", "UNCERTAINTY", 15, 17], ["extensive", "OBSERVATION_MODIFIER", 18, 27]]], ["BCV strains M and PQ possessed similar physicochemical and biological properties [3] , but differed by counterimmuno-electrophoresis and immunodiffusion [4] .", [["PQ", "CHEMICAL", 18, 20], ["PQ", "SIMPLE_CHEMICAL", 18, 20], ["BCV", "SPECIES", 0, 3], ["BCV strains M", "PROBLEM", 0, 13], ["immunodiffusion", "TEST", 137, 152]]], ["Four British isolates, 1 from the enteric tract and 3 from the respiratory tract, were compared by a neutralisation (NT) test using pig antisera to three of these isolates.", [["enteric tract", "ANATOMY", 34, 47], ["respiratory tract", "ANATOMY", 63, 80], ["enteric tract", "ORGANISM_SUBDIVISION", 34, 47], ["respiratory tract", "ORGANISM_SUBDIVISION", 63, 80], ["pig", "ORGANISM", 132, 135], ["pig", "SPECIES", 132, 135], ["pig", "SPECIES", 132, 135], ["a neutralisation (NT) test", "TEST", 99, 125], ["pig antisera", "TREATMENT", 132, 144], ["these isolates", "TREATMENT", 157, 171], ["enteric tract", "ANATOMY", 34, 47], ["respiratory tract", "ANATOMY", 63, 80]]], ["There was complete virus neutralisation with homologous sera and significant cross-reactions with heterologous sera [ 14] .", [["sera", "ANATOMY", 56, 60], ["sera", "ANATOMY", 111, 115], ["sera", "ORGANISM_SUBSTANCE", 56, 60], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["complete virus neutralisation", "PROBLEM", 10, 39], ["homologous sera", "TREATMENT", 45, 60], ["significant cross-reactions", "PROBLEM", 65, 92], ["heterologous sera", "TEST", 98, 115]]], ["Slight variation in molecular weight of the structural proteins of BCV strains were reported [5, 7, 10, 12] .IntroductionIn this study, a comprehensive serological comparison of 5 BCV strains and a HCV-OC43 strain was undertaken using polyclonal and monoclonal antibodies in order to investigate possible variation.VirusesThree reference BCV strains already adapted to cell culture were obtained from other laboratories.", [["cell culture", "ANATOMY", 369, 381], ["BCV", "ORGANISM", 67, 70], ["BCV", "ORGANISM", 180, 183], ["HCV-OC43", "ORGANISM", 198, 206], ["BCV", "ORGANISM", 338, 341], ["cell", "CELL", 369, 373], ["structural proteins", "PROTEIN", 44, 63], ["monoclonal antibodies", "PROTEIN", 250, 271], ["BCV", "SPECIES", 180, 183], ["HCV-OC43 strain", "SPECIES", 198, 213], ["BCV", "SPECIES", 338, 341], ["Slight variation", "PROBLEM", 0, 16], ["BCV strains", "PROBLEM", 67, 78], ["this study", "TEST", 124, 134], ["5 BCV strains", "PROBLEM", 178, 191], ["a HCV-OC43 strain", "PROBLEM", 196, 213], ["polyclonal and monoclonal antibodies", "TREATMENT", 235, 271], ["Viruses", "PROBLEM", 315, 322], ["BCV strains", "PROBLEM", 338, 349], ["cell culture", "TEST", 369, 381], ["variation", "OBSERVATION_MODIFIER", 7, 16], ["molecular weight", "OBSERVATION", 20, 36], ["BCV", "ANATOMY", 67, 70]]], ["The American M strain of BCV was kindly supplied by Dr. M. S. McNulty, Veterinary Research Laboratory, Belfast [13] ; the Canadian PQ strain by Dr. L. A. Babiuk, University of Saskatchewan, Canada [3] ; and the British CK strain by Dr. J. C. Bridger at the Institute for Animal Health, Compton [14] .", [["PQ", "CHEMICAL", 131, 133], ["BCV", "ORGANISM", 25, 28], ["CK", "GENE_OR_GENE_PRODUCT", 219, 221], ["BCV", "SPECIES", 25, 28]]], ["Two Scottish field isolates of BCV (designated S 1 and S 2) were adapted to grow in a human rectal tumour cell line (HRT 18) following initial isolation in bovine fetal tracheal organ culture as described elsewhere [8] .", [["rectal tumour cell line", "ANATOMY", 92, 115], ["fetal tracheal organ culture", "ANATOMY", 163, 191], ["rectal tumour", "DISEASE", 92, 105], ["BCV", "ORGANISM", 31, 34], ["human", "ORGANISM", 86, 91], ["rectal tumour cell line", "CELL", 92, 115], ["bovine", "ORGANISM", 156, 162], ["human rectal tumour cell line", "CELL_LINE", 86, 115], ["HRT 18", "CELL_LINE", 117, 123], ["bovine fetal tracheal organ culture", "CELL_LINE", 156, 191], ["human", "SPECIES", 86, 91], ["bovine", "SPECIES", 156, 162], ["BCV", "SPECIES", 31, 34], ["human", "SPECIES", 86, 91], ["bovine", "SPECIES", 156, 162], ["BCV", "TEST", 31, 34], ["a human rectal tumour cell line", "TREATMENT", 84, 115], ["HRT", "TEST", 117, 120], ["initial isolation in bovine fetal tracheal organ culture", "TEST", 135, 191], ["BCV", "ANATOMY", 31, 34], ["rectal", "ANATOMY", 92, 98], ["tumour cell line", "OBSERVATION", 99, 115], ["tracheal organ", "ANATOMY", 169, 183]]], ["These five BCV strains were biologically cloned by three terminal dilutions and grown in roller cultures in HRT 18 cells [16] .", [["cultures", "ANATOMY", 96, 104], ["HRT 18 cells", "ANATOMY", 108, 120], ["BCV", "ORGANISM", 11, 14], ["HRT 18 cells", "CELL", 108, 120], ["roller cultures", "CELL_LINE", 89, 104], ["HRT 18 cells", "CELL_LINE", 108, 120], ["BCV", "SPECIES", 11, 14], ["These five BCV strains", "PROBLEM", 0, 22], ["roller cultures", "TEST", 89, 104], ["HRT", "TEST", 108, 111]]], ["The virus inoculum was pre-treated with 10gg/ml trypsin for 1 hour at 37\u00b0C and 1 gg/ml trypsin was incorporated in the maintenance medium.VirusesHuman coronavirus OC 43 which had been passaged in newborn mice by intracerebral inoculation was kindly supplied by Mr. G. Winters of the City Hospital, Edinburgh.", [["intracerebral", "ANATOMY", 212, 225], ["OC", "CHEMICAL", 163, 165], ["trypsin", "GENE_OR_GENE_PRODUCT", 48, 55], ["trypsin", "GENE_OR_GENE_PRODUCT", 87, 94], ["VirusesHuman coronavirus OC 43", "ORGANISM", 138, 168], ["mice", "ORGANISM", 204, 208], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 212, 225], ["trypsin", "PROTEIN", 48, 55], ["trypsin", "PROTEIN", 87, 94], ["VirusesHuman coronavirus", "SPECIES", 138, 162], ["mice", "SPECIES", 204, 208], ["VirusesHuman coronavirus", "SPECIES", 138, 162], ["mice", "SPECIES", 204, 208], ["The virus inoculum", "PROBLEM", 0, 18], ["10gg/ml trypsin", "TREATMENT", 40, 55], ["trypsin", "TREATMENT", 87, 94], ["VirusesHuman coronavirus OC", "PROBLEM", 138, 165], ["virus inoculum", "OBSERVATION", 4, 18]]], ["A 1/ 100 mouse brain homogenate in phosphate buffered saline (PBS) was treated with 10 gg/ ml trypsin for 1 hour at 37 \u00b0C and inoculated on to HRT 18 cells.", [["brain homogenate", "ANATOMY", 15, 31], ["HRT 18 cells", "ANATOMY", 143, 155], ["phosphate", "CHEMICAL", 35, 44], ["phosphate", "CHEMICAL", 35, 44], ["mouse", "ORGANISM", 9, 14], ["brain", "ORGAN", 15, 20], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 35, 60], ["trypsin", "GENE_OR_GENE_PRODUCT", 94, 101], ["HRT 18 cells", "CELL", 143, 155], ["trypsin", "PROTEIN", 94, 101], ["HRT 18 cells", "CELL_LINE", 143, 155], ["mouse", "SPECIES", 9, 14], ["mouse", "SPECIES", 9, 14], ["A 1/ 100 mouse brain homogenate in phosphate buffered saline (PBS)", "TREATMENT", 0, 66], ["brain", "ANATOMY", 15, 20]]], ["This virus was adapted to this cell line by 5 passages and was detected in cells by immunofluorescence (IF) using o~4ne anti-BCV/S 1 serum.Rabbit antiseraEach of the six virus strains was pelleted by ultracentrifugation [8] , and antiserum was raised in a rabbit by intramuscular inoculation of virus pellet emulsified in Freund's complete adjuvant.", [["cell line", "ANATOMY", 31, 40], ["cells", "ANATOMY", 75, 80], ["serum", "ANATOMY", 133, 138], ["intramuscular", "ANATOMY", 266, 279], ["cell line", "CELL", 31, 40], ["cells", "CELL", 75, 80], ["serum", "ORGANISM_SUBSTANCE", 133, 138], ["Rabbit", "ORGANISM", 139, 145], ["antiserum", "ORGANISM_SUBSTANCE", 230, 239], ["rabbit", "ORGANISM", 256, 262], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 266, 279], ["anti-BCV", "PROTEIN", 120, 128], ["Rabbit", "SPECIES", 139, 145], ["rabbit", "SPECIES", 256, 262], ["Rabbit", "SPECIES", 139, 145], ["rabbit", "SPECIES", 256, 262], ["This virus", "PROBLEM", 0, 10], ["this cell line", "TREATMENT", 26, 40], ["Rabbit antiseraEach", "TREATMENT", 139, 158], ["the six virus strains", "PROBLEM", 162, 183], ["antiserum", "TREATMENT", 230, 239], ["virus pellet", "TREATMENT", 295, 307]]], ["After 4 weeks, each rabbit received an intramuscular boost of the same virus pellet in Freund's incomplete adjuvant, and was bled out under anaesthesia 2 weeks later.Monoclonal antibodiesMouse monoclonal antibodies to the BCV/S 2 strain were raised and ascites produced using a standard technique [7] .", [["intramuscular", "ANATOMY", 39, 52], ["ascites", "ANATOMY", 253, 260], ["ascites", "DISEASE", 253, 260], ["rabbit", "ORGANISM", 20, 26], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["Mouse", "ORGANISM", 187, 192], ["BCV", "ORGANISM", 222, 225], ["Monoclonal antibodies", "PROTEIN", 166, 187], ["Mouse monoclonal antibodies", "PROTEIN", 187, 214], ["rabbit", "SPECIES", 20, 26], ["Mouse", "SPECIES", 187, 192], ["rabbit", "SPECIES", 20, 26], ["Mouse", "SPECIES", 187, 192], ["an intramuscular boost", "TREATMENT", 36, 58], ["the same virus pellet", "TREATMENT", 62, 83], ["Monoclonal antibodies", "TEST", 166, 187], ["Mouse monoclonal antibodies", "TEST", 187, 214], ["the BCV/S 2 strain", "TEST", 218, 236], ["ascites", "PROBLEM", 253, 260], ["a standard technique", "TREATMENT", 276, 296], ["ascites", "OBSERVATION", 253, 260]]], ["Hybridoma-containing wells were screened by IF, haemagglutination inhibition (HAI) and NT.", [["IF", "PROTEIN", 44, 46], ["Hybridoma-containing wells", "TREATMENT", 0, 26], ["NT", "PROBLEM", 87, 89]]], ["Positive hybridomas were cloned by three terminal dilutions.", [["hybridomas", "ANATOMY", 9, 19], ["Positive hybridomas", "PROBLEM", 0, 19], ["hybridomas", "OBSERVATION", 9, 19]]], ["In this study only two monoclonal antibodies were available: MAB/S 2/1 which had the characteristics IF + ,HAI + and NT + , and MAB/S 2/2 which was IF + , HAI-and NT +.", [["NT +", "SIMPLE_CHEMICAL", 117, 121], ["IF +", "SIMPLE_CHEMICAL", 148, 152], ["NT +", "SIMPLE_CHEMICAL", 163, 167], ["monoclonal antibodies", "PROTEIN", 23, 44], ["MAB", "PROTEIN", 61, 64], ["IF", "PROTEIN", 101, 103], ["IF", "PROTEIN", 148, 150], ["this study", "TEST", 3, 13], ["two monoclonal antibodies", "TEST", 19, 44], ["MAB/S", "TEST", 61, 66], ["the characteristics", "TEST", 81, 100], ["HAI", "TEST", 107, 110], ["NT", "TEST", 117, 119], ["MAB/S", "TEST", 128, 133], ["HAI", "TEST", 155, 158], ["NT", "PROBLEM", 163, 165]]], ["Both were of the IgG 2a isotype, and both reacted with the haemagglutinin protein by Western blotting (data not shown).Immunofluorescence testConfluent monolayers of HRT 18 cells in microtitre plates were inoculated with 103 TCIDs0 of virus, incubated at 37 \u00b0C for 2 days, washed twice with PBS and fixed in acetone.", [["Confluent monolayers", "ANATOMY", 142, 162], ["HRT 18 cells", "ANATOMY", 166, 178], ["acetone", "CHEMICAL", 308, 315], ["acetone", "CHEMICAL", 308, 315], ["IgG 2a", "GENE_OR_GENE_PRODUCT", 17, 23], ["Confluent monolayers", "CELL", 142, 162], ["HRT 18 cells", "CELL", 166, 178], ["acetone", "SIMPLE_CHEMICAL", 308, 315], ["IgG 2a isotype", "PROTEIN", 17, 31], ["haemagglutinin protein", "PROTEIN", 59, 81], ["HRT 18 cells", "CELL_LINE", 166, 178], ["the IgG 2a isotype", "TREATMENT", 13, 31], ["the haemagglutinin protein", "TREATMENT", 55, 81], ["Immunofluorescence test", "TEST", 119, 142], ["Confluent monolayers", "TEST", 142, 162], ["HRT", "TEST", 166, 169], ["microtitre plates", "TEST", 182, 199], ["103 TCIDs0 of virus", "PROBLEM", 221, 240], ["PBS", "TREATMENT", 291, 294], ["IgG 2a isotype", "OBSERVATION", 17, 31], ["Confluent", "OBSERVATION_MODIFIER", 142, 151], ["monolayers", "OBSERVATION_MODIFIER", 152, 162]]], ["Doubling dilutions of each serum sample were made in PBS and added in duplicate to the fixed cells.", [["serum sample", "ANATOMY", 27, 39], ["cells", "ANATOMY", 93, 98], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["cells", "CELL", 93, 98], ["each serum sample", "TEST", 22, 39], ["PBS", "TREATMENT", 53, 56], ["fixed cells", "OBSERVATION", 87, 98]]], ["After 30 min incubation at 37 \u00b0C, the plates were washed twice in PBS and the appropriate FITC conjugate (either goat anti-rabbit or swine anti-mouse; Wellcome) added and incubated at 37 \u00b0C for a further 30min.", [["FITC", "CHEMICAL", 90, 94], ["FITC conjugate", "SIMPLE_CHEMICAL", 90, 104], ["FITC conjugate", "PROTEIN", 90, 104], ["goat anti-rabbit", "PROTEIN", 113, 129], ["swine anti-mouse", "PROTEIN", 133, 149], ["goat", "SPECIES", 113, 117], ["anti-rabbit", "SPECIES", 118, 129], ["swine", "SPECIES", 133, 138], ["anti-mouse", "SPECIES", 139, 149], ["goat", "SPECIES", 113, 117], ["swine", "SPECIES", 133, 138], ["the plates", "TREATMENT", 34, 44], ["PBS", "TREATMENT", 66, 69], ["the appropriate FITC conjugate", "TREATMENT", 74, 104], ["swine anti-mouse", "TREATMENT", 133, 149]]], ["The plates were washed twice more in PBS and examined under incident UV light using a Leitz UV microscope.", [["The plates", "TREATMENT", 0, 10], ["a Leitz UV microscope", "TREATMENT", 84, 105], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["IF titres were recorded as the highest dilutions to provide clear fluorescing cells when compared to uninoculated controls.Haemagglutination inhibition testThe HAI test was performed by standard techniques [15] .", [["cells", "ANATOMY", 78, 83], ["IF", "GENE_OR_GENE_PRODUCT", 0, 2], ["cells", "CELL", 78, 83], ["fluorescing cells", "CELL_TYPE", 66, 83], ["titres", "PROBLEM", 3, 9], ["the highest dilutions", "TREATMENT", 27, 48], ["clear fluorescing cells", "PROBLEM", 60, 83], ["Haemagglutination inhibition", "TEST", 123, 151], ["The HAI test", "TEST", 156, 168]]], ["Each serum sample and monoclonat antibody was extracted with kaolin, treated with rat erythrocytes and heat inactivated.Neutralisation testNTs were performed by standard techniques on HRT 18 cell in microplates, using virus at a titre of 20-200 fluorescing cells per microscope field.", [["serum sample", "ANATOMY", 5, 17], ["erythrocytes", "ANATOMY", 86, 98], ["cell", "ANATOMY", 191, 195], ["cells", "ANATOMY", 257, 262], ["kaolin", "CHEMICAL", 61, 67], ["kaolin", "CHEMICAL", 61, 67], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["kaolin", "SIMPLE_CHEMICAL", 61, 67], ["rat", "ORGANISM", 82, 85], ["erythrocytes", "CELL", 86, 98], ["cell", "CELL", 191, 195], ["cells", "CELL", 257, 262], ["monoclonat antibody", "PROTEIN", 22, 41], ["rat erythrocytes", "CELL_TYPE", 82, 98], ["rat", "SPECIES", 82, 85], ["rat", "SPECIES", 82, 85], ["Each serum sample", "TEST", 0, 17], ["monoclonat antibody", "TEST", 22, 41], ["kaolin", "TREATMENT", 61, 67], ["rat erythrocytes", "TREATMENT", 82, 98], ["heat", "TREATMENT", 103, 107], ["Neutralisation testNTs", "TEST", 120, 142], ["HRT 18 cell in microplates", "TREATMENT", 184, 210], ["virus", "TREATMENT", 218, 223]]], ["After incubation at 37 \u00b0C for 2 days, cells were washed, fixed in acetone and the infected cells visualised by IF using a gnotobiotic calf anti-BCV serum and a swine anti-sheep FITC conjugate (equally efficacious with either bovine or ovine immunoglobulins).", [["cells", "ANATOMY", 38, 43], ["cells", "ANATOMY", 91, 96], ["serum", "ANATOMY", 148, 153], ["acetone", "CHEMICAL", 66, 73], ["FITC", "CHEMICAL", 177, 181], ["cells", "CELL", 38, 43], ["acetone", "SIMPLE_CHEMICAL", 66, 73], ["cells", "CELL", 91, 96], ["calf", "ORGANISM", 134, 138], ["serum", "ORGANISM_SUBSTANCE", 148, 153], ["FITC conjugate", "SIMPLE_CHEMICAL", 177, 191], ["bovine", "ORGANISM", 225, 231], ["ovine", "ORGANISM", 235, 240], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 241, 256], ["infected cells", "CELL_TYPE", 82, 96], ["IF", "PROTEIN", 111, 113], ["swine anti-sheep FITC conjugate", "PROTEIN", 160, 191], ["ovine immunoglobulins", "PROTEIN", 235, 256], ["calf", "SPECIES", 134, 138], ["swine", "SPECIES", 160, 165], ["bovine", "SPECIES", 225, 231], ["gnotobiotic", "SPECIES", 122, 133], ["anti-BCV", "SPECIES", 139, 147], ["swine", "SPECIES", 160, 165], ["bovine", "SPECIES", 225, 231], ["ovine", "SPECIES", 235, 240], ["cells", "PROBLEM", 38, 43], ["acetone", "TREATMENT", 66, 73], ["the infected cells", "TREATMENT", 78, 96], ["a gnotobiotic calf anti-BCV serum", "TEST", 120, 153], ["a swine anti-sheep FITC conjugate", "TREATMENT", 158, 191], ["bovine or ovine immunoglobulins", "TREATMENT", 225, 256], ["infected cells", "OBSERVATION", 82, 96]]], ["The recorded titre of serum samples was the highest dilution to cause a 90% reduction in the number of fluorescing cells compared to the mean of the'. virus control wells.Comparison of strainsThe antigenic relationship (R) between the strains was calculated using the formula (1):Comparison of strainswhere r 1 = heterologous titre (strain 2) / homologous titre (strain 1) and r 2 = heterologous titre (strain 1) / homologous titre (strain 2)Comparison of strainsTitres were calculated using the geometric mean of duplicate results.", [["serum samples", "ANATOMY", 22, 35], ["cells", "ANATOMY", 115, 120], ["serum samples", "ORGANISM_SUBSTANCE", 22, 35], ["cells", "CELL", 115, 120], ["fluorescing cells", "CELL_TYPE", 103, 120], ["serum samples", "TEST", 22, 35], ["fluorescing cells", "PROBLEM", 103, 120], ["virus control wells", "TREATMENT", 151, 170], ["strains", "PROBLEM", 185, 192], ["the strains", "PROBLEM", 231, 242], ["strainswhere", "TEST", 294, 306], ["heterologous titre (strain", "PROBLEM", 313, 339], ["heterologous titre (strain", "TREATMENT", 383, 409], ["homologous titre (strain", "PROBLEM", 415, 439], ["strains", "PROBLEM", 456, 463], ["90%", "OBSERVATION_MODIFIER", 72, 75], ["reduction", "OBSERVATION_MODIFIER", 76, 85], ["fluorescing cells", "OBSERVATION", 103, 120]]], ["A greater than 20-fold difference in titre in both directions is used as indication of serotype in rotaviruses and picornaviruses [ 18] and this equates to R < 5 %.Virus cultureDuring this study no CPE was detected in HRT 18 cells at any stage with any of the strains and the use of trypsin was essential for virus replication.", [["HRT 18 cells", "ANATOMY", 218, 230], ["rotaviruses", "ORGANISM", 99, 110], ["Virus", "ORGANISM", 164, 169], ["HRT 18 cells", "CELL", 218, 230], ["trypsin", "GENE_OR_GENE_PRODUCT", 283, 290], ["HRT 18 cells", "CELL_LINE", 218, 230], ["trypsin", "PROTEIN", 283, 290], ["A greater than 20-fold difference", "PROBLEM", 0, 33], ["serotype in rotaviruses", "PROBLEM", 87, 110], ["picornaviruses", "PROBLEM", 115, 129], ["Virus cultureDuring", "TEST", 164, 183], ["this study", "TEST", 184, 194], ["CPE", "PROBLEM", 198, 201], ["HRT 18 cells", "PROBLEM", 218, 230], ["the strains", "PROBLEM", 256, 267], ["trypsin", "TREATMENT", 283, 290], ["virus replication", "TREATMENT", 309, 326], ["greater", "OBSERVATION_MODIFIER", 2, 9]]], ["Virus was detected in cell culture by IF and haemagglutination.Immunofluorescence testThe 5 BCV strains and the HCV-OC43 strain were not significantly distinct when reacted with polyclonal antisera (Table 1) as the lowest calculated R value was 15% (data not shown).Immunofluorescence testHCV-OC43 was clearly distinguished from the bovine strains (Table 1 ) by the monoclonal antibodies to strain S 2.", [["cell", "ANATOMY", 22, 26], ["Virus", "ORGANISM", 0, 5], ["cell culture", "CELL", 22, 34], ["IF", "CELL", 38, 40], ["BCV", "ORGANISM", 92, 95], ["HCV-OC43 strain", "ORGANISM", 112, 127], ["bovine", "ORGANISM", 333, 339], ["IF", "PROTEIN", 38, 40], ["testHCV", "PROTEIN", 285, 292], ["OC43", "DNA", 293, 297], ["monoclonal antibodies", "PROTEIN", 366, 387], ["bovine", "SPECIES", 333, 339], ["BCV", "SPECIES", 92, 95], ["HCV-OC43 strain", "SPECIES", 112, 127], ["bovine", "SPECIES", 333, 339], ["Virus", "PROBLEM", 0, 5], ["cell culture", "TEST", 22, 34], ["haemagglutination", "PROBLEM", 45, 62], ["Immunofluorescence test", "TEST", 63, 86], ["The 5 BCV strains", "PROBLEM", 86, 103], ["the HCV", "TEST", 108, 115], ["OC43 strain", "PROBLEM", 116, 127], ["polyclonal antisera", "TREATMENT", 178, 197], ["the lowest calculated R value", "TEST", 211, 240], ["Immunofluorescence testHCV", "TEST", 266, 292], ["OC43", "PROBLEM", 293, 297], ["the bovine strains", "PROBLEM", 329, 347], ["the monoclonal antibodies", "TEST", 362, 387]]], ["Both monoclonal antibodies had ~> 32fold lower IF titres when tested against the M and S 1 strains than against the homologous strain.", [["IF", "GENE_OR_GENE_PRODUCT", 47, 49], ["monoclonal antibodies", "PROTEIN", 5, 26], ["IF", "PROTEIN", 47, 49], ["Both monoclonal antibodies", "TEST", 0, 26], ["the homologous strain", "PROBLEM", 112, 133]]], ["MAB/S 2/2 in addition had a 32-fold lower IF titre against strain CK.Haemagglutination inhibition testThe results of the HAI test are shown in Table2.", [["S 2/2", "GENE_OR_GENE_PRODUCT", 4, 9], ["IF", "GENE_OR_GENE_PRODUCT", 42, 44], ["CK", "GENE_OR_GENE_PRODUCT", 66, 68], ["IF", "PROTEIN", 42, 44], ["CK", "PROTEIN", 66, 68], ["MAB/S", "TEST", 0, 5], ["strain CK", "TEST", 59, 68], ["Haemagglutination inhibition test", "TEST", 69, 102], ["the HAI test", "TEST", 117, 129]]], ["HCV-OC43 was clearly distinguished from the BCV strains by the polyclonal antisera, with R = 4-9%.", [["HCV-OC43", "ORGANISM", 0, 8], ["BCV", "ORGANISM", 44, 47], ["HCV", "SPECIES", 0, 3], ["BCV", "SPECIES", 44, 47], ["HCV", "PROBLEM", 0, 3], ["OC43", "PROBLEM", 4, 8], ["the BCV strains", "PROBLEM", 40, 55], ["the polyclonal antisera", "TEST", 59, 82], ["R", "TEST", 89, 90]]], ["Strain BCV/S 1 also showed weaker reactions with the other BCV strains (R = 5-21%).", [["BCV", "ORGANISM", 59, 62], ["BCV/S 1", "SPECIES", 7, 14], ["Strain BCV/S", "TEST", 0, 12], ["weaker reactions", "PROBLEM", 27, 43], ["the other BCV strains", "TEST", 49, 70], ["R", "TEST", 72, 73], ["weaker", "OBSERVATION_MODIFIER", 27, 33], ["reactions", "OBSERVATION", 34, 43]]], ["'One-way' reactions were detected in this test between the CK and M, CK and PQ, and between the S 2 and M strains.Haemagglutination inhibition testMAB/S 2/2 had no HAI activity.", [["PQ", "CHEMICAL", 76, 78], ["CK", "GENE_OR_GENE_PRODUCT", 59, 61], ["CK", "GENE_OR_GENE_PRODUCT", 69, 71], ["PQ", "SIMPLE_CHEMICAL", 76, 78], ["CK", "PROTEIN", 59, 61], ["this test", "TEST", 37, 46], ["the CK", "TEST", 55, 61], ["CK", "TEST", 69, 71], ["Haemagglutination inhibition", "TEST", 114, 142], ["testMAB/S", "TEST", 143, 152], ["HAI activity", "PROBLEM", 164, 176]]], ["MAB/S 2/1 differentiated HCV-OC 43 and also had only a weaker crossreaction with the BCV/S 1 strain.Neutralisation testThe NT results are shown in Table 3 .", [["HCV-OC", "CHEMICAL", 25, 31], ["HCV-OC 43", "ORGANISM", 25, 34], ["HCV-OC 43", "SPECIES", 25, 34], ["BCV/S 1", "SPECIES", 85, 92], ["MAB/S", "TEST", 0, 5], ["HCV", "PROBLEM", 25, 28], ["a weaker crossreaction", "PROBLEM", 53, 75], ["the BCV/S 1 strain", "PROBLEM", 81, 99], ["Neutralisation test", "TEST", 100, 119], ["The NT results", "TEST", 119, 133]]], ["HCV-OC 43 was clearly distinct from all the BCV strains (R--1-11%).", [["OC", "CHEMICAL", 4, 6], ["HCV-OC 43", "ORGANISM", 0, 9], ["BCV", "ORGANISM", 44, 47], ["HCV", "SPECIES", 0, 3], ["BCV", "SPECIES", 44, 47], ["HCV", "PROBLEM", 0, 3], ["the BCV strains", "TEST", 40, 55], ["R", "TEST", 57, 58]]], ["A high degree of relatedness was apparent between the BCV strains using polyclonal antisera (R> 30%).", [["BCV", "ORGANISM", 54, 57], ["BCV", "SPECIES", 54, 57], ["A high degree of relatedness", "PROBLEM", 0, 28], ["the BCV strains", "PROBLEM", 50, 65], ["polyclonal antisera", "TREATMENT", 72, 91], ["high degree", "OBSERVATION_MODIFIER", 2, 13], ["relatedness", "OBSERVATION", 17, 28], ["BCV", "ANATOMY", 54, 57]]], ["Both monoclonal antibodies differentiated the HCV-OC43.", [["HCV-OC43", "ORGANISM", 46, 54], ["monoclonal antibodies", "PROTEIN", 5, 26], ["HCV-OC43", "SPECIES", 46, 54], ["Both monoclonal antibodies", "TEST", 0, 26], ["OC43", "PROBLEM", 50, 54], ["monoclonal antibodies", "OBSERVATION", 5, 26], ["HCV", "OBSERVATION", 46, 49]]], ["MAB/S2/1 clearly distinguished between M, PQ, and S 2 on the one hand and CK and S 1 on the other, while MAB/S 2/2 neutralised all 5 strains of BCV to a similar extent.DiscussionPolyclonal antibodies are directed against many different epitopes on viral proteins and differences may be masked as only a proportion of these epitopes need remain constant for the antiserum to react with the virus.", [["hand", "ANATOMY", 65, 69], ["PQ", "CHEMICAL", 42, 44], ["MAB", "GENE_OR_GENE_PRODUCT", 0, 3], ["CK", "GENE_OR_GENE_PRODUCT", 74, 76], ["BCV", "ORGANISM", 144, 147], ["antiserum", "ORGANISM_SUBSTANCE", 361, 370], ["MAB", "PROTEIN", 0, 3], ["S2/1", "PROTEIN", 4, 8], ["CK", "PROTEIN", 74, 76], ["Polyclonal antibodies", "PROTEIN", 178, 199], ["epitopes", "PROTEIN", 236, 244], ["viral proteins", "PROTEIN", 248, 262], ["epitopes", "PROTEIN", 323, 331], ["BCV", "SPECIES", 144, 147], ["MAB", "TEST", 0, 3], ["PQ", "TEST", 42, 44], ["CK", "TEST", 74, 76], ["MAB/S", "TEST", 105, 110], ["Polyclonal antibodies", "TREATMENT", 178, 199], ["many different epitopes on viral proteins", "PROBLEM", 221, 262], ["these epitopes", "PROBLEM", 317, 331], ["the antiserum", "TREATMENT", 357, 370], ["the virus", "PROBLEM", 385, 394], ["BCV", "ANATOMY", 144, 147], ["similar extent", "OBSERVATION_MODIFIER", 153, 167], ["viral proteins", "OBSERVATION", 248, 262]]], ["This can be highlighted in the case of BCV by the haemagglutinin and peplomer proteins, both of which elicit neut.ralising activity [6] .", [["BCV", "ORGANISM", 39, 42], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 50, 64], ["peplomer", "GENE_OR_GENE_PRODUCT", 69, 77], ["haemagglutinin and peplomer proteins", "PROTEIN", 50, 86], ["BCV", "SPECIES", 39, 42], ["the haemagglutinin and peplomer proteins", "PROBLEM", 46, 86]]], ["In a neutralisation test, if the peplomer protein remained unchanged, differences in the haemagglutinin protein would not be detected using polyclonal antiserum.", [["peplomer", "GENE_OR_GENE_PRODUCT", 33, 41], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 89, 103], ["antiserum", "ORGANISM_SUBSTANCE", 151, 160], ["peplomer protein", "PROTEIN", 33, 49], ["haemagglutinin protein", "PROTEIN", 89, 111], ["a neutralisation test", "TEST", 3, 24], ["the peplomer protein", "TEST", 29, 49], ["the haemagglutinin protein", "TEST", 85, 111], ["polyclonal antiserum", "TREATMENT", 140, 160], ["unchanged", "OBSERVATION_MODIFIER", 59, 68]]], ["This also applied in the case of different epitopes on one protein.", [["epitopes", "PROTEIN", 43, 51]]], ["On the other hand, monoclonal antibodies may be so specific that minor antigenic differences detected by these antibodies may have no biological significance.", [["monoclonal antibodies", "PROTEIN", 19, 40], ["antibodies", "PROTEIN", 111, 121], ["monoclonal antibodies", "TEST", 19, 40], ["minor antigenic differences", "PROBLEM", 65, 92], ["these antibodies", "TEST", 105, 121]]], ["Alternatively, monoclonal antibodies may be directed against a common antigen and may not detect important differences between strains.", [["monoclonal antibodies", "PROTEIN", 15, 36], ["monoclonal antibodies", "TREATMENT", 15, 36], ["strains", "PROBLEM", 127, 134]]], ["For these reasons both monoclonal and polyclonal antibodies were used in three serological tests to determine the extent of differences between isolates.DiscussionUsing polyclonal antisera, the relationship of HCV-OC43 to BCV was confirmed by the IF test, although only a limited crossreaction was obtained with HAI and NT assays and the monoclonal antibodies did not recognise shared epitopes.", [["HCV-OC43", "ORGANISM", 210, 218], ["BCV", "ORGANISM", 222, 225], ["monoclonal and polyclonal antibodies", "PROTEIN", 23, 59], ["monoclonal antibodies", "PROTEIN", 338, 359], ["epitopes", "PROTEIN", 385, 393], ["HCV", "SPECIES", 210, 213], ["BCV", "SPECIES", 222, 225], ["monoclonal and polyclonal antibodies", "TEST", 23, 59], ["three serological tests", "TEST", 73, 96], ["polyclonal antisera", "TREATMENT", 169, 188], ["HCV", "PROBLEM", 210, 213], ["OC43", "PROBLEM", 214, 218], ["the IF test", "TEST", 243, 254], ["HAI", "TEST", 312, 315], ["NT assays", "TEST", 320, 329], ["the monoclonal antibodies", "TEST", 334, 359]]], ["An antigenic relationship has been shown for each of the structural proteins of BCV strain M and HCV-OC43 [11] .", [["BCV strain M", "ORGANISM", 80, 92], ["HCV-OC43", "ORGANISM", 97, 105], ["structural proteins", "PROTEIN", 57, 76], ["HCV-OC43", "SPECIES", 97, 105]]], ["These polyclonal antisera did not distinguish between the BCV strains by IF or NT, but showed a lower degree of crossreactivity in HAI particularly for strain S 1.", [["HAI", "DISEASE", 131, 134], ["BCV", "ORGANISM", 58, 61], ["IF", "GENE_OR_GENE_PRODUCT", 73, 75], ["IF", "PROTEIN", 73, 75], ["BCV", "SPECIES", 58, 61], ["S 1", "SPECIES", 159, 162], ["These polyclonal antisera", "TEST", 0, 25], ["the BCV strains", "PROBLEM", 54, 69], ["NT", "PROBLEM", 79, 81], ["a lower degree of crossreactivity in HAI", "PROBLEM", 94, 134], ["lower degree", "OBSERVATION_MODIFIER", 96, 108], ["crossreactivity", "OBSERVATION", 112, 127]]], ["There is no evidence from this study of distinction of these BCV strains into classical serotypes.DiscussionThe monoclonal antibodies reacted with separate epitopes on the BCV haemagglutinin protein, Mab/S 2/1 with an haemagglutinating epitope, Mab/S 2/ 2 with a non-haemagglutinating epitope, although both epitopes were obviously separately involved in virus neutralisation.", [["BCV", "ORGANISM", 61, 64], ["BCV haemagglutinin", "ORGANISM", 172, 190], ["Mab", "GENE_OR_GENE_PRODUCT", 200, 203], ["monoclonal antibodies", "PROTEIN", 112, 133], ["epitopes", "PROTEIN", 156, 164], ["BCV haemagglutinin protein", "PROTEIN", 172, 198], ["Mab", "PROTEIN", 200, 203], ["S 2/1", "PROTEIN", 204, 209], ["haemagglutinating epitope", "PROTEIN", 218, 243], ["Mab", "PROTEIN", 245, 248], ["S 2", "PROTEIN", 249, 252], ["non-haemagglutinating epitope", "PROTEIN", 263, 292], ["epitopes", "PROTEIN", 308, 316], ["BCV", "SPECIES", 61, 64], ["this study", "TEST", 26, 36], ["classical serotypes", "PROBLEM", 78, 97], ["The monoclonal antibodies", "TEST", 108, 133], ["the BCV haemagglutinin protein", "TREATMENT", 168, 198], ["Mab/S", "TREATMENT", 200, 205], ["an haemagglutinating epitope", "TREATMENT", 215, 243], ["a non-haemagglutinating epitope", "TREATMENT", 261, 292], ["virus neutralisation", "PROBLEM", 355, 375], ["no evidence from", "UNCERTAINTY", 9, 25], ["serotypes", "OBSERVATION", 88, 97]]], ["It is of interest that the epitope reacting with Mab/S 2/1 allowed a very clear distinction by NT of BCV strains into those possessing this epitope (S 2, M, and PQ), and those without (CK and S 1).", [["Mab", "GENE_OR_GENE_PRODUCT", 49, 52], ["BCV", "ORGANISM", 101, 104], ["Mab", "PROTEIN", 49, 52], ["S 2/1", "PROTEIN", 53, 58], ["CK", "PROTEIN", 185, 187], ["BCV", "SPECIES", 101, 104], ["Mab/S", "TREATMENT", 49, 54], ["CK and S", "TEST", 185, 193]]], ["By contrast, the IF results showed poor reactivity with M and S 1, and the HAI results showed low reactions only with S 1.", [["IF", "PROTEIN", 17, 19], ["poor reactivity", "PROBLEM", 35, 50], ["the HAI", "TEST", 71, 78], ["low reactions", "PROBLEM", 94, 107], ["low reactions", "OBSERVATION", 94, 107]]], ["It is possible that this is a large epitope containing separate sequences responsible for each serological function accounting for the varying strain relationships.", [["a large epitope containing separate sequences", "PROBLEM", 28, 73], ["each serological function", "TEST", 90, 115], ["large", "OBSERVATION_MODIFIER", 30, 35], ["epitope", "OBSERVATION", 36, 43]]], ["However, the distinction of strain S 1 runs consistently through these results which confirms the findings with polyclonal reagents.", [["polyclonal reagents", "TREATMENT", 112, 131]]], ["There was a marked difference in the relative titres of MAB/S 2/1 for the M strain in the HAI and IF tests.", [["MAB", "PROTEIN", 56, 59], ["a marked difference", "PROBLEM", 10, 29], ["MAB/S", "TREATMENT", 56, 61], ["the M strain", "PROBLEM", 70, 82], ["tests", "TEST", 101, 106], ["marked", "OBSERVATION_MODIFIER", 12, 18], ["difference", "OBSERVATION_MODIFIER", 19, 29]]], ["No such difference was detected with any of the other strains.DiscussionThe 5 BCV strains examined were clearly closely related, to an extent that would be likely to confer in vivo crossprotection.", [["BCV", "ORGANISM", 78, 81], ["BCV", "SPECIES", 78, 81], ["the other strains", "PROBLEM", 44, 61], ["The 5 BCV strains", "TEST", 72, 89]]], ["It will be useful to compare a larger number of BCV strains with both polyclonal and monoclonal reagents to further investigate possible strain variation.", [["BCV", "ORGANISM", 48, 51], ["BCV", "SPECIES", 48, 51], ["BCV strains", "PROBLEM", 48, 59], ["both polyclonal and monoclonal reagents", "TREATMENT", 65, 104], ["strain variation", "PROBLEM", 137, 153]]]]}